{"src": "PMC", "id": "PMC5810984", "provider": "OpenTargets", "anns": [{"type": "Gene Disease Relationship", "exact": "Cardiomyopathy was defined based on characteristic abnormalities on electrocardiogram (ECG) (atrial fibrillation or flutter, atrioventricular blocks, bradycardia <50 beats per minute, bundle branch blocks, junctional rhythms), and/or cardiac insufficiency based on ejection fraction (EF) by echocardiogram (EF<53% for women, <51% for men).", "section": "METHODS", "tags": [{"name": "electrocardiogram", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "atrioventricular", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "A total of 38 T. cruzi-infected cases (male n = 19, mean/median age: 62/65; female n = 19, mean/median age: 55/58) with a clinical cardiomyopathy diagnosis and 24 asymptomatic T. cruzi-infected controls (male n = 12, mean/median age: 56/56; female n = 12, mean/median age: 53/55) were selected as a stratified sample from the parent study, frequency-matched by age and sex.", "section": "METHODS", "tags": [{"name": "frequency-matched", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "cruzi-infected", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Confirmed T. cruzi infection was based on having positive results on 2 different commercial assays for anti-T. cruzi IgG antibodies (Wiener Recombinant 3.0 enzyme linked immunosorbent assay, Rosario, Argentina and Chagas Polychaco indirect hemagglutination test kit, Lemos Laboratories, Santiago del Estero, Argentina).", "section": "METHODS", "tags": [{"name": "hemagglutination", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "immunosorbent", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "The Johns Hopkins Bloomberg School of Public Health Institutional Review Board (IRB) approved this study (entitled \u201cPredictors of Cardiomyopathy Progression in a Chagas Disease Cohort in Bolivia\u201d, IRB No: 00005598) on September 30, 2015 in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki.", "section": "METHODS", "tags": [{"name": "Cardiomyopathy", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "Institutional", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "The HapMap populations include: ASW: African ancestry in Southwest USA; CEU: Utah residents with Northern and Western European ancestry from the CEPH collection; CHB: Han Chinese in Beijing, China; CHD: Chinese in Metropolitan Denver, Colorado; GIH: Gujarati Indians in Houston, Texas; JPT: Japanese in Tokyo, Japan; LWK: Luhya in Webuye, Kenya; MEX: Mexican ancestry in Los Angeles, California; MKK: Maasai in Kinyawa, Kenya; TSI: Tuscans in Italy; YRI: Yoruba in Ibadan, Nigeria.", "section": "METHODS", "tags": [{"name": "Metropolitan", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "populations", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "The Johns Hopkins Bloomberg School of Public Health Institutional Review Board (IRB) approved this study (entitled \u201cPredictors of Cardiomyopathy Progression in a Chagas Disease Cohort in Bolivia\u201d, IRB No: 00005598) on September 30, 2015 in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki.", "section": "METHODS", "tags": [{"name": "Cardiomyopathy", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "Institutional", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "The HapMap populations include: ASW: African ancestry in Southwest USA; CEU: Utah residents with Northern and Western European ancestry from the CEPH collection; CHB: Han Chinese in Beijing, China; CHD: Chinese in Metropolitan Denver, Colorado; GIH: Gujarati Indians in Houston, Texas; JPT: Japanese in Tokyo, Japan; LWK: Luhya in Webuye, Kenya; MEX: Mexican ancestry in Los Angeles, California; MKK: Maasai in Kinyawa, Kenya; TSI: Tuscans in Italy; YRI: Yoruba in Ibadan, Nigeria.", "section": "METHODS", "tags": [{"name": "Metropolitan", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "populations", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "The Johns Hopkins Bloomberg School of Public Health Institutional Review Board (IRB) approved this study (entitled \u201cPredictors of Cardiomyopathy Progression in a Chagas Disease Cohort in Bolivia\u201d, IRB No: 00005598) on September 30, 2015 in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki.", "section": "METHODS", "tags": [{"name": "Cardiomyopathy", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "Institutional", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Cardiomyopathy was defined based on characteristic abnormalities on electrocardiogram (ECG) (atrial fibrillation or flutter, atrioventricular blocks, bradycardia <50 beats per minute, bundle branch blocks, junctional rhythms), and/or cardiac insufficiency based on ejection fraction (EF) by echocardiogram (EF<53% for women, <51% for men).", "section": "METHODS", "tags": [{"name": "electrocardiogram", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "atrioventricular", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "The HapMap populations include: ASW: African ancestry in Southwest USA; CEU: Utah residents with Northern and Western European ancestry from the CEPH collection; CHB: Han Chinese in Beijing, China; CHD: Chinese in Metropolitan Denver, Colorado; GIH: Gujarati Indians in Houston, Texas; JPT: Japanese in Tokyo, Japan; LWK: Luhya in Webuye, Kenya; MEX: Mexican ancestry in Los Angeles, California; MKK: Maasai in Kinyawa, Kenya; TSI: Tuscans in Italy; YRI: Yoruba in Ibadan, Nigeria.", "section": "METHODS", "tags": [{"name": "Metropolitan", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "populations", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Confirmed T. cruzi infection was based on having positive results on 2 different commercial assays for anti-T. cruzi IgG antibodies (Wiener Recombinant 3.0 enzyme linked immunosorbent assay, Rosario, Argentina and Chagas Polychaco indirect hemagglutination test kit, Lemos Laboratories, Santiago del Estero, Argentina).", "section": "METHODS", "tags": [{"name": "hemagglutination", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "immunosorbent", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Confirmed T. cruzi infection was based on having positive results on 2 different commercial assays for anti-T. cruzi IgG antibodies (Wiener Recombinant 3.0 enzyme linked immunosorbent assay, Rosario, Argentina and Chagas Polychaco indirect hemagglutination test kit, Lemos Laboratories, Santiago del Estero, Argentina).", "section": "METHODS", "tags": [{"name": "hemagglutination", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "immunosorbent", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "A total of 38 T. cruzi-infected cases (male n = 19, mean/median age: 62/65; female n = 19, mean/median age: 55/58) with a clinical cardiomyopathy diagnosis and 24 asymptomatic T. cruzi-infected controls (male n = 12, mean/median age: 56/56; female n = 12, mean/median age: 53/55) were selected as a stratified sample from the parent study, frequency-matched by age and sex.", "section": "METHODS", "tags": [{"name": "frequency-matched", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "cruzi-infected", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "The Johns Hopkins Bloomberg School of Public Health Institutional Review Board (IRB) approved this study (entitled \u201cPredictors of Cardiomyopathy Progression in a Chagas Disease Cohort in Bolivia\u201d, IRB No: 00005598) on September 30, 2015 in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki.", "section": "METHODS", "tags": [{"name": "Cardiomyopathy", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "Institutional", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Cardiomyopathy was defined based on characteristic abnormalities on electrocardiogram (ECG) (atrial fibrillation or flutter, atrioventricular blocks, bradycardia <50 beats per minute, bundle branch blocks, junctional rhythms), and/or cardiac insufficiency based on ejection fraction (EF) by echocardiogram (EF<53% for women, <51% for men).", "section": "METHODS", "tags": [{"name": "electrocardiogram", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "atrioventricular", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "A total of 38 T. cruzi-infected cases (male n = 19, mean/median age: 62/65; female n = 19, mean/median age: 55/58) with a clinical cardiomyopathy diagnosis and 24 asymptomatic T. cruzi-infected controls (male n = 12, mean/median age: 56/56; female n = 12, mean/median age: 53/55) were selected as a stratified sample from the parent study, frequency-matched by age and sex.", "section": "METHODS", "tags": [{"name": "frequency-matched", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "cruzi-infected", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "The Johns Hopkins Bloomberg School of Public Health Institutional Review Board (IRB) approved this study (entitled \u201cPredictors of Cardiomyopathy Progression in a Chagas Disease Cohort in Bolivia\u201d, IRB No: 00005598) on September 30, 2015 in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki.", "section": "METHODS", "tags": [{"name": "Cardiomyopathy", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "Institutional", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "The HapMap populations include: ASW: African ancestry in Southwest USA; CEU: Utah residents with Northern and Western European ancestry from the CEPH collection; CHB: Han Chinese in Beijing, China; CHD: Chinese in Metropolitan Denver, Colorado; GIH: Gujarati Indians in Houston, Texas; JPT: Japanese in Tokyo, Japan; LWK: Luhya in Webuye, Kenya; MEX: Mexican ancestry in Los Angeles, California; MKK: Maasai in Kinyawa, Kenya; TSI: Tuscans in Italy; YRI: Yoruba in Ibadan, Nigeria.", "section": "METHODS", "tags": [{"name": "Metropolitan", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "populations", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "A total of 38 T. cruzi-infected cases (male n = 19, mean/median age: 62/65; female n = 19, mean/median age: 55/58) with a clinical cardiomyopathy diagnosis and 24 asymptomatic T. cruzi-infected controls (male n = 12, mean/median age: 56/56; female n = 12, mean/median age: 53/55) were selected as a stratified sample from the parent study, frequency-matched by age and sex.", "section": "METHODS", "tags": [{"name": "frequency-matched", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "cruzi-infected", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Confirmed T. cruzi infection was based on having positive results on 2 different commercial assays for anti-T. cruzi IgG antibodies (Wiener Recombinant 3.0 enzyme linked immunosorbent assay, Rosario, Argentina and Chagas Polychaco indirect hemagglutination test kit, Lemos Laboratories, Santiago del Estero, Argentina).", "section": "METHODS", "tags": [{"name": "hemagglutination", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "immunosorbent", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "A total of 38 T. cruzi-infected cases (male n = 19, mean/median age: 62/65; female n = 19, mean/median age: 55/58) with a clinical cardiomyopathy diagnosis and 24 asymptomatic T. cruzi-infected controls (male n = 12, mean/median age: 56/56; female n = 12, mean/median age: 53/55) were selected as a stratified sample from the parent study, frequency-matched by age and sex.", "section": "METHODS", "tags": [{"name": "frequency-matched", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "cruzi-infected", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}]}
{"src": "PMC", "id": "PMC5671944", "provider": "OpenTargets", "anns": [{"type": "Gene Disease Relationship", "exact": "We demonstrated previously that BIM-induction by FOXO3 triggers a biphasic ROS-accumulation, which critically regulates cell death-induction by FOXO3-activation and/or by addition of DNA-damaging agents in NB.3, 31 The primary ROS-wave is detected after 12\u2009h post FOXO3-activation, the second, much more pronounced ROS-wave reaches a climax between 36 and 48\u2009h after FOXO3-activation in NB15/FOXO3 cells.3 We therefore investigated, whether FOXO3-resistant NB4/FOXO3 and NB8/FOXO3 cells show comparable ROS-accumulation or whether this ROS-burst is absent in the resistant cell lines.", "section": "RESULTS", "tags": [{"name": "ROS-accumulation,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "FOXO3-activation,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "The retroviral vectors pLIB-MCS2-iresNeo and pLIB-FOXO3(A3)-ERtm-iresNeo have been described.5 The lentivirus-vector coding for FOXO3-specific shRNA (pLKO-shFOXO3-91617-puro) and SESN3-specific shRNA (pLKO-shSESN3-141228-puro and pLKO-shSESN3-143446-puro) and the control-vector pLKO.1 were described.3 The lentivirus-vectors coding for TP53-specific shRNA pLKO-shTP53-puro, pLKO-shTP53-941-puro and pLKO-shTP53-427-puro were provided by T. Waldmann,52 the pGL3-Bim-promoter was provided by A. Villunger.53 The vector pLIB-EYFP-TP53mut-puro was generated by amplification of mutant-TP53 from NB15 cDNA (p53-fwd: 5\u2032-GAATTCATGGATGATTTGATGC-3\u2032 p53-rev: 5\u2032-GGATCCTCAGTCTGAGTCAG)-3\u2032 and inserted into the EcoR1- and BamH1-site of pLIB-EYFP-Mcl1JAM-iresPuro54 replacing MCL1JAM by the TP53-mutant and generating pLIB-EYFP-p53m-iresPuro.", "section": "OTHER", "tags": [{"name": "5\u2032-GAATTCATGGATGATTTGATGC-3\u2032", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "pLIB-EYFP-Mcl1JAM-iresPuro54", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "The retroviral vectors pLIB-MCS2-iresNeo and pLIB-FOXO3(A3)-ERtm-iresNeo have been described.5 The lentivirus-vector coding for FOXO3-specific shRNA (pLKO-shFOXO3-91617-puro) and SESN3-specific shRNA (pLKO-shSESN3-141228-puro and pLKO-shSESN3-143446-puro) and the control-vector pLKO.1 were described.3 The lentivirus-vectors coding for TP53-specific shRNA pLKO-shTP53-puro, pLKO-shTP53-941-puro and pLKO-shTP53-427-puro were provided by T. Waldmann,52 the pGL3-Bim-promoter was provided by A. Villunger.53 The vector pLIB-EYFP-TP53mut-puro was generated by amplification of mutant-TP53 from NB15 cDNA (p53-fwd: 5\u2032-GAATTCATGGATGATTTGATGC-3\u2032 p53-rev: 5\u2032-GGATCCTCAGTCTGAGTCAG)-3\u2032 and inserted into the EcoR1- and BamH1-site of pLIB-EYFP-Mcl1JAM-iresPuro54 replacing MCL1JAM by the TP53-mutant and generating pLIB-EYFP-p53m-iresPuro.", "section": "OTHER", "tags": [{"name": "5\u2032-GAATTCATGGATGATTTGATGC-3\u2032", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "pLIB-EYFP-Mcl1JAM-iresPuro54", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "One binding partner of FOXO3 is the tumor protein TP53/p53 which is mutated in over 50% of cancer types.20 In NB, however, mutations of TP53 are rare at diagnosis (less than 2% of patients), but frequent loss of function is observed in relapsed tumors.21 FOXO3 and TP53 share numerous target genes such as CDKN1/P21CIP1, GADD45A or BBC3/PUMA; hence, they are involved in the same cellular processes like cell-cycle-arrest, DNA-damage-repair and apoptosis.22, 23, 24, 25", "section": "INTRO", "tags": [{"name": "cell-cycle-arrest,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "DNA-damage-repair", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "We demonstrated previously that BIM-induction by FOXO3 triggers a biphasic ROS-accumulation, which critically regulates cell death-induction by FOXO3-activation and/or by addition of DNA-damaging agents in NB.3, 31 The primary ROS-wave is detected after 12\u2009h post FOXO3-activation, the second, much more pronounced ROS-wave reaches a climax between 36 and 48\u2009h after FOXO3-activation in NB15/FOXO3 cells.3 We therefore investigated, whether FOXO3-resistant NB4/FOXO3 and NB8/FOXO3 cells show comparable ROS-accumulation or whether this ROS-burst is absent in the resistant cell lines.", "section": "RESULTS", "tags": [{"name": "ROS-accumulation,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "FOXO3-activation,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Protein-kinase-B (PKB) which is frequently hyper-activated in high-stage NB due to aberrant expression of the brain-derived-neurotrophic-factor and its cognate receptor NTRK2/TRKB10 directly phosphorylates FOXO3 causing association with 14-3-3 proteins, nuclear exclusion and transcriptional inactivation of FOXO3 in malignant NB cells.5, 11, 12, 13 We previously demonstrated that in patient biopsies FOXO3 localizes to the nucleus even when phosphorylated at the PKB-site threonine-32.14 Stress conditions, such as chemotherapy, override growth-factor-mediated phosphorylation/inactivation of FOXO3 by PKB, which results in the relocation of FOXO3 to the nucleus.3, 9", "section": "INTRO", "tags": [{"name": "brain-derived-neurotrophic-factor", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "phosphorylation/inactivation", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "In NB, FOXO3-induced cell death depends on the induction of the pro-apoptotic BH3-only proteins BIM and NOXA, the repression of the pro-survival BCL2-protein BCLXL and the inhibitor-of-apoptosis-protein survivin.3, 4, 5 Expression analysis of these proteins in FOXO3-resistant NB4/FOXO3 and NB8/FOXO3 and FOXO3-sensitive NB15/FOXO3 cells as well as in their corresponding controls revealed that in NB15/FOXO3 cells BIM and NOXA strongly increased5 on protein- and mRNA-level, and BCLXL and survivin were repressed (Figures 2a and b and Supplementary Figure S3).", "section": "RESULTS", "tags": [{"name": "inhibitor-of-apoptosis-protein", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "FOXO3-resistant", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "In NB, FOXO3-induced cell death depends on the induction of the pro-apoptotic BH3-only proteins BIM and NOXA, the repression of the pro-survival BCL2-protein BCLXL and the inhibitor-of-apoptosis-protein survivin.3, 4, 5 Expression analysis of these proteins in FOXO3-resistant NB4/FOXO3 and NB8/FOXO3 and FOXO3-sensitive NB15/FOXO3 cells as well as in their corresponding controls revealed that in NB15/FOXO3 cells BIM and NOXA strongly increased5 on protein- and mRNA-level, and BCLXL and survivin were repressed (Figures 2a and b and Supplementary Figure S3).", "section": "RESULTS", "tags": [{"name": "inhibitor-of-apoptosis-protein", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "FOXO3-resistant", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Hyper-activation of the phosphatidylinositol3-kinase/PKB signaling pathway frequently observed in NB is associated with FOXO3-inactivation and its re-localization into the cytoplasm.4, 5, 11, 12, 13 However, in high-stage-derived NB cell lines FOXO3 partly localizes to the nucleus despite high PKB-activity and regulates the response to hypoxia within these cells (Figure 1).14 Activation by etoposide-treatment further increases the amount of nuclear FOXO3 (Figure 1c) suggesting that shuttling and oxidative stress response regulation of FOXO3 is still intact within these cells.", "section": "DISCUSS", "tags": [{"name": "phosphatidylinositol3-kinase/PKB", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "etoposide-treatment", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "One binding partner of FOXO3 is the tumor protein TP53/p53 which is mutated in over 50% of cancer types.20 In NB, however, mutations of TP53 are rare at diagnosis (less than 2% of patients), but frequent loss of function is observed in relapsed tumors.21 FOXO3 and TP53 share numerous target genes such as CDKN1/P21CIP1, GADD45A or BBC3/PUMA; hence, they are involved in the same cellular processes like cell-cycle-arrest, DNA-damage-repair and apoptosis.22, 23, 24, 25", "section": "INTRO", "tags": [{"name": "cell-cycle-arrest,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "DNA-damage-repair", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "The retroviral vectors pLIB-MCS2-iresNeo and pLIB-FOXO3(A3)-ERtm-iresNeo have been described.5 The lentivirus-vector coding for FOXO3-specific shRNA (pLKO-shFOXO3-91617-puro) and SESN3-specific shRNA (pLKO-shSESN3-141228-puro and pLKO-shSESN3-143446-puro) and the control-vector pLKO.1 were described.3 The lentivirus-vectors coding for TP53-specific shRNA pLKO-shTP53-puro, pLKO-shTP53-941-puro and pLKO-shTP53-427-puro were provided by T. Waldmann,52 the pGL3-Bim-promoter was provided by A. Villunger.53 The vector pLIB-EYFP-TP53mut-puro was generated by amplification of mutant-TP53 from NB15 cDNA (p53-fwd: 5\u2032-GAATTCATGGATGATTTGATGC-3\u2032 p53-rev: 5\u2032-GGATCCTCAGTCTGAGTCAG)-3\u2032 and inserted into the EcoR1- and BamH1-site of pLIB-EYFP-Mcl1JAM-iresPuro54 replacing MCL1JAM by the TP53-mutant and generating pLIB-EYFP-p53m-iresPuro.", "section": "OTHER", "tags": [{"name": "5\u2032-GAATTCATGGATGATTTGATGC-3\u2032", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "pLIB-EYFP-Mcl1JAM-iresPuro54", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "The retroviral vectors pLIB-MCS2-iresNeo and pLIB-FOXO3(A3)-ERtm-iresNeo have been described.5 The lentivirus-vector coding for FOXO3-specific shRNA (pLKO-shFOXO3-91617-puro) and SESN3-specific shRNA (pLKO-shSESN3-141228-puro and pLKO-shSESN3-143446-puro) and the control-vector pLKO.1 were described.3 The lentivirus-vectors coding for TP53-specific shRNA pLKO-shTP53-puro, pLKO-shTP53-941-puro and pLKO-shTP53-427-puro were provided by T. Waldmann,52 the pGL3-Bim-promoter was provided by A. Villunger.53 The vector pLIB-EYFP-TP53mut-puro was generated by amplification of mutant-TP53 from NB15 cDNA (p53-fwd: 5\u2032-GAATTCATGGATGATTTGATGC-3\u2032 p53-rev: 5\u2032-GGATCCTCAGTCTGAGTCAG)-3\u2032 and inserted into the EcoR1- and BamH1-site of pLIB-EYFP-Mcl1JAM-iresPuro54 replacing MCL1JAM by the TP53-mutant and generating pLIB-EYFP-p53m-iresPuro.", "section": "OTHER", "tags": [{"name": "5\u2032-GAATTCATGGATGATTTGATGC-3\u2032", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "pLIB-EYFP-Mcl1JAM-iresPuro54", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "We demonstrated previously that BIM-induction by FOXO3 triggers a biphasic ROS-accumulation, which critically regulates cell death-induction by FOXO3-activation and/or by addition of DNA-damaging agents in NB.3, 31 The primary ROS-wave is detected after 12\u2009h post FOXO3-activation, the second, much more pronounced ROS-wave reaches a climax between 36 and 48\u2009h after FOXO3-activation in NB15/FOXO3 cells.3 We therefore investigated, whether FOXO3-resistant NB4/FOXO3 and NB8/FOXO3 cells show comparable ROS-accumulation or whether this ROS-burst is absent in the resistant cell lines.", "section": "RESULTS", "tags": [{"name": "ROS-accumulation,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "FOXO3-activation,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "In NB, FOXO3-induced cell death depends on the induction of the pro-apoptotic BH3-only proteins BIM and NOXA, the repression of the pro-survival BCL2-protein BCLXL and the inhibitor-of-apoptosis-protein survivin.3, 4, 5 Expression analysis of these proteins in FOXO3-resistant NB4/FOXO3 and NB8/FOXO3 and FOXO3-sensitive NB15/FOXO3 cells as well as in their corresponding controls revealed that in NB15/FOXO3 cells BIM and NOXA strongly increased5 on protein- and mRNA-level, and BCLXL and survivin were repressed (Figures 2a and b and Supplementary Figure S3).", "section": "RESULTS", "tags": [{"name": "inhibitor-of-apoptosis-protein", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "FOXO3-resistant", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Protein-kinase-B (PKB) which is frequently hyper-activated in high-stage NB due to aberrant expression of the brain-derived-neurotrophic-factor and its cognate receptor NTRK2/TRKB10 directly phosphorylates FOXO3 causing association with 14-3-3 proteins, nuclear exclusion and transcriptional inactivation of FOXO3 in malignant NB cells.5, 11, 12, 13 We previously demonstrated that in patient biopsies FOXO3 localizes to the nucleus even when phosphorylated at the PKB-site threonine-32.14 Stress conditions, such as chemotherapy, override growth-factor-mediated phosphorylation/inactivation of FOXO3 by PKB, which results in the relocation of FOXO3 to the nucleus.3, 9", "section": "INTRO", "tags": [{"name": "brain-derived-neurotrophic-factor", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "phosphorylation/inactivation", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "We demonstrated previously that BIM-induction by FOXO3 triggers a biphasic ROS-accumulation, which critically regulates cell death-induction by FOXO3-activation and/or by addition of DNA-damaging agents in NB.3, 31 The primary ROS-wave is detected after 12\u2009h post FOXO3-activation, the second, much more pronounced ROS-wave reaches a climax between 36 and 48\u2009h after FOXO3-activation in NB15/FOXO3 cells.3 We therefore investigated, whether FOXO3-resistant NB4/FOXO3 and NB8/FOXO3 cells show comparable ROS-accumulation or whether this ROS-burst is absent in the resistant cell lines.", "section": "RESULTS", "tags": [{"name": "ROS-accumulation,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "FOXO3-activation,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "In NB, FOXO3-induced cell death depends on the induction of the pro-apoptotic BH3-only proteins BIM and NOXA, the repression of the pro-survival BCL2-protein BCLXL and the inhibitor-of-apoptosis-protein survivin.3, 4, 5 Expression analysis of these proteins in FOXO3-resistant NB4/FOXO3 and NB8/FOXO3 and FOXO3-sensitive NB15/FOXO3 cells as well as in their corresponding controls revealed that in NB15/FOXO3 cells BIM and NOXA strongly increased5 on protein- and mRNA-level, and BCLXL and survivin were repressed (Figures 2a and b and Supplementary Figure S3).", "section": "RESULTS", "tags": [{"name": "inhibitor-of-apoptosis-protein", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "FOXO3-resistant", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}]}
{"src": "PMC", "id": "PMC4902368", "provider": "OpenTargets", "anns": [{"type": "Gene Disease Relationship", "exact": "In a subgroup of thymic T-lymphocytes, PD-1 is produced in a way of constitutively expression, with up-regulated expression found in activated T-cells, B-cells, and myeloid cells.9,10 Through interactions between PD-1 and its ligands PD-L1 (B7-H1; CD274) or PD-L2 (B7-DC; CD273), PD-1 strongly inhibits the proliferation of CD4 and CD8 T lymphocytes and their cytokine production.11\u201313 Previous studies have emphasized the significant role of PD-1 in human disease.", "section": "INTRO", "tags": [{"name": "production.11\u201313", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "T-lymphocytes,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Data outlining the clinicopathological characteristics of the patients, including tumor size, clinical stages, lymph node involvement, menopausal status, procreative times, estrogenic receptor (ER) status, progesterone receptor (PR) status, and human epidermal growth factor receptor type 2 (Her-2) status, were obtained from the patients\u2019 medical records (Table 1).", "section": "METHODS", "tags": [{"name": "clinicopathological", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "characteristics", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Previous studies have shown that blocking the PD-1/PD-L1 pathway can result in an efficient antitumor T-cell response and better control of tumor growth.24 Immunotherapy clinical trials using antibody-mediated PD-1 blockade as a strategy are in progress in patients with various cancers.25,26 Patients suffering from melanoma, renal cell carcinoma, or nonsmall cell lung cancer, showed objective responses (responses rates, 6\u201328%), with intravenous injection of these antibodies.", "section": "INTRO", "tags": [{"name": "antibody-mediated", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "Immunotherapy", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Data outlining the clinicopathological characteristics of the patients, including tumor size, clinical stages, lymph node involvement, menopausal status, procreative times, estrogenic receptor (ER) status, progesterone receptor (PR) status, and human epidermal growth factor receptor type 2 (Her-2) status, were obtained from the patients\u2019 medical records (Table 1).", "section": "METHODS", "tags": [{"name": "clinicopathological", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "characteristics", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "These results conflict with studies in hepatocellular carcinoma29 and esophageal cancer.30 These studies also found that the G allele of this SNP was likely to be associated with the decreased risk of hepatocellular carcinoma and esophageal squamous cell carcinoma, suggesting that the PD-1 rs10204525 G allele may be related to the increase in T-cell activity.", "section": "DISCUSS", "tags": [{"name": "hepatocellular", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "hepatocellular", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "In a subgroup of thymic T-lymphocytes, PD-1 is produced in a way of constitutively expression, with up-regulated expression found in activated T-cells, B-cells, and myeloid cells.9,10 Through interactions between PD-1 and its ligands PD-L1 (B7-H1; CD274) or PD-L2 (B7-DC; CD273), PD-1 strongly inhibits the proliferation of CD4 and CD8 T lymphocytes and their cytokine production.11\u201313 Previous studies have emphasized the significant role of PD-1 in human disease.", "section": "INTRO", "tags": [{"name": "production.11\u201313", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "T-lymphocytes,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}]}
{"src": "PMC", "id": "PMC4766352", "provider": "OpenTargets", "anns": [{"type": "Gene Disease Relationship", "exact": "PCR products were purified on spin columns (Watson Biotechnologies Inc., Shanghai, China) and directly sequenced by the PCR or sequencing primers described above using the BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems) performed on a 3730 DNA analyzer according to the manufacturer's manual.", "section": "METHODS", "tags": [{"name": "Biotechnologies", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "manufacturer's", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Forty-eight hours after transfection, HeLa cells in the 6-well plates were washed twice with phosphate-buffered saline (PBS) and scraped into 200\u2009\u03bcL/well of lysis buffer [150\u2009mM NaCl, 50\u2009mM Tris-HCl (pH 7.5), 1% NP40, 0.25% sodium deoxycholate, and 1\u2009mM EDTA with one tablet of protease inhibitor cocktail tablet (Complete Mini, Roche) per 10\u2009mL], sonicated for 2-3\u2009s, and then centrifuged.", "section": "METHODS", "tags": [{"name": "phosphate-buffered", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "transfection,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Interestingly, threonine (T130) residue is located within two putative protein kinase C phosphorylation sites (PKC phosphorylation sites, 129\u2013131: STR and 130\u2013132: TRR), while the isoleucine (I130) mutation would only allow one of these PKC phosphorylation sites (129\u2013131: SIR) to be retained.", "section": "DISCUSS", "tags": [{"name": "phosphorylation", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "phosphorylation", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "PCR products were purified on spin columns (Watson Biotechnologies Inc., Shanghai, China) and directly sequenced by the PCR or sequencing primers described above using the BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems) performed on a 3730 DNA analyzer according to the manufacturer's manual.", "section": "METHODS", "tags": [{"name": "Biotechnologies", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "manufacturer's", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "PCR products were purified on spin columns (Watson Biotechnologies Inc., Shanghai, China) and directly sequenced by the PCR or sequencing primers described above using the BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems) performed on a 3730 DNA analyzer according to the manufacturer's manual.", "section": "METHODS", "tags": [{"name": "Biotechnologies", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "manufacturer's", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "PCR products were purified on spin columns (Watson Biotechnologies Inc., Shanghai, China) and directly sequenced by the PCR or sequencing primers described above using the BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems) performed on a 3730 DNA analyzer according to the manufacturer's manual.", "section": "METHODS", "tags": [{"name": "Biotechnologies", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "manufacturer's", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}]}
{"src": "PMC", "id": "PMC4735314", "provider": "OpenTargets", "anns": [{"type": "Gene Disease Relationship", "exact": "Previous studies have shown that exercise lowers IL-6 serum levels only in IL-6 -174 C allele carriers.23 Similarly, exercise and lifestyle interventions have been documented to increase HDL levels significantly more in the IL-6 -174 C allele carriers than in the G allele carriers.25\n26 In line with these studies, our results suggest that the HDL levels are more prone to decrease by H. pylori infection in the IL-6 -174 C carriers than in the other genotypes.", "section": "DISCUSS", "tags": [{"name": "interventions", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "significantly", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "The association between H. pylori infection and low HDL has been demonstrated previously in several studies.1\n3\n5\n6\n9\u201315\nH. pylori eradication has also been documented to increase serum HDL levels.7\n8\n13\n40\n41 On the basis of our results, we hypothesise that the benefits of eradication, especially considering HDL levels, could be more prominent in the IL-6 -174 CC genotype patients than in the patients of other IL-6 -174 genotypes.", "section": "DISCUSS", "tags": [{"name": "demonstrated", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "eradication,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "On the basis of our current findings, which indicate that the IL-6 -174 polymorphism modifies systemic effects induced by changes in the composition of gastric bacteria, we suggest that IL-6 polymorphisms should be investigated as a possible mechanism explaining associations between intestinal microbiome and the cardiovascular disease risk factors.", "section": "DISCUSS", "tags": [{"name": "cardiovascular", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "polymorphisms", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "On the basis of the sample size and the specified significance and power levels, we conclude that the association of H. pylori infection on the HDL serum level is notable in the IL-6 -174 CC genotype patients, but in the other genotypes, especially in the GG genotype, the association is smaller and possibly clinically insignificant.", "section": "DISCUSS", "tags": [{"name": "insignificant.", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "significance", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "H. pylori infection and peptic ulcers have been associated with increased IL-6 expression18\n36 and high IL-6 serum levels have been associated with low HDL serum levels.37 IL-6 has been documented to reduce the activity of lipoprotein lipase38 and decreased lipoprotein lipase activity has been associated with a decrease in HDL,39 which offers a possible mechanism for the interaction between IL-6 and HDL.", "section": "DISCUSS", "tags": [{"name": "expression18", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "lipoprotein", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Recent observations have suggested that improvement of diet by whole grain supplement may induce concurrent intestinal microbiota changes, decreased IL-6 levels and associate with changes indicating improvement of metabolic function.42 These results suggest a role for IL-6 in systemic responses caused by dietary changes and their associated changes in the commensal mucosal flora.", "section": "DISCUSS", "tags": [{"name": "observations", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "improvement", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "The IL-6 -174 genotype frequencies did not associate with the Sydney system-based variables of histopathological findings.30 The HDL serum levels showed strong negative correlations with the antrum mononuclear cell score (r=\u22120.579), antrum neutrophil score (r=\u22120.636), antrum H. pylori score (r=\u22120.525), body mononuclear cell score (r=\u22120.685), body neutrophil score (r=\u22120.494) and body H. pylori score (r=\u22120.585; all p values<0.001) in the IL-6 -174 CC genotype patients but not in the GG or GC patients.", "section": "RESULTS", "tags": [{"name": "histopathological", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "values<0.001)", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "The association between H. pylori infection and low HDL has been demonstrated previously in several studies.1\n3\n5\n6\n9\u201315\nH. pylori eradication has also been documented to increase serum HDL levels.7\n8\n13\n40\n41 On the basis of our results, we hypothesise that the benefits of eradication, especially considering HDL levels, could be more prominent in the IL-6 -174 CC genotype patients than in the patients of other IL-6 -174 genotypes.", "section": "DISCUSS", "tags": [{"name": "demonstrated", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "eradication,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "We also did not have data on the use of statin medication, but statin use was not common in Finland during the study period.35 Since there are no clear reasons, why the use of statins would be enriched in H. pylori negative patients, who had higher HDL levels, it is unlikely that the use of statin medication confounds our results.", "section": "DISCUSS", "tags": [{"name": "medication,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "medication", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "On the basis of our current findings, which indicate that the IL-6 -174 polymorphism modifies systemic effects induced by changes in the composition of gastric bacteria, we suggest that IL-6 polymorphisms should be investigated as a possible mechanism explaining associations between intestinal microbiome and the cardiovascular disease risk factors.", "section": "DISCUSS", "tags": [{"name": "cardiovascular", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "polymorphisms", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "The association between H. pylori infection and low HDL has been demonstrated previously in several studies.1\n3\n5\n6\n9\u201315\nH. pylori eradication has also been documented to increase serum HDL levels.7\n8\n13\n40\n41 On the basis of our results, we hypothesise that the benefits of eradication, especially considering HDL levels, could be more prominent in the IL-6 -174 CC genotype patients than in the patients of other IL-6 -174 genotypes.", "section": "DISCUSS", "tags": [{"name": "demonstrated", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "eradication,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Recent observations have suggested that improvement of diet by whole grain supplement may induce concurrent intestinal microbiota changes, decreased IL-6 levels and associate with changes indicating improvement of metabolic function.42 These results suggest a role for IL-6 in systemic responses caused by dietary changes and their associated changes in the commensal mucosal flora.", "section": "DISCUSS", "tags": [{"name": "observations", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "improvement", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "We also did not have data on the use of statin medication, but statin use was not common in Finland during the study period.35 Since there are no clear reasons, why the use of statins would be enriched in H. pylori negative patients, who had higher HDL levels, it is unlikely that the use of statin medication confounds our results.", "section": "DISCUSS", "tags": [{"name": "medication,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "medication", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Previous studies have shown that exercise lowers IL-6 serum levels only in IL-6 -174 C allele carriers.23 Similarly, exercise and lifestyle interventions have been documented to increase HDL levels significantly more in the IL-6 -174 C allele carriers than in the G allele carriers.25\n26 In line with these studies, our results suggest that the HDL levels are more prone to decrease by H. pylori infection in the IL-6 -174 C carriers than in the other genotypes.", "section": "DISCUSS", "tags": [{"name": "interventions", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "significantly", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "On the basis of the sample size and the specified significance and power levels, we conclude that the association of H. pylori infection on the HDL serum level is notable in the IL-6 -174 CC genotype patients, but in the other genotypes, especially in the GG genotype, the association is smaller and possibly clinically insignificant.", "section": "DISCUSS", "tags": [{"name": "insignificant.", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "significance", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "The cut-off point of <1.00\u2005mmol/L for low HDL was chosen because it is a common cut-off point in Finnish guidelines.32 The patients\u2019 DNA was extracted from blood leucocytes as previously described.29 The restriction fragment length polymorphism method with an NlaIII restriction enzyme using previously published primers20 was used to detect the IL-6 -174 gene polymorphisms from the DNA samples.", "section": "METHODS", "tags": [{"name": "guidelines.32", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "polymorphisms", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "H. pylori infection causes a varied cytokine response including the release of interleukin 6.18 High IL-6 serum levels have been connected to changes in lipid metabolism and to coronary heart disease.19 A polymorphic allele, guanine/cytosine (G/C), at the IL-6 gene promoter at location -174 in the 5\u2019 flanking region (rs1800795) has been previously associated with higher IL-6 serum levels20 and the effect has also been documented in Finnish populations.21 The relationship between IL-6 -174 polymorphisms and IL-6 serum levels seems to vary in different participant groups22 and to be modified by external factors such as exercise.23 The IL-6 -174 polymorphism has also been associated with lipid abnormalities24 and serum lipid changes during lifestyle interventions.25\n26 IL-6 -174 has also been associated with the risk of coronary heart disease, but this association seems to vary between different participant groups.27\n28", "section": "INTRO", "tags": [{"name": "guanine/cytosine", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "interventions.25", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "H. pylori infection and peptic ulcers have been associated with increased IL-6 expression18\n36 and high IL-6 serum levels have been associated with low HDL serum levels.37 IL-6 has been documented to reduce the activity of lipoprotein lipase38 and decreased lipoprotein lipase activity has been associated with a decrease in HDL,39 which offers a possible mechanism for the interaction between IL-6 and HDL.", "section": "DISCUSS", "tags": [{"name": "expression18", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "lipoprotein", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "The IL-6 -174 genotype frequencies did not associate with the Sydney system-based variables of histopathological findings.30 The HDL serum levels showed strong negative correlations with the antrum mononuclear cell score (r=\u22120.579), antrum neutrophil score (r=\u22120.636), antrum H. pylori score (r=\u22120.525), body mononuclear cell score (r=\u22120.685), body neutrophil score (r=\u22120.494) and body H. pylori score (r=\u22120.585; all p values<0.001) in the IL-6 -174 CC genotype patients but not in the GG or GC patients.", "section": "RESULTS", "tags": [{"name": "histopathological", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "values<0.001)", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}]}
{"src": "PMC", "id": "PMC4713070", "provider": "OpenTargets", "anns": [{"type": "Gene Disease Relationship", "exact": "Third, the multiplex SNaPshot sequencing reactions were carried out in a final volume of 7 \u03bcl containing 2 \u03bcl of purified multiple PCR products, 1 \u03bcl SNaPshot Multiplex Mix, 1 \u03bcl 5\u00d7Sequencing buffer (Applied Biosystems) and 3 \u03bcl SNaPshot sequencing primers (the final concentrations are listed in Table 2).", "section": "METHODS", "tags": [{"name": "concentrations", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "5\u00d7Sequencing", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Immunohistochemical staining of Lewis a indicated increased expression in the cryptic epithelium of inflammatory lesions in UC patients than the normal mucosa of patients with benign colonic polyps (P = 0.028), although there was no difference of Lewis a expression in surface epithelium between the two groups.", "section": "RESULTS", "tags": [{"name": "Immunohistochemical", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "inflammatory", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "In recent years, several studies have linked several nucleotide polymorphisms in FUT2 to intestinal microbiota composition [21] and predisposition to CD [22, 23], celiac disease [24], type 1 diabetes [25] and primary sclerosing cholangitis [26], highlighting the essential role of host gene-microbiota interaction in autoimmune diseases.", "section": "INTRO", "tags": [{"name": "gene-microbiota", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "predisposition", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Immunohistochemical staining of Lewis a indicated increased expression in the cryptic epithelium of inflammatory lesions in UC patients than the normal mucosa of patients with benign colonic polyps (P = 0.028), although there was no difference of Lewis a expression in surface epithelium between the two groups.", "section": "RESULTS", "tags": [{"name": "Immunohistochemical", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "inflammatory", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "However, in a Finnish population the wild GG genotype of FUT2 (rs601338) was associated with enhanced risk of UC [24]. And in a Chinese Han population mutations in FUT2 (rs281377 and rs601338) predisposed patients to UC, while FUT2 (rs1047781 and rs601338) polymorphisms were associated with UC in Uyghur population from northwest China [37].", "section": "DISCUSS", "tags": [{"name": "polymorphisms", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "predisposed", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "First, 10 ng of genomic DNA was added to a 10 \u03bcl PCR mixture containing 20 \u03bcmol dNTPs (Promega, Wisconsin, USA), 0.5 U FastStart Taq DNA polymerase (Roche, Basel, Switzerland), 1\u03bcl 10\u00d7PCR buffer with MgCl2 (15 mmol/L) (Roche, Basel, Switzerland) and amplification primers with a specific final concentration (Table 2).", "section": "METHODS", "tags": [{"name": "Switzerland),", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "amplification", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Third, the multiplex SNaPshot sequencing reactions were carried out in a final volume of 7 \u03bcl containing 2 \u03bcl of purified multiple PCR products, 1 \u03bcl SNaPshot Multiplex Mix, 1 \u03bcl 5\u00d7Sequencing buffer (Applied Biosystems) and 3 \u03bcl SNaPshot sequencing primers (the final concentrations are listed in Table 2).", "section": "METHODS", "tags": [{"name": "concentrations", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "5\u00d7Sequencing", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Immunohistochemical staining of Lewis a indicated increased expression in the cryptic epithelium of inflammatory lesions in UC patients than the normal mucosa of patients with benign colonic polyps (P = 0.028), although there was no difference of Lewis a expression in surface epithelium between the two groups.", "section": "RESULTS", "tags": [{"name": "Immunohistochemical", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "inflammatory", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Two LD blocks were presented as follows: block rs281377-rs1047781 in FUT2 (D' = 0.96, r2 = 0.11) and block rs3894326-rs3745635-rs28362459 in FUT3 [rs3894326/rs3745635 (D' = 1, r2 = 0.01), rs3894326/rs28362459 (D' = 0.86, r2 = 0.23), rs3745635/rs28362459 (D' = 0.92, r2 = 0.47)] (Fig 1).", "section": "METHODS", "tags": [{"name": "rs3894326-rs3745635-rs28362459", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "[rs3894326/rs3745635", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "First, 10 ng of genomic DNA was added to a 10 \u03bcl PCR mixture containing 20 \u03bcmol dNTPs (Promega, Wisconsin, USA), 0.5 U FastStart Taq DNA polymerase (Roche, Basel, Switzerland), 1\u03bcl 10\u00d7PCR buffer with MgCl2 (15 mmol/L) (Roche, Basel, Switzerland) and amplification primers with a specific final concentration (Table 2).", "section": "METHODS", "tags": [{"name": "Switzerland),", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "amplification", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Third, the multiplex SNaPshot sequencing reactions were carried out in a final volume of 7 \u03bcl containing 2 \u03bcl of purified multiple PCR products, 1 \u03bcl SNaPshot Multiplex Mix, 1 \u03bcl 5\u00d7Sequencing buffer (Applied Biosystems) and 3 \u03bcl SNaPshot sequencing primers (the final concentrations are listed in Table 2).", "section": "METHODS", "tags": [{"name": "concentrations", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "5\u00d7Sequencing", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "First, 10 ng of genomic DNA was added to a 10 \u03bcl PCR mixture containing 20 \u03bcmol dNTPs (Promega, Wisconsin, USA), 0.5 U FastStart Taq DNA polymerase (Roche, Basel, Switzerland), 1\u03bcl 10\u00d7PCR buffer with MgCl2 (15 mmol/L) (Roche, Basel, Switzerland) and amplification primers with a specific final concentration (Table 2).", "section": "METHODS", "tags": [{"name": "Switzerland),", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "amplification", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Two LD blocks were presented as follows: block rs281377-rs1047781 in FUT2 (D' = 0.96, r2 = 0.11) and block rs3894326-rs3745635-rs28362459 in FUT3 [rs3894326/rs3745635 (D' = 1, r2 = 0.01), rs3894326/rs28362459 (D' = 0.86, r2 = 0.23), rs3745635/rs28362459 (D' = 0.92, r2 = 0.47)] (Fig 1).", "section": "METHODS", "tags": [{"name": "rs3894326-rs3745635-rs28362459", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "[rs3894326/rs3745635", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Third, the multiplex SNaPshot sequencing reactions were carried out in a final volume of 7 \u03bcl containing 2 \u03bcl of purified multiple PCR products, 1 \u03bcl SNaPshot Multiplex Mix, 1 \u03bcl 5\u00d7Sequencing buffer (Applied Biosystems) and 3 \u03bcl SNaPshot sequencing primers (the final concentrations are listed in Table 2).", "section": "METHODS", "tags": [{"name": "concentrations", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "5\u00d7Sequencing", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Immunohistochemical staining of Lewis a indicated increased expression in the cryptic epithelium of inflammatory lesions in UC patients than the normal mucosa of patients with benign colonic polyps (P = 0.028), although there was no difference of Lewis a expression in surface epithelium between the two groups.", "section": "RESULTS", "tags": [{"name": "Immunohistochemical", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "inflammatory", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "In recent years, several studies have linked several nucleotide polymorphisms in FUT2 to intestinal microbiota composition [21] and predisposition to CD [22, 23], celiac disease [24], type 1 diabetes [25] and primary sclerosing cholangitis [26], highlighting the essential role of host gene-microbiota interaction in autoimmune diseases.", "section": "INTRO", "tags": [{"name": "gene-microbiota", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "predisposition", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "However, in a Finnish population the wild GG genotype of FUT2 (rs601338) was associated with enhanced risk of UC [24]. And in a Chinese Han population mutations in FUT2 (rs281377 and rs601338) predisposed patients to UC, while FUT2 (rs1047781 and rs601338) polymorphisms were associated with UC in Uyghur population from northwest China [37].", "section": "DISCUSS", "tags": [{"name": "polymorphisms", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "predisposed", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Two LD blocks were presented as follows: block rs281377-rs1047781 in FUT2 (D' = 0.96, r2 = 0.11) and block rs3894326-rs3745635-rs28362459 in FUT3 [rs3894326/rs3745635 (D' = 1, r2 = 0.01), rs3894326/rs28362459 (D' = 0.86, r2 = 0.23), rs3745635/rs28362459 (D' = 0.92, r2 = 0.47)] (Fig 1).", "section": "METHODS", "tags": [{"name": "rs3894326-rs3745635-rs28362459", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "[rs3894326/rs3745635", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Third, the multiplex SNaPshot sequencing reactions were carried out in a final volume of 7 \u03bcl containing 2 \u03bcl of purified multiple PCR products, 1 \u03bcl SNaPshot Multiplex Mix, 1 \u03bcl 5\u00d7Sequencing buffer (Applied Biosystems) and 3 \u03bcl SNaPshot sequencing primers (the final concentrations are listed in Table 2).", "section": "METHODS", "tags": [{"name": "concentrations", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "5\u00d7Sequencing", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Immunohistochemical staining of Lewis a indicated increased expression in the cryptic epithelium of inflammatory lesions in UC patients than the normal mucosa of patients with benign colonic polyps (P = 0.028), although there was no difference of Lewis a expression in surface epithelium between the two groups.", "section": "RESULTS", "tags": [{"name": "Immunohistochemical", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "inflammatory", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "However, in a Finnish population the wild GG genotype of FUT2 (rs601338) was associated with enhanced risk of UC [24]. And in a Chinese Han population mutations in FUT2 (rs281377 and rs601338) predisposed patients to UC, while FUT2 (rs1047781 and rs601338) polymorphisms were associated with UC in Uyghur population from northwest China [37].", "section": "DISCUSS", "tags": [{"name": "polymorphisms", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "predisposed", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "First, 10 ng of genomic DNA was added to a 10 \u03bcl PCR mixture containing 20 \u03bcmol dNTPs (Promega, Wisconsin, USA), 0.5 U FastStart Taq DNA polymerase (Roche, Basel, Switzerland), 1\u03bcl 10\u00d7PCR buffer with MgCl2 (15 mmol/L) (Roche, Basel, Switzerland) and amplification primers with a specific final concentration (Table 2).", "section": "METHODS", "tags": [{"name": "Switzerland),", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "amplification", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "First, 10 ng of genomic DNA was added to a 10 \u03bcl PCR mixture containing 20 \u03bcmol dNTPs (Promega, Wisconsin, USA), 0.5 U FastStart Taq DNA polymerase (Roche, Basel, Switzerland), 1\u03bcl 10\u00d7PCR buffer with MgCl2 (15 mmol/L) (Roche, Basel, Switzerland) and amplification primers with a specific final concentration (Table 2).", "section": "METHODS", "tags": [{"name": "Switzerland),", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "amplification", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "In recent years, several studies have linked several nucleotide polymorphisms in FUT2 to intestinal microbiota composition [21] and predisposition to CD [22, 23], celiac disease [24], type 1 diabetes [25] and primary sclerosing cholangitis [26], highlighting the essential role of host gene-microbiota interaction in autoimmune diseases.", "section": "INTRO", "tags": [{"name": "gene-microbiota", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "predisposition", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Third, the multiplex SNaPshot sequencing reactions were carried out in a final volume of 7 \u03bcl containing 2 \u03bcl of purified multiple PCR products, 1 \u03bcl SNaPshot Multiplex Mix, 1 \u03bcl 5\u00d7Sequencing buffer (Applied Biosystems) and 3 \u03bcl SNaPshot sequencing primers (the final concentrations are listed in Table 2).", "section": "METHODS", "tags": [{"name": "concentrations", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "5\u00d7Sequencing", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}]}
{"src": "PMC", "id": "PMC4682834", "provider": "OpenTargets", "anns": [{"type": "Gene Disease Relationship", "exact": "Concerning age at presentation, our results indicate that many patients who are not in the age groups at greatest risk of death or who have no comorbidities associated with an increased risk of death from influenza may have genetic characteristics that make them more susceptible to developing influenza and presenting with greater disease severity.", "section": "DISCUSS", "tags": [{"name": "characteristics", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "presentation,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "When the pA/H1N1 group was compared with the AHC group, we observed that the LTA rs909253 TC heterozygous genotype showed a risk association with disease susceptibility (p = 0.003; OR = 1.9, 95% CI: 1.25\u20132.87); a similar association occurred with the IL1B rs3136558 CC genotype (p = 0.041; OR = 1.89, 95% CI: 1.02\u20133.51).", "section": "RESULTS", "tags": [{"name": "susceptibility", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "heterozygous", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "In a 2013 study by Chiaretti et al., influenza A (H1N1) virus infection was shown to induce the early and significant up-regulation of IL-1\u03b2 and IL-6 in plasma, suggesting that these cytokines are responsible for different molecular reactions that lead to inflammation of the airway and increased disease severity [32].", "section": "DISCUSS", "tags": [{"name": "up-regulation", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "inflammation", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "One major limitation of this study was that samples were only collected in the central region of the country where mortality was higher; therefore, we believe that expanding the sampling area to other geographical regions would enable us to clearly identify areas with greater \"genetic vulnerability\" to be able to overcome future challenges of potentially lethal subtypes of influenza.", "section": "DISCUSS", "tags": [{"name": "vulnerability\"", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "geographical", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Ten cytokines (GM-CSF, TNF-\u03b1, IL-2, IL-1\u03b2, IL-6, IL-8, IFN-\u03b3, IL-10, IL-5, and IL-4) were measured on a Luminex 100 (Luminex Corporation, Austin, TX, USA) using a multiplex cytokine kit as well as the Cytokine Human 10-Plex Panel (Novex, Life Technologies, CA, USA) in accordance with the manufacturer's instructions.", "section": "METHODS", "tags": [{"name": "manufacturer's", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "Technologies,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "In this study, we included a greater number of patients from the fourth wave of virus infection and aimed to establish the association between polymorphisms in inflammation-related genes (TNF, IL6, IL8, IL1B, LTA, CCL1) and disease development, severity and death from influenza A (H1N1) virus infection in patients from the central region of Mexico.", "section": "INTRO", "tags": [{"name": "inflammation-related", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "polymorphisms", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "This study was reviewed and approved by both the Bioethics Committee and Science Committee in Research, with protocol number B05-10 at INER (National Institute of Respiratory Diseases Ismael Cosio Villegas) and Institutional Review Board No. 13CI 09015 213 at IMSS (Mexican Institute of Social Security) authorized by COFEPRIS/SSA.", "section": "METHODS", "tags": [{"name": "Institutional", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "COFEPRIS/SSA.", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "This study was reviewed and approved by both the Bioethics Committee and Science Committee in Research, with protocol number B05-10 at INER (National Institute of Respiratory Diseases Ismael Cosio Villegas) and Institutional Review Board No. 13CI 09015 213 at IMSS (Mexican Institute of Social Security) authorized by COFEPRIS/SSA.", "section": "METHODS", "tags": [{"name": "Institutional", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "COFEPRIS/SSA.", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Concerning age at presentation, our results indicate that many patients who are not in the age groups at greatest risk of death or who have no comorbidities associated with an increased risk of death from influenza may have genetic characteristics that make them more susceptible to developing influenza and presenting with greater disease severity.", "section": "DISCUSS", "tags": [{"name": "characteristics", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "presentation,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "The greatest number of deaths from influenza A (H1N1) pdm09 occurred in the central region of the country where healthcare systems are better than in the rest of the country and where access to healthcare services is greater because of better transportation routes and the presence of hospitals that provide care to patients with severe illnesses.", "section": "INTRO", "tags": [{"name": "transportation", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "healthcare", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "In this study, we included a greater number of patients from the fourth wave of virus infection and aimed to establish the association between polymorphisms in inflammation-related genes (TNF, IL6, IL8, IL1B, LTA, CCL1) and disease development, severity and death from influenza A (H1N1) virus infection in patients from the central region of Mexico.", "section": "INTRO", "tags": [{"name": "inflammation-related", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "polymorphisms", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Ten cytokines (GM-CSF, TNF-\u03b1, IL-2, IL-1\u03b2, IL-6, IL-8, IFN-\u03b3, IL-10, IL-5, and IL-4) were measured on a Luminex 100 (Luminex Corporation, Austin, TX, USA) using a multiplex cytokine kit as well as the Cytokine Human 10-Plex Panel (Novex, Life Technologies, CA, USA) in accordance with the manufacturer's instructions.", "section": "METHODS", "tags": [{"name": "manufacturer's", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "Technologies,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "In a 2013 study by Chiaretti et al., influenza A (H1N1) virus infection was shown to induce the early and significant up-regulation of IL-1\u03b2 and IL-6 in plasma, suggesting that these cytokines are responsible for different molecular reactions that lead to inflammation of the airway and increased disease severity [32].", "section": "DISCUSS", "tags": [{"name": "up-regulation", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "inflammation", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "One major limitation of this study was that samples were only collected in the central region of the country where mortality was higher; therefore, we believe that expanding the sampling area to other geographical regions would enable us to clearly identify areas with greater \"genetic vulnerability\" to be able to overcome future challenges of potentially lethal subtypes of influenza.", "section": "DISCUSS", "tags": [{"name": "vulnerability\"", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "geographical", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "When the pA/H1N1 group was compared with the AHC group, we observed that the LTA rs909253 TC heterozygous genotype showed a risk association with disease susceptibility (p = 0.003; OR = 1.9, 95% CI: 1.25\u20132.87); a similar association occurred with the IL1B rs3136558 CC genotype (p = 0.041; OR = 1.89, 95% CI: 1.02\u20133.51).", "section": "RESULTS", "tags": [{"name": "susceptibility", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "heterozygous", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "One major limitation of this study was that samples were only collected in the central region of the country where mortality was higher; therefore, we believe that expanding the sampling area to other geographical regions would enable us to clearly identify areas with greater \"genetic vulnerability\" to be able to overcome future challenges of potentially lethal subtypes of influenza.", "section": "DISCUSS", "tags": [{"name": "vulnerability\"", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "geographical", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}]}
{"src": "PMC", "id": "PMC4690073", "provider": "OpenTargets", "anns": [{"type": "Gene Disease Relationship", "exact": "Respiratory allergy was defined as a positive skin prick test to an inhalant allergen, in combination with two or more of the following criteria: wheeze in the past year, doctor\u2019s diagnosed asthma, asthma inhalation treatment, or a positive answer to the question: \u201cHave you had any signs of pollen allergy or allergy to furry pets during the last 12 months?\u201d.", "section": "METHODS", "tags": [{"name": "Respiratory", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "combination", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Respiratory allergy was defined as a positive skin prick test to an inhalant allergen, in combination with two or more of the following criteria: wheeze in the past year, doctor\u2019s diagnosed asthma, asthma inhalation treatment, or a positive answer to the question: \u201cHave you had any signs of pollen allergy or allergy to furry pets during the last 12 months?\u201d.", "section": "METHODS", "tags": [{"name": "Respiratory", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "combination", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "The power of this study may be limited by the relative small population size, however, the prospective birth cohort design allowed us to select very clear cases with only one allergic manifestations as well as non-allergic controls that had not been sensitized nor had any allergic symptoms in any of the follow-ups at 1, 4, 7, or 13 years of age.", "section": "DISCUSS", "tags": [{"name": "manifestations", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "non-allergic", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "1 All subjects that were invited to take part in the follow up at 13 years of age; 2 Subjects that were selected for blood sampling at 13 years of age and approved participation in genetic analyses; 3 No allergy and no sensitization at any of the follow-ups (1, 4, 7, and 13 years of age); 4 Atopic eczema was defined as a pruritic, chronic, or chronically relapsing non-infectious dermatitis with typical features and distribution, fulfilling three of the main criteria suggested by Hanifin and Rajka 6; 5 Respiratory allergy was defined as a positive skin prick test to an inhalant allergen, in combination with two or more of the following criteria: wheeze in the past year, doctor\u2019s diagnosed asthma, asthma inhalation treatment, or a positive answer to the question: \u201cHave you had any signs of pollen allergy or allergy to furry pets during the last 12 months?\u201d; 6 Data obtained from the Swedish Medical Birth Register kept by The Swedish National Board of Health and Welfare (Stockholm, Sweden).", "section": "METHODS", "tags": [{"name": "non-infectious", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "participation", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Based on the questionnaires and sensitization tests at 13 years of age, the subjects were divided into three diagnostic groups: (1) atopic eczema with no other allergic manifestations, in all, 79 adolescents out of the 788 fulfilled these criteria; (2) respiratory allergy with no other allergic manifestations, all of whom were also sensitized to airborne allergens, in all, 130 adolescents in the cohort fulfilled these criteria and (3) no allergy and no sensitization at any of the follow-ups (1, 4, 7 and 13 years of age), in all, 331 adolescents in the cohort fulfilled these criteria.", "section": "METHODS", "tags": [{"name": "manifestations,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "manifestations,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "However, as expected, the significance of rs102275 and rs174448 with atopic eczema disappeared when any of the five fatty acids that are associated with eczema as well as the SNP are added to the logistic model, suggesting that the association between the minor FADS allele and protection from atopic eczema development acts via a reduced capacity to elongate precursor n-6 PUFAs to arachidonic acid (20:4 n-6).", "section": "DISCUSS", "tags": [{"name": "significance", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "disappeared", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "For each gene separately and for three separate outcome groups\u201415 phospholipid variables in cord serum and in adolescent serum and also for the two diagnosis atopic eczema and respiratory allergy\u2014100 000 permutations were carried out to get an empirical null distribution of the minP (minimum p-value) statistic from which the corrected p-values could be estimated Two-tailed p \u2264 0.05 was considered significant [41].", "section": "METHODS", "tags": [{"name": "phospholipid", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "permutations", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "1 All subjects that were invited to take part in the follow up at 13 years of age; 2 Subjects that were selected for blood sampling at 13 years of age and approved participation in genetic analyses; 3 No allergy and no sensitization at any of the follow-ups (1, 4, 7, and 13 years of age); 4 Atopic eczema was defined as a pruritic, chronic, or chronically relapsing non-infectious dermatitis with typical features and distribution, fulfilling three of the main criteria suggested by Hanifin and Rajka 6; 5 Respiratory allergy was defined as a positive skin prick test to an inhalant allergen, in combination with two or more of the following criteria: wheeze in the past year, doctor\u2019s diagnosed asthma, asthma inhalation treatment, or a positive answer to the question: \u201cHave you had any signs of pollen allergy or allergy to furry pets during the last 12 months?\u201d; 6 Data obtained from the Swedish Medical Birth Register kept by The Swedish National Board of Health and Welfare (Stockholm, Sweden).", "section": "METHODS", "tags": [{"name": "non-infectious", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "participation", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "For each gene separately and for three separate outcome groups\u201415 phospholipid variables in cord serum and in adolescent serum and also for the two diagnosis atopic eczema and respiratory allergy\u2014100 000 permutations were carried out to get an empirical null distribution of the minP (minimum p-value) statistic from which the corrected p-values could be estimated Two-tailed p \u2264 0.05 was considered significant [41].", "section": "METHODS", "tags": [{"name": "phospholipid", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "permutations", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Based on the questionnaires and sensitization tests at 13 years of age, the subjects were divided into three diagnostic groups: (1) atopic eczema with no other allergic manifestations, in all, 79 adolescents out of the 788 fulfilled these criteria; (2) respiratory allergy with no other allergic manifestations, all of whom were also sensitized to airborne allergens, in all, 130 adolescents in the cohort fulfilled these criteria and (3) no allergy and no sensitization at any of the follow-ups (1, 4, 7 and 13 years of age), in all, 331 adolescents in the cohort fulfilled these criteria.", "section": "METHODS", "tags": [{"name": "manifestations,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "manifestations,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "1 All subjects that were invited to take part in the follow up at 13 years of age; 2 Subjects that were selected for blood sampling at 13 years of age and approved participation in genetic analyses; 3 No allergy and no sensitization at any of the follow-ups (1, 4, 7, and 13 years of age); 4 Atopic eczema was defined as a pruritic, chronic, or chronically relapsing non-infectious dermatitis with typical features and distribution, fulfilling three of the main criteria suggested by Hanifin and Rajka 6; 5 Respiratory allergy was defined as a positive skin prick test to an inhalant allergen, in combination with two or more of the following criteria: wheeze in the past year, doctor\u2019s diagnosed asthma, asthma inhalation treatment, or a positive answer to the question: \u201cHave you had any signs of pollen allergy or allergy to furry pets during the last 12 months?\u201d; 6 Data obtained from the Swedish Medical Birth Register kept by The Swedish National Board of Health and Welfare (Stockholm, Sweden).", "section": "METHODS", "tags": [{"name": "non-infectious", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "participation", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Respiratory allergy was defined as a positive skin prick test to an inhalant allergen, in combination with two or more of the following criteria: wheeze in the past year, doctor\u2019s diagnosed asthma, asthma inhalation treatment, or a positive answer to the question: \u201cHave you had any signs of pollen allergy or allergy to furry pets during the last 12 months?\u201d.", "section": "METHODS", "tags": [{"name": "Respiratory", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "combination", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "1 All subjects that were invited to take part in the follow up at 13 years of age; 2 Subjects that were selected for blood sampling at 13 years of age and approved participation in genetic analyses; 3 No allergy and no sensitization at any of the follow-ups (1, 4, 7, and 13 years of age); 4 Atopic eczema was defined as a pruritic, chronic, or chronically relapsing non-infectious dermatitis with typical features and distribution, fulfilling three of the main criteria suggested by Hanifin and Rajka 6; 5 Respiratory allergy was defined as a positive skin prick test to an inhalant allergen, in combination with two or more of the following criteria: wheeze in the past year, doctor\u2019s diagnosed asthma, asthma inhalation treatment, or a positive answer to the question: \u201cHave you had any signs of pollen allergy or allergy to furry pets during the last 12 months?\u201d; 6 Data obtained from the Swedish Medical Birth Register kept by The Swedish National Board of Health and Welfare (Stockholm, Sweden).", "section": "METHODS", "tags": [{"name": "non-infectious", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "participation", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "For each gene separately and for three separate outcome groups\u201415 phospholipid variables in cord serum and in adolescent serum and also for the two diagnosis atopic eczema and respiratory allergy\u2014100 000 permutations were carried out to get an empirical null distribution of the minP (minimum p-value) statistic from which the corrected p-values could be estimated Two-tailed p \u2264 0.05 was considered significant [41].", "section": "METHODS", "tags": [{"name": "phospholipid", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "permutations", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Respiratory allergy was defined as a positive skin prick test to an inhalant allergen, in combination with two or more of the following criteria: wheeze in the past year, doctor\u2019s diagnosed asthma, asthma inhalation treatment, or a positive answer to the question: \u201cHave you had any signs of pollen allergy or allergy to furry pets during the last 12 months?\u201d.", "section": "METHODS", "tags": [{"name": "Respiratory", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "combination", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Based on the questionnaires and sensitization tests at 13 years of age, the subjects were divided into three diagnostic groups: (1) atopic eczema with no other allergic manifestations, in all, 79 adolescents out of the 788 fulfilled these criteria; (2) respiratory allergy with no other allergic manifestations, all of whom were also sensitized to airborne allergens, in all, 130 adolescents in the cohort fulfilled these criteria and (3) no allergy and no sensitization at any of the follow-ups (1, 4, 7 and 13 years of age), in all, 331 adolescents in the cohort fulfilled these criteria.", "section": "METHODS", "tags": [{"name": "manifestations,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "manifestations,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}]}
{"src": "PMC", "id": "PMC4593004", "provider": "OpenTargets", "anns": [{"type": "Gene Disease Relationship", "exact": "siRNA targeting transcripts for KCNQ5, PLCB1, PLCB4, and PLCL1 (5\u2032\u20133\u2032; siKCNQ5: duplex 1, GGGCAAAUCACAUCAGAUA; duplex 2, CAACACAGGUGCCAAUUAG; duplex 3, GACAUGUUGUGUAGAAUUA; duplex 4, GGGAGGCACUUGGAAAUUA; siPLCB1: duplex 1, GAAGAUAACAGAAGCUAAA; duplex 2, GCAAUUGGCUGCUUUGACA; duplex 3, GAUGAUGACUCAACUAUUG; duplex 4, CAACAGAAAUCGUUUGUGA; siPLCB4: duplex 1, GUAAUUGUCUCGAAAUGAA; duplex 2, GAGAAUAGCUGUGUAUGAU; duplex 3, CAAGAAAGGUAUUGAACUU; duplex 4, CCACUAAUAUCCAUCCAUA; siPLCL1: duplex 1, GCACAGAAGCGCAGUCUUU; duplex 2, GGUAAUGGCUCAACAGAUG; duplex 3, GAAGAAAGUUCGGGAAUAU; duplex 4, GUAGGGAGCUCUCUGAUUU) were purchased from Invitrogen (Carlsbad, CA, USA), as were the non-targeting siRNA scrambled controls (siNC: duplex 1, AUGAACGUGAAUUGCUCAA; duplex 2, UAAGGCUAUGAAGAGAUAC; duplex 3, AUGUAUUGGCCUGUAUUAG; duplex 4, UAGCGACUAAACACAUCAA).", "section": "OTHER", "tags": [{"name": "UAGCGACUAAACACAUCAA).", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "GGGCAAAUCACAUCAGAUA;", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "All patients were diagnosed according to KD criteria5556, including fever lasting 5 days or more and at least 4 of the following symptoms: (1) changes in extremities (e.g., erythema, edema, or desquamation), (2) bilateral conjunctivitis, (3) polymorphous rash, (4) cervical lymphadenopathy, and (5) changes in the lips or oral cavity (e.g. pharyngeal erythema, dry/fissured or swollen lips, or \u201cstrawberry tongue\u201d).", "section": "OTHER", "tags": [{"name": "lymphadenopathy,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "conjunctivitis,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "The primers used for quantitative PCR (qPCR) amplification were as follows: KCNQ5, forward: 5\u2032- AGGGGAAGCATCAAGCAGTA -3\u2032 and reverse: 5\u2032- CGCACTCGCTCCTTAAAACT -3\u2032; PLCB1, forward: 5\u2032- GTGGGAGACACGCCAAAG -3\u2032 and reverse: 5\u2032- GGCCCATACACCACTGTGA -3\u2032; PLCB4, forward: 5\u2032- CGGGAAGTCTTCGGTAGAAA -3\u2032 and reverse: 5\u2032- CCCAGCAGTCAAGTTCAACA -3\u2032; PLCL1, forward: 5\u2032- TCACTTGTGATGAAAGACAGCTT -3\u2032 and reverse: 5\u2032- GAGAAACCGGCTCTCTTGAA -3\u2032; IL-1 beta, forward: 5\u2032-TACCTGTCCTGCGTGTTGAA-3\u2032 and reverse: 5\u2032-TCTTTGGGTAATTTTTGGGATCT -3\u2032; IL-6, forward: 5\u2032- CAGGAGCCCAGCTATGAACT -3\u2032 and reverse: 5\u2032- GAAGGCAGCAGGCAACAC -3\u2032; IL-8, forward: 5\u2032- GAGCACTCCATAAGGCACAAA -3\u2032 and reverse: 5\u2032- ATGGTTCCTTCCGGTGGT -3\u2032. Reverse transcription was performed in a 10\u2009\u03bcL reaction mixture consisting of 2\u2009\u03bcL RNA template, 1\u2009\u03bcL RT primer mix, 1\u2009\u03bcL dNTP mix (10\u2009mm each), and 6\u2009\u03bcL RNA/DNAse-free water at 65\u2009\u00b0C for 5\u2009min.", "section": "OTHER", "tags": [{"name": "5\u2032-TACCTGTCCTGCGTGTTGAA-3\u2032", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "5\u2032-TCTTTGGGTAATTTTTGGGATCT", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "For synovial fibroblasts, macrophages, dendritic cells, and ECs, inflammation induced by thrombin, bradykinin, LPS, porphyromonas gingivalis, or advanced glycation end products has been shown to be affected by PLC inhibitors, suggesting that PLC might also be involved in NF-\u03baB activation and proinflammatory cytokine release in inflammatory diseases3334353637.", "section": "DISCUSS", "tags": [{"name": "diseases3334353637.", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "proinflammatory", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "All patients were diagnosed according to KD criteria5556, including fever lasting 5 days or more and at least 4 of the following symptoms: (1) changes in extremities (e.g., erythema, edema, or desquamation), (2) bilateral conjunctivitis, (3) polymorphous rash, (4) cervical lymphadenopathy, and (5) changes in the lips or oral cavity (e.g. pharyngeal erythema, dry/fissured or swollen lips, or \u201cstrawberry tongue\u201d).", "section": "OTHER", "tags": [{"name": "lymphadenopathy,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "conjunctivitis,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "All patients were diagnosed according to KD criteria5556, including fever lasting 5 days or more and at least 4 of the following symptoms: (1) changes in extremities (e.g., erythema, edema, or desquamation), (2) bilateral conjunctivitis, (3) polymorphous rash, (4) cervical lymphadenopathy, and (5) changes in the lips or oral cavity (e.g. pharyngeal erythema, dry/fissured or swollen lips, or \u201cstrawberry tongue\u201d).", "section": "OTHER", "tags": [{"name": "lymphadenopathy,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "conjunctivitis,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "siRNA targeting transcripts for KCNQ5, PLCB1, PLCB4, and PLCL1 (5\u2032\u20133\u2032; siKCNQ5: duplex 1, GGGCAAAUCACAUCAGAUA; duplex 2, CAACACAGGUGCCAAUUAG; duplex 3, GACAUGUUGUGUAGAAUUA; duplex 4, GGGAGGCACUUGGAAAUUA; siPLCB1: duplex 1, GAAGAUAACAGAAGCUAAA; duplex 2, GCAAUUGGCUGCUUUGACA; duplex 3, GAUGAUGACUCAACUAUUG; duplex 4, CAACAGAAAUCGUUUGUGA; siPLCB4: duplex 1, GUAAUUGUCUCGAAAUGAA; duplex 2, GAGAAUAGCUGUGUAUGAU; duplex 3, CAAGAAAGGUAUUGAACUU; duplex 4, CCACUAAUAUCCAUCCAUA; siPLCL1: duplex 1, GCACAGAAGCGCAGUCUUU; duplex 2, GGUAAUGGCUCAACAGAUG; duplex 3, GAAGAAAGUUCGGGAAUAU; duplex 4, GUAGGGAGCUCUCUGAUUU) were purchased from Invitrogen (Carlsbad, CA, USA), as were the non-targeting siRNA scrambled controls (siNC: duplex 1, AUGAACGUGAAUUGCUCAA; duplex 2, UAAGGCUAUGAAGAGAUAC; duplex 3, AUGUAUUGGCCUGUAUUAG; duplex 4, UAGCGACUAAACACAUCAA).", "section": "OTHER", "tags": [{"name": "UAGCGACUAAACACAUCAA).", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "GGGCAAAUCACAUCAGAUA;", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "HUVECs (BCRC Number: H-UV001) were grown in 90% GIBCO medium 199 (Life Technologies) with 25\u2009U/mL heparin (Sigma, St. Louis, MO, USA), 30\u2009\u03bcg/mL endothelial cell growth supplement (Millipore, Billerica, MA, USA) adjusted to contain 1.5\u2009g/L sodium bicarbonate + 10% fetal bovine serum and 100\u2009U/mL penicillin/streptomycin.", "section": "OTHER", "tags": [{"name": "penicillin/streptomycin.", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "Technologies)", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "The primers used for quantitative PCR (qPCR) amplification were as follows: KCNQ5, forward: 5\u2032- AGGGGAAGCATCAAGCAGTA -3\u2032 and reverse: 5\u2032- CGCACTCGCTCCTTAAAACT -3\u2032; PLCB1, forward: 5\u2032- GTGGGAGACACGCCAAAG -3\u2032 and reverse: 5\u2032- GGCCCATACACCACTGTGA -3\u2032; PLCB4, forward: 5\u2032- CGGGAAGTCTTCGGTAGAAA -3\u2032 and reverse: 5\u2032- CCCAGCAGTCAAGTTCAACA -3\u2032; PLCL1, forward: 5\u2032- TCACTTGTGATGAAAGACAGCTT -3\u2032 and reverse: 5\u2032- GAGAAACCGGCTCTCTTGAA -3\u2032; IL-1 beta, forward: 5\u2032-TACCTGTCCTGCGTGTTGAA-3\u2032 and reverse: 5\u2032-TCTTTGGGTAATTTTTGGGATCT -3\u2032; IL-6, forward: 5\u2032- CAGGAGCCCAGCTATGAACT -3\u2032 and reverse: 5\u2032- GAAGGCAGCAGGCAACAC -3\u2032; IL-8, forward: 5\u2032- GAGCACTCCATAAGGCACAAA -3\u2032 and reverse: 5\u2032- ATGGTTCCTTCCGGTGGT -3\u2032. Reverse transcription was performed in a 10\u2009\u03bcL reaction mixture consisting of 2\u2009\u03bcL RNA template, 1\u2009\u03bcL RT primer mix, 1\u2009\u03bcL dNTP mix (10\u2009mm each), and 6\u2009\u03bcL RNA/DNAse-free water at 65\u2009\u00b0C for 5\u2009min.", "section": "OTHER", "tags": [{"name": "5\u2032-TACCTGTCCTGCGTGTTGAA-3\u2032", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "5\u2032-TCTTTGGGTAATTTTTGGGATCT", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "For synovial fibroblasts, macrophages, dendritic cells, and ECs, inflammation induced by thrombin, bradykinin, LPS, porphyromonas gingivalis, or advanced glycation end products has been shown to be affected by PLC inhibitors, suggesting that PLC might also be involved in NF-\u03baB activation and proinflammatory cytokine release in inflammatory diseases3334353637.", "section": "DISCUSS", "tags": [{"name": "diseases3334353637.", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "proinflammatory", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "The primers used for quantitative PCR (qPCR) amplification were as follows: KCNQ5, forward: 5\u2032- AGGGGAAGCATCAAGCAGTA -3\u2032 and reverse: 5\u2032- CGCACTCGCTCCTTAAAACT -3\u2032; PLCB1, forward: 5\u2032- GTGGGAGACACGCCAAAG -3\u2032 and reverse: 5\u2032- GGCCCATACACCACTGTGA -3\u2032; PLCB4, forward: 5\u2032- CGGGAAGTCTTCGGTAGAAA -3\u2032 and reverse: 5\u2032- CCCAGCAGTCAAGTTCAACA -3\u2032; PLCL1, forward: 5\u2032- TCACTTGTGATGAAAGACAGCTT -3\u2032 and reverse: 5\u2032- GAGAAACCGGCTCTCTTGAA -3\u2032; IL-1 beta, forward: 5\u2032-TACCTGTCCTGCGTGTTGAA-3\u2032 and reverse: 5\u2032-TCTTTGGGTAATTTTTGGGATCT -3\u2032; IL-6, forward: 5\u2032- CAGGAGCCCAGCTATGAACT -3\u2032 and reverse: 5\u2032- GAAGGCAGCAGGCAACAC -3\u2032; IL-8, forward: 5\u2032- GAGCACTCCATAAGGCACAAA -3\u2032 and reverse: 5\u2032- ATGGTTCCTTCCGGTGGT -3\u2032. Reverse transcription was performed in a 10\u2009\u03bcL reaction mixture consisting of 2\u2009\u03bcL RNA template, 1\u2009\u03bcL RT primer mix, 1\u2009\u03bcL dNTP mix (10\u2009mm each), and 6\u2009\u03bcL RNA/DNAse-free water at 65\u2009\u00b0C for 5\u2009min.", "section": "OTHER", "tags": [{"name": "5\u2032-TACCTGTCCTGCGTGTTGAA-3\u2032", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "5\u2032-TCTTTGGGTAATTTTTGGGATCT", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Our results demonstrated that the effect of LPS-induced EC inflammation was inhibited with the most significant inhibition by using siPLCB1 or a PLC inhibitor, suggesting that PLCB1 might be involved in EC inflammation, a possibility that has important implications for understanding the pathogenesis of immune-mediated vascular diseases.", "section": "DISCUSS", "tags": [{"name": "immune-mediated", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "inflammation,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "All patients were diagnosed according to KD criteria5556, including fever lasting 5 days or more and at least 4 of the following symptoms: (1) changes in extremities (e.g., erythema, edema, or desquamation), (2) bilateral conjunctivitis, (3) polymorphous rash, (4) cervical lymphadenopathy, and (5) changes in the lips or oral cavity (e.g. pharyngeal erythema, dry/fissured or swollen lips, or \u201cstrawberry tongue\u201d).", "section": "OTHER", "tags": [{"name": "lymphadenopathy,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "conjunctivitis,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "siRNA targeting transcripts for KCNQ5, PLCB1, PLCB4, and PLCL1 (5\u2032\u20133\u2032; siKCNQ5: duplex 1, GGGCAAAUCACAUCAGAUA; duplex 2, CAACACAGGUGCCAAUUAG; duplex 3, GACAUGUUGUGUAGAAUUA; duplex 4, GGGAGGCACUUGGAAAUUA; siPLCB1: duplex 1, GAAGAUAACAGAAGCUAAA; duplex 2, GCAAUUGGCUGCUUUGACA; duplex 3, GAUGAUGACUCAACUAUUG; duplex 4, CAACAGAAAUCGUUUGUGA; siPLCB4: duplex 1, GUAAUUGUCUCGAAAUGAA; duplex 2, GAGAAUAGCUGUGUAUGAU; duplex 3, CAAGAAAGGUAUUGAACUU; duplex 4, CCACUAAUAUCCAUCCAUA; siPLCL1: duplex 1, GCACAGAAGCGCAGUCUUU; duplex 2, GGUAAUGGCUCAACAGAUG; duplex 3, GAAGAAAGUUCGGGAAUAU; duplex 4, GUAGGGAGCUCUCUGAUUU) were purchased from Invitrogen (Carlsbad, CA, USA), as were the non-targeting siRNA scrambled controls (siNC: duplex 1, AUGAACGUGAAUUGCUCAA; duplex 2, UAAGGCUAUGAAGAGAUAC; duplex 3, AUGUAUUGGCCUGUAUUAG; duplex 4, UAGCGACUAAACACAUCAA).", "section": "OTHER", "tags": [{"name": "UAGCGACUAAACACAUCAA).", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "GGGCAAAUCACAUCAGAUA;", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "For synovial fibroblasts, macrophages, dendritic cells, and ECs, inflammation induced by thrombin, bradykinin, LPS, porphyromonas gingivalis, or advanced glycation end products has been shown to be affected by PLC inhibitors, suggesting that PLC might also be involved in NF-\u03baB activation and proinflammatory cytokine release in inflammatory diseases3334353637.", "section": "DISCUSS", "tags": [{"name": "diseases3334353637.", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "proinflammatory", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "The primers used for quantitative PCR (qPCR) amplification were as follows: KCNQ5, forward: 5\u2032- AGGGGAAGCATCAAGCAGTA -3\u2032 and reverse: 5\u2032- CGCACTCGCTCCTTAAAACT -3\u2032; PLCB1, forward: 5\u2032- GTGGGAGACACGCCAAAG -3\u2032 and reverse: 5\u2032- GGCCCATACACCACTGTGA -3\u2032; PLCB4, forward: 5\u2032- CGGGAAGTCTTCGGTAGAAA -3\u2032 and reverse: 5\u2032- CCCAGCAGTCAAGTTCAACA -3\u2032; PLCL1, forward: 5\u2032- TCACTTGTGATGAAAGACAGCTT -3\u2032 and reverse: 5\u2032- GAGAAACCGGCTCTCTTGAA -3\u2032; IL-1 beta, forward: 5\u2032-TACCTGTCCTGCGTGTTGAA-3\u2032 and reverse: 5\u2032-TCTTTGGGTAATTTTTGGGATCT -3\u2032; IL-6, forward: 5\u2032- CAGGAGCCCAGCTATGAACT -3\u2032 and reverse: 5\u2032- GAAGGCAGCAGGCAACAC -3\u2032; IL-8, forward: 5\u2032- GAGCACTCCATAAGGCACAAA -3\u2032 and reverse: 5\u2032- ATGGTTCCTTCCGGTGGT -3\u2032. Reverse transcription was performed in a 10\u2009\u03bcL reaction mixture consisting of 2\u2009\u03bcL RNA template, 1\u2009\u03bcL RT primer mix, 1\u2009\u03bcL dNTP mix (10\u2009mm each), and 6\u2009\u03bcL RNA/DNAse-free water at 65\u2009\u00b0C for 5\u2009min.", "section": "OTHER", "tags": [{"name": "5\u2032-TACCTGTCCTGCGTGTTGAA-3\u2032", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "5\u2032-TCTTTGGGTAATTTTTGGGATCT", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "siRNA targeting transcripts for KCNQ5, PLCB1, PLCB4, and PLCL1 (5\u2032\u20133\u2032; siKCNQ5: duplex 1, GGGCAAAUCACAUCAGAUA; duplex 2, CAACACAGGUGCCAAUUAG; duplex 3, GACAUGUUGUGUAGAAUUA; duplex 4, GGGAGGCACUUGGAAAUUA; siPLCB1: duplex 1, GAAGAUAACAGAAGCUAAA; duplex 2, GCAAUUGGCUGCUUUGACA; duplex 3, GAUGAUGACUCAACUAUUG; duplex 4, CAACAGAAAUCGUUUGUGA; siPLCB4: duplex 1, GUAAUUGUCUCGAAAUGAA; duplex 2, GAGAAUAGCUGUGUAUGAU; duplex 3, CAAGAAAGGUAUUGAACUU; duplex 4, CCACUAAUAUCCAUCCAUA; siPLCL1: duplex 1, GCACAGAAGCGCAGUCUUU; duplex 2, GGUAAUGGCUCAACAGAUG; duplex 3, GAAGAAAGUUCGGGAAUAU; duplex 4, GUAGGGAGCUCUCUGAUUU) were purchased from Invitrogen (Carlsbad, CA, USA), as were the non-targeting siRNA scrambled controls (siNC: duplex 1, AUGAACGUGAAUUGCUCAA; duplex 2, UAAGGCUAUGAAGAGAUAC; duplex 3, AUGUAUUGGCCUGUAUUAG; duplex 4, UAGCGACUAAACACAUCAA).", "section": "OTHER", "tags": [{"name": "UAGCGACUAAACACAUCAA).", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "GGGCAAAUCACAUCAGAUA;", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "For cardiomyocytes, PLC beta is the immediate downstream target of G\u03b1q, a heterotrimeric G protein that regulates its activation, and hydrolyzes the plasma membrane phosphatidylinositol 4,5-bisphosphate (PIP2) protein to produce the second messengers inositol 1,4,5-triphosphate (IP3; a regulator of the intracellular calcium response) and diacylglycerol (DAG, an activator of protein kinase C subtypes)50.", "section": "DISCUSS", "tags": [{"name": "phosphatidylinositol", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "1,4,5-triphosphate", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}]}
{"src": "PMC", "id": "PMC4539664", "provider": "OpenTargets", "anns": [{"type": "Gene Disease Relationship", "exact": "Nineteen different truncating variants were identified in 30 individuals in this study, 26 of these variants were detected among 1996 breast cancer index cases (1.3 %) and four among 1998 controls (0.2 %), demonstrating a significant enrichment in cases (p\u2009=\u20090.0001, chi-squared test; odds ratio (OR) 6.58, 95 % confidence interval (CI) 2.3\u201318.9) (Table\u00a01).", "section": "RESULTS", "tags": [{"name": "demonstrating", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "individuals", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Five previously reported variants were detected recurrently (c.196C\u2009>\u2009T (p.Gln66*) and c.758dupT (p.Ser254Illefs*3) each in two cases, c.3113G\u2009>\u2009A (p.Trp1038*) in seven cases and one control, and c.3116delA (p.Asn1039Ilefs*2) and c.3362delG (p.Gly1121Valfs*3) each in one case and one control) with the remaining variants detected in single cases or controls only.", "section": "RESULTS", "tags": [{"name": "(p.Ser254Illefs*3)", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "(p.Asn1039Ilefs*2)", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Leu1150Argrs45566737..0.0000368-1-18.2DeleteriousPossibly damagingDeleterious\nHAPS Hunter Area Pathology Service, FCC Familial Cancer Centre, ViP Variants in Practice\naVariant positions are reported in reference to NCBI RefSeq NM_024675.3 (mRNA) and NP_078951.2 (protein)\nbMinor allele frequency (MAF) reported in the 1000 Genomes (1000 G) cohort Phase 1\ncMAF reported in the Exome Variant Server, NHLBI GO Exome Sequencing Project (ESP) [46] (data release ESP6500SI-V2)\ndMAF reported in ExAC [45] from non-Finnish Europeans, excluding individuals in the database who were part of The Cancer Genome Atlas and therefore known to have had cancer\neNumber of individuals carrying the variant.", "section": "RESULTS", "tags": [{"name": "Leu1150Argrs45566737..0.0000368-1-18.2DeleteriousPossibly", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "damagingDeleterious", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Table 4Synonymous variantsExonNucleotide changea\nProtein changea\ndbSNP IDFirst reported1000 G MAFb\nNHBLI GO ESP MAFc\nExACd\nHAPS cases (n\u2009=\u2009997)e\nFCC-ViP cases (n\u2009=\u2009999)d\nControls (n\u2009=\u20091998)e\nCADD scaledC score1c.12 T\u2009>\u2009Cp.(=)rs145291423-..0.00012-1111.24c.768C\u2009>\u2009Tp.(=)rs45487491..0.00003710.34c.1188C\u2009>\u2009Tp.(=).-..0.00003--17.64c.1194G\u2009>\u2009Ap.(=)rs61755173Rahman (2007) [3]0.00090.001540.001143286.44c.1194G\u2009>\u2009Tp.(=).-...1--6.14c.1242A\u2009>\u2009Cp.(=).-...--17.74c.1431C\u2009>\u2009Tp.(=).Teo (2013)..02--0.04c.1470C\u2009>\u2009Tp.(=)rs45612837Rahman (2007) [3]0.00050.000150.0004051-25.84c.1572A\u2009>\u2009Gp.(=)rs45472400Rahman (2007) [3]0.00320.003390.00411212275.64c.1623G\u2009>\u2009Ap.(=).-..0-124.25c.2067G\u2009>\u2009Ap.(=).Phuah (2013) [38].0.000150.0000181--4.15c.2082A\u2009>\u2009Gp.(=)rs150569240-..0.000055--15.85c.2091C\u2009>\u2009Ap.(=).-..0--14.75c.2244A\u2009>\u2009Gp.(=).-..0.000037--15.65c.2328C\u2009>\u2009Tp.(=)rs45508997-.0.0000801--4.05c.2337A\u2009>\u2009Cp.(=).-...-1-5.25c.2379C\u2009>\u2009Tp.(=).-.0.000080.00011111-0.15c.2478C\u2009>\u2009Tp.(=).-...--14.25c.2484C\u2009>\u2009Tp.(=).-...--16.07c.2742C\u2009>\u2009Tp.(=)rs115759702-0.00180.001460.000032--0.712c.3294G\u2009>\u2009Ap.(=).-...--19.912c.3300 T\u2009>\u2009Gp.(=)rs45516100Rahman (2007) [3]0.01830.028010.027864 (1)68 (4)123 (1)7.913c.3495G\u2009>\u2009Ap.(=)rs45439097Bogdanova (2010).0.001080.0009944798.6\nHAPS Hunter Area Pathology Service, FCC Familial Cancer Centre, ViP Variants in Practice\naVariant positions are reported in reference to NCBI RefSeq NM_024675.3 (mRNA) and NP_078951.2 (protein)\nbMinor allele frequency (MAF) reported in the 1000 Genomes (1000 G) cohort Phase 1\ncMAF reported in the Exome Variant Server, NHLBI GO Exome Sequencing Project (ESP) [46] (data release ESP6500SI-V2)\ndMAF reported in ExAC [45] from non-Finnish Europeans, excluding individuals in the database who were part of The Cancer Genome Atlas and therefore known to have had cancer\neNumber of individuals carrying the variant.", "section": "RESULTS", "tags": [{"name": "Tp.(=)rs115759702-0.00180.001460.000032--0.712c.3294G", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "Gp.(=)rs150569240-..0.000055--15.85c.2091C", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Table 4Synonymous variantsExonNucleotide changea\nProtein changea\ndbSNP IDFirst reported1000 G MAFb\nNHBLI GO ESP MAFc\nExACd\nHAPS cases (n\u2009=\u2009997)e\nFCC-ViP cases (n\u2009=\u2009999)d\nControls (n\u2009=\u20091998)e\nCADD scaledC score1c.12 T\u2009>\u2009Cp.(=)rs145291423-..0.00012-1111.24c.768C\u2009>\u2009Tp.(=)rs45487491..0.00003710.34c.1188C\u2009>\u2009Tp.(=).-..0.00003--17.64c.1194G\u2009>\u2009Ap.(=)rs61755173Rahman (2007) [3]0.00090.001540.001143286.44c.1194G\u2009>\u2009Tp.(=).-...1--6.14c.1242A\u2009>\u2009Cp.(=).-...--17.74c.1431C\u2009>\u2009Tp.(=).Teo (2013)..02--0.04c.1470C\u2009>\u2009Tp.(=)rs45612837Rahman (2007) [3]0.00050.000150.0004051-25.84c.1572A\u2009>\u2009Gp.(=)rs45472400Rahman (2007) [3]0.00320.003390.00411212275.64c.1623G\u2009>\u2009Ap.(=).-..0-124.25c.2067G\u2009>\u2009Ap.(=).Phuah (2013) [38].0.000150.0000181--4.15c.2082A\u2009>\u2009Gp.(=)rs150569240-..0.000055--15.85c.2091C\u2009>\u2009Ap.(=).-..0--14.75c.2244A\u2009>\u2009Gp.(=).-..0.000037--15.65c.2328C\u2009>\u2009Tp.(=)rs45508997-.0.0000801--4.05c.2337A\u2009>\u2009Cp.(=).-...-1-5.25c.2379C\u2009>\u2009Tp.(=).-.0.000080.00011111-0.15c.2478C\u2009>\u2009Tp.(=).-...--14.25c.2484C\u2009>\u2009Tp.(=).-...--16.07c.2742C\u2009>\u2009Tp.(=)rs115759702-0.00180.001460.000032--0.712c.3294G\u2009>\u2009Ap.(=).-...--19.912c.3300 T\u2009>\u2009Gp.(=)rs45516100Rahman (2007) [3]0.01830.028010.027864 (1)68 (4)123 (1)7.913c.3495G\u2009>\u2009Ap.(=)rs45439097Bogdanova (2010).0.001080.0009944798.6\nHAPS Hunter Area Pathology Service, FCC Familial Cancer Centre, ViP Variants in Practice\naVariant positions are reported in reference to NCBI RefSeq NM_024675.3 (mRNA) and NP_078951.2 (protein)\nbMinor allele frequency (MAF) reported in the 1000 Genomes (1000 G) cohort Phase 1\ncMAF reported in the Exome Variant Server, NHLBI GO Exome Sequencing Project (ESP) [46] (data release ESP6500SI-V2)\ndMAF reported in ExAC [45] from non-Finnish Europeans, excluding individuals in the database who were part of The Cancer Genome Atlas and therefore known to have had cancer\neNumber of individuals carrying the variant.", "section": "RESULTS", "tags": [{"name": "Tp.(=)rs115759702-0.00180.001460.000032--0.712c.3294G", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "Gp.(=)rs150569240-..0.000055--15.85c.2091C", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Because early studies focused on screening just for the presumed common pathogenic mutations, in Australia (eviQ Cancer Treatments Online; [11]) it is not recommended to test for PALB2 truncating mutations aside from the recurring c.3113G\u2009>\u2009A variant, however, it is likely that all truncating mutations confer an equivalent loss of gene function and consequent breast cancer risk.", "section": "INTRO", "tags": [{"name": "recommended", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "pathogenic", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Leu1150Argrs45566737..0.0000368-1-18.2DeleteriousPossibly damagingDeleterious\nHAPS Hunter Area Pathology Service, FCC Familial Cancer Centre, ViP Variants in Practice\naVariant positions are reported in reference to NCBI RefSeq NM_024675.3 (mRNA) and NP_078951.2 (protein)\nbMinor allele frequency (MAF) reported in the 1000 Genomes (1000 G) cohort Phase 1\ncMAF reported in the Exome Variant Server, NHLBI GO Exome Sequencing Project (ESP) [46] (data release ESP6500SI-V2)\ndMAF reported in ExAC [45] from non-Finnish Europeans, excluding individuals in the database who were part of The Cancer Genome Atlas and therefore known to have had cancer\neNumber of individuals carrying the variant.", "section": "RESULTS", "tags": [{"name": "Leu1150Argrs45566737..0.0000368-1-18.2DeleteriousPossibly", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "damagingDeleterious", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Tyr1183*rs118203998Reid (2007) [2]1--37.0\nHAPS Hunter Area Pathology Service, FCC Familial Cancer Centre, ViP Variants in Practice\naVariant positions are reported in reference to NCBI RefSeq NM_024675.3 (mRNA) and NP_078951.2 (protein)\nbNumber of individuals carrying the variant\ncc.3113G\u2009>\u2009A produces three different PALB2 mRNA sequences: complete deletion of exon 10 (117 bp); use of an alternative splice site within exon 10, and deletion of 31 bp; and an immediate stop at codon 1038 [29]", "section": "RESULTS", "tags": [{"name": "Tyr1183*rs118203998Reid", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "NM_024675.3", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Tyr1183*rs118203998Reid (2007) [2]1--37.0\nHAPS Hunter Area Pathology Service, FCC Familial Cancer Centre, ViP Variants in Practice\naVariant positions are reported in reference to NCBI RefSeq NM_024675.3 (mRNA) and NP_078951.2 (protein)\nbNumber of individuals carrying the variant\ncc.3113G\u2009>\u2009A produces three different PALB2 mRNA sequences: complete deletion of exon 10 (117 bp); use of an alternative splice site within exon 10, and deletion of 31 bp; and an immediate stop at codon 1038 [29]", "section": "RESULTS", "tags": [{"name": "Tyr1183*rs118203998Reid", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "NM_024675.3", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Because early studies focused on screening just for the presumed common pathogenic mutations, in Australia (eviQ Cancer Treatments Online; [11]) it is not recommended to test for PALB2 truncating mutations aside from the recurring c.3113G\u2009>\u2009A variant, however, it is likely that all truncating mutations confer an equivalent loss of gene function and consequent breast cancer risk.", "section": "INTRO", "tags": [{"name": "recommended", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "pathogenic", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Nineteen different truncating variants were identified in 30 individuals in this study, 26 of these variants were detected among 1996 breast cancer index cases (1.3 %) and four among 1998 controls (0.2 %), demonstrating a significant enrichment in cases (p\u2009=\u20090.0001, chi-squared test; odds ratio (OR) 6.58, 95 % confidence interval (CI) 2.3\u201318.9) (Table\u00a01).", "section": "RESULTS", "tags": [{"name": "demonstrating", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "individuals", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Five previously reported variants were detected recurrently (c.196C\u2009>\u2009T (p.Gln66*) and c.758dupT (p.Ser254Illefs*3) each in two cases, c.3113G\u2009>\u2009A (p.Trp1038*) in seven cases and one control, and c.3116delA (p.Asn1039Ilefs*2) and c.3362delG (p.Gly1121Valfs*3) each in one case and one control) with the remaining variants detected in single cases or controls only.", "section": "RESULTS", "tags": [{"name": "(p.Ser254Illefs*3)", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "(p.Asn1039Ilefs*2)", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Table 4Synonymous variantsExonNucleotide changea\nProtein changea\ndbSNP IDFirst reported1000 G MAFb\nNHBLI GO ESP MAFc\nExACd\nHAPS cases (n\u2009=\u2009997)e\nFCC-ViP cases (n\u2009=\u2009999)d\nControls (n\u2009=\u20091998)e\nCADD scaledC score1c.12 T\u2009>\u2009Cp.(=)rs145291423-..0.00012-1111.24c.768C\u2009>\u2009Tp.(=)rs45487491..0.00003710.34c.1188C\u2009>\u2009Tp.(=).-..0.00003--17.64c.1194G\u2009>\u2009Ap.(=)rs61755173Rahman (2007) [3]0.00090.001540.001143286.44c.1194G\u2009>\u2009Tp.(=).-...1--6.14c.1242A\u2009>\u2009Cp.(=).-...--17.74c.1431C\u2009>\u2009Tp.(=).Teo (2013)..02--0.04c.1470C\u2009>\u2009Tp.(=)rs45612837Rahman (2007) [3]0.00050.000150.0004051-25.84c.1572A\u2009>\u2009Gp.(=)rs45472400Rahman (2007) [3]0.00320.003390.00411212275.64c.1623G\u2009>\u2009Ap.(=).-..0-124.25c.2067G\u2009>\u2009Ap.(=).Phuah (2013) [38].0.000150.0000181--4.15c.2082A\u2009>\u2009Gp.(=)rs150569240-..0.000055--15.85c.2091C\u2009>\u2009Ap.(=).-..0--14.75c.2244A\u2009>\u2009Gp.(=).-..0.000037--15.65c.2328C\u2009>\u2009Tp.(=)rs45508997-.0.0000801--4.05c.2337A\u2009>\u2009Cp.(=).-...-1-5.25c.2379C\u2009>\u2009Tp.(=).-.0.000080.00011111-0.15c.2478C\u2009>\u2009Tp.(=).-...--14.25c.2484C\u2009>\u2009Tp.(=).-...--16.07c.2742C\u2009>\u2009Tp.(=)rs115759702-0.00180.001460.000032--0.712c.3294G\u2009>\u2009Ap.(=).-...--19.912c.3300 T\u2009>\u2009Gp.(=)rs45516100Rahman (2007) [3]0.01830.028010.027864 (1)68 (4)123 (1)7.913c.3495G\u2009>\u2009Ap.(=)rs45439097Bogdanova (2010).0.001080.0009944798.6\nHAPS Hunter Area Pathology Service, FCC Familial Cancer Centre, ViP Variants in Practice\naVariant positions are reported in reference to NCBI RefSeq NM_024675.3 (mRNA) and NP_078951.2 (protein)\nbMinor allele frequency (MAF) reported in the 1000 Genomes (1000 G) cohort Phase 1\ncMAF reported in the Exome Variant Server, NHLBI GO Exome Sequencing Project (ESP) [46] (data release ESP6500SI-V2)\ndMAF reported in ExAC [45] from non-Finnish Europeans, excluding individuals in the database who were part of The Cancer Genome Atlas and therefore known to have had cancer\neNumber of individuals carrying the variant.", "section": "RESULTS", "tags": [{"name": "Tp.(=)rs115759702-0.00180.001460.000032--0.712c.3294G", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "Gp.(=)rs150569240-..0.000055--15.85c.2091C", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Five previously reported variants were detected recurrently (c.196C\u2009>\u2009T (p.Gln66*) and c.758dupT (p.Ser254Illefs*3) each in two cases, c.3113G\u2009>\u2009A (p.Trp1038*) in seven cases and one control, and c.3116delA (p.Asn1039Ilefs*2) and c.3362delG (p.Gly1121Valfs*3) each in one case and one control) with the remaining variants detected in single cases or controls only.", "section": "RESULTS", "tags": [{"name": "(p.Ser254Illefs*3)", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "(p.Asn1039Ilefs*2)", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Tyr1183*rs118203998Reid (2007) [2]1--37.0\nHAPS Hunter Area Pathology Service, FCC Familial Cancer Centre, ViP Variants in Practice\naVariant positions are reported in reference to NCBI RefSeq NM_024675.3 (mRNA) and NP_078951.2 (protein)\nbNumber of individuals carrying the variant\ncc.3113G\u2009>\u2009A produces three different PALB2 mRNA sequences: complete deletion of exon 10 (117 bp); use of an alternative splice site within exon 10, and deletion of 31 bp; and an immediate stop at codon 1038 [29]", "section": "RESULTS", "tags": [{"name": "Tyr1183*rs118203998Reid", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "NM_024675.3", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Table 4Synonymous variantsExonNucleotide changea\nProtein changea\ndbSNP IDFirst reported1000 G MAFb\nNHBLI GO ESP MAFc\nExACd\nHAPS cases (n\u2009=\u2009997)e\nFCC-ViP cases (n\u2009=\u2009999)d\nControls (n\u2009=\u20091998)e\nCADD scaledC score1c.12 T\u2009>\u2009Cp.(=)rs145291423-..0.00012-1111.24c.768C\u2009>\u2009Tp.(=)rs45487491..0.00003710.34c.1188C\u2009>\u2009Tp.(=).-..0.00003--17.64c.1194G\u2009>\u2009Ap.(=)rs61755173Rahman (2007) [3]0.00090.001540.001143286.44c.1194G\u2009>\u2009Tp.(=).-...1--6.14c.1242A\u2009>\u2009Cp.(=).-...--17.74c.1431C\u2009>\u2009Tp.(=).Teo (2013)..02--0.04c.1470C\u2009>\u2009Tp.(=)rs45612837Rahman (2007) [3]0.00050.000150.0004051-25.84c.1572A\u2009>\u2009Gp.(=)rs45472400Rahman (2007) [3]0.00320.003390.00411212275.64c.1623G\u2009>\u2009Ap.(=).-..0-124.25c.2067G\u2009>\u2009Ap.(=).Phuah (2013) [38].0.000150.0000181--4.15c.2082A\u2009>\u2009Gp.(=)rs150569240-..0.000055--15.85c.2091C\u2009>\u2009Ap.(=).-..0--14.75c.2244A\u2009>\u2009Gp.(=).-..0.000037--15.65c.2328C\u2009>\u2009Tp.(=)rs45508997-.0.0000801--4.05c.2337A\u2009>\u2009Cp.(=).-...-1-5.25c.2379C\u2009>\u2009Tp.(=).-.0.000080.00011111-0.15c.2478C\u2009>\u2009Tp.(=).-...--14.25c.2484C\u2009>\u2009Tp.(=).-...--16.07c.2742C\u2009>\u2009Tp.(=)rs115759702-0.00180.001460.000032--0.712c.3294G\u2009>\u2009Ap.(=).-...--19.912c.3300 T\u2009>\u2009Gp.(=)rs45516100Rahman (2007) [3]0.01830.028010.027864 (1)68 (4)123 (1)7.913c.3495G\u2009>\u2009Ap.(=)rs45439097Bogdanova (2010).0.001080.0009944798.6\nHAPS Hunter Area Pathology Service, FCC Familial Cancer Centre, ViP Variants in Practice\naVariant positions are reported in reference to NCBI RefSeq NM_024675.3 (mRNA) and NP_078951.2 (protein)\nbMinor allele frequency (MAF) reported in the 1000 Genomes (1000 G) cohort Phase 1\ncMAF reported in the Exome Variant Server, NHLBI GO Exome Sequencing Project (ESP) [46] (data release ESP6500SI-V2)\ndMAF reported in ExAC [45] from non-Finnish Europeans, excluding individuals in the database who were part of The Cancer Genome Atlas and therefore known to have had cancer\neNumber of individuals carrying the variant.", "section": "RESULTS", "tags": [{"name": "Tp.(=)rs115759702-0.00180.001460.000032--0.712c.3294G", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "Gp.(=)rs150569240-..0.000055--15.85c.2091C", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Tyr1183*rs118203998Reid (2007) [2]1--37.0\nHAPS Hunter Area Pathology Service, FCC Familial Cancer Centre, ViP Variants in Practice\naVariant positions are reported in reference to NCBI RefSeq NM_024675.3 (mRNA) and NP_078951.2 (protein)\nbNumber of individuals carrying the variant\ncc.3113G\u2009>\u2009A produces three different PALB2 mRNA sequences: complete deletion of exon 10 (117 bp); use of an alternative splice site within exon 10, and deletion of 31 bp; and an immediate stop at codon 1038 [29]", "section": "RESULTS", "tags": [{"name": "Tyr1183*rs118203998Reid", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "NM_024675.3", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Leu1150Argrs45566737..0.0000368-1-18.2DeleteriousPossibly damagingDeleterious\nHAPS Hunter Area Pathology Service, FCC Familial Cancer Centre, ViP Variants in Practice\naVariant positions are reported in reference to NCBI RefSeq NM_024675.3 (mRNA) and NP_078951.2 (protein)\nbMinor allele frequency (MAF) reported in the 1000 Genomes (1000 G) cohort Phase 1\ncMAF reported in the Exome Variant Server, NHLBI GO Exome Sequencing Project (ESP) [46] (data release ESP6500SI-V2)\ndMAF reported in ExAC [45] from non-Finnish Europeans, excluding individuals in the database who were part of The Cancer Genome Atlas and therefore known to have had cancer\neNumber of individuals carrying the variant.", "section": "RESULTS", "tags": [{"name": "Leu1150Argrs45566737..0.0000368-1-18.2DeleteriousPossibly", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "damagingDeleterious", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Leu1150Argrs45566737..0.0000368-1-18.2DeleteriousPossibly damagingDeleterious\nHAPS Hunter Area Pathology Service, FCC Familial Cancer Centre, ViP Variants in Practice\naVariant positions are reported in reference to NCBI RefSeq NM_024675.3 (mRNA) and NP_078951.2 (protein)\nbMinor allele frequency (MAF) reported in the 1000 Genomes (1000 G) cohort Phase 1\ncMAF reported in the Exome Variant Server, NHLBI GO Exome Sequencing Project (ESP) [46] (data release ESP6500SI-V2)\ndMAF reported in ExAC [45] from non-Finnish Europeans, excluding individuals in the database who were part of The Cancer Genome Atlas and therefore known to have had cancer\neNumber of individuals carrying the variant.", "section": "RESULTS", "tags": [{"name": "Leu1150Argrs45566737..0.0000368-1-18.2DeleteriousPossibly", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "damagingDeleterious", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Five previously reported variants were detected recurrently (c.196C\u2009>\u2009T (p.Gln66*) and c.758dupT (p.Ser254Illefs*3) each in two cases, c.3113G\u2009>\u2009A (p.Trp1038*) in seven cases and one control, and c.3116delA (p.Asn1039Ilefs*2) and c.3362delG (p.Gly1121Valfs*3) each in one case and one control) with the remaining variants detected in single cases or controls only.", "section": "RESULTS", "tags": [{"name": "(p.Ser254Illefs*3)", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "(p.Asn1039Ilefs*2)", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}]}
{"src": "PMC", "id": "PMC4588721", "provider": "OpenTargets", "anns": [{"type": "Gene Disease Relationship", "exact": "The possibility of less severe hearing loss associated with mutations residing in the N-terminal extension domain had already been suggested; Belyantseva et al. (2005) transfected a class 2 myosin XVa isoform that had no N-terminal extension, into shaker-2 hair cells, which had abnormally short stereocilia.", "section": "DISCUSS", "tags": [{"name": "stereocilia.", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "possibility", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Since there is no known 3D structure of motor domain of MYO15A in the Protein Data Bank, the structure for motor domain of MYO15A was built using the homolog modeling method (BLAST, http://blast.ncbi.nlm.nih.gov/Blast.cgi/; HHpred, http://toolkit.tuebingen.mpg.de/hhpred/; PDB, http://pdb.org/pdb/home/home.do/; UNIPROT.", "section": "METHODS", "tags": [{"name": "http://blast.ncbi.nlm.nih.gov/Blast.cgi/;", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "http://toolkit.tuebingen.mpg.de/hhpred/;", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Based on our findings and analysis of audiologic features of MYO15A mutations, we suggest a hypothetical genotype-phenotype correlation whereby MYO15A mutations that affect domains other than the N-terminal domain, lead to profound SNHL throughout all frequencies, while mutations that affect the N-terminal domain, result in residual hearing at low frequencies, which could make contribution to language development and speech perception.", "section": "DISCUSS", "tags": [{"name": "genotype-phenotype", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "hypothetical", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Recently, conflicting descriptions of auditory phenotypes of the MYO15A mutation have been reported; Fattahi et al. (2012) reported seven mutations throughout the N-terminal extension, motor domain, IQ domain and FERM domain of MYO15A and suggested that a down-sloping audioprofile was the defining audiologic feature of MYO15A-associated deafness.", "section": "DISCUSS", "tags": [{"name": "MYO15A-associated", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "descriptions", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Alternatively, alterations in the N-terminal extension domain, or even the absence of the class 1 myosin XVA, might be related to functional problems or minor structural defects in the staircase architecture of the hair bundle (Nal et al., 2007), thereby leading to a milder auditory phenotype.", "section": "DISCUSS", "tags": [{"name": "Alternatively,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "architecture", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Therefore our hypothetical genotype-phenotype correlation suggests a customized treatment that preservation of residual hearing during cochlear implantation should be intended for those who carry mutations in the N-terminal domain and that the individuals with mutations elsewhere in MYO15A require early cochlear implantation to timely initiate speech development.", "section": "DISCUSS", "tags": [{"name": "genotype-phenotype", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "hypothetical", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Based on our findings and analysis of audiologic features of MYO15A mutations, we suggest a hypothetical genotype-phenotype correlation whereby MYO15A mutations that affect domains other than the N-terminal domain, lead to profound SNHL throughout all frequencies, while mutations that affect the N-terminal domain, result in residual hearing at low frequencies, which could make contribution to language development and speech perception.", "section": "DISCUSS", "tags": [{"name": "genotype-phenotype", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "hypothetical", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Since there is no known 3D structure of motor domain of MYO15A in the Protein Data Bank, the structure for motor domain of MYO15A was built using the homolog modeling method (BLAST, http://blast.ncbi.nlm.nih.gov/Blast.cgi/; HHpred, http://toolkit.tuebingen.mpg.de/hhpred/; PDB, http://pdb.org/pdb/home/home.do/; UNIPROT.", "section": "METHODS", "tags": [{"name": "http://blast.ncbi.nlm.nih.gov/Blast.cgi/;", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "http://toolkit.tuebingen.mpg.de/hhpred/;", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "This feature has been observed in other studies in which mutations in exon 2 (p.E1105*, p.R1113Vfs*12 and p.Y289* homozygote), which encodes the N-terminal extension of MYO15A, resulted in better residual hearing at low frequencies, or even moderate to severe hearing loss compared with mutations in other regions of MYO15A (Cengiz et al., 2010; Nal et al., 2007).", "section": "DISCUSS", "tags": [{"name": "p.R1113Vfs*12", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "homozygote),", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Since there is no known 3D structure of motor domain of MYO15A in the Protein Data Bank, the structure for motor domain of MYO15A was built using the homolog modeling method (BLAST, http://blast.ncbi.nlm.nih.gov/Blast.cgi/; HHpred, http://toolkit.tuebingen.mpg.de/hhpred/; PDB, http://pdb.org/pdb/home/home.do/; UNIPROT.", "section": "METHODS", "tags": [{"name": "http://blast.ncbi.nlm.nih.gov/Blast.cgi/;", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "http://toolkit.tuebingen.mpg.de/hhpred/;", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Recently, conflicting descriptions of auditory phenotypes of the MYO15A mutation have been reported; Fattahi et al. (2012) reported seven mutations throughout the N-terminal extension, motor domain, IQ domain and FERM domain of MYO15A and suggested that a down-sloping audioprofile was the defining audiologic feature of MYO15A-associated deafness.", "section": "DISCUSS", "tags": [{"name": "MYO15A-associated", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "descriptions", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Based on our findings and analysis of audiologic features of MYO15A mutations, we suggest a hypothetical genotype-phenotype correlation whereby MYO15A mutations that affect domains other than the N-terminal domain, lead to profound SNHL throughout all frequencies, while mutations that affect the N-terminal domain, result in residual hearing at low frequencies, which could make contribution to language development and speech perception.", "section": "DISCUSS", "tags": [{"name": "genotype-phenotype", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "hypothetical", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Since there is no known 3D structure of motor domain of MYO15A in the Protein Data Bank, the structure for motor domain of MYO15A was built using the homolog modeling method (BLAST, http://blast.ncbi.nlm.nih.gov/Blast.cgi/; HHpred, http://toolkit.tuebingen.mpg.de/hhpred/; PDB, http://pdb.org/pdb/home/home.do/; UNIPROT.", "section": "METHODS", "tags": [{"name": "http://blast.ncbi.nlm.nih.gov/Blast.cgi/;", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "http://toolkit.tuebingen.mpg.de/hhpred/;", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Alternatively, alterations in the N-terminal extension domain, or even the absence of the class 1 myosin XVA, might be related to functional problems or minor structural defects in the staircase architecture of the hair bundle (Nal et al., 2007), thereby leading to a milder auditory phenotype.", "section": "DISCUSS", "tags": [{"name": "Alternatively,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "architecture", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "The possibility of less severe hearing loss associated with mutations residing in the N-terminal extension domain had already been suggested; Belyantseva et al. (2005) transfected a class 2 myosin XVa isoform that had no N-terminal extension, into shaker-2 hair cells, which had abnormally short stereocilia.", "section": "DISCUSS", "tags": [{"name": "stereocilia.", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "possibility", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Conversely, it can be hypothesized that if MYO15A mutations affect a common region shared by both isoforms, other than exon 2, then the phenotype would be profound throughout all frequencies and have no, or minimal, residual hearing to trigger linguistic development, thereby requiring early cochlear implantation for speech development.", "section": "DISCUSS", "tags": [{"name": "hypothesized", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "development,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Studies of the MYO15A mutation in humans have usually been performed in the Middle East, where consanguineous families are more common (Bashir et al., 2012; Belguith et al., 2009; Brownstein et al., 2011; Cengiz et al., 2010; Diaz-Horta et al., 2012; Duman et al., 2011; Fattahi et al., 2012; Kalay et al., 2007; Liburd et al., 2001; Nal et al., 2007; Shearer et al., 2009).", "section": "DISCUSS", "tags": [{"name": "consanguineous", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "Brownstein", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Therefore our hypothetical genotype-phenotype correlation suggests a customized treatment that preservation of residual hearing during cochlear implantation should be intended for those who carry mutations in the N-terminal domain and that the individuals with mutations elsewhere in MYO15A require early cochlear implantation to timely initiate speech development.", "section": "DISCUSS", "tags": [{"name": "genotype-phenotype", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "hypothetical", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Since there is no known 3D structure of motor domain of MYO15A in the Protein Data Bank, the structure for motor domain of MYO15A was built using the homolog modeling method (BLAST, http://blast.ncbi.nlm.nih.gov/Blast.cgi/; HHpred, http://toolkit.tuebingen.mpg.de/hhpred/; PDB, http://pdb.org/pdb/home/home.do/; UNIPROT.", "section": "METHODS", "tags": [{"name": "http://blast.ncbi.nlm.nih.gov/Blast.cgi/;", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "http://toolkit.tuebingen.mpg.de/hhpred/;", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "This feature has been observed in other studies in which mutations in exon 2 (p.E1105*, p.R1113Vfs*12 and p.Y289* homozygote), which encodes the N-terminal extension of MYO15A, resulted in better residual hearing at low frequencies, or even moderate to severe hearing loss compared with mutations in other regions of MYO15A (Cengiz et al., 2010; Nal et al., 2007).", "section": "DISCUSS", "tags": [{"name": "p.R1113Vfs*12", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "homozygote),", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}]}
{"src": "PMC", "id": "PMC4471120", "provider": "OpenTargets", "anns": [{"type": "Gene Disease Relationship", "exact": "For analyses of the ARIC sub-sample with sRAGE levels (N = 2,318), covariates included self-reported age, sex, race (black or white), and educational level (less than high school, high school or any college, more than four years post-high school); body mass index calculated as measured weight/height2 in kg/m2 [15]; prevalent diabetes mellitus (self-reported diabetes, use of diabetes medications, and/or fasting glucose \u22656.99 mmol/l among those with fasting samples); estimated glomerular filtration rate (eGFR) calculated from measured creatinine [16] and age, sex, and race using the Modification of Diet in Renal Disease Study Group method [17]; and prevalent coronary heart disease by self-report or diagnosis by ARIC procedures described below.", "section": "METHODS", "tags": [{"name": "weight/height2", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "(self-reported", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "In our study, BMI and fasting glucose were higher in black vs. white participants; outside of known racial disparities in these factors and their downstream inflammatory diseases (e.g., diabetes and coronary heart disease), proximal environmental factors suggested to underlie the observed increased inflammation among blacks include lower socioeconomic status [39, 41], stress [42] and racial discrimination [43].", "section": "DISCUSS", "tags": [{"name": "discrimination", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "participants;", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "To clarify mixed findings of large associations between sRAGE and outcomes in prior studies and to further understand the black-white difference in sRAGE levels, we used the Atherosclerosis Risk in Communities (ARIC) Study, a multi-ethnic, community-based cohort study to 1) conduct genome-wide association studies (GWAS) of sRAGE levels in whites and blacks separately; 2) evaluate if genetic variation underlies the black-white difference in sRAGE; and 3) conduct a Mendelian randomization study to evaluate the association between genetic determinants of sRAGE and mortality, coronary heart disease, congestive heart failure, diabetes, and chronic kidney disease.", "section": "INTRO", "tags": [{"name": "Atherosclerosis", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "community-based", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "For the analysis of AGER (Gene ID: 177; Entrez Gene) SNPs and clinical outcomes, we were not limited to the ARIC subsample in which sRAGE was available and of the entire cohort of black and white participants with follow-up from visit 1 (1987\u20131989) who consented to non-cardiovascular disease-related research (N = 15,703), we excluded participants without genotyping data (N = 2,778) and those with genotyping samples that did not pass quality control measures (N = 1,037).", "section": "METHODS", "tags": [{"name": "non-cardiovascular", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "disease-related", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "In the Atherosclerosis Risk in Communities Study (ARIC), Dallas Heart Study, and the Northern Manhattan Study, non-Hispanic blacks [4, 8] and Hispanics [9] had significantly lower sRAGE levels than whites, and adjustment for multiple confounding variables did not change this racial difference in sRAGE levels [4, 9], leading to a hypothesis that genetic factors may explain at least a proportion of the observed racial difference.", "section": "INTRO", "tags": [{"name": "Atherosclerosis", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "significantly", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "For the analysis of AGER (Gene ID: 177; Entrez Gene) SNPs and clinical outcomes, we were not limited to the ARIC subsample in which sRAGE was available and of the entire cohort of black and white participants with follow-up from visit 1 (1987\u20131989) who consented to non-cardiovascular disease-related research (N = 15,703), we excluded participants without genotyping data (N = 2,778) and those with genotyping samples that did not pass quality control measures (N = 1,037).", "section": "METHODS", "tags": [{"name": "non-cardiovascular", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "disease-related", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "While some case-control studies have identified associations between AGER SNPs and myocardial infarction and stroke [31] and prevalent coronary heart disease based on angiographic evidence of stenosis >50% [32], two recent meta-analyses including over 25 case-control studies (maximum N for single SNP = 7,111) [29] did not find a consistent association between AGER polymorphisms and coronary heart disease (odds ratios from meta-analyses ranged from 0.97 to 1.16 with P >0.05) [29, 30].", "section": "DISCUSS", "tags": [{"name": "meta-analyses", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "polymorphisms", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "We performed a post-hoc power calculation for blacks and whites separately using the non-centrality-parameter-based method for estimating power in Mendelian randomization studies described by Brion et al, 2013 [23, 24] and estimated power for the analyses of clinical outcomes assuming the following: type I error rate of 0.05; proportion of variance in ln(sRAGE) explained by SNP as reported in this study; event rates observed in this study; odds ratios for ln(sRAGE) and the clinical outcomes estimated using logistic regression in this study (Table B in S1 File).", "section": "METHODS", "tags": [{"name": "non-centrality-parameter-based", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "randomization", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "For analyses of the ARIC sub-sample with sRAGE levels (N = 2,318), covariates included self-reported age, sex, race (black or white), and educational level (less than high school, high school or any college, more than four years post-high school); body mass index calculated as measured weight/height2 in kg/m2 [15]; prevalent diabetes mellitus (self-reported diabetes, use of diabetes medications, and/or fasting glucose \u22656.99 mmol/l among those with fasting samples); estimated glomerular filtration rate (eGFR) calculated from measured creatinine [16] and age, sex, and race using the Modification of Diet in Renal Disease Study Group method [17]; and prevalent coronary heart disease by self-report or diagnosis by ARIC procedures described below.", "section": "METHODS", "tags": [{"name": "weight/height2", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "(self-reported", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "To clarify mixed findings of large associations between sRAGE and outcomes in prior studies and to further understand the black-white difference in sRAGE levels, we used the Atherosclerosis Risk in Communities (ARIC) Study, a multi-ethnic, community-based cohort study to 1) conduct genome-wide association studies (GWAS) of sRAGE levels in whites and blacks separately; 2) evaluate if genetic variation underlies the black-white difference in sRAGE; and 3) conduct a Mendelian randomization study to evaluate the association between genetic determinants of sRAGE and mortality, coronary heart disease, congestive heart failure, diabetes, and chronic kidney disease.", "section": "INTRO", "tags": [{"name": "Atherosclerosis", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "community-based", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "In our study, BMI and fasting glucose were higher in black vs. white participants; outside of known racial disparities in these factors and their downstream inflammatory diseases (e.g., diabetes and coronary heart disease), proximal environmental factors suggested to underlie the observed increased inflammation among blacks include lower socioeconomic status [39, 41], stress [42] and racial discrimination [43].", "section": "DISCUSS", "tags": [{"name": "discrimination", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "participants;", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "We performed a post-hoc power calculation for blacks and whites separately using the non-centrality-parameter-based method for estimating power in Mendelian randomization studies described by Brion et al, 2013 [23, 24] and estimated power for the analyses of clinical outcomes assuming the following: type I error rate of 0.05; proportion of variance in ln(sRAGE) explained by SNP as reported in this study; event rates observed in this study; odds ratios for ln(sRAGE) and the clinical outcomes estimated using logistic regression in this study (Table B in S1 File).", "section": "METHODS", "tags": [{"name": "non-centrality-parameter-based", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "randomization", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "In the Atherosclerosis Risk in Communities Study (ARIC), Dallas Heart Study, and the Northern Manhattan Study, non-Hispanic blacks [4, 8] and Hispanics [9] had significantly lower sRAGE levels than whites, and adjustment for multiple confounding variables did not change this racial difference in sRAGE levels [4, 9], leading to a hypothesis that genetic factors may explain at least a proportion of the observed racial difference.", "section": "INTRO", "tags": [{"name": "Atherosclerosis", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "significantly", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "We performed a post-hoc power calculation for blacks and whites separately using the non-centrality-parameter-based method for estimating power in Mendelian randomization studies described by Brion et al, 2013 [23, 24] and estimated power for the analyses of clinical outcomes assuming the following: type I error rate of 0.05; proportion of variance in ln(sRAGE) explained by SNP as reported in this study; event rates observed in this study; odds ratios for ln(sRAGE) and the clinical outcomes estimated using logistic regression in this study (Table B in S1 File).", "section": "METHODS", "tags": [{"name": "non-centrality-parameter-based", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "randomization", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}]}
{"src": "PMC", "id": "PMC4539360", "provider": "OpenTargets", "anns": [{"type": "Gene Disease Relationship", "exact": "Asn71TyrVaried (11\u201330\u00a0years)LLDistal weakness and wasting, mild sensory lossMild weakness, wasting mild sensory lossSymmetricm 38.1p absentMS[5]F1/P2LLMild weakness and wastingNoneSymmetricFrenchF1/P16c.986G>Ap.Arg329HisVaried (6\u201354\u00a0years)LLBilateral distal weakness, distal sensory lossDistal weakness, distal sensory lossSymmetricm 32.4\u201350MS[4]F1/P1LLSevere distal wasting, sensory lossNoneAsymmetricm 45FrenchF2/P1c.986G>Ap.", "section": "INTRO", "tags": [{"name": "wastingNoneSymmetricFrenchF1/P16c.986G>Ap.Arg329HisVaried", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "32.4\u201350MS[4]F1/P1LLSevere", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Based on the electrophysiological and pathological characteristics it can be classified further into a demyelinating form (CMT1), where the nerve conduction velocity is reduced due to altered myelination, and to an axonal form (CMT2), where the primary axonal dysfunction leads to reduced amplitudes of evoked muscle action potentials.", "section": "INTRO", "tags": [{"name": "electrophysiological", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "characteristics", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Wasting and weakness of intrinsic hand muscles resulted in split hand deformity (Fig.\u00a01; Table\u00a02).Table\u00a02Genetic and clinical characteristics of patients with AARS-related neuropathy in the UK/Irish cohortFamily/patient/age/sexOriginNucleotide/amino acid changeAge onsetClinical courseFirst signClinical signsMobility/orthoticsNerve conduction studyDistal lower limbDistal upper limbMotor NCV (m/s)Motor/sensoryMotorSensoryDeformityMotorSensoryDeformityF1/PIII.1/50\u00a0years/MUKc.986G>A/p.", "section": "OTHER", "tags": [{"name": "(m/s)Motor/sensoryMotorSensoryDeformityMotorSensoryDeformityF1/PIII.1/50", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "cohortFamily/patient/age/sexOriginNucleotide/amino", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Wasting and weakness of intrinsic hand muscles resulted in split hand deformity (Fig.\u00a01; Table\u00a02).Table\u00a02Genetic and clinical characteristics of patients with AARS-related neuropathy in the UK/Irish cohortFamily/patient/age/sexOriginNucleotide/amino acid changeAge onsetClinical courseFirst signClinical signsMobility/orthoticsNerve conduction studyDistal lower limbDistal upper limbMotor NCV (m/s)Motor/sensoryMotorSensoryDeformityMotorSensoryDeformityF1/PIII.1/50\u00a0years/MUKc.986G>A/p.", "section": "OTHER", "tags": [{"name": "(m/s)Motor/sensoryMotorSensoryDeformityMotorSensoryDeformityF1/PIII.1/50", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "cohortFamily/patient/age/sexOriginNucleotide/amino", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Genetic diagnosis is particularly difficult to achieve in the axonal form (CMT2) which shows genotypic and phenotypic overlap with distal hereditary motor neuropathies (dHMN) or distal spinal muscular atrophy (dSMA), a subgroup of rare inherited motor axonal neuropathies with no significant sensory involvement [9].", "section": "INTRO", "tags": [{"name": "particularly", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "neuropathies", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Additionally autosomal recessive loss of function AARS mutations (compound heterozygous p.Lys81Thr and p.Arg751Gly and homozygous p.Arg751Gly) were also described in two unrelated families, causing severe infantile epileptic encephalopathy with a central myelin defect and peripheral neuropathy [12].Table\u00a01Summary of the clinical and electrophysiology findings accompanying the reported different AARS variantsOriginFamily/patient numberNucleotide changeAmino acid changeAge onsetFirst signClinical symptomsNerve conduction studyReferencesLower limbUpper limbSymmetryMotor NCV (m/s)Motor/sensoryTaiwaneseF1/P5c.211A>Tp.", "section": "INTRO", "tags": [{"name": "(m/s)Motor/sensoryTaiwaneseF1/P5c.211A>Tp.", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "variantsOriginFamily/patient", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "The relevance of methionyl-tRNA synthetase (MARS, MIM#156560) and histidyl-tRNA synthetase (HARS, MIM#142810) mutations for CMT is supported by strong functional and evolutionary evidence, yet incomplete segregation and absence of additional unrelated cases warrant future studies to substantiate this conclusion [2, 14].", "section": "INTRO", "tags": [{"name": "methionyl-tRNA", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "histidyl-tRNA", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Some of these genes have been already associated with axonal dysfunction, such as mitofusin 2 (MFN2) which is responsible for 5\u201310\u00a0% of CMT2 cases, neurofilament light chain (NEFL) in 1\u20135\u00a0% and ganglioside-induced differentiation-associated protein (GDAP1) in less than 1\u00a0% of the cases [1, 3, 4, 11, 13].", "section": "INTRO", "tags": [{"name": "differentiation-associated", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "ganglioside-induced", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Wasting and weakness of intrinsic hand muscles resulted in split hand deformity (Fig.\u00a01; Table\u00a02).Table\u00a02Genetic and clinical characteristics of patients with AARS-related neuropathy in the UK/Irish cohortFamily/patient/age/sexOriginNucleotide/amino acid changeAge onsetClinical courseFirst signClinical signsMobility/orthoticsNerve conduction studyDistal lower limbDistal upper limbMotor NCV (m/s)Motor/sensoryMotorSensoryDeformityMotorSensoryDeformityF1/PIII.1/50\u00a0years/MUKc.986G>A/p.", "section": "OTHER", "tags": [{"name": "(m/s)Motor/sensoryMotorSensoryDeformityMotorSensoryDeformityF1/PIII.1/50", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "cohortFamily/patient/age/sexOriginNucleotide/amino", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Glu688Gly<1\u00a0yearsSlow progressSymmetricLL+n/aBilateral tight AchillesBilateral foot drop+n/aMild split handTiptoe walking bilateral AFOsm 29.3MS\nF family, P patient, M male, F female, UL upper limb, LL lower limb, + mild, ++ moderate, +++ severe, AFO ankle foot orthesis, n/a not available, m/s metre per second, m median nerve, p peroneal nerve, u ulnar nerve, intermed. intermediate, MS motor and sensory", "section": "OTHER", "tags": [{"name": "progressSymmetricLL+n/aBilateral", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "AchillesBilateral", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Glu688Gly<1\u00a0yearsSlow progressSymmetricLL+n/aBilateral tight AchillesBilateral foot drop+n/aMild split handTiptoe walking bilateral AFOsm 29.3MS\nF family, P patient, M male, F female, UL upper limb, LL lower limb, + mild, ++ moderate, +++ severe, AFO ankle foot orthesis, n/a not available, m/s metre per second, m median nerve, p peroneal nerve, u ulnar nerve, intermed. intermediate, MS motor and sensory", "section": "OTHER", "tags": [{"name": "progressSymmetricLL+n/aBilateral", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "AchillesBilateral", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Glu688Gly<1\u00a0yearsSlow progressSymmetricLL+n/aBilateral tight AchillesBilateral foot drop+n/aMild split handTiptoe walking bilateral AFOsm 29.3MS\nF family, P patient, M male, F female, UL upper limb, LL lower limb, + mild, ++ moderate, +++ severe, AFO ankle foot orthesis, n/a not available, m/s metre per second, m median nerve, p peroneal nerve, u ulnar nerve, intermed. intermediate, MS motor and sensory", "section": "OTHER", "tags": [{"name": "progressSymmetricLL+n/aBilateral", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "AchillesBilateral", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}]}
{"src": "PMC", "id": "PMC4457031", "provider": "OpenTargets", "anns": [{"type": "Gene Disease Relationship", "exact": "Mutations in this gene cause Ellis van Creveld syndrome and Weyers acrofacial dysostosis, clinically characterized by polydactyly, short ribs and limbs, growth retardation, congenital heart disease and ectodermal dysplasia (Baujat and Le Merrer, 2007; D'Asdia et al., 2013; Shen et al., 2011; Ye et al., 2006), which are phenotypes commonly associated with microtia.", "section": "DISCUSS", "tags": [{"name": "characterized", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "polydactyly,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "These findings are in agreement with the knowledge that HOXA1 plays a crucial multifaceted role during embryonic patterning and organogenesis, and are also consistent with the fact that the human and mouse HOXA1-related phenotypic presentations often have cardiovascular defects, renal abnormalities, rib deformities and mental retardation (Barrow et al., 2000; Chisaka et al., 1992; Harris et al., 1996; Mastroiacovo et al., 1995; Wang et al., 2001).", "section": "DISCUSS", "tags": [{"name": "organogenesis,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "cardiovascular", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Microtia-affected piglets in our study manifest many symptoms that are present in humans with HOXA1 truncating mutations (Bosley et al., 2008, 2007; Tischfield et al., 2005) or seen in Hoxa1-null mice (Chisaka et al., 1992; Lufkin et al., 1991), including abnormally shaped outer and middle ears, deafness, eyelid defects and, at least in affected humans, hypoventilation, swallowing dysfunction mainly due to cleft palate and mental retardation.", "section": "DISCUSS", "tags": [{"name": "Microtia-affected", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "hypoventilation,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "We then applied a series of exclusion steps to identify the causative mutation: (1) we removed variants that were heterozygous in the affected animal; (2) we excluded variants that were homozygous in one of the two parents; (3) we rejected variants that were inconsistent with the Mendelian inheritance model; (4) we excluded variants in the non-coding regions.", "section": "RESULTS", "tags": [{"name": "heterozygous", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "inconsistent", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "We explored 16,272 qualified SNPs to perform a genome-wide association analysis on the F2 family, after excluding the following single-nucleotide polymorphisms (SNPs): SNPs that had a low call rate (90%) or Hardy\u2013Weinberg equilibrium deviation >10\u22126, were non-informative (minor allele frequencies <0.05), or were not mapped to the reference genome (Sscrofa 10.2).", "section": "RESULTS", "tags": [{"name": "single-nucleotide", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "non-informative", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Mutations in this gene cause Ellis van Creveld syndrome and Weyers acrofacial dysostosis, clinically characterized by polydactyly, short ribs and limbs, growth retardation, congenital heart disease and ectodermal dysplasia (Baujat and Le Merrer, 2007; D'Asdia et al., 2013; Shen et al., 2011; Ye et al., 2006), which are phenotypes commonly associated with microtia.", "section": "DISCUSS", "tags": [{"name": "characterized", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "polydactyly,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "We then searched for potentially pathogenic variants by applying the following filtering criteria: we selected variants that have functional impacts as predicted by Polyphen2 (Adzhubei et al., 2013), are conserved across multiple species, and are absent in the database of The 1000 Genome project (http://www.1000genomes.org/), dbSNP (http://www.ncbi.nlm.nih.gov/SNP/) and The NHLBI Exome Variant Server (http://evs.gs.washington.edu/EVS/).", "section": "RESULTS", "tags": [{"name": "(http://evs.gs.washington.edu/EVS/).", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "(http://www.ncbi.nlm.nih.gov/SNP/)", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "The analysis generated \u2018Acute renal failure panel\u2019 (P=5.86E\u201304, ratio 6/62), \u2018NRF2-mediated oxidative stress response\u2019 (P=6.07E\u201304, ratio 12/234), \u2018Renal necrosis/Cell death\u2019 (P=8.13E\u201304, ratio 18/461), \u2018Oxidative stress\u2019 (P=2.62E\u201303, ratio 5/57) and \u2018Renal safety biomarker panel\u2019 (P=4.01E\u201303, ratio 2/6) as the top five most significant effects (supplementary material Table\u00a0S5).", "section": "RESULTS", "tags": [{"name": "\u2018NRF2-mediated", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "(supplementary", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Microtia-affected piglets in our study manifest many symptoms that are present in humans with HOXA1 truncating mutations (Bosley et al., 2008, 2007; Tischfield et al., 2005) or seen in Hoxa1-null mice (Chisaka et al., 1992; Lufkin et al., 1991), including abnormally shaped outer and middle ears, deafness, eyelid defects and, at least in affected humans, hypoventilation, swallowing dysfunction mainly due to cleft palate and mental retardation.", "section": "DISCUSS", "tags": [{"name": "Microtia-affected", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "hypoventilation,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "These findings are in agreement with the knowledge that HOXA1 plays a crucial multifaceted role during embryonic patterning and organogenesis, and are also consistent with the fact that the human and mouse HOXA1-related phenotypic presentations often have cardiovascular defects, renal abnormalities, rib deformities and mental retardation (Barrow et al., 2000; Chisaka et al., 1992; Harris et al., 1996; Mastroiacovo et al., 1995; Wang et al., 2001).", "section": "DISCUSS", "tags": [{"name": "organogenesis,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "cardiovascular", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "The analysis generated \u2018Acute renal failure panel\u2019 (P=5.86E\u201304, ratio 6/62), \u2018NRF2-mediated oxidative stress response\u2019 (P=6.07E\u201304, ratio 12/234), \u2018Renal necrosis/Cell death\u2019 (P=8.13E\u201304, ratio 18/461), \u2018Oxidative stress\u2019 (P=2.62E\u201303, ratio 5/57) and \u2018Renal safety biomarker panel\u2019 (P=4.01E\u201303, ratio 2/6) as the top five most significant effects (supplementary material Table\u00a0S5).", "section": "RESULTS", "tags": [{"name": "\u2018NRF2-mediated", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "(supplementary", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Mutations in this gene cause Ellis van Creveld syndrome and Weyers acrofacial dysostosis, clinically characterized by polydactyly, short ribs and limbs, growth retardation, congenital heart disease and ectodermal dysplasia (Baujat and Le Merrer, 2007; D'Asdia et al., 2013; Shen et al., 2011; Ye et al., 2006), which are phenotypes commonly associated with microtia.", "section": "DISCUSS", "tags": [{"name": "characterized", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "polydactyly,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "We explored 16,272 qualified SNPs to perform a genome-wide association analysis on the F2 family, after excluding the following single-nucleotide polymorphisms (SNPs): SNPs that had a low call rate (90%) or Hardy\u2013Weinberg equilibrium deviation >10\u22126, were non-informative (minor allele frequencies <0.05), or were not mapped to the reference genome (Sscrofa 10.2).", "section": "RESULTS", "tags": [{"name": "single-nucleotide", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "non-informative", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "We then searched for potentially pathogenic variants by applying the following filtering criteria: we selected variants that have functional impacts as predicted by Polyphen2 (Adzhubei et al., 2013), are conserved across multiple species, and are absent in the database of The 1000 Genome project (http://www.1000genomes.org/), dbSNP (http://www.ncbi.nlm.nih.gov/SNP/) and The NHLBI Exome Variant Server (http://evs.gs.washington.edu/EVS/).", "section": "RESULTS", "tags": [{"name": "(http://evs.gs.washington.edu/EVS/).", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "(http://www.ncbi.nlm.nih.gov/SNP/)", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "We explored 16,272 qualified SNPs to perform a genome-wide association analysis on the F2 family, after excluding the following single-nucleotide polymorphisms (SNPs): SNPs that had a low call rate (90%) or Hardy\u2013Weinberg equilibrium deviation >10\u22126, were non-informative (minor allele frequencies <0.05), or were not mapped to the reference genome (Sscrofa 10.2).", "section": "RESULTS", "tags": [{"name": "single-nucleotide", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "non-informative", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "We then applied a series of exclusion steps to identify the causative mutation: (1) we removed variants that were heterozygous in the affected animal; (2) we excluded variants that were homozygous in one of the two parents; (3) we rejected variants that were inconsistent with the Mendelian inheritance model; (4) we excluded variants in the non-coding regions.", "section": "RESULTS", "tags": [{"name": "heterozygous", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "inconsistent", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Microtia-affected piglets in our study manifest many symptoms that are present in humans with HOXA1 truncating mutations (Bosley et al., 2008, 2007; Tischfield et al., 2005) or seen in Hoxa1-null mice (Chisaka et al., 1992; Lufkin et al., 1991), including abnormally shaped outer and middle ears, deafness, eyelid defects and, at least in affected humans, hypoventilation, swallowing dysfunction mainly due to cleft palate and mental retardation.", "section": "DISCUSS", "tags": [{"name": "Microtia-affected", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "hypoventilation,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "These findings are in agreement with the knowledge that HOXA1 plays a crucial multifaceted role during embryonic patterning and organogenesis, and are also consistent with the fact that the human and mouse HOXA1-related phenotypic presentations often have cardiovascular defects, renal abnormalities, rib deformities and mental retardation (Barrow et al., 2000; Chisaka et al., 1992; Harris et al., 1996; Mastroiacovo et al., 1995; Wang et al., 2001).", "section": "DISCUSS", "tags": [{"name": "organogenesis,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "cardiovascular", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "The analysis generated \u2018Acute renal failure panel\u2019 (P=5.86E\u201304, ratio 6/62), \u2018NRF2-mediated oxidative stress response\u2019 (P=6.07E\u201304, ratio 12/234), \u2018Renal necrosis/Cell death\u2019 (P=8.13E\u201304, ratio 18/461), \u2018Oxidative stress\u2019 (P=2.62E\u201303, ratio 5/57) and \u2018Renal safety biomarker panel\u2019 (P=4.01E\u201303, ratio 2/6) as the top five most significant effects (supplementary material Table\u00a0S5).", "section": "RESULTS", "tags": [{"name": "\u2018NRF2-mediated", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "(supplementary", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "We then searched for potentially pathogenic variants by applying the following filtering criteria: we selected variants that have functional impacts as predicted by Polyphen2 (Adzhubei et al., 2013), are conserved across multiple species, and are absent in the database of The 1000 Genome project (http://www.1000genomes.org/), dbSNP (http://www.ncbi.nlm.nih.gov/SNP/) and The NHLBI Exome Variant Server (http://evs.gs.washington.edu/EVS/).", "section": "RESULTS", "tags": [{"name": "(http://evs.gs.washington.edu/EVS/).", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "(http://www.ncbi.nlm.nih.gov/SNP/)", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "The analysis generated \u2018Acute renal failure panel\u2019 (P=5.86E\u201304, ratio 6/62), \u2018NRF2-mediated oxidative stress response\u2019 (P=6.07E\u201304, ratio 12/234), \u2018Renal necrosis/Cell death\u2019 (P=8.13E\u201304, ratio 18/461), \u2018Oxidative stress\u2019 (P=2.62E\u201303, ratio 5/57) and \u2018Renal safety biomarker panel\u2019 (P=4.01E\u201303, ratio 2/6) as the top five most significant effects (supplementary material Table\u00a0S5).", "section": "RESULTS", "tags": [{"name": "\u2018NRF2-mediated", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "(supplementary", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}]}
{"src": "PMC", "id": "PMC4460277", "provider": "OpenTargets", "anns": [{"type": "Gene Disease Relationship", "exact": "The primer sequences were as follows: forward primer exon 19, 5\u2032-CCCACGCTCTTCTCACTCAT-3\u2032; reverse primer exon 19; 5\u2032-TCCTTCCTGTCCTCCTAGCA-3\u2032; forward primer exon 20, 5\u2032-TGGTCTCCCATACCCTCTCA-3\u2032; and reverse primer exon 20, 5\u2032-CAAAGAGCCCAGGTGCATA-3\u2032. Sequence analysis was performed using the 3500 genetic analyzer (Applied Biosystems).", "section": "METHODS", "tags": [{"name": "5\u2032-CCCACGCTCTTCTCACTCAT-3\u2032;", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "5\u2032-TCCTTCCTGTCCTCCTAGCA-3\u2032;", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Fig. 4HER2 immunohistochemistry: a strong membranous positivity in 100\u00a0% of the tumor cells of a conventional urothelial bladder cancer, score 3+; b score 3+ in a micropapillary variant; c mosaic pattern, score 3+; d strong positivity in carcinoma in situ, negativity in the adjacent normal urothelium", "section": "OTHER", "tags": [{"name": "immunohistochemistry:", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "micropapillary", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Comparison of HER2 amplified and non-amplified urothelial bladder cancers (n=13 each) in regard to their morphology (the tumor components are given as percentage in relation to the total tumor mass in each group): micropapillary architecture is a key feature of HER2 amplified urothelial bladder cancer", "section": "OTHER", "tags": [{"name": "micropapillary", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "non-amplified", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Taken together, these histomorphological features of HER2 amplified UBC\u2014frequent micropapillary architecture, morphological heterogeneity and marked tumor-associated chronic inflammation\u2014allow pathologists to better identify this clinically important, particularly aggressive subset of UBC [12] and herewith to contribute to enhanced survival prediction and preselection for potential anti-HER2 therapies in the future.", "section": "DISCUSS", "tags": [{"name": "histomorphological", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "inflammation\u2014allow", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "The primer sequences were as follows: forward primer exon 19, 5\u2032-CCCACGCTCTTCTCACTCAT-3\u2032; reverse primer exon 19; 5\u2032-TCCTTCCTGTCCTCCTAGCA-3\u2032; forward primer exon 20, 5\u2032-TGGTCTCCCATACCCTCTCA-3\u2032; and reverse primer exon 20, 5\u2032-CAAAGAGCCCAGGTGCATA-3\u2032. Sequence analysis was performed using the 3500 genetic analyzer (Applied Biosystems).", "section": "METHODS", "tags": [{"name": "5\u2032-CCCACGCTCTTCTCACTCAT-3\u2032;", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "5\u2032-TCCTTCCTGTCCTCCTAGCA-3\u2032;", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "HER2 amplified urothelial bladder cancer often presents with marked tumor-associated chronic inflammation (d HE\u2009\u00d7\u200920)\nFig. 2\nHER2 non-amplified urothelial bladder cancers mostly show conventional solid morphology (a HE\u2009\u00d7\u200910); b sarcomatoid variant (HE\u2009\u00d7\u200920)\nFig. 3Comparison of HER2 amplified and non-amplified urothelial bladder cancers (n=13 each) in regard to their morphology (the tumor components are given as percentage in relation to the total tumor mass in each group): micropapillary architecture is a key feature of HER2 amplified urothelial bladder cancer", "section": "OTHER", "tags": [{"name": "tumor-associated", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "micropapillary", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "HER2 immunohistochemistry: a strong membranous positivity in 100\u00a0% of the tumor cells of a conventional urothelial bladder cancer, score 3+; b score 3+ in a micropapillary variant; c mosaic pattern, score 3+; d strong positivity in carcinoma in situ, negativity in the adjacent normal urothelium", "section": "OTHER", "tags": [{"name": "immunohistochemistry:", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "micropapillary", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Comparison of HER2 amplified and non-amplified urothelial bladder cancers (n=13 each) in regard to their morphology (the tumor components are given as percentage in relation to the total tumor mass in each group): micropapillary architecture is a key feature of HER2 amplified urothelial bladder cancer", "section": "OTHER", "tags": [{"name": "micropapillary", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "non-amplified", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "HER2 amplified urothelial bladder cancer often presents with marked tumor-associated chronic inflammation (d HE\u2009\u00d7\u200920)\nFig. 2\nHER2 non-amplified urothelial bladder cancers mostly show conventional solid morphology (a HE\u2009\u00d7\u200910); b sarcomatoid variant (HE\u2009\u00d7\u200920)\nFig. 3Comparison of HER2 amplified and non-amplified urothelial bladder cancers (n=13 each) in regard to their morphology (the tumor components are given as percentage in relation to the total tumor mass in each group): micropapillary architecture is a key feature of HER2 amplified urothelial bladder cancer", "section": "OTHER", "tags": [{"name": "tumor-associated", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "micropapillary", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Comparison of HER2 amplified and non-amplified urothelial bladder cancers (n=13 each) in regard to their morphology (the tumor components are given as percentage in relation to the total tumor mass in each group): micropapillary architecture is a key feature of HER2 amplified urothelial bladder cancer", "section": "OTHER", "tags": [{"name": "micropapillary", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "non-amplified", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "The primer sequences were as follows: forward primer exon 19, 5\u2032-CCCACGCTCTTCTCACTCAT-3\u2032; reverse primer exon 19; 5\u2032-TCCTTCCTGTCCTCCTAGCA-3\u2032; forward primer exon 20, 5\u2032-TGGTCTCCCATACCCTCTCA-3\u2032; and reverse primer exon 20, 5\u2032-CAAAGAGCCCAGGTGCATA-3\u2032. Sequence analysis was performed using the 3500 genetic analyzer (Applied Biosystems).", "section": "METHODS", "tags": [{"name": "5\u2032-CCCACGCTCTTCTCACTCAT-3\u2032;", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "5\u2032-TCCTTCCTGTCCTCCTAGCA-3\u2032;", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "The primer sequences were as follows: forward primer exon 19, 5\u2032-CCCACGCTCTTCTCACTCAT-3\u2032; reverse primer exon 19; 5\u2032-TCCTTCCTGTCCTCCTAGCA-3\u2032; forward primer exon 20, 5\u2032-TGGTCTCCCATACCCTCTCA-3\u2032; and reverse primer exon 20, 5\u2032-CAAAGAGCCCAGGTGCATA-3\u2032. Sequence analysis was performed using the 3500 genetic analyzer (Applied Biosystems).", "section": "METHODS", "tags": [{"name": "5\u2032-CCCACGCTCTTCTCACTCAT-3\u2032;", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "5\u2032-TCCTTCCTGTCCTCCTAGCA-3\u2032;", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Fig. 4HER2 immunohistochemistry: a strong membranous positivity in 100\u00a0% of the tumor cells of a conventional urothelial bladder cancer, score 3+; b score 3+ in a micropapillary variant; c mosaic pattern, score 3+; d strong positivity in carcinoma in situ, negativity in the adjacent normal urothelium", "section": "OTHER", "tags": [{"name": "immunohistochemistry:", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "micropapillary", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "HER2 amplified urothelial bladder cancer often presents with marked tumor-associated chronic inflammation (d HE\u2009\u00d7\u200920)\nFig. 2\nHER2 non-amplified urothelial bladder cancers mostly show conventional solid morphology (a HE\u2009\u00d7\u200910); b sarcomatoid variant (HE\u2009\u00d7\u200920)\nFig. 3Comparison of HER2 amplified and non-amplified urothelial bladder cancers (n=13 each) in regard to their morphology (the tumor components are given as percentage in relation to the total tumor mass in each group): micropapillary architecture is a key feature of HER2 amplified urothelial bladder cancer", "section": "OTHER", "tags": [{"name": "tumor-associated", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "micropapillary", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "The primer sequences were as follows: forward primer exon 19, 5\u2032-CCCACGCTCTTCTCACTCAT-3\u2032; reverse primer exon 19; 5\u2032-TCCTTCCTGTCCTCCTAGCA-3\u2032; forward primer exon 20, 5\u2032-TGGTCTCCCATACCCTCTCA-3\u2032; and reverse primer exon 20, 5\u2032-CAAAGAGCCCAGGTGCATA-3\u2032. Sequence analysis was performed using the 3500 genetic analyzer (Applied Biosystems).", "section": "METHODS", "tags": [{"name": "5\u2032-CCCACGCTCTTCTCACTCAT-3\u2032;", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "5\u2032-TCCTTCCTGTCCTCCTAGCA-3\u2032;", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Fig. 4HER2 immunohistochemistry: a strong membranous positivity in 100\u00a0% of the tumor cells of a conventional urothelial bladder cancer, score 3+; b score 3+ in a micropapillary variant; c mosaic pattern, score 3+; d strong positivity in carcinoma in situ, negativity in the adjacent normal urothelium", "section": "OTHER", "tags": [{"name": "immunohistochemistry:", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "micropapillary", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "HER2 immunohistochemistry: a strong membranous positivity in 100\u00a0% of the tumor cells of a conventional urothelial bladder cancer, score 3+; b score 3+ in a micropapillary variant; c mosaic pattern, score 3+; d strong positivity in carcinoma in situ, negativity in the adjacent normal urothelium", "section": "OTHER", "tags": [{"name": "immunohistochemistry:", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "micropapillary", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Taken together, these histomorphological features of HER2 amplified UBC\u2014frequent micropapillary architecture, morphological heterogeneity and marked tumor-associated chronic inflammation\u2014allow pathologists to better identify this clinically important, particularly aggressive subset of UBC [12] and herewith to contribute to enhanced survival prediction and preselection for potential anti-HER2 therapies in the future.", "section": "DISCUSS", "tags": [{"name": "histomorphological", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "inflammation\u2014allow", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "HER2 amplified urothelial bladder cancer often presents with marked tumor-associated chronic inflammation (d HE\u2009\u00d7\u200920)\nFig. 2\nHER2 non-amplified urothelial bladder cancers mostly show conventional solid morphology (a HE\u2009\u00d7\u200910); b sarcomatoid variant (HE\u2009\u00d7\u200920)\nFig. 3Comparison of HER2 amplified and non-amplified urothelial bladder cancers (n=13 each) in regard to their morphology (the tumor components are given as percentage in relation to the total tumor mass in each group): micropapillary architecture is a key feature of HER2 amplified urothelial bladder cancer", "section": "OTHER", "tags": [{"name": "tumor-associated", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "micropapillary", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "The primer sequences were as follows: forward primer exon 19, 5\u2032-CCCACGCTCTTCTCACTCAT-3\u2032; reverse primer exon 19; 5\u2032-TCCTTCCTGTCCTCCTAGCA-3\u2032; forward primer exon 20, 5\u2032-TGGTCTCCCATACCCTCTCA-3\u2032; and reverse primer exon 20, 5\u2032-CAAAGAGCCCAGGTGCATA-3\u2032. Sequence analysis was performed using the 3500 genetic analyzer (Applied Biosystems).", "section": "METHODS", "tags": [{"name": "5\u2032-CCCACGCTCTTCTCACTCAT-3\u2032;", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "5\u2032-TCCTTCCTGTCCTCCTAGCA-3\u2032;", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Fig. 4HER2 immunohistochemistry: a strong membranous positivity in 100\u00a0% of the tumor cells of a conventional urothelial bladder cancer, score 3+; b score 3+ in a micropapillary variant; c mosaic pattern, score 3+; d strong positivity in carcinoma in situ, negativity in the adjacent normal urothelium", "section": "OTHER", "tags": [{"name": "immunohistochemistry:", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "micropapillary", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Comparison of HER2 amplified and non-amplified urothelial bladder cancers (n=13 each) in regard to their morphology (the tumor components are given as percentage in relation to the total tumor mass in each group): micropapillary architecture is a key feature of HER2 amplified urothelial bladder cancer", "section": "OTHER", "tags": [{"name": "micropapillary", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "non-amplified", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Comparison of HER2 amplified and non-amplified urothelial bladder cancers (n=13 each) in regard to their morphology (the tumor components are given as percentage in relation to the total tumor mass in each group): micropapillary architecture is a key feature of HER2 amplified urothelial bladder cancer", "section": "OTHER", "tags": [{"name": "micropapillary", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "non-amplified", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}]}
{"src": "PMC", "id": "PMC4454778", "provider": "OpenTargets", "anns": [{"type": "Gene Disease Relationship", "exact": "Our finding expands further the clinical variability among TRPV4 mutations and highlight that the presence of skeletal abnormalities in a patient with an axonal neuropathy or neuronopathy should raise the possibility of TRPV4 gene mutations.", "section": "DISCUSS", "tags": [{"name": "abnormalities", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "neuronopathy", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Among the skeletal dysplasias, TRPV4 mutations have been described in patients with brachyolmia (OMIM 113500), spondylometaphyseal dysplasia Kozlowski type (SMD-K; OMIM 184252), metatropic dysplasia (OMIM 156530), parastremmatic dysplasia (OMIM 168400), and spondyloepimetaphyseal dysplasia Maroteaux type (SEMD-M; OMIM 184095).", "section": "INTRO", "tags": [{"name": "spondyloepimetaphyseal", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "spondylometaphyseal", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "We assume that the differences between our patient and the ones reported by Astrea et\u00a0al. [20] and Oates et\u00a0al. [17] are due to the fact that our case is a late onset form of the disease (CMT2C) while the later ones corresponded to congenital forms of SMA.", "section": "DISCUSS", "tags": [{"name": "corresponded", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "differences", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Whole-exome sequencing was carried out in both patients using genomic DNA extracted from peripheral blood lymphocytes, fragmented, and exome enriched by Illumina TruSeq\u2122 62\u2009Mb and sequenced on a HiSeq 2000 with 100\u2009bp paired-end reads.", "section": "METHODS", "tags": [{"name": "lymphocytes,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "Whole-exome", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Results were further filtered for variants with a minor allele frequency less than 0.01 in several databases: dbSNP135, 1000 genomes (February 2012 data release), the National Heart, Lung and Blood Institute (NHLBI, NIH, Bethesda, MD) Exome Sequencing Project (ESP) 6500 exomes, and 238 unrelated in-house controls, in order to detect rare variants.", "section": "METHODS", "tags": [{"name": "databases:", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "Sequencing", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Results were further filtered for variants with a minor allele frequency less than 0.01 in several databases: dbSNP135, 1000 genomes (February 2012 data release), the National Heart, Lung and Blood Institute (NHLBI, NIH, Bethesda, MD) Exome Sequencing Project (ESP) 6500 exomes, and 238 unrelated in-house controls, in order to detect rare variants.", "section": "METHODS", "tags": [{"name": "databases:", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "Sequencing", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "PNSS include hereditary motor and sensory neuropathy type 2C or Charcot\u2013Marie\u2013Tooth disease type 2C (HMSN2C or CMT2C; OMIM 606071), congenital spinal muscular atrophy and arthrogryposis (CSMAA; OMIM 600175) and scapuloperoneal spinal muscular atrophy (SPSMA; OMIM 181405).", "section": "INTRO", "tags": [{"name": "Charcot\u2013Marie\u2013Tooth", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "scapuloperoneal", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Whole-exome sequencing was carried out in both patients using genomic DNA extracted from peripheral blood lymphocytes, fragmented, and exome enriched by Illumina TruSeq\u2122 62\u2009Mb and sequenced on a HiSeq 2000 with 100\u2009bp paired-end reads.", "section": "METHODS", "tags": [{"name": "lymphocytes,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "Whole-exome", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Among the skeletal dysplasias, TRPV4 mutations have been described in patients with brachyolmia (OMIM 113500), spondylometaphyseal dysplasia Kozlowski type (SMD-K; OMIM 184252), metatropic dysplasia (OMIM 156530), parastremmatic dysplasia (OMIM 168400), and spondyloepimetaphyseal dysplasia Maroteaux type (SEMD-M; OMIM 184095).", "section": "INTRO", "tags": [{"name": "spondyloepimetaphyseal", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "spondylometaphyseal", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Results were further filtered for variants with a minor allele frequency less than 0.01 in several databases: dbSNP135, 1000 genomes (February 2012 data release), the National Heart, Lung and Blood Institute (NHLBI, NIH, Bethesda, MD) Exome Sequencing Project (ESP) 6500 exomes, and 238 unrelated in-house controls, in order to detect rare variants.", "section": "METHODS", "tags": [{"name": "databases:", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "Sequencing", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Our finding expands further the clinical variability among TRPV4 mutations and highlight that the presence of skeletal abnormalities in a patient with an axonal neuropathy or neuronopathy should raise the possibility of TRPV4 gene mutations.", "section": "DISCUSS", "tags": [{"name": "abnormalities", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "neuronopathy", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Our finding expands further the clinical variability among TRPV4 mutations and highlight that the presence of skeletal abnormalities in a patient with an axonal neuropathy or neuronopathy should raise the possibility of TRPV4 gene mutations.", "section": "DISCUSS", "tags": [{"name": "abnormalities", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "neuronopathy", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}]}
{"src": "PMC", "id": "PMC4363147", "provider": "OpenTargets", "anns": [{"type": "Gene Disease Relationship", "exact": "Depressive symptoms after hip fracture have a pernicious effect on the recovery process: they are associated with higher discharge rates to and increased length of stay in nursing homes [13\u201315], poorer occupational and physical therapy participation, and poorer functional recovery [16,17].", "section": "INTRO", "tags": [{"name": "participation,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "occupational", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Washington University's Human Research Protection Office, Washington University School of Medicine Institutional Review Board, and the review boards at the applicable participating research site (The Christian Hospital Research Committee for Christian Hospital, DePaul Institutional Review Board for DePaul Health Center, Missouri Baptist Medical Center Institutional Review Board for Missouri Baptist Medical Center, Saint Anthony\u2019s Medical Center Institutional Review Board for Saint Anthony's Medical Center, SSM Saint Louis Institutional Review Board for SSM Saint Clare Health Center, Saint Louis University Institutional Review Board for Saint Louis University Medical Center Campus and Saint Mary\u2019s Health Center, and Washington University School of Medicine Institutional Review Board for Barnes-Jewish Hospital) approved this study and approved the informed written consent document that was signed by all participants.", "section": "OTHER", "tags": [{"name": "Institutional", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "participating", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Participants with hip fracture were excluded if they were unable to provide written informed consent after complete description of the study, were unable to cooperate with the protocol, had a current diagnosis of major depression, had metastatic cancer, were significantly impaired by language, visual or hearing barriers, lived more than one hour away, were taking interferon medications, or had an inoperable fracture.", "section": "OTHER", "tags": [{"name": "significantly", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "Participants", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Washington University's Human Research Protection Office, Washington University School of Medicine Institutional Review Board, and the review boards at the applicable participating research site (The Christian Hospital Research Committee for Christian Hospital, DePaul Institutional Review Board for DePaul Health Center, Missouri Baptist Medical Center Institutional Review Board for Missouri Baptist Medical Center, Saint Anthony\u2019s Medical Center Institutional Review Board for Saint Anthony's Medical Center, SSM Saint Louis Institutional Review Board for SSM Saint Clare Health Center, Saint Louis University Institutional Review Board for Saint Louis University Medical Center Campus and Saint Mary\u2019s Health Center, and Washington University School of Medicine Institutional Review Board for Barnes-Jewish Hospital) approved this study and approved the informed written consent document that was signed by all participants.", "section": "OTHER", "tags": [{"name": "Institutional", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "participating", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "The gene SLC6A4 encodes for the serotonin transporter (5HTT) and this transporter\u2019s efficiency is altered by both a genetic variation of the serotonin transporter gene-linked polymorphic region (5HTTLPR) and a functional A to G single-nucleotide polymorphism (SNP; refSNP: rs25531) [37,38].", "section": "INTRO", "tags": [{"name": "single-nucleotide", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "transporter\u2019s", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Participants with hip fracture were excluded if they were unable to provide written informed consent after complete description of the study, were unable to cooperate with the protocol, had a current diagnosis of major depression, had metastatic cancer, were significantly impaired by language, visual or hearing barriers, lived more than one hour away, were taking interferon medications, or had an inoperable fracture.", "section": "OTHER", "tags": [{"name": "significantly", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "Participants", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "The gene SLC6A4 encodes for the serotonin transporter (5HTT) and this transporter\u2019s efficiency is altered by both a genetic variation of the serotonin transporter gene-linked polymorphic region (5HTTLPR) and a functional A to G single-nucleotide polymorphism (SNP; refSNP: rs25531) [37,38].", "section": "INTRO", "tags": [{"name": "single-nucleotide", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "transporter\u2019s", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Depressive symptoms after hip fracture have a pernicious effect on the recovery process: they are associated with higher discharge rates to and increased length of stay in nursing homes [13\u201315], poorer occupational and physical therapy participation, and poorer functional recovery [16,17].", "section": "INTRO", "tags": [{"name": "participation,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "occupational", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "The gene SLC6A4 encodes for the serotonin transporter (5HTT) and this transporter\u2019s efficiency is altered by both a genetic variation of the serotonin transporter gene-linked polymorphic region (5HTTLPR) and a functional A to G single-nucleotide polymorphism (SNP; refSNP: rs25531) [37,38].", "section": "INTRO", "tags": [{"name": "single-nucleotide", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "transporter\u2019s", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Participants with hip fracture were excluded if they were unable to provide written informed consent after complete description of the study, were unable to cooperate with the protocol, had a current diagnosis of major depression, had metastatic cancer, were significantly impaired by language, visual or hearing barriers, lived more than one hour away, were taking interferon medications, or had an inoperable fracture.", "section": "OTHER", "tags": [{"name": "significantly", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "Participants", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "The gene SLC6A4 encodes for the serotonin transporter (5HTT) and this transporter\u2019s efficiency is altered by both a genetic variation of the serotonin transporter gene-linked polymorphic region (5HTTLPR) and a functional A to G single-nucleotide polymorphism (SNP; refSNP: rs25531) [37,38].", "section": "INTRO", "tags": [{"name": "single-nucleotide", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "transporter\u2019s", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Washington University's Human Research Protection Office, Washington University School of Medicine Institutional Review Board, and the review boards at the applicable participating research site (The Christian Hospital Research Committee for Christian Hospital, DePaul Institutional Review Board for DePaul Health Center, Missouri Baptist Medical Center Institutional Review Board for Missouri Baptist Medical Center, Saint Anthony\u2019s Medical Center Institutional Review Board for Saint Anthony's Medical Center, SSM Saint Louis Institutional Review Board for SSM Saint Clare Health Center, Saint Louis University Institutional Review Board for Saint Louis University Medical Center Campus and Saint Mary\u2019s Health Center, and Washington University School of Medicine Institutional Review Board for Barnes-Jewish Hospital) approved this study and approved the informed written consent document that was signed by all participants.", "section": "OTHER", "tags": [{"name": "Institutional", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "participating", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "As Kendler [79] argues, it is unlikely we will uncover an exclusive genetic pattern revealing a heterogeneous illness such as depression; but it is possible to identify subsets of genetic interactions that delineate particular molecular pathways susceptible under certain genetic and environmental conditions.", "section": "DISCUSS", "tags": [{"name": "heterogeneous", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "environmental", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Washington University's Human Research Protection Office, Washington University School of Medicine Institutional Review Board, and the review boards at the applicable participating research site (The Christian Hospital Research Committee for Christian Hospital, DePaul Institutional Review Board for DePaul Health Center, Missouri Baptist Medical Center Institutional Review Board for Missouri Baptist Medical Center, Saint Anthony\u2019s Medical Center Institutional Review Board for Saint Anthony's Medical Center, SSM Saint Louis Institutional Review Board for SSM Saint Clare Health Center, Saint Louis University Institutional Review Board for Saint Louis University Medical Center Campus and Saint Mary\u2019s Health Center, and Washington University School of Medicine Institutional Review Board for Barnes-Jewish Hospital) approved this study and approved the informed written consent document that was signed by all participants.", "section": "OTHER", "tags": [{"name": "Institutional", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "participating", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Participants with hip fracture were excluded if they were unable to provide written informed consent after complete description of the study, were unable to cooperate with the protocol, had a current diagnosis of major depression, had metastatic cancer, were significantly impaired by language, visual or hearing barriers, lived more than one hour away, were taking interferon medications, or had an inoperable fracture.", "section": "OTHER", "tags": [{"name": "significantly", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "Participants", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Considering previous studies have indicated that atrophy of the hippocampus [22,33] and reduced hippocampal activity [32] are associated with the Met allele, BDNF Met/Met carriers may be vulnerable to the development of depressive symptoms due to inadequate synaptic formation in the hippocampus, a structure important for mood regulation [26,34,35,65,66].", "section": "DISCUSS", "tags": [{"name": "[26,34,35,65,66].", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "hippocampus,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}]}
{"src": "PMC", "id": "PMC6680266", "provider": "OpenTargets", "anns": [{"type": "Gene Disease Relationship", "exact": "Each component of the model was: co\u2010dominant model (major allele homozygotes vs. heterozygotes vs. minor allele homozygotes), dominant model (major allele homozygotes vs. heterozygotes + minor allele homozygotes), recessive model (major allele homozygotes vs. minor allele homozygotes), overdominant model (major allele homozygotes + heterozygotes vs. minor allele homozygotes) and log\u2010additive model.", "section": "METHODS", "tags": [{"name": "heterozygotes", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "homozygotes),", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "These were: TLR3 rs3775296, TLR4 rs11536889 and rs1927907, TLR5 rs5744174, TLR9 rs352140, MYD88 rs7744, IRAK1 rs1059702 and rs1059703, IFNG rs2069705, IFNGR1 rs3799488 and rs10457655, IFNGR2 rs1059293 and rs2834211, IL15 rs10519613 and rs10833, IL28B rs12979860 and rs8099917, IL29 rs30461, IL6 rs1800796, IL27B rs4905 and rs6613, IL12B rs3212227, NFKB1 rs4648068, NFKB2 rs7897947, IL1B rs1143623, rs1143627, and rs16944, IL2 rs2069772, IL10 rs1800872 and rs1800896, IL12A rs2243115 and rs568408, CXCL10 rs4256246, rs4508917, and rs8878, MX1 rs1557370, rs2070229, rs467960, and rs469390.", "section": "METHODS", "tags": [{"name": "rs10457655,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "rs3775296,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "These were: TLR3 rs3775296, TLR4 rs11536889 and rs1927907, TLR5 rs5744174, TLR9 rs352140, MYD88 rs7744, IRAK1 rs1059702 and rs1059703, IFNG rs2069705, IFNGR1 rs3799488 and rs10457655, IFNGR2 rs1059293 and rs2834211, IL15 rs10519613 and rs10833, IL28B rs12979860 and rs8099917, IL29 rs30461, IL6 rs1800796, IL27B rs4905 and rs6613, IL12B rs3212227, NFKB1 rs4648068, NFKB2 rs7897947, IL1B rs1143623, rs1143627, and rs16944, IL2 rs2069772, IL10 rs1800872 and rs1800896, IL12A rs2243115 and rs568408, CXCL10 rs4256246, rs4508917, and rs8878, MX1 rs1557370, rs2070229, rs467960, and rs469390.", "section": "METHODS", "tags": [{"name": "rs10457655,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "rs3775296,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "A significant association was seen in several of the TLR\u2013IFN pathway genes, TLR9 rs352140 (OR\u00a0=\u00a00.70, P\u00a0=\u00a00.0088), IL1B rs16944 (OR\u00a0=\u00a00.67, P\u00a0=\u00a00.016), IL12B rs3212227 (OR\u00a0=\u00a01.38, P\u00a0=\u00a00.021), IFNGR1 rs3799488 (OR\u00a0=\u00a01.48, P\u00a0=\u00a00.0048), IFNGR2 rs1059293 (OR\u00a0=\u00a00.27, P\u00a0=\u00a00.011), MX1 rs467960 (OR\u00a0=\u00a00.68, P\u00a0=\u00a00.022), as well as four loci in HLA, rs3077 (OR\u00a0=\u00a00.55, P\u00a0<\u00a00.0001), rs2856718 (OR\u00a0=\u00a00.60, P\u00a0=\u00a04e\u201004), rs9277535 (OR\u00a0=\u00a00.54, P\u00a0<\u00a00.0001) and rs7453920 (OR\u00a0=\u00a00.43, P\u00a0<\u00a00.0001).", "section": "RESULTS", "tags": [{"name": "significant", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "association", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Each component of the model was: co\u2010dominant model (major allele homozygotes vs. heterozygotes vs. minor allele homozygotes), dominant model (major allele homozygotes vs. heterozygotes + minor allele homozygotes), recessive model (major allele homozygotes vs. minor allele homozygotes), overdominant model (major allele homozygotes + heterozygotes vs. minor allele homozygotes) and log\u2010additive model.", "section": "METHODS", "tags": [{"name": "heterozygotes", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "homozygotes),", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Exclusion criteria consisted of the following: (a) co\u2010infectionwith HCV, hepatitis D virus or human immunodeficiency virus (HIV); (b) coexisting serious medical or psychiatric illness; (c) organ or bone marrow transplantation; (d) recent treatment with systemic corticosteroids, immunosuppressants or chemotherapeutic agents.", "section": "METHODS", "tags": [{"name": "immunosuppressants", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "co\u2010infectionwith", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "These genes included TLRs (TLR3, TLR4, TLR5 and TLR9), the TLR adaptin MYD88, the TLR effector molecule IRAK1, receptors for IFNs (IFNGR1, IFNGR2, IL27B and IL12B), ligands for IFN receptors (IFNG and IL15), other genes related to IFNs (IL28A, IL29 and IL6), proteins induced by IFN (MX1, CXCL10), and genes of the NF\u03baB pathway (NFKB1, NFKB2, IL1B, IL2, IL10 and IL12A).", "section": "METHODS", "tags": [{"name": "receptors", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "receptors", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Susceptibility to chronic infection rather than virus clearance after HBV exposure, presentation of various clinical phenotypes and differing clinical outcomes in chronic HBV infection, as well as differing responses to antivirus treatment demonstrate that the genetic background of the innate immune system is a crucial factor in determining the outcome of HBV infection.", "section": "DISCUSS", "tags": [{"name": "Susceptibility", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "presentation", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "These genes included TLRs (TLR3, TLR4, TLR5 and TLR9), the TLR adaptin MYD88, the TLR effector molecule IRAK1, receptors for IFNs (IFNGR1, IFNGR2, IL27B and IL12B), ligands for IFN receptors (IFNG and IL15), other genes related to IFNs (IL28A, IL29 and IL6), proteins induced by IFN (MX1, CXCL10), and genes of the NF\u03baB pathway (NFKB1, NFKB2, IL1B, IL2, IL10 and IL12A).", "section": "METHODS", "tags": [{"name": "receptors", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "receptors", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "A significant association was seen in several of the TLR\u2013IFN pathway genes, TLR9 rs352140 (OR\u00a0=\u00a00.70, P\u00a0=\u00a00.0088), IL1B rs16944 (OR\u00a0=\u00a00.67, P\u00a0=\u00a00.016), IL12B rs3212227 (OR\u00a0=\u00a01.38, P\u00a0=\u00a00.021), IFNGR1 rs3799488 (OR\u00a0=\u00a01.48, P\u00a0=\u00a00.0048), IFNGR2 rs1059293 (OR\u00a0=\u00a00.27, P\u00a0=\u00a00.011), MX1 rs467960 (OR\u00a0=\u00a00.68, P\u00a0=\u00a00.022), as well as four loci in HLA, rs3077 (OR\u00a0=\u00a00.55, P\u00a0<\u00a00.0001), rs2856718 (OR\u00a0=\u00a00.60, P\u00a0=\u00a04e\u201004), rs9277535 (OR\u00a0=\u00a00.54, P\u00a0<\u00a00.0001) and rs7453920 (OR\u00a0=\u00a00.43, P\u00a0<\u00a00.0001).", "section": "RESULTS", "tags": [{"name": "significant", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "association", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "These were: TLR3 rs3775296, TLR4 rs11536889 and rs1927907, TLR5 rs5744174, TLR9 rs352140, MYD88 rs7744, IRAK1 rs1059702 and rs1059703, IFNG rs2069705, IFNGR1 rs3799488 and rs10457655, IFNGR2 rs1059293 and rs2834211, IL15 rs10519613 and rs10833, IL28B rs12979860 and rs8099917, IL29 rs30461, IL6 rs1800796, IL27B rs4905 and rs6613, IL12B rs3212227, NFKB1 rs4648068, NFKB2 rs7897947, IL1B rs1143623, rs1143627, and rs16944, IL2 rs2069772, IL10 rs1800872 and rs1800896, IL12A rs2243115 and rs568408, CXCL10 rs4256246, rs4508917, and rs8878, MX1 rs1557370, rs2070229, rs467960, and rs469390.", "section": "METHODS", "tags": [{"name": "rs10457655,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "rs3775296,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Each component of the model was: co\u2010dominant model (major allele homozygotes vs. heterozygotes vs. minor allele homozygotes), dominant model (major allele homozygotes vs. heterozygotes + minor allele homozygotes), recessive model (major allele homozygotes vs. minor allele homozygotes), overdominant model (major allele homozygotes + heterozygotes vs. minor allele homozygotes) and log\u2010additive model.", "section": "METHODS", "tags": [{"name": "heterozygotes", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "homozygotes),", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}]}
{"src": "PMC", "id": "PMC4583332", "provider": "OpenTargets", "anns": [{"type": "Gene Disease Relationship", "exact": "Further evidence implicating PKC deficits has emerged from clinical studies that showed with autopsy-confirmation that AD patients have significant abnormalities in PKC isozymes and PKC-elicited phosphorylation of downstream substrates [15, 16, 23, 24].", "section": "OTHER", "tags": [{"name": "autopsy-confirmation", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "phosphorylation", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Given the continuing decline in cost of next generation sequencing reagents, automation of variant calling methods, and potential diagnostic value susceptibility variants such as APOE\u025b4, whole exome approaches should be considered to be a more comprehensive, cost-effective alternative to candidate gene sequencing for the diagnosis of atypical dementias.", "section": "DISCUSS", "tags": [{"name": "susceptibility", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "comprehensive,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Since variants in known causal loci only explain a fraction of early-onset dementias, we performed whole exome sequencing with discrete filtering on two affected family members in order to identify causal variants and make a more accurate diagnosis.", "section": "INTRO", "tags": [{"name": "early-onset", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "dementias,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Scores of disease processes may ultimately lead to dementia, but there are four major primary disorders with dementia as their main clinical feature: Alzheimer\u2019s disease (AD), frontotemporal lobe degeneration (FTLD), cerebrovascular disease, and dementia with Lewy bodies [1, 2].", "section": "INTRO", "tags": [{"name": "cerebrovascular", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "frontotemporal", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Given the continuing decline in cost of next generation sequencing reagents, automation of variant calling methods, and potential diagnostic value susceptibility variants such as APOE\u025b4, whole exome approaches should be considered to be a more comprehensive, cost-effective alternative to candidate gene sequencing for the diagnosis of atypical dementias.", "section": "DISCUSS", "tags": [{"name": "susceptibility", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "comprehensive,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "We believe that the Thr147Ile variant is the primary or sole cause of the disease in our patients for the following reasons: 1) Polyphen-2 analysis indicates the variant is probably damaging; 2) The substitution is located on the helical face of a PS1 transmembrane domain where all deleterious transmembrane variants are known to cluster [25]; 3) The same variant was present in four affected members of three generations of a French family (ALZ047) with early-onset autosomal dominant AD and absent from asymptomatic ALZ047 members \u226560 years of age [19]; 4) The variant was present in four affected members of our family (III-29, IV-1, IV-2, and IV-18); and 5) At least 185 mutations in PSEN1 are known to cause EOAD [12].", "section": "DISCUSS", "tags": [{"name": "transmembrane", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "transmembrane", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Further evidence implicating PKC deficits has emerged from clinical studies that showed with autopsy-confirmation that AD patients have significant abnormalities in PKC isozymes and PKC-elicited phosphorylation of downstream substrates [15, 16, 23, 24].", "section": "OTHER", "tags": [{"name": "autopsy-confirmation", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "phosphorylation", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Scores of disease processes may ultimately lead to dementia, but there are four major primary disorders with dementia as their main clinical feature: Alzheimer\u2019s disease (AD), frontotemporal lobe degeneration (FTLD), cerebrovascular disease, and dementia with Lewy bodies [1, 2].", "section": "INTRO", "tags": [{"name": "cerebrovascular", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "frontotemporal", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Given the continuing decline in cost of next generation sequencing reagents, automation of variant calling methods, and potential diagnostic value susceptibility variants such as APOE\u025b4, whole exome approaches should be considered to be a more comprehensive, cost-effective alternative to candidate gene sequencing for the diagnosis of atypical dementias.", "section": "DISCUSS", "tags": [{"name": "susceptibility", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "comprehensive,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Since variants in known causal loci only explain a fraction of early-onset dementias, we performed whole exome sequencing with discrete filtering on two affected family members in order to identify causal variants and make a more accurate diagnosis.", "section": "INTRO", "tags": [{"name": "early-onset", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "dementias,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Further evidence implicating PKC deficits has emerged from clinical studies that showed with autopsy-confirmation that AD patients have significant abnormalities in PKC isozymes and PKC-elicited phosphorylation of downstream substrates [15, 16, 23, 24].", "section": "OTHER", "tags": [{"name": "autopsy-confirmation", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "phosphorylation", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Extensive pre-clinical research with AD-transgenic mice [14] and clinical data that included autopsy-confirmed diagnostic specificity of the protein kinase C (PKC) pathway [15, 16] provided a rationale for an FDA approval for a Phase 2a clinical trial with the highly potent PKC activator, bryostatin.", "section": "INTRO", "tags": [{"name": "autopsy-confirmed", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "AD-transgenic", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "We believe that the Thr147Ile variant is the primary or sole cause of the disease in our patients for the following reasons: 1) Polyphen-2 analysis indicates the variant is probably damaging; 2) The substitution is located on the helical face of a PS1 transmembrane domain where all deleterious transmembrane variants are known to cluster [25]; 3) The same variant was present in four affected members of three generations of a French family (ALZ047) with early-onset autosomal dominant AD and absent from asymptomatic ALZ047 members \u226560 years of age [19]; 4) The variant was present in four affected members of our family (III-29, IV-1, IV-2, and IV-18); and 5) At least 185 mutations in PSEN1 are known to cause EOAD [12].", "section": "DISCUSS", "tags": [{"name": "transmembrane", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "transmembrane", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "The latter pathology frequently leads to speech patterns consistent with the logopenic variant of primary progressive aphasia, with single word retrieval issues and impaired repetition of words or phrases [17], whereas these abnormalities were specifically denied in her history and not seen on earlier neuropsychological testing.", "section": "METHODS", "tags": [{"name": "neuropsychological", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "abnormalities", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Further evidence implicating PKC deficits has emerged from clinical studies that showed with autopsy-confirmation that AD patients have significant abnormalities in PKC isozymes and PKC-elicited phosphorylation of downstream substrates [15, 16, 23, 24].", "section": "OTHER", "tags": [{"name": "autopsy-confirmation", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "phosphorylation", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}]}
{"src": "PMC", "id": "PMC4151597", "provider": "OpenTargets", "anns": [{"type": "Gene Disease Relationship", "exact": "As shown in Table 3 and Figure 3, there was no association in these four genotypes (A versus G: OR = 0.99, 95% CI = 0.94\u20131.04, P = 0.69; homozygote comparison (AA versus GG): OR = 1.01, 95% CI = 0.88\u20131.15, P = 0.93; heterozygote comparison (AG versus GG): OR = 0.98, 95% CI = 0.92\u20131.05, P = 0.59; recessive model (AA versus GG + AG): OR = 1.01, 95% CI = 0.89\u20131.15, P = 0.85).", "section": "METHODS", "tags": [{"name": "heterozygote", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "association", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "The meta-analysis assessed association by using 4 different genetic models: (1) dominant genetic model\u2014the comparison groups were the wild-type homozygous genotype versus the variant allele-positive genotypes (AA + Aa versus aa); (2) recessive genetic model\u2014the comparison groups were the variant homozygous genotype versus the rest (AA versus aa + Aa); (3) homozygous genetic model\u2014comparison was between the 2 homozygous genotypes (AA versus aa); and (4) allele contrast genetic model\u2014the comparison was between the heterozygous and the homozygous wild-type genotype groups (Aa versus aa (where \u201ca\u201d is the wild-type allele and \u201cA\u201d is the variant allele)).", "section": "METHODS", "tags": [{"name": "model\u2014comparison", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "allele-positive", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "As shown in Table 3 and Figure 4, there was no significant association in rs5275 polymorphism (homozygote comparison: OR = 1.04, 95% CI = 0.96\u20131.12, P = 0.34; heterozygote comparison: OR = 0.99, 95% CI = 0.95\u20131.04, P = 0.81; dominant model: OR = 1.02, 95% CI = 0.98\u20131.07, P = 0.33, and recessive model: OR = 1.04, 95% CI = 0.97\u20131.12, P = 0.27).", "section": "METHODS", "tags": [{"name": "polymorphism", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "heterozygote", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "As shown in Table 3 and Figure 3, there was no association in these four genotypes (A versus G: OR = 0.99, 95% CI = 0.94\u20131.04, P = 0.69; homozygote comparison (AA versus GG): OR = 1.01, 95% CI = 0.88\u20131.15, P = 0.93; heterozygote comparison (AG versus GG): OR = 0.98, 95% CI = 0.92\u20131.05, P = 0.59; recessive model (AA versus GG + AG): OR = 1.01, 95% CI = 0.89\u20131.15, P = 0.85).", "section": "METHODS", "tags": [{"name": "heterozygote", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "association", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "The following criteria were used to select studies for further meta-analysis: (1) case-control studies; (2) studies that evaluated the associations between COX-2 polymorphisms and breast cancer risk; (3) studies that contained at least two comparison groups (cancer versus control); (4) studies that included detailed genotyping data.", "section": "METHODS", "tags": [{"name": "meta-analysis:", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "polymorphisms", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "The meta-analysis assessed association by using 4 different genetic models: (1) dominant genetic model\u2014the comparison groups were the wild-type homozygous genotype versus the variant allele-positive genotypes (AA + Aa versus aa); (2) recessive genetic model\u2014the comparison groups were the variant homozygous genotype versus the rest (AA versus aa + Aa); (3) homozygous genetic model\u2014comparison was between the 2 homozygous genotypes (AA versus aa); and (4) allele contrast genetic model\u2014the comparison was between the heterozygous and the homozygous wild-type genotype groups (Aa versus aa (where \u201ca\u201d is the wild-type allele and \u201cA\u201d is the variant allele)).", "section": "METHODS", "tags": [{"name": "model\u2014comparison", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "allele-positive", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "We found no significant association of rs5275 polymorphism with breast cancer risk (homozygote comparison: OR = 1.04, 95% CI = 0.96\u20131.12, P = 0.34; heterozygote comparison: OR = 0.99, 95% CI = 0.95\u20131.04, P = 0.81; dominant model: OR = 1.02, 95% CI = 0.98\u20131.07, P = 0.33, and recessive model: OR = 1.04, 95% CI = 0.97\u20131.12, P = 0.27).", "section": "DISCUSS", "tags": [{"name": "polymorphism", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "heterozygote", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "The following criteria were used to select studies for further meta-analysis: (1) case-control studies; (2) studies that evaluated the associations between COX-2 polymorphisms and breast cancer risk; (3) studies that contained at least two comparison groups (cancer versus control); (4) studies that included detailed genotyping data.", "section": "METHODS", "tags": [{"name": "meta-analysis:", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "polymorphisms", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "In breast cancer, several studies have suggested that moderate to high COX-2 expression is related to the genesis of mammary tumors and the expression level is associated with the aggressiveness of breast cancer, including large tumor size, positive axillary lymph node metastases, and HER2-positive tumor status [9\u201311].", "section": "INTRO", "tags": [{"name": "aggressiveness", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "HER2-positive", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "As shown in Table 3 and Figure 4, there was no significant association in rs5275 polymorphism (homozygote comparison: OR = 1.04, 95% CI = 0.96\u20131.12, P = 0.34; heterozygote comparison: OR = 0.99, 95% CI = 0.95\u20131.04, P = 0.81; dominant model: OR = 1.02, 95% CI = 0.98\u20131.07, P = 0.33, and recessive model: OR = 1.04, 95% CI = 0.97\u20131.12, P = 0.27).", "section": "METHODS", "tags": [{"name": "polymorphism", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "heterozygote", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "As shown in Table 3 and Figure 4, there was no significant association in rs5275 polymorphism (homozygote comparison: OR = 1.04, 95% CI = 0.96\u20131.12, P = 0.34; heterozygote comparison: OR = 0.99, 95% CI = 0.95\u20131.04, P = 0.81; dominant model: OR = 1.02, 95% CI = 0.98\u20131.07, P = 0.33, and recessive model: OR = 1.04, 95% CI = 0.97\u20131.12, P = 0.27).", "section": "METHODS", "tags": [{"name": "polymorphism", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "heterozygote", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "The following criteria were used to select studies for further meta-analysis: (1) case-control studies; (2) studies that evaluated the associations between COX-2 polymorphisms and breast cancer risk; (3) studies that contained at least two comparison groups (cancer versus control); (4) studies that included detailed genotyping data.", "section": "METHODS", "tags": [{"name": "meta-analysis:", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "polymorphisms", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "The meta-analysis assessed association by using 4 different genetic models: (1) dominant genetic model\u2014the comparison groups were the wild-type homozygous genotype versus the variant allele-positive genotypes (AA + Aa versus aa); (2) recessive genetic model\u2014the comparison groups were the variant homozygous genotype versus the rest (AA versus aa + Aa); (3) homozygous genetic model\u2014comparison was between the 2 homozygous genotypes (AA versus aa); and (4) allele contrast genetic model\u2014the comparison was between the heterozygous and the homozygous wild-type genotype groups (Aa versus aa (where \u201ca\u201d is the wild-type allele and \u201cA\u201d is the variant allele)).", "section": "METHODS", "tags": [{"name": "model\u2014comparison", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "allele-positive", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "In breast cancer, several studies have suggested that moderate to high COX-2 expression is related to the genesis of mammary tumors and the expression level is associated with the aggressiveness of breast cancer, including large tumor size, positive axillary lymph node metastases, and HER2-positive tumor status [9\u201311].", "section": "INTRO", "tags": [{"name": "aggressiveness", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "HER2-positive", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "The meta-analysis assessed association by using 4 different genetic models: (1) dominant genetic model\u2014the comparison groups were the wild-type homozygous genotype versus the variant allele-positive genotypes (AA + Aa versus aa); (2) recessive genetic model\u2014the comparison groups were the variant homozygous genotype versus the rest (AA versus aa + Aa); (3) homozygous genetic model\u2014comparison was between the 2 homozygous genotypes (AA versus aa); and (4) allele contrast genetic model\u2014the comparison was between the heterozygous and the homozygous wild-type genotype groups (Aa versus aa (where \u201ca\u201d is the wild-type allele and \u201cA\u201d is the variant allele)).", "section": "METHODS", "tags": [{"name": "model\u2014comparison", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "allele-positive", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "The following criteria were used to select studies for further meta-analysis: (1) case-control studies; (2) studies that evaluated the associations between COX-2 polymorphisms and breast cancer risk; (3) studies that contained at least two comparison groups (cancer versus control); (4) studies that included detailed genotyping data.", "section": "METHODS", "tags": [{"name": "meta-analysis:", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "polymorphisms", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "As shown in Table 3 and Figure 4, there was no significant association in rs5275 polymorphism (homozygote comparison: OR = 1.04, 95% CI = 0.96\u20131.12, P = 0.34; heterozygote comparison: OR = 0.99, 95% CI = 0.95\u20131.04, P = 0.81; dominant model: OR = 1.02, 95% CI = 0.98\u20131.07, P = 0.33, and recessive model: OR = 1.04, 95% CI = 0.97\u20131.12, P = 0.27).", "section": "METHODS", "tags": [{"name": "polymorphism", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "heterozygote", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "As shown in Table 3 and Figure 3, there was no association in these four genotypes (A versus G: OR = 0.99, 95% CI = 0.94\u20131.04, P = 0.69; homozygote comparison (AA versus GG): OR = 1.01, 95% CI = 0.88\u20131.15, P = 0.93; heterozygote comparison (AG versus GG): OR = 0.98, 95% CI = 0.92\u20131.05, P = 0.59; recessive model (AA versus GG + AG): OR = 1.01, 95% CI = 0.89\u20131.15, P = 0.85).", "section": "METHODS", "tags": [{"name": "heterozygote", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "association", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "As shown in Table 3 and Figure 3, there was no association in these four genotypes (A versus G: OR = 0.99, 95% CI = 0.94\u20131.04, P = 0.69; homozygote comparison (AA versus GG): OR = 1.01, 95% CI = 0.88\u20131.15, P = 0.93; heterozygote comparison (AG versus GG): OR = 0.98, 95% CI = 0.92\u20131.05, P = 0.59; recessive model (AA versus GG + AG): OR = 1.01, 95% CI = 0.89\u20131.15, P = 0.85).", "section": "METHODS", "tags": [{"name": "heterozygote", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "association", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "The meta-analysis assessed association by using 4 different genetic models: (1) dominant genetic model\u2014the comparison groups were the wild-type homozygous genotype versus the variant allele-positive genotypes (AA + Aa versus aa); (2) recessive genetic model\u2014the comparison groups were the variant homozygous genotype versus the rest (AA versus aa + Aa); (3) homozygous genetic model\u2014comparison was between the 2 homozygous genotypes (AA versus aa); and (4) allele contrast genetic model\u2014the comparison was between the heterozygous and the homozygous wild-type genotype groups (Aa versus aa (where \u201ca\u201d is the wild-type allele and \u201cA\u201d is the variant allele)).", "section": "METHODS", "tags": [{"name": "model\u2014comparison", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "allele-positive", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "We found no significant association of rs5275 polymorphism with breast cancer risk (homozygote comparison: OR = 1.04, 95% CI = 0.96\u20131.12, P = 0.34; heterozygote comparison: OR = 0.99, 95% CI = 0.95\u20131.04, P = 0.81; dominant model: OR = 1.02, 95% CI = 0.98\u20131.07, P = 0.33, and recessive model: OR = 1.04, 95% CI = 0.97\u20131.12, P = 0.27).", "section": "DISCUSS", "tags": [{"name": "polymorphism", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "heterozygote", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "The following criteria were used to select studies for further meta-analysis: (1) case-control studies; (2) studies that evaluated the associations between COX-2 polymorphisms and breast cancer risk; (3) studies that contained at least two comparison groups (cancer versus control); (4) studies that included detailed genotyping data.", "section": "METHODS", "tags": [{"name": "meta-analysis:", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "polymorphisms", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "As shown in Table 3 and Figure 4, there was no significant association in rs5275 polymorphism (homozygote comparison: OR = 1.04, 95% CI = 0.96\u20131.12, P = 0.34; heterozygote comparison: OR = 0.99, 95% CI = 0.95\u20131.04, P = 0.81; dominant model: OR = 1.02, 95% CI = 0.98\u20131.07, P = 0.33, and recessive model: OR = 1.04, 95% CI = 0.97\u20131.12, P = 0.27).", "section": "METHODS", "tags": [{"name": "polymorphism", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "heterozygote", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}]}
{"src": "PMC", "id": "PMC5810984", "provider": "OpenTargets", "anns": [{"type": "Gene Disease Relationship", "exact": "The Johns Hopkins Bloomberg School of Public Health Institutional Review Board (IRB) approved this study (entitled \u201cPredictors of Cardiomyopathy Progression in a Chagas Disease Cohort in Bolivia\u201d, IRB No: 00005598) on September 30, 2015 in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki.", "section": "METHODS", "tags": [{"name": "Cardiomyopathy", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "Institutional", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "The Johns Hopkins Bloomberg School of Public Health Institutional Review Board (IRB) approved this study (entitled \u201cPredictors of Cardiomyopathy Progression in a Chagas Disease Cohort in Bolivia\u201d, IRB No: 00005598) on September 30, 2015 in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki.", "section": "METHODS", "tags": [{"name": "Cardiomyopathy", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "Institutional", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "A total of 38 T. cruzi-infected cases (male n = 19, mean/median age: 62/65; female n = 19, mean/median age: 55/58) with a clinical cardiomyopathy diagnosis and 24 asymptomatic T. cruzi-infected controls (male n = 12, mean/median age: 56/56; female n = 12, mean/median age: 53/55) were selected as a stratified sample from the parent study, frequency-matched by age and sex.", "section": "METHODS", "tags": [{"name": "frequency-matched", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "cruzi-infected", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "The Johns Hopkins Bloomberg School of Public Health Institutional Review Board (IRB) approved this study (entitled \u201cPredictors of Cardiomyopathy Progression in a Chagas Disease Cohort in Bolivia\u201d, IRB No: 00005598) on September 30, 2015 in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki.", "section": "METHODS", "tags": [{"name": "Cardiomyopathy", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "Institutional", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Cardiomyopathy was defined based on characteristic abnormalities on electrocardiogram (ECG) (atrial fibrillation or flutter, atrioventricular blocks, bradycardia <50 beats per minute, bundle branch blocks, junctional rhythms), and/or cardiac insufficiency based on ejection fraction (EF) by echocardiogram (EF<53% for women, <51% for men).", "section": "METHODS", "tags": [{"name": "electrocardiogram", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "atrioventricular", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Confirmed T. cruzi infection was based on having positive results on 2 different commercial assays for anti-T. cruzi IgG antibodies (Wiener Recombinant 3.0 enzyme linked immunosorbent assay, Rosario, Argentina and Chagas Polychaco indirect hemagglutination test kit, Lemos Laboratories, Santiago del Estero, Argentina).", "section": "METHODS", "tags": [{"name": "hemagglutination", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "immunosorbent", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Confirmed T. cruzi infection was based on having positive results on 2 different commercial assays for anti-T. cruzi IgG antibodies (Wiener Recombinant 3.0 enzyme linked immunosorbent assay, Rosario, Argentina and Chagas Polychaco indirect hemagglutination test kit, Lemos Laboratories, Santiago del Estero, Argentina).", "section": "METHODS", "tags": [{"name": "hemagglutination", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "immunosorbent", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "A total of 38 T. cruzi-infected cases (male n = 19, mean/median age: 62/65; female n = 19, mean/median age: 55/58) with a clinical cardiomyopathy diagnosis and 24 asymptomatic T. cruzi-infected controls (male n = 12, mean/median age: 56/56; female n = 12, mean/median age: 53/55) were selected as a stratified sample from the parent study, frequency-matched by age and sex.", "section": "METHODS", "tags": [{"name": "frequency-matched", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "cruzi-infected", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Cardiomyopathy was defined based on characteristic abnormalities on electrocardiogram (ECG) (atrial fibrillation or flutter, atrioventricular blocks, bradycardia <50 beats per minute, bundle branch blocks, junctional rhythms), and/or cardiac insufficiency based on ejection fraction (EF) by echocardiogram (EF<53% for women, <51% for men).", "section": "METHODS", "tags": [{"name": "electrocardiogram", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "atrioventricular", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "The HapMap populations include: ASW: African ancestry in Southwest USA; CEU: Utah residents with Northern and Western European ancestry from the CEPH collection; CHB: Han Chinese in Beijing, China; CHD: Chinese in Metropolitan Denver, Colorado; GIH: Gujarati Indians in Houston, Texas; JPT: Japanese in Tokyo, Japan; LWK: Luhya in Webuye, Kenya; MEX: Mexican ancestry in Los Angeles, California; MKK: Maasai in Kinyawa, Kenya; TSI: Tuscans in Italy; YRI: Yoruba in Ibadan, Nigeria.", "section": "METHODS", "tags": [{"name": "Metropolitan", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "populations", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "The Johns Hopkins Bloomberg School of Public Health Institutional Review Board (IRB) approved this study (entitled \u201cPredictors of Cardiomyopathy Progression in a Chagas Disease Cohort in Bolivia\u201d, IRB No: 00005598) on September 30, 2015 in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki.", "section": "METHODS", "tags": [{"name": "Cardiomyopathy", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "Institutional", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "The HapMap populations include: ASW: African ancestry in Southwest USA; CEU: Utah residents with Northern and Western European ancestry from the CEPH collection; CHB: Han Chinese in Beijing, China; CHD: Chinese in Metropolitan Denver, Colorado; GIH: Gujarati Indians in Houston, Texas; JPT: Japanese in Tokyo, Japan; LWK: Luhya in Webuye, Kenya; MEX: Mexican ancestry in Los Angeles, California; MKK: Maasai in Kinyawa, Kenya; TSI: Tuscans in Italy; YRI: Yoruba in Ibadan, Nigeria.", "section": "METHODS", "tags": [{"name": "Metropolitan", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "populations", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "A total of 38 T. cruzi-infected cases (male n = 19, mean/median age: 62/65; female n = 19, mean/median age: 55/58) with a clinical cardiomyopathy diagnosis and 24 asymptomatic T. cruzi-infected controls (male n = 12, mean/median age: 56/56; female n = 12, mean/median age: 53/55) were selected as a stratified sample from the parent study, frequency-matched by age and sex.", "section": "METHODS", "tags": [{"name": "frequency-matched", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "cruzi-infected", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Cardiomyopathy was defined based on characteristic abnormalities on electrocardiogram (ECG) (atrial fibrillation or flutter, atrioventricular blocks, bradycardia <50 beats per minute, bundle branch blocks, junctional rhythms), and/or cardiac insufficiency based on ejection fraction (EF) by echocardiogram (EF<53% for women, <51% for men).", "section": "METHODS", "tags": [{"name": "electrocardiogram", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "atrioventricular", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "A total of 38 T. cruzi-infected cases (male n = 19, mean/median age: 62/65; female n = 19, mean/median age: 55/58) with a clinical cardiomyopathy diagnosis and 24 asymptomatic T. cruzi-infected controls (male n = 12, mean/median age: 56/56; female n = 12, mean/median age: 53/55) were selected as a stratified sample from the parent study, frequency-matched by age and sex.", "section": "METHODS", "tags": [{"name": "frequency-matched", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "cruzi-infected", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Confirmed T. cruzi infection was based on having positive results on 2 different commercial assays for anti-T. cruzi IgG antibodies (Wiener Recombinant 3.0 enzyme linked immunosorbent assay, Rosario, Argentina and Chagas Polychaco indirect hemagglutination test kit, Lemos Laboratories, Santiago del Estero, Argentina).", "section": "METHODS", "tags": [{"name": "hemagglutination", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "immunosorbent", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}]}
{"src": "PMC", "id": "PMC5671944", "provider": "OpenTargets", "anns": [{"type": "Gene Disease Relationship", "exact": "We demonstrated previously that BIM-induction by FOXO3 triggers a biphasic ROS-accumulation, which critically regulates cell death-induction by FOXO3-activation and/or by addition of DNA-damaging agents in NB.3, 31 The primary ROS-wave is detected after 12\u2009h post FOXO3-activation, the second, much more pronounced ROS-wave reaches a climax between 36 and 48\u2009h after FOXO3-activation in NB15/FOXO3 cells.3 We therefore investigated, whether FOXO3-resistant NB4/FOXO3 and NB8/FOXO3 cells show comparable ROS-accumulation or whether this ROS-burst is absent in the resistant cell lines.", "section": "RESULTS", "tags": [{"name": "ROS-accumulation,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "FOXO3-activation,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Protein-kinase-B (PKB) which is frequently hyper-activated in high-stage NB due to aberrant expression of the brain-derived-neurotrophic-factor and its cognate receptor NTRK2/TRKB10 directly phosphorylates FOXO3 causing association with 14-3-3 proteins, nuclear exclusion and transcriptional inactivation of FOXO3 in malignant NB cells.5, 11, 12, 13 We previously demonstrated that in patient biopsies FOXO3 localizes to the nucleus even when phosphorylated at the PKB-site threonine-32.14 Stress conditions, such as chemotherapy, override growth-factor-mediated phosphorylation/inactivation of FOXO3 by PKB, which results in the relocation of FOXO3 to the nucleus.3, 9", "section": "INTRO", "tags": [{"name": "brain-derived-neurotrophic-factor", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "phosphorylation/inactivation", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "In NB, FOXO3-induced cell death depends on the induction of the pro-apoptotic BH3-only proteins BIM and NOXA, the repression of the pro-survival BCL2-protein BCLXL and the inhibitor-of-apoptosis-protein survivin.3, 4, 5 Expression analysis of these proteins in FOXO3-resistant NB4/FOXO3 and NB8/FOXO3 and FOXO3-sensitive NB15/FOXO3 cells as well as in their corresponding controls revealed that in NB15/FOXO3 cells BIM and NOXA strongly increased5 on protein- and mRNA-level, and BCLXL and survivin were repressed (Figures 2a and b and Supplementary Figure S3).", "section": "RESULTS", "tags": [{"name": "inhibitor-of-apoptosis-protein", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "FOXO3-resistant", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "The retroviral vectors pLIB-MCS2-iresNeo and pLIB-FOXO3(A3)-ERtm-iresNeo have been described.5 The lentivirus-vector coding for FOXO3-specific shRNA (pLKO-shFOXO3-91617-puro) and SESN3-specific shRNA (pLKO-shSESN3-141228-puro and pLKO-shSESN3-143446-puro) and the control-vector pLKO.1 were described.3 The lentivirus-vectors coding for TP53-specific shRNA pLKO-shTP53-puro, pLKO-shTP53-941-puro and pLKO-shTP53-427-puro were provided by T. Waldmann,52 the pGL3-Bim-promoter was provided by A. Villunger.53 The vector pLIB-EYFP-TP53mut-puro was generated by amplification of mutant-TP53 from NB15 cDNA (p53-fwd: 5\u2032-GAATTCATGGATGATTTGATGC-3\u2032 p53-rev: 5\u2032-GGATCCTCAGTCTGAGTCAG)-3\u2032 and inserted into the EcoR1- and BamH1-site of pLIB-EYFP-Mcl1JAM-iresPuro54 replacing MCL1JAM by the TP53-mutant and generating pLIB-EYFP-p53m-iresPuro.", "section": "OTHER", "tags": [{"name": "5\u2032-GAATTCATGGATGATTTGATGC-3\u2032", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "pLIB-EYFP-Mcl1JAM-iresPuro54", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "One binding partner of FOXO3 is the tumor protein TP53/p53 which is mutated in over 50% of cancer types.20 In NB, however, mutations of TP53 are rare at diagnosis (less than 2% of patients), but frequent loss of function is observed in relapsed tumors.21 FOXO3 and TP53 share numerous target genes such as CDKN1/P21CIP1, GADD45A or BBC3/PUMA; hence, they are involved in the same cellular processes like cell-cycle-arrest, DNA-damage-repair and apoptosis.22, 23, 24, 25", "section": "INTRO", "tags": [{"name": "cell-cycle-arrest,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "DNA-damage-repair", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "The mammalian forkhead box O (FOXO) transcription factor family consists of four members, FOXO1/FKHR, FOXO3/FKHRL1, FOXO4/AFX and FOXO6, which are involved in multiple cellular processes ranging from apoptosis induction to longevity.1 FOXO3-mediated cell death in neuroblastoma (NB), an aggressive childhood tumor that develops form precursor cells of the neural crest during embryogenesis,2 has been associated with induction of the pro-apoptotic BH3-only proteins B-cell-lymphoma-gene-2-like-11 (BCL2L11/BIM), phorbol-12-myristate-13-acetate-induced-protein-1 (PMAIP1/NOXA) and repression of pro-survival BCL2-like-1 (BCL2L1/BCLXL) and the baculoviral-inhibitor-of-apoptosis-repeat-containing-5 (BIRC5/survivin) and is modulated by the ROS-regulating chromosome-10-open-reading-frame-10-protein (C10ORF10/DEPP).3, 4, 5, 6, 7 FOXO3-activity is mainly regulated by post-translational modifications (reviewed in Ausserlechner et al.8 and Hagenbuchner and Ausserlechner9), resulting in changes of its cellular localization or affecting its binding to DNA or proteins.", "section": "INTRO", "tags": [{"name": "baculoviral-inhibitor-of-apoptosis-repeat-containing-5", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "phorbol-12-myristate-13-acetate-induced-protein-1", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "The retroviral vectors pLIB-MCS2-iresNeo and pLIB-FOXO3(A3)-ERtm-iresNeo have been described.5 The lentivirus-vector coding for FOXO3-specific shRNA (pLKO-shFOXO3-91617-puro) and SESN3-specific shRNA (pLKO-shSESN3-141228-puro and pLKO-shSESN3-143446-puro) and the control-vector pLKO.1 were described.3 The lentivirus-vectors coding for TP53-specific shRNA pLKO-shTP53-puro, pLKO-shTP53-941-puro and pLKO-shTP53-427-puro were provided by T. Waldmann,52 the pGL3-Bim-promoter was provided by A. Villunger.53 The vector pLIB-EYFP-TP53mut-puro was generated by amplification of mutant-TP53 from NB15 cDNA (p53-fwd: 5\u2032-GAATTCATGGATGATTTGATGC-3\u2032 p53-rev: 5\u2032-GGATCCTCAGTCTGAGTCAG)-3\u2032 and inserted into the EcoR1- and BamH1-site of pLIB-EYFP-Mcl1JAM-iresPuro54 replacing MCL1JAM by the TP53-mutant and generating pLIB-EYFP-p53m-iresPuro.", "section": "OTHER", "tags": [{"name": "5\u2032-GAATTCATGGATGATTTGATGC-3\u2032", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "pLIB-EYFP-Mcl1JAM-iresPuro54", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Hyper-activation of the phosphatidylinositol3-kinase/PKB signaling pathway frequently observed in NB is associated with FOXO3-inactivation and its re-localization into the cytoplasm.4, 5, 11, 12, 13 However, in high-stage-derived NB cell lines FOXO3 partly localizes to the nucleus despite high PKB-activity and regulates the response to hypoxia within these cells (Figure 1).14 Activation by etoposide-treatment further increases the amount of nuclear FOXO3 (Figure 1c) suggesting that shuttling and oxidative stress response regulation of FOXO3 is still intact within these cells.", "section": "DISCUSS", "tags": [{"name": "phosphatidylinositol3-kinase/PKB", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "etoposide-treatment", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "We demonstrated previously that BIM-induction by FOXO3 triggers a biphasic ROS-accumulation, which critically regulates cell death-induction by FOXO3-activation and/or by addition of DNA-damaging agents in NB.3, 31 The primary ROS-wave is detected after 12\u2009h post FOXO3-activation, the second, much more pronounced ROS-wave reaches a climax between 36 and 48\u2009h after FOXO3-activation in NB15/FOXO3 cells.3 We therefore investigated, whether FOXO3-resistant NB4/FOXO3 and NB8/FOXO3 cells show comparable ROS-accumulation or whether this ROS-burst is absent in the resistant cell lines.", "section": "RESULTS", "tags": [{"name": "ROS-accumulation,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "FOXO3-activation,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "In NB, FOXO3-induced cell death depends on the induction of the pro-apoptotic BH3-only proteins BIM and NOXA, the repression of the pro-survival BCL2-protein BCLXL and the inhibitor-of-apoptosis-protein survivin.3, 4, 5 Expression analysis of these proteins in FOXO3-resistant NB4/FOXO3 and NB8/FOXO3 and FOXO3-sensitive NB15/FOXO3 cells as well as in their corresponding controls revealed that in NB15/FOXO3 cells BIM and NOXA strongly increased5 on protein- and mRNA-level, and BCLXL and survivin were repressed (Figures 2a and b and Supplementary Figure S3).", "section": "RESULTS", "tags": [{"name": "inhibitor-of-apoptosis-protein", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "FOXO3-resistant", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "The retroviral vectors pLIB-MCS2-iresNeo and pLIB-FOXO3(A3)-ERtm-iresNeo have been described.5 The lentivirus-vector coding for FOXO3-specific shRNA (pLKO-shFOXO3-91617-puro) and SESN3-specific shRNA (pLKO-shSESN3-141228-puro and pLKO-shSESN3-143446-puro) and the control-vector pLKO.1 were described.3 The lentivirus-vectors coding for TP53-specific shRNA pLKO-shTP53-puro, pLKO-shTP53-941-puro and pLKO-shTP53-427-puro were provided by T. Waldmann,52 the pGL3-Bim-promoter was provided by A. Villunger.53 The vector pLIB-EYFP-TP53mut-puro was generated by amplification of mutant-TP53 from NB15 cDNA (p53-fwd: 5\u2032-GAATTCATGGATGATTTGATGC-3\u2032 p53-rev: 5\u2032-GGATCCTCAGTCTGAGTCAG)-3\u2032 and inserted into the EcoR1- and BamH1-site of pLIB-EYFP-Mcl1JAM-iresPuro54 replacing MCL1JAM by the TP53-mutant and generating pLIB-EYFP-p53m-iresPuro.", "section": "OTHER", "tags": [{"name": "5\u2032-GAATTCATGGATGATTTGATGC-3\u2032", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "pLIB-EYFP-Mcl1JAM-iresPuro54", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "The retroviral vectors pLIB-MCS2-iresNeo and pLIB-FOXO3(A3)-ERtm-iresNeo have been described.5 The lentivirus-vector coding for FOXO3-specific shRNA (pLKO-shFOXO3-91617-puro) and SESN3-specific shRNA (pLKO-shSESN3-141228-puro and pLKO-shSESN3-143446-puro) and the control-vector pLKO.1 were described.3 The lentivirus-vectors coding for TP53-specific shRNA pLKO-shTP53-puro, pLKO-shTP53-941-puro and pLKO-shTP53-427-puro were provided by T. Waldmann,52 the pGL3-Bim-promoter was provided by A. Villunger.53 The vector pLIB-EYFP-TP53mut-puro was generated by amplification of mutant-TP53 from NB15 cDNA (p53-fwd: 5\u2032-GAATTCATGGATGATTTGATGC-3\u2032 p53-rev: 5\u2032-GGATCCTCAGTCTGAGTCAG)-3\u2032 and inserted into the EcoR1- and BamH1-site of pLIB-EYFP-Mcl1JAM-iresPuro54 replacing MCL1JAM by the TP53-mutant and generating pLIB-EYFP-p53m-iresPuro.", "section": "OTHER", "tags": [{"name": "5\u2032-GAATTCATGGATGATTTGATGC-3\u2032", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "pLIB-EYFP-Mcl1JAM-iresPuro54", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Protein-kinase-B (PKB) which is frequently hyper-activated in high-stage NB due to aberrant expression of the brain-derived-neurotrophic-factor and its cognate receptor NTRK2/TRKB10 directly phosphorylates FOXO3 causing association with 14-3-3 proteins, nuclear exclusion and transcriptional inactivation of FOXO3 in malignant NB cells.5, 11, 12, 13 We previously demonstrated that in patient biopsies FOXO3 localizes to the nucleus even when phosphorylated at the PKB-site threonine-32.14 Stress conditions, such as chemotherapy, override growth-factor-mediated phosphorylation/inactivation of FOXO3 by PKB, which results in the relocation of FOXO3 to the nucleus.3, 9", "section": "INTRO", "tags": [{"name": "brain-derived-neurotrophic-factor", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "phosphorylation/inactivation", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}]}
{"src": "PMC", "id": "PMC4902368", "provider": "OpenTargets", "anns": [{"type": "Gene Disease Relationship", "exact": "Previous studies have shown that blocking the PD-1/PD-L1 pathway can result in an efficient antitumor T-cell response and better control of tumor growth.24 Immunotherapy clinical trials using antibody-mediated PD-1 blockade as a strategy are in progress in patients with various cancers.25,26 Patients suffering from melanoma, renal cell carcinoma, or nonsmall cell lung cancer, showed objective responses (responses rates, 6\u201328%), with intravenous injection of these antibodies.", "section": "INTRO", "tags": [{"name": "antibody-mediated", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "Immunotherapy", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "The Sequenom MassARRAY Assay Design 3.0 software was used to design the Multiplexed SNP MassEXTEND assay.33 Single nucleotide polymorphism (SNP) genotyping was performed by using the Sequenom MassARRAY RS1000 according to the standard protocol recommended by the manufacturer.34 The corresponding primers used for each SNP in the present study are listed in Table 2.", "section": "METHODS", "tags": [{"name": "manufacturer.34", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "corresponding", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Data outlining the clinicopathological characteristics of the patients, including tumor size, clinical stages, lymph node involvement, menopausal status, procreative times, estrogenic receptor (ER) status, progesterone receptor (PR) status, and human epidermal growth factor receptor type 2 (Her-2) status, were obtained from the patients\u2019 medical records (Table 1).", "section": "METHODS", "tags": [{"name": "clinicopathological", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "characteristics", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "The rs7421861 CT genotype was significantly associated with the risk of colorectal cancer compared to the wild-type TT genotype.41 However, rs7421861 was found to have no association with gastric cardia adenocarcinoma.35 In the present study, there was also no significant association between the rs7421861 polymorphism and breast cancer risk in any of the genetic models.", "section": "DISCUSS", "tags": [{"name": "adenocarcinoma.35", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "significantly", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "In a subgroup of thymic T-lymphocytes, PD-1 is produced in a way of constitutively expression, with up-regulated expression found in activated T-cells, B-cells, and myeloid cells.9,10 Through interactions between PD-1 and its ligands PD-L1 (B7-H1; CD274) or PD-L2 (B7-DC; CD273), PD-1 strongly inhibits the proliferation of CD4 and CD8 T lymphocytes and their cytokine production.11\u201313 Previous studies have emphasized the significant role of PD-1 in human disease.", "section": "INTRO", "tags": [{"name": "production.11\u201313", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "T-lymphocytes,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Data outlining the clinicopathological characteristics of the patients, including tumor size, clinical stages, lymph node involvement, menopausal status, procreative times, estrogenic receptor (ER) status, progesterone receptor (PR) status, and human epidermal growth factor receptor type 2 (Her-2) status, were obtained from the patients\u2019 medical records (Table 1).", "section": "METHODS", "tags": [{"name": "clinicopathological", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "characteristics", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "The Sequenom MassARRAY Assay Design 3.0 software was used to design the Multiplexed SNP MassEXTEND assay.33 Single nucleotide polymorphism (SNP) genotyping was performed by using the Sequenom MassARRAY RS1000 according to the standard protocol recommended by the manufacturer.34 The corresponding primers used for each SNP in the present study are listed in Table 2.", "section": "METHODS", "tags": [{"name": "manufacturer.34", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "corresponding", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Data outlining the clinicopathological characteristics of the patients, including tumor size, clinical stages, lymph node involvement, menopausal status, procreative times, estrogenic receptor (ER) status, progesterone receptor (PR) status, and human epidermal growth factor receptor type 2 (Her-2) status, were obtained from the patients\u2019 medical records (Table 1).", "section": "METHODS", "tags": [{"name": "clinicopathological", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "characteristics", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "In a subgroup of thymic T-lymphocytes, PD-1 is produced in a way of constitutively expression, with up-regulated expression found in activated T-cells, B-cells, and myeloid cells.9,10 Through interactions between PD-1 and its ligands PD-L1 (B7-H1; CD274) or PD-L2 (B7-DC; CD273), PD-1 strongly inhibits the proliferation of CD4 and CD8 T lymphocytes and their cytokine production.11\u201313 Previous studies have emphasized the significant role of PD-1 in human disease.", "section": "INTRO", "tags": [{"name": "production.11\u201313", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "T-lymphocytes,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Previous studies have shown that blocking the PD-1/PD-L1 pathway can result in an efficient antitumor T-cell response and better control of tumor growth.24 Immunotherapy clinical trials using antibody-mediated PD-1 blockade as a strategy are in progress in patients with various cancers.25,26 Patients suffering from melanoma, renal cell carcinoma, or nonsmall cell lung cancer, showed objective responses (responses rates, 6\u201328%), with intravenous injection of these antibodies.", "section": "INTRO", "tags": [{"name": "antibody-mediated", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "Immunotherapy", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "The rs7421861 CT genotype was significantly associated with the risk of colorectal cancer compared to the wild-type TT genotype.41 However, rs7421861 was found to have no association with gastric cardia adenocarcinoma.35 In the present study, there was also no significant association between the rs7421861 polymorphism and breast cancer risk in any of the genetic models.", "section": "DISCUSS", "tags": [{"name": "adenocarcinoma.35", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "significantly", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Genetic mutations and environmental factors play an important role in the development and progression of breast cancer.3 The APE1 656 T>G polymorphism is reported to have a protective effect against breast cancer.4 In Caucasians, the CC homozygote of rs1800872 polymorphism in IL-10 gene has a 25% decreased risk of breast cancer compared to patients with the AA and AC genotypes.5 An increasing number of studies have shown that the immune system plays an important role in resisting and eliminating cancer cells, and can influence the occurrence of breast cancer.6,7 T cells have been shown to play the major role in the antitumor immune response.8", "section": "INTRO", "tags": [{"name": "environmental", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "polymorphism", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "The genetic variation in rs2227982 may result in an amino acid substitution from alanine to valine, which could lead to a different structure and different function for PD-1 and further influence the progression of different diseases.39,40 Therefore, whether this amino acid change alters the protein structure or affects its function needs to be further studied.", "section": "DISCUSS", "tags": [{"name": "diseases.39,40", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "substitution", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Data outlining the clinicopathological characteristics of the patients, including tumor size, clinical stages, lymph node involvement, menopausal status, procreative times, estrogenic receptor (ER) status, progesterone receptor (PR) status, and human epidermal growth factor receptor type 2 (Her-2) status, were obtained from the patients\u2019 medical records (Table 1).", "section": "METHODS", "tags": [{"name": "clinicopathological", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "characteristics", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "The Sequenom MassARRAY Assay Design 3.0 software was used to design the Multiplexed SNP MassEXTEND assay.33 Single nucleotide polymorphism (SNP) genotyping was performed by using the Sequenom MassARRAY RS1000 according to the standard protocol recommended by the manufacturer.34 The corresponding primers used for each SNP in the present study are listed in Table 2.", "section": "METHODS", "tags": [{"name": "manufacturer.34", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "corresponding", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "The genetic variation in rs2227982 may result in an amino acid substitution from alanine to valine, which could lead to a different structure and different function for PD-1 and further influence the progression of different diseases.39,40 Therefore, whether this amino acid change alters the protein structure or affects its function needs to be further studied.", "section": "DISCUSS", "tags": [{"name": "diseases.39,40", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "substitution", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "In a subgroup of thymic T-lymphocytes, PD-1 is produced in a way of constitutively expression, with up-regulated expression found in activated T-cells, B-cells, and myeloid cells.9,10 Through interactions between PD-1 and its ligands PD-L1 (B7-H1; CD274) or PD-L2 (B7-DC; CD273), PD-1 strongly inhibits the proliferation of CD4 and CD8 T lymphocytes and their cytokine production.11\u201313 Previous studies have emphasized the significant role of PD-1 in human disease.", "section": "INTRO", "tags": [{"name": "production.11\u201313", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "T-lymphocytes,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Previous studies have shown that blocking the PD-1/PD-L1 pathway can result in an efficient antitumor T-cell response and better control of tumor growth.24 Immunotherapy clinical trials using antibody-mediated PD-1 blockade as a strategy are in progress in patients with various cancers.25,26 Patients suffering from melanoma, renal cell carcinoma, or nonsmall cell lung cancer, showed objective responses (responses rates, 6\u201328%), with intravenous injection of these antibodies.", "section": "INTRO", "tags": [{"name": "antibody-mediated", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "Immunotherapy", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Data outlining the clinicopathological characteristics of the patients, including tumor size, clinical stages, lymph node involvement, menopausal status, procreative times, estrogenic receptor (ER) status, progesterone receptor (PR) status, and human epidermal growth factor receptor type 2 (Her-2) status, were obtained from the patients\u2019 medical records (Table 1).", "section": "METHODS", "tags": [{"name": "clinicopathological", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "characteristics", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}]}
{"src": "PMC", "id": "PMC4766352", "provider": "OpenTargets", "anns": [{"type": "Gene Disease Relationship", "exact": "An evolutionary conservation analysis revealed that mutations p.T130I in HNF4A and p.S487N in HNF1A occur at highly conserved positions in the protein sequences and do not involve similar amino acids, while mutation p.I27L in HNF1A is a conservative change at a relatively conserved isoleucine (Figure 4).", "section": "OTHER", "tags": [{"name": "evolutionary", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "conservation", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Forty-eight hours after transfection, HeLa cells in the 6-well plates were washed twice with phosphate-buffered saline (PBS) and scraped into 200\u2009\u03bcL/well of lysis buffer [150\u2009mM NaCl, 50\u2009mM Tris-HCl (pH 7.5), 1% NP40, 0.25% sodium deoxycholate, and 1\u2009mM EDTA with one tablet of protease inhibitor cocktail tablet (Complete Mini, Roche) per 10\u2009mL], sonicated for 2-3\u2009s, and then centrifuged.", "section": "METHODS", "tags": [{"name": "phosphate-buffered", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "transfection,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "After washing, membranes were reblocked and incubated for 2\u2009h at room temperature in the presence of horseradish peroxidase-linked donkey anti-rabbit IgG antibody (1\u2009:\u200910,000; GE Healthcare, Little Chalfont, UK) and developed using the SuperSignal West Dura Extended Duration Substrate (Thermo Scientific, Waltham, MA, USA).", "section": "METHODS", "tags": [{"name": "peroxidase-linked", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "temperature", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "An evolutionary conservation analysis revealed that mutations p.T130I in HNF4A and p.S487N in HNF1A occur at highly conserved positions in the protein sequences and do not involve similar amino acids, while mutation p.I27L in HNF1A is a conservative change at a relatively conserved isoleucine (Figure 4).", "section": "OTHER", "tags": [{"name": "evolutionary", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "conservation", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Interestingly, threonine (T130) residue is located within two putative protein kinase C phosphorylation sites (PKC phosphorylation sites, 129\u2013131: STR and 130\u2013132: TRR), while the isoleucine (I130) mutation would only allow one of these PKC phosphorylation sites (129\u2013131: SIR) to be retained.", "section": "DISCUSS", "tags": [{"name": "phosphorylation", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "phosphorylation", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Although p.I27L and p.S487N have been identified as polymorphisms that might not be associated with DM by some researchers [36], our evolutionary conservation analysis and protein tertiary structure predictions indicate that these two missense mutations, especially p.I27L, still might play role in the development of DM in the family examined in our study.", "section": "DISCUSS", "tags": [{"name": "polymorphisms", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "evolutionary", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "PCR products were purified on spin columns (Watson Biotechnologies Inc., Shanghai, China) and directly sequenced by the PCR or sequencing primers described above using the BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems) performed on a 3730 DNA analyzer according to the manufacturer's manual.", "section": "METHODS", "tags": [{"name": "Biotechnologies", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "manufacturer's", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "An evolutionary conservation analysis revealed that mutations p.T130I in HNF4A and p.S487N in HNF1A occur at highly conserved positions in the protein sequences and do not involve similar amino acids, while mutation p.I27L in HNF1A is a conservative change at a relatively conserved isoleucine (Figure 4).", "section": "OTHER", "tags": [{"name": "evolutionary", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "conservation", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "PCR products were purified on spin columns (Watson Biotechnologies Inc., Shanghai, China) and directly sequenced by the PCR or sequencing primers described above using the BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems) performed on a 3730 DNA analyzer according to the manufacturer's manual.", "section": "METHODS", "tags": [{"name": "Biotechnologies", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "manufacturer's", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "An evolutionary conservation analysis revealed that mutations p.T130I in HNF4A and p.S487N in HNF1A occur at highly conserved positions in the protein sequences and do not involve similar amino acids, while mutation p.I27L in HNF1A is a conservative change at a relatively conserved isoleucine (Figure 4).", "section": "OTHER", "tags": [{"name": "evolutionary", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "conservation", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "After washing, membranes were reblocked and incubated for 2\u2009h at room temperature in the presence of horseradish peroxidase-linked donkey anti-rabbit IgG antibody (1\u2009:\u200910,000; GE Healthcare, Little Chalfont, UK) and developed using the SuperSignal West Dura Extended Duration Substrate (Thermo Scientific, Waltham, MA, USA).", "section": "METHODS", "tags": [{"name": "peroxidase-linked", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "temperature", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}]}
{"src": "PMC", "id": "PMC4735314", "provider": "OpenTargets", "anns": [{"type": "Gene Disease Relationship", "exact": "The association between H. pylori infection and low HDL has been demonstrated previously in several studies.1\n3\n5\n6\n9\u201315\nH. pylori eradication has also been documented to increase serum HDL levels.7\n8\n13\n40\n41 On the basis of our results, we hypothesise that the benefits of eradication, especially considering HDL levels, could be more prominent in the IL-6 -174 CC genotype patients than in the patients of other IL-6 -174 genotypes.", "section": "DISCUSS", "tags": [{"name": "demonstrated", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "eradication,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "The IL-6 -174 genotype frequencies did not associate with the Sydney system-based variables of histopathological findings.30 The HDL serum levels showed strong negative correlations with the antrum mononuclear cell score (r=\u22120.579), antrum neutrophil score (r=\u22120.636), antrum H. pylori score (r=\u22120.525), body mononuclear cell score (r=\u22120.685), body neutrophil score (r=\u22120.494) and body H. pylori score (r=\u22120.585; all p values<0.001) in the IL-6 -174 CC genotype patients but not in the GG or GC patients.", "section": "RESULTS", "tags": [{"name": "histopathological", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "values<0.001)", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "The cut-off point of <1.00\u2005mmol/L for low HDL was chosen because it is a common cut-off point in Finnish guidelines.32 The patients\u2019 DNA was extracted from blood leucocytes as previously described.29 The restriction fragment length polymorphism method with an NlaIII restriction enzyme using previously published primers20 was used to detect the IL-6 -174 gene polymorphisms from the DNA samples.", "section": "METHODS", "tags": [{"name": "guidelines.32", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "polymorphisms", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "H. pylori infection causes a varied cytokine response including the release of interleukin 6.18 High IL-6 serum levels have been connected to changes in lipid metabolism and to coronary heart disease.19 A polymorphic allele, guanine/cytosine (G/C), at the IL-6 gene promoter at location -174 in the 5\u2019 flanking region (rs1800795) has been previously associated with higher IL-6 serum levels20 and the effect has also been documented in Finnish populations.21 The relationship between IL-6 -174 polymorphisms and IL-6 serum levels seems to vary in different participant groups22 and to be modified by external factors such as exercise.23 The IL-6 -174 polymorphism has also been associated with lipid abnormalities24 and serum lipid changes during lifestyle interventions.25\n26 IL-6 -174 has also been associated with the risk of coronary heart disease, but this association seems to vary between different participant groups.27\n28", "section": "INTRO", "tags": [{"name": "guanine/cytosine", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "interventions.25", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Previous studies have shown that exercise lowers IL-6 serum levels only in IL-6 -174 C allele carriers.23 Similarly, exercise and lifestyle interventions have been documented to increase HDL levels significantly more in the IL-6 -174 C allele carriers than in the G allele carriers.25\n26 In line with these studies, our results suggest that the HDL levels are more prone to decrease by H. pylori infection in the IL-6 -174 C carriers than in the other genotypes.", "section": "DISCUSS", "tags": [{"name": "interventions", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "significantly", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "H. pylori infection and peptic ulcers have been associated with increased IL-6 expression18\n36 and high IL-6 serum levels have been associated with low HDL serum levels.37 IL-6 has been documented to reduce the activity of lipoprotein lipase38 and decreased lipoprotein lipase activity has been associated with a decrease in HDL,39 which offers a possible mechanism for the interaction between IL-6 and HDL.", "section": "DISCUSS", "tags": [{"name": "expression18", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "lipoprotein", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Recent observations have suggested that improvement of diet by whole grain supplement may induce concurrent intestinal microbiota changes, decreased IL-6 levels and associate with changes indicating improvement of metabolic function.42 These results suggest a role for IL-6 in systemic responses caused by dietary changes and their associated changes in the commensal mucosal flora.", "section": "DISCUSS", "tags": [{"name": "observations", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "improvement", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "We also did not have data on the use of statin medication, but statin use was not common in Finland during the study period.35 Since there are no clear reasons, why the use of statins would be enriched in H. pylori negative patients, who had higher HDL levels, it is unlikely that the use of statin medication confounds our results.", "section": "DISCUSS", "tags": [{"name": "medication,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "medication", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "On the basis of the sample size and the specified significance and power levels, we conclude that the association of H. pylori infection on the HDL serum level is notable in the IL-6 -174 CC genotype patients, but in the other genotypes, especially in the GG genotype, the association is smaller and possibly clinically insignificant.", "section": "DISCUSS", "tags": [{"name": "insignificant.", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "significance", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "On the basis of our current findings, which indicate that the IL-6 -174 polymorphism modifies systemic effects induced by changes in the composition of gastric bacteria, we suggest that IL-6 polymorphisms should be investigated as a possible mechanism explaining associations between intestinal microbiome and the cardiovascular disease risk factors.", "section": "DISCUSS", "tags": [{"name": "cardiovascular", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "polymorphisms", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Previous studies have shown that exercise lowers IL-6 serum levels only in IL-6 -174 C allele carriers.23 Similarly, exercise and lifestyle interventions have been documented to increase HDL levels significantly more in the IL-6 -174 C allele carriers than in the G allele carriers.25\n26 In line with these studies, our results suggest that the HDL levels are more prone to decrease by H. pylori infection in the IL-6 -174 C carriers than in the other genotypes.", "section": "DISCUSS", "tags": [{"name": "interventions", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "significantly", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "The association between H. pylori infection and low HDL has been demonstrated previously in several studies.1\n3\n5\n6\n9\u201315\nH. pylori eradication has also been documented to increase serum HDL levels.7\n8\n13\n40\n41 On the basis of our results, we hypothesise that the benefits of eradication, especially considering HDL levels, could be more prominent in the IL-6 -174 CC genotype patients than in the patients of other IL-6 -174 genotypes.", "section": "DISCUSS", "tags": [{"name": "demonstrated", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "eradication,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "On the basis of our current findings, which indicate that the IL-6 -174 polymorphism modifies systemic effects induced by changes in the composition of gastric bacteria, we suggest that IL-6 polymorphisms should be investigated as a possible mechanism explaining associations between intestinal microbiome and the cardiovascular disease risk factors.", "section": "DISCUSS", "tags": [{"name": "cardiovascular", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "polymorphisms", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "We also did not have data on the use of statin medication, but statin use was not common in Finland during the study period.35 Since there are no clear reasons, why the use of statins would be enriched in H. pylori negative patients, who had higher HDL levels, it is unlikely that the use of statin medication confounds our results.", "section": "DISCUSS", "tags": [{"name": "medication,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "medication", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Recent observations have suggested that improvement of diet by whole grain supplement may induce concurrent intestinal microbiota changes, decreased IL-6 levels and associate with changes indicating improvement of metabolic function.42 These results suggest a role for IL-6 in systemic responses caused by dietary changes and their associated changes in the commensal mucosal flora.", "section": "DISCUSS", "tags": [{"name": "observations", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "improvement", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "H. pylori infection causes a varied cytokine response including the release of interleukin 6.18 High IL-6 serum levels have been connected to changes in lipid metabolism and to coronary heart disease.19 A polymorphic allele, guanine/cytosine (G/C), at the IL-6 gene promoter at location -174 in the 5\u2019 flanking region (rs1800795) has been previously associated with higher IL-6 serum levels20 and the effect has also been documented in Finnish populations.21 The relationship between IL-6 -174 polymorphisms and IL-6 serum levels seems to vary in different participant groups22 and to be modified by external factors such as exercise.23 The IL-6 -174 polymorphism has also been associated with lipid abnormalities24 and serum lipid changes during lifestyle interventions.25\n26 IL-6 -174 has also been associated with the risk of coronary heart disease, but this association seems to vary between different participant groups.27\n28", "section": "INTRO", "tags": [{"name": "guanine/cytosine", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "interventions.25", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "The IL-6 -174 genotype frequencies did not associate with the Sydney system-based variables of histopathological findings.30 The HDL serum levels showed strong negative correlations with the antrum mononuclear cell score (r=\u22120.579), antrum neutrophil score (r=\u22120.636), antrum H. pylori score (r=\u22120.525), body mononuclear cell score (r=\u22120.685), body neutrophil score (r=\u22120.494) and body H. pylori score (r=\u22120.585; all p values<0.001) in the IL-6 -174 CC genotype patients but not in the GG or GC patients.", "section": "RESULTS", "tags": [{"name": "histopathological", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "values<0.001)", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "On the basis of our current findings, which indicate that the IL-6 -174 polymorphism modifies systemic effects induced by changes in the composition of gastric bacteria, we suggest that IL-6 polymorphisms should be investigated as a possible mechanism explaining associations between intestinal microbiome and the cardiovascular disease risk factors.", "section": "DISCUSS", "tags": [{"name": "cardiovascular", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "polymorphisms", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "On the basis of the sample size and the specified significance and power levels, we conclude that the association of H. pylori infection on the HDL serum level is notable in the IL-6 -174 CC genotype patients, but in the other genotypes, especially in the GG genotype, the association is smaller and possibly clinically insignificant.", "section": "DISCUSS", "tags": [{"name": "insignificant.", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "significance", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Previous studies have shown that exercise lowers IL-6 serum levels only in IL-6 -174 C allele carriers.23 Similarly, exercise and lifestyle interventions have been documented to increase HDL levels significantly more in the IL-6 -174 C allele carriers than in the G allele carriers.25\n26 In line with these studies, our results suggest that the HDL levels are more prone to decrease by H. pylori infection in the IL-6 -174 C carriers than in the other genotypes.", "section": "DISCUSS", "tags": [{"name": "interventions", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "significantly", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "The association between H. pylori infection and low HDL has been demonstrated previously in several studies.1\n3\n5\n6\n9\u201315\nH. pylori eradication has also been documented to increase serum HDL levels.7\n8\n13\n40\n41 On the basis of our results, we hypothesise that the benefits of eradication, especially considering HDL levels, could be more prominent in the IL-6 -174 CC genotype patients than in the patients of other IL-6 -174 genotypes.", "section": "DISCUSS", "tags": [{"name": "demonstrated", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "eradication,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "H. pylori infection and peptic ulcers have been associated with increased IL-6 expression18\n36 and high IL-6 serum levels have been associated with low HDL serum levels.37 IL-6 has been documented to reduce the activity of lipoprotein lipase38 and decreased lipoprotein lipase activity has been associated with a decrease in HDL,39 which offers a possible mechanism for the interaction between IL-6 and HDL.", "section": "DISCUSS", "tags": [{"name": "expression18", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "lipoprotein", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "The cut-off point of <1.00\u2005mmol/L for low HDL was chosen because it is a common cut-off point in Finnish guidelines.32 The patients\u2019 DNA was extracted from blood leucocytes as previously described.29 The restriction fragment length polymorphism method with an NlaIII restriction enzyme using previously published primers20 was used to detect the IL-6 -174 gene polymorphisms from the DNA samples.", "section": "METHODS", "tags": [{"name": "guidelines.32", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "polymorphisms", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}]}
{"src": "PMC", "id": "PMC4713070", "provider": "OpenTargets", "anns": [{"type": "Gene Disease Relationship", "exact": "Two LD blocks were presented as follows: block rs281377-rs1047781 in FUT2 (D' = 0.96, r2 = 0.11) and block rs3894326-rs3745635-rs28362459 in FUT3 [rs3894326/rs3745635 (D' = 1, r2 = 0.01), rs3894326/rs28362459 (D' = 0.86, r2 = 0.23), rs3745635/rs28362459 (D' = 0.92, r2 = 0.47)] (Fig 1).", "section": "METHODS", "tags": [{"name": "rs3894326-rs3745635-rs28362459", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "[rs3894326/rs3745635", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Immunohistochemical staining of Lewis a indicated increased expression in the cryptic epithelium of inflammatory lesions in UC patients than the normal mucosa of patients with benign colonic polyps (P = 0.028), although there was no difference of Lewis a expression in surface epithelium between the two groups.", "section": "RESULTS", "tags": [{"name": "Immunohistochemical", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "inflammatory", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Third, the multiplex SNaPshot sequencing reactions were carried out in a final volume of 7 \u03bcl containing 2 \u03bcl of purified multiple PCR products, 1 \u03bcl SNaPshot Multiplex Mix, 1 \u03bcl 5\u00d7Sequencing buffer (Applied Biosystems) and 3 \u03bcl SNaPshot sequencing primers (the final concentrations are listed in Table 2).", "section": "METHODS", "tags": [{"name": "concentrations", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "5\u00d7Sequencing", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "In recent years, several studies have linked several nucleotide polymorphisms in FUT2 to intestinal microbiota composition [21] and predisposition to CD [22, 23], celiac disease [24], type 1 diabetes [25] and primary sclerosing cholangitis [26], highlighting the essential role of host gene-microbiota interaction in autoimmune diseases.", "section": "INTRO", "tags": [{"name": "gene-microbiota", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "predisposition", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "First, 10 ng of genomic DNA was added to a 10 \u03bcl PCR mixture containing 20 \u03bcmol dNTPs (Promega, Wisconsin, USA), 0.5 U FastStart Taq DNA polymerase (Roche, Basel, Switzerland), 1\u03bcl 10\u00d7PCR buffer with MgCl2 (15 mmol/L) (Roche, Basel, Switzerland) and amplification primers with a specific final concentration (Table 2).", "section": "METHODS", "tags": [{"name": "Switzerland),", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "amplification", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Two LD blocks were presented as follows: block rs281377-rs1047781 in FUT2 (D' = 0.96, r2 = 0.11) and block rs3894326-rs3745635-rs28362459 in FUT3 [rs3894326/rs3745635 (D' = 1, r2 = 0.01), rs3894326/rs28362459 (D' = 0.86, r2 = 0.23), rs3745635/rs28362459 (D' = 0.92, r2 = 0.47)] (Fig 1).", "section": "METHODS", "tags": [{"name": "rs3894326-rs3745635-rs28362459", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "[rs3894326/rs3745635", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Third, the multiplex SNaPshot sequencing reactions were carried out in a final volume of 7 \u03bcl containing 2 \u03bcl of purified multiple PCR products, 1 \u03bcl SNaPshot Multiplex Mix, 1 \u03bcl 5\u00d7Sequencing buffer (Applied Biosystems) and 3 \u03bcl SNaPshot sequencing primers (the final concentrations are listed in Table 2).", "section": "METHODS", "tags": [{"name": "concentrations", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "5\u00d7Sequencing", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "First, 10 ng of genomic DNA was added to a 10 \u03bcl PCR mixture containing 20 \u03bcmol dNTPs (Promega, Wisconsin, USA), 0.5 U FastStart Taq DNA polymerase (Roche, Basel, Switzerland), 1\u03bcl 10\u00d7PCR buffer with MgCl2 (15 mmol/L) (Roche, Basel, Switzerland) and amplification primers with a specific final concentration (Table 2).", "section": "METHODS", "tags": [{"name": "Switzerland),", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "amplification", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "However, in a Finnish population the wild GG genotype of FUT2 (rs601338) was associated with enhanced risk of UC [24]. And in a Chinese Han population mutations in FUT2 (rs281377 and rs601338) predisposed patients to UC, while FUT2 (rs1047781 and rs601338) polymorphisms were associated with UC in Uyghur population from northwest China [37].", "section": "DISCUSS", "tags": [{"name": "polymorphisms", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "predisposed", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Immunohistochemical staining of Lewis a indicated increased expression in the cryptic epithelium of inflammatory lesions in UC patients than the normal mucosa of patients with benign colonic polyps (P = 0.028), although there was no difference of Lewis a expression in surface epithelium between the two groups.", "section": "RESULTS", "tags": [{"name": "Immunohistochemical", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "inflammatory", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Two LD blocks were presented as follows: block rs281377-rs1047781 in FUT2 (D' = 0.96, r2 = 0.11) and block rs3894326-rs3745635-rs28362459 in FUT3 [rs3894326/rs3745635 (D' = 1, r2 = 0.01), rs3894326/rs28362459 (D' = 0.86, r2 = 0.23), rs3745635/rs28362459 (D' = 0.92, r2 = 0.47)] (Fig 1).", "section": "METHODS", "tags": [{"name": "rs3894326-rs3745635-rs28362459", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "[rs3894326/rs3745635", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "First, 10 ng of genomic DNA was added to a 10 \u03bcl PCR mixture containing 20 \u03bcmol dNTPs (Promega, Wisconsin, USA), 0.5 U FastStart Taq DNA polymerase (Roche, Basel, Switzerland), 1\u03bcl 10\u00d7PCR buffer with MgCl2 (15 mmol/L) (Roche, Basel, Switzerland) and amplification primers with a specific final concentration (Table 2).", "section": "METHODS", "tags": [{"name": "Switzerland),", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "amplification", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "However, in a Finnish population the wild GG genotype of FUT2 (rs601338) was associated with enhanced risk of UC [24]. And in a Chinese Han population mutations in FUT2 (rs281377 and rs601338) predisposed patients to UC, while FUT2 (rs1047781 and rs601338) polymorphisms were associated with UC in Uyghur population from northwest China [37].", "section": "DISCUSS", "tags": [{"name": "polymorphisms", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "predisposed", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Two LD blocks were presented as follows: block rs281377-rs1047781 in FUT2 (D' = 0.96, r2 = 0.11) and block rs3894326-rs3745635-rs28362459 in FUT3 [rs3894326/rs3745635 (D' = 1, r2 = 0.01), rs3894326/rs28362459 (D' = 0.86, r2 = 0.23), rs3745635/rs28362459 (D' = 0.92, r2 = 0.47)] (Fig 1).", "section": "METHODS", "tags": [{"name": "rs3894326-rs3745635-rs28362459", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "[rs3894326/rs3745635", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "In recent years, several studies have linked several nucleotide polymorphisms in FUT2 to intestinal microbiota composition [21] and predisposition to CD [22, 23], celiac disease [24], type 1 diabetes [25] and primary sclerosing cholangitis [26], highlighting the essential role of host gene-microbiota interaction in autoimmune diseases.", "section": "INTRO", "tags": [{"name": "gene-microbiota", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "predisposition", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "First, 10 ng of genomic DNA was added to a 10 \u03bcl PCR mixture containing 20 \u03bcmol dNTPs (Promega, Wisconsin, USA), 0.5 U FastStart Taq DNA polymerase (Roche, Basel, Switzerland), 1\u03bcl 10\u00d7PCR buffer with MgCl2 (15 mmol/L) (Roche, Basel, Switzerland) and amplification primers with a specific final concentration (Table 2).", "section": "METHODS", "tags": [{"name": "Switzerland),", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "amplification", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Immunohistochemical staining of Lewis a indicated increased expression in the cryptic epithelium of inflammatory lesions in UC patients than the normal mucosa of patients with benign colonic polyps (P = 0.028), although there was no difference of Lewis a expression in surface epithelium between the two groups.", "section": "RESULTS", "tags": [{"name": "Immunohistochemical", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "inflammatory", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Immunohistochemical staining of Lewis a indicated increased expression in the cryptic epithelium of inflammatory lesions in UC patients than the normal mucosa of patients with benign colonic polyps (P = 0.028), although there was no difference of Lewis a expression in surface epithelium between the two groups.", "section": "RESULTS", "tags": [{"name": "Immunohistochemical", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "inflammatory", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Third, the multiplex SNaPshot sequencing reactions were carried out in a final volume of 7 \u03bcl containing 2 \u03bcl of purified multiple PCR products, 1 \u03bcl SNaPshot Multiplex Mix, 1 \u03bcl 5\u00d7Sequencing buffer (Applied Biosystems) and 3 \u03bcl SNaPshot sequencing primers (the final concentrations are listed in Table 2).", "section": "METHODS", "tags": [{"name": "concentrations", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "5\u00d7Sequencing", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Third, the multiplex SNaPshot sequencing reactions were carried out in a final volume of 7 \u03bcl containing 2 \u03bcl of purified multiple PCR products, 1 \u03bcl SNaPshot Multiplex Mix, 1 \u03bcl 5\u00d7Sequencing buffer (Applied Biosystems) and 3 \u03bcl SNaPshot sequencing primers (the final concentrations are listed in Table 2).", "section": "METHODS", "tags": [{"name": "concentrations", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "5\u00d7Sequencing", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "First, 10 ng of genomic DNA was added to a 10 \u03bcl PCR mixture containing 20 \u03bcmol dNTPs (Promega, Wisconsin, USA), 0.5 U FastStart Taq DNA polymerase (Roche, Basel, Switzerland), 1\u03bcl 10\u00d7PCR buffer with MgCl2 (15 mmol/L) (Roche, Basel, Switzerland) and amplification primers with a specific final concentration (Table 2).", "section": "METHODS", "tags": [{"name": "Switzerland),", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "amplification", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "However, in a Finnish population the wild GG genotype of FUT2 (rs601338) was associated with enhanced risk of UC [24]. And in a Chinese Han population mutations in FUT2 (rs281377 and rs601338) predisposed patients to UC, while FUT2 (rs1047781 and rs601338) polymorphisms were associated with UC in Uyghur population from northwest China [37].", "section": "DISCUSS", "tags": [{"name": "polymorphisms", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "predisposed", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Third, the multiplex SNaPshot sequencing reactions were carried out in a final volume of 7 \u03bcl containing 2 \u03bcl of purified multiple PCR products, 1 \u03bcl SNaPshot Multiplex Mix, 1 \u03bcl 5\u00d7Sequencing buffer (Applied Biosystems) and 3 \u03bcl SNaPshot sequencing primers (the final concentrations are listed in Table 2).", "section": "METHODS", "tags": [{"name": "concentrations", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "5\u00d7Sequencing", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Immunohistochemical staining of Lewis a indicated increased expression in the cryptic epithelium of inflammatory lesions in UC patients than the normal mucosa of patients with benign colonic polyps (P = 0.028), although there was no difference of Lewis a expression in surface epithelium between the two groups.", "section": "RESULTS", "tags": [{"name": "Immunohistochemical", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "inflammatory", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "In recent years, several studies have linked several nucleotide polymorphisms in FUT2 to intestinal microbiota composition [21] and predisposition to CD [22, 23], celiac disease [24], type 1 diabetes [25] and primary sclerosing cholangitis [26], highlighting the essential role of host gene-microbiota interaction in autoimmune diseases.", "section": "INTRO", "tags": [{"name": "gene-microbiota", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "predisposition", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "First, 10 ng of genomic DNA was added to a 10 \u03bcl PCR mixture containing 20 \u03bcmol dNTPs (Promega, Wisconsin, USA), 0.5 U FastStart Taq DNA polymerase (Roche, Basel, Switzerland), 1\u03bcl 10\u00d7PCR buffer with MgCl2 (15 mmol/L) (Roche, Basel, Switzerland) and amplification primers with a specific final concentration (Table 2).", "section": "METHODS", "tags": [{"name": "Switzerland),", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "amplification", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Two LD blocks were presented as follows: block rs281377-rs1047781 in FUT2 (D' = 0.96, r2 = 0.11) and block rs3894326-rs3745635-rs28362459 in FUT3 [rs3894326/rs3745635 (D' = 1, r2 = 0.01), rs3894326/rs28362459 (D' = 0.86, r2 = 0.23), rs3745635/rs28362459 (D' = 0.92, r2 = 0.47)] (Fig 1).", "section": "METHODS", "tags": [{"name": "rs3894326-rs3745635-rs28362459", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "[rs3894326/rs3745635", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Two LD blocks were presented as follows: block rs281377-rs1047781 in FUT2 (D' = 0.96, r2 = 0.11) and block rs3894326-rs3745635-rs28362459 in FUT3 [rs3894326/rs3745635 (D' = 1, r2 = 0.01), rs3894326/rs28362459 (D' = 0.86, r2 = 0.23), rs3745635/rs28362459 (D' = 0.92, r2 = 0.47)] (Fig 1).", "section": "METHODS", "tags": [{"name": "rs3894326-rs3745635-rs28362459", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "[rs3894326/rs3745635", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Immunohistochemical staining of Lewis a indicated increased expression in the cryptic epithelium of inflammatory lesions in UC patients than the normal mucosa of patients with benign colonic polyps (P = 0.028), although there was no difference of Lewis a expression in surface epithelium between the two groups.", "section": "RESULTS", "tags": [{"name": "Immunohistochemical", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "inflammatory", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}]}
{"src": "PMC", "id": "PMC4682834", "provider": "OpenTargets", "anns": [{"type": "Gene Disease Relationship", "exact": "This study was reviewed and approved by both the Bioethics Committee and Science Committee in Research, with protocol number B05-10 at INER (National Institute of Respiratory Diseases Ismael Cosio Villegas) and Institutional Review Board No. 13CI 09015 213 at IMSS (Mexican Institute of Social Security) authorized by COFEPRIS/SSA.", "section": "METHODS", "tags": [{"name": "Institutional", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "COFEPRIS/SSA.", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "In a 2013 study by Chiaretti et al., influenza A (H1N1) virus infection was shown to induce the early and significant up-regulation of IL-1\u03b2 and IL-6 in plasma, suggesting that these cytokines are responsible for different molecular reactions that lead to inflammation of the airway and increased disease severity [32].", "section": "DISCUSS", "tags": [{"name": "up-regulation", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "inflammation", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "One major limitation of this study was that samples were only collected in the central region of the country where mortality was higher; therefore, we believe that expanding the sampling area to other geographical regions would enable us to clearly identify areas with greater \"genetic vulnerability\" to be able to overcome future challenges of potentially lethal subtypes of influenza.", "section": "DISCUSS", "tags": [{"name": "vulnerability\"", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "geographical", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "In this study, we included a greater number of patients from the fourth wave of virus infection and aimed to establish the association between polymorphisms in inflammation-related genes (TNF, IL6, IL8, IL1B, LTA, CCL1) and disease development, severity and death from influenza A (H1N1) virus infection in patients from the central region of Mexico.", "section": "INTRO", "tags": [{"name": "inflammation-related", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "polymorphisms", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "When the pA/H1N1 group was compared with the AHC group, we observed that the LTA rs909253 TC heterozygous genotype showed a risk association with disease susceptibility (p = 0.003; OR = 1.9, 95% CI: 1.25\u20132.87); a similar association occurred with the IL1B rs3136558 CC genotype (p = 0.041; OR = 1.89, 95% CI: 1.02\u20133.51).", "section": "RESULTS", "tags": [{"name": "susceptibility", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "heterozygous", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Ten cytokines (GM-CSF, TNF-\u03b1, IL-2, IL-1\u03b2, IL-6, IL-8, IFN-\u03b3, IL-10, IL-5, and IL-4) were measured on a Luminex 100 (Luminex Corporation, Austin, TX, USA) using a multiplex cytokine kit as well as the Cytokine Human 10-Plex Panel (Novex, Life Technologies, CA, USA) in accordance with the manufacturer's instructions.", "section": "METHODS", "tags": [{"name": "manufacturer's", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "Technologies,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "The greatest number of deaths from influenza A (H1N1) pdm09 occurred in the central region of the country where healthcare systems are better than in the rest of the country and where access to healthcare services is greater because of better transportation routes and the presence of hospitals that provide care to patients with severe illnesses.", "section": "INTRO", "tags": [{"name": "transportation", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "healthcare", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "In a 2013 study by Chiaretti et al., influenza A (H1N1) virus infection was shown to induce the early and significant up-regulation of IL-1\u03b2 and IL-6 in plasma, suggesting that these cytokines are responsible for different molecular reactions that lead to inflammation of the airway and increased disease severity [32].", "section": "DISCUSS", "tags": [{"name": "up-regulation", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "inflammation", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "This study was reviewed and approved by both the Bioethics Committee and Science Committee in Research, with protocol number B05-10 at INER (National Institute of Respiratory Diseases Ismael Cosio Villegas) and Institutional Review Board No. 13CI 09015 213 at IMSS (Mexican Institute of Social Security) authorized by COFEPRIS/SSA.", "section": "METHODS", "tags": [{"name": "Institutional", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "COFEPRIS/SSA.", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "This study was reviewed and approved by both the Bioethics Committee and Science Committee in Research, with protocol number B05-10 at INER (National Institute of Respiratory Diseases Ismael Cosio Villegas) and Institutional Review Board No. 13CI 09015 213 at IMSS (Mexican Institute of Social Security) authorized by COFEPRIS/SSA.", "section": "METHODS", "tags": [{"name": "Institutional", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "COFEPRIS/SSA.", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "The greatest number of deaths from influenza A (H1N1) pdm09 occurred in the central region of the country where healthcare systems are better than in the rest of the country and where access to healthcare services is greater because of better transportation routes and the presence of hospitals that provide care to patients with severe illnesses.", "section": "INTRO", "tags": [{"name": "transportation", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "healthcare", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Concerning age at presentation, our results indicate that many patients who are not in the age groups at greatest risk of death or who have no comorbidities associated with an increased risk of death from influenza may have genetic characteristics that make them more susceptible to developing influenza and presenting with greater disease severity.", "section": "DISCUSS", "tags": [{"name": "characteristics", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "presentation,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Ten cytokines (GM-CSF, TNF-\u03b1, IL-2, IL-1\u03b2, IL-6, IL-8, IFN-\u03b3, IL-10, IL-5, and IL-4) were measured on a Luminex 100 (Luminex Corporation, Austin, TX, USA) using a multiplex cytokine kit as well as the Cytokine Human 10-Plex Panel (Novex, Life Technologies, CA, USA) in accordance with the manufacturer's instructions.", "section": "METHODS", "tags": [{"name": "manufacturer's", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "Technologies,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "One major limitation of this study was that samples were only collected in the central region of the country where mortality was higher; therefore, we believe that expanding the sampling area to other geographical regions would enable us to clearly identify areas with greater \"genetic vulnerability\" to be able to overcome future challenges of potentially lethal subtypes of influenza.", "section": "DISCUSS", "tags": [{"name": "vulnerability\"", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "geographical", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "When the pA/H1N1 group was compared with the AHC group, we observed that the LTA rs909253 TC heterozygous genotype showed a risk association with disease susceptibility (p = 0.003; OR = 1.9, 95% CI: 1.25\u20132.87); a similar association occurred with the IL1B rs3136558 CC genotype (p = 0.041; OR = 1.89, 95% CI: 1.02\u20133.51).", "section": "RESULTS", "tags": [{"name": "susceptibility", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "heterozygous", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "In this study, we included a greater number of patients from the fourth wave of virus infection and aimed to establish the association between polymorphisms in inflammation-related genes (TNF, IL6, IL8, IL1B, LTA, CCL1) and disease development, severity and death from influenza A (H1N1) virus infection in patients from the central region of Mexico.", "section": "INTRO", "tags": [{"name": "inflammation-related", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "polymorphisms", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}]}
{"src": "PMC", "id": "PMC4690073", "provider": "OpenTargets", "anns": [{"type": "Gene Disease Relationship", "exact": "For each gene separately and for three separate outcome groups\u201415 phospholipid variables in cord serum and in adolescent serum and also for the two diagnosis atopic eczema and respiratory allergy\u2014100 000 permutations were carried out to get an empirical null distribution of the minP (minimum p-value) statistic from which the corrected p-values could be estimated Two-tailed p \u2264 0.05 was considered significant [41].", "section": "METHODS", "tags": [{"name": "phospholipid", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "permutations", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "1 All subjects that were invited to take part in the follow up at 13 years of age; 2 Subjects that were selected for blood sampling at 13 years of age and approved participation in genetic analyses; 3 No allergy and no sensitization at any of the follow-ups (1, 4, 7, and 13 years of age); 4 Atopic eczema was defined as a pruritic, chronic, or chronically relapsing non-infectious dermatitis with typical features and distribution, fulfilling three of the main criteria suggested by Hanifin and Rajka 6; 5 Respiratory allergy was defined as a positive skin prick test to an inhalant allergen, in combination with two or more of the following criteria: wheeze in the past year, doctor\u2019s diagnosed asthma, asthma inhalation treatment, or a positive answer to the question: \u201cHave you had any signs of pollen allergy or allergy to furry pets during the last 12 months?\u201d; 6 Data obtained from the Swedish Medical Birth Register kept by The Swedish National Board of Health and Welfare (Stockholm, Sweden).", "section": "METHODS", "tags": [{"name": "non-infectious", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "participation", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "The power of this study may be limited by the relative small population size, however, the prospective birth cohort design allowed us to select very clear cases with only one allergic manifestations as well as non-allergic controls that had not been sensitized nor had any allergic symptoms in any of the follow-ups at 1, 4, 7, or 13 years of age.", "section": "DISCUSS", "tags": [{"name": "manifestations", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "non-allergic", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Based on the questionnaires and sensitization tests at 13 years of age, the subjects were divided into three diagnostic groups: (1) atopic eczema with no other allergic manifestations, in all, 79 adolescents out of the 788 fulfilled these criteria; (2) respiratory allergy with no other allergic manifestations, all of whom were also sensitized to airborne allergens, in all, 130 adolescents in the cohort fulfilled these criteria and (3) no allergy and no sensitization at any of the follow-ups (1, 4, 7 and 13 years of age), in all, 331 adolescents in the cohort fulfilled these criteria.", "section": "METHODS", "tags": [{"name": "manifestations,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "manifestations,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "1 All subjects that were invited to take part in the follow up at 13 years of age; 2 Subjects that were selected for blood sampling at 13 years of age and approved participation in genetic analyses; 3 No allergy and no sensitization at any of the follow-ups (1, 4, 7, and 13 years of age); 4 Atopic eczema was defined as a pruritic, chronic, or chronically relapsing non-infectious dermatitis with typical features and distribution, fulfilling three of the main criteria suggested by Hanifin and Rajka 6; 5 Respiratory allergy was defined as a positive skin prick test to an inhalant allergen, in combination with two or more of the following criteria: wheeze in the past year, doctor\u2019s diagnosed asthma, asthma inhalation treatment, or a positive answer to the question: \u201cHave you had any signs of pollen allergy or allergy to furry pets during the last 12 months?\u201d; 6 Data obtained from the Swedish Medical Birth Register kept by The Swedish National Board of Health and Welfare (Stockholm, Sweden).", "section": "METHODS", "tags": [{"name": "non-infectious", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "participation", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "For each gene separately and for three separate outcome groups\u201415 phospholipid variables in cord serum and in adolescent serum and also for the two diagnosis atopic eczema and respiratory allergy\u2014100 000 permutations were carried out to get an empirical null distribution of the minP (minimum p-value) statistic from which the corrected p-values could be estimated Two-tailed p \u2264 0.05 was considered significant [41].", "section": "METHODS", "tags": [{"name": "phospholipid", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "permutations", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Based on the questionnaires and sensitization tests at 13 years of age, the subjects were divided into three diagnostic groups: (1) atopic eczema with no other allergic manifestations, in all, 79 adolescents out of the 788 fulfilled these criteria; (2) respiratory allergy with no other allergic manifestations, all of whom were also sensitized to airborne allergens, in all, 130 adolescents in the cohort fulfilled these criteria and (3) no allergy and no sensitization at any of the follow-ups (1, 4, 7 and 13 years of age), in all, 331 adolescents in the cohort fulfilled these criteria.", "section": "METHODS", "tags": [{"name": "manifestations,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "manifestations,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "1 All subjects that were invited to take part in the follow up at 13 years of age; 2 Subjects that were selected for blood sampling at 13 years of age and approved participation in genetic analyses; 3 No allergy and no sensitization at any of the follow-ups (1, 4, 7, and 13 years of age); 4 Atopic eczema was defined as a pruritic, chronic, or chronically relapsing non-infectious dermatitis with typical features and distribution, fulfilling three of the main criteria suggested by Hanifin and Rajka 6; 5 Respiratory allergy was defined as a positive skin prick test to an inhalant allergen, in combination with two or more of the following criteria: wheeze in the past year, doctor\u2019s diagnosed asthma, asthma inhalation treatment, or a positive answer to the question: \u201cHave you had any signs of pollen allergy or allergy to furry pets during the last 12 months?\u201d; 6 Data obtained from the Swedish Medical Birth Register kept by The Swedish National Board of Health and Welfare (Stockholm, Sweden).", "section": "METHODS", "tags": [{"name": "non-infectious", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "participation", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "However, as expected, the significance of rs102275 and rs174448 with atopic eczema disappeared when any of the five fatty acids that are associated with eczema as well as the SNP are added to the logistic model, suggesting that the association between the minor FADS allele and protection from atopic eczema development acts via a reduced capacity to elongate precursor n-6 PUFAs to arachidonic acid (20:4 n-6).", "section": "DISCUSS", "tags": [{"name": "significance", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "disappeared", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "For each gene separately and for three separate outcome groups\u201415 phospholipid variables in cord serum and in adolescent serum and also for the two diagnosis atopic eczema and respiratory allergy\u2014100 000 permutations were carried out to get an empirical null distribution of the minP (minimum p-value) statistic from which the corrected p-values could be estimated Two-tailed p \u2264 0.05 was considered significant [41].", "section": "METHODS", "tags": [{"name": "phospholipid", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "permutations", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Respiratory allergy was defined as a positive skin prick test to an inhalant allergen, in combination with two or more of the following criteria: wheeze in the past year, doctor\u2019s diagnosed asthma, asthma inhalation treatment, or a positive answer to the question: \u201cHave you had any signs of pollen allergy or allergy to furry pets during the last 12 months?\u201d.", "section": "METHODS", "tags": [{"name": "Respiratory", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "combination", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "The power of this study may be limited by the relative small population size, however, the prospective birth cohort design allowed us to select very clear cases with only one allergic manifestations as well as non-allergic controls that had not been sensitized nor had any allergic symptoms in any of the follow-ups at 1, 4, 7, or 13 years of age.", "section": "DISCUSS", "tags": [{"name": "manifestations", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "non-allergic", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Based on the questionnaires and sensitization tests at 13 years of age, the subjects were divided into three diagnostic groups: (1) atopic eczema with no other allergic manifestations, in all, 79 adolescents out of the 788 fulfilled these criteria; (2) respiratory allergy with no other allergic manifestations, all of whom were also sensitized to airborne allergens, in all, 130 adolescents in the cohort fulfilled these criteria and (3) no allergy and no sensitization at any of the follow-ups (1, 4, 7 and 13 years of age), in all, 331 adolescents in the cohort fulfilled these criteria.", "section": "METHODS", "tags": [{"name": "manifestations,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "manifestations,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "The power of this study may be limited by the relative small population size, however, the prospective birth cohort design allowed us to select very clear cases with only one allergic manifestations as well as non-allergic controls that had not been sensitized nor had any allergic symptoms in any of the follow-ups at 1, 4, 7, or 13 years of age.", "section": "DISCUSS", "tags": [{"name": "manifestations", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "non-allergic", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "However, as expected, the significance of rs102275 and rs174448 with atopic eczema disappeared when any of the five fatty acids that are associated with eczema as well as the SNP are added to the logistic model, suggesting that the association between the minor FADS allele and protection from atopic eczema development acts via a reduced capacity to elongate precursor n-6 PUFAs to arachidonic acid (20:4 n-6).", "section": "DISCUSS", "tags": [{"name": "significance", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "disappeared", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "For each gene separately and for three separate outcome groups\u201415 phospholipid variables in cord serum and in adolescent serum and also for the two diagnosis atopic eczema and respiratory allergy\u2014100 000 permutations were carried out to get an empirical null distribution of the minP (minimum p-value) statistic from which the corrected p-values could be estimated Two-tailed p \u2264 0.05 was considered significant [41].", "section": "METHODS", "tags": [{"name": "phospholipid", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "permutations", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "1 All subjects that were invited to take part in the follow up at 13 years of age; 2 Subjects that were selected for blood sampling at 13 years of age and approved participation in genetic analyses; 3 No allergy and no sensitization at any of the follow-ups (1, 4, 7, and 13 years of age); 4 Atopic eczema was defined as a pruritic, chronic, or chronically relapsing non-infectious dermatitis with typical features and distribution, fulfilling three of the main criteria suggested by Hanifin and Rajka 6; 5 Respiratory allergy was defined as a positive skin prick test to an inhalant allergen, in combination with two or more of the following criteria: wheeze in the past year, doctor\u2019s diagnosed asthma, asthma inhalation treatment, or a positive answer to the question: \u201cHave you had any signs of pollen allergy or allergy to furry pets during the last 12 months?\u201d; 6 Data obtained from the Swedish Medical Birth Register kept by The Swedish National Board of Health and Welfare (Stockholm, Sweden).", "section": "METHODS", "tags": [{"name": "non-infectious", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "participation", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Based on the questionnaires and sensitization tests at 13 years of age, the subjects were divided into three diagnostic groups: (1) atopic eczema with no other allergic manifestations, in all, 79 adolescents out of the 788 fulfilled these criteria; (2) respiratory allergy with no other allergic manifestations, all of whom were also sensitized to airborne allergens, in all, 130 adolescents in the cohort fulfilled these criteria and (3) no allergy and no sensitization at any of the follow-ups (1, 4, 7 and 13 years of age), in all, 331 adolescents in the cohort fulfilled these criteria.", "section": "METHODS", "tags": [{"name": "manifestations,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "manifestations,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "1 All subjects that were invited to take part in the follow up at 13 years of age; 2 Subjects that were selected for blood sampling at 13 years of age and approved participation in genetic analyses; 3 No allergy and no sensitization at any of the follow-ups (1, 4, 7, and 13 years of age); 4 Atopic eczema was defined as a pruritic, chronic, or chronically relapsing non-infectious dermatitis with typical features and distribution, fulfilling three of the main criteria suggested by Hanifin and Rajka 6; 5 Respiratory allergy was defined as a positive skin prick test to an inhalant allergen, in combination with two or more of the following criteria: wheeze in the past year, doctor\u2019s diagnosed asthma, asthma inhalation treatment, or a positive answer to the question: \u201cHave you had any signs of pollen allergy or allergy to furry pets during the last 12 months?\u201d; 6 Data obtained from the Swedish Medical Birth Register kept by The Swedish National Board of Health and Welfare (Stockholm, Sweden).", "section": "METHODS", "tags": [{"name": "non-infectious", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "participation", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "For each gene separately and for three separate outcome groups\u201415 phospholipid variables in cord serum and in adolescent serum and also for the two diagnosis atopic eczema and respiratory allergy\u2014100 000 permutations were carried out to get an empirical null distribution of the minP (minimum p-value) statistic from which the corrected p-values could be estimated Two-tailed p \u2264 0.05 was considered significant [41].", "section": "METHODS", "tags": [{"name": "phospholipid", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "permutations", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Respiratory allergy was defined as a positive skin prick test to an inhalant allergen, in combination with two or more of the following criteria: wheeze in the past year, doctor\u2019s diagnosed asthma, asthma inhalation treatment, or a positive answer to the question: \u201cHave you had any signs of pollen allergy or allergy to furry pets during the last 12 months?\u201d.", "section": "METHODS", "tags": [{"name": "Respiratory", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "combination", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Respiratory allergy was defined as a positive skin prick test to an inhalant allergen, in combination with two or more of the following criteria: wheeze in the past year, doctor\u2019s diagnosed asthma, asthma inhalation treatment, or a positive answer to the question: \u201cHave you had any signs of pollen allergy or allergy to furry pets during the last 12 months?\u201d.", "section": "METHODS", "tags": [{"name": "Respiratory", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "combination", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}]}
{"src": "PMC", "id": "PMC4593004", "provider": "OpenTargets", "anns": [{"type": "Gene Disease Relationship", "exact": "The primers used for quantitative PCR (qPCR) amplification were as follows: KCNQ5, forward: 5\u2032- AGGGGAAGCATCAAGCAGTA -3\u2032 and reverse: 5\u2032- CGCACTCGCTCCTTAAAACT -3\u2032; PLCB1, forward: 5\u2032- GTGGGAGACACGCCAAAG -3\u2032 and reverse: 5\u2032- GGCCCATACACCACTGTGA -3\u2032; PLCB4, forward: 5\u2032- CGGGAAGTCTTCGGTAGAAA -3\u2032 and reverse: 5\u2032- CCCAGCAGTCAAGTTCAACA -3\u2032; PLCL1, forward: 5\u2032- TCACTTGTGATGAAAGACAGCTT -3\u2032 and reverse: 5\u2032- GAGAAACCGGCTCTCTTGAA -3\u2032; IL-1 beta, forward: 5\u2032-TACCTGTCCTGCGTGTTGAA-3\u2032 and reverse: 5\u2032-TCTTTGGGTAATTTTTGGGATCT -3\u2032; IL-6, forward: 5\u2032- CAGGAGCCCAGCTATGAACT -3\u2032 and reverse: 5\u2032- GAAGGCAGCAGGCAACAC -3\u2032; IL-8, forward: 5\u2032- GAGCACTCCATAAGGCACAAA -3\u2032 and reverse: 5\u2032- ATGGTTCCTTCCGGTGGT -3\u2032. Reverse transcription was performed in a 10\u2009\u03bcL reaction mixture consisting of 2\u2009\u03bcL RNA template, 1\u2009\u03bcL RT primer mix, 1\u2009\u03bcL dNTP mix (10\u2009mm each), and 6\u2009\u03bcL RNA/DNAse-free water at 65\u2009\u00b0C for 5\u2009min.", "section": "OTHER", "tags": [{"name": "5\u2032-TACCTGTCCTGCGTGTTGAA-3\u2032", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "5\u2032-TCTTTGGGTAATTTTTGGGATCT", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "All patients were diagnosed according to KD criteria5556, including fever lasting 5 days or more and at least 4 of the following symptoms: (1) changes in extremities (e.g., erythema, edema, or desquamation), (2) bilateral conjunctivitis, (3) polymorphous rash, (4) cervical lymphadenopathy, and (5) changes in the lips or oral cavity (e.g. pharyngeal erythema, dry/fissured or swollen lips, or \u201cstrawberry tongue\u201d).", "section": "OTHER", "tags": [{"name": "lymphadenopathy,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "conjunctivitis,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "For synovial fibroblasts, macrophages, dendritic cells, and ECs, inflammation induced by thrombin, bradykinin, LPS, porphyromonas gingivalis, or advanced glycation end products has been shown to be affected by PLC inhibitors, suggesting that PLC might also be involved in NF-\u03baB activation and proinflammatory cytokine release in inflammatory diseases3334353637.", "section": "DISCUSS", "tags": [{"name": "diseases3334353637.", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "proinflammatory", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "siRNA targeting transcripts for KCNQ5, PLCB1, PLCB4, and PLCL1 (5\u2032\u20133\u2032; siKCNQ5: duplex 1, GGGCAAAUCACAUCAGAUA; duplex 2, CAACACAGGUGCCAAUUAG; duplex 3, GACAUGUUGUGUAGAAUUA; duplex 4, GGGAGGCACUUGGAAAUUA; siPLCB1: duplex 1, GAAGAUAACAGAAGCUAAA; duplex 2, GCAAUUGGCUGCUUUGACA; duplex 3, GAUGAUGACUCAACUAUUG; duplex 4, CAACAGAAAUCGUUUGUGA; siPLCB4: duplex 1, GUAAUUGUCUCGAAAUGAA; duplex 2, GAGAAUAGCUGUGUAUGAU; duplex 3, CAAGAAAGGUAUUGAACUU; duplex 4, CCACUAAUAUCCAUCCAUA; siPLCL1: duplex 1, GCACAGAAGCGCAGUCUUU; duplex 2, GGUAAUGGCUCAACAGAUG; duplex 3, GAAGAAAGUUCGGGAAUAU; duplex 4, GUAGGGAGCUCUCUGAUUU) were purchased from Invitrogen (Carlsbad, CA, USA), as were the non-targeting siRNA scrambled controls (siNC: duplex 1, AUGAACGUGAAUUGCUCAA; duplex 2, UAAGGCUAUGAAGAGAUAC; duplex 3, AUGUAUUGGCCUGUAUUAG; duplex 4, UAGCGACUAAACACAUCAA).", "section": "OTHER", "tags": [{"name": "UAGCGACUAAACACAUCAA).", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "GGGCAAAUCACAUCAGAUA;", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Our results demonstrated that the effect of LPS-induced EC inflammation was inhibited with the most significant inhibition by using siPLCB1 or a PLC inhibitor, suggesting that PLCB1 might be involved in EC inflammation, a possibility that has important implications for understanding the pathogenesis of immune-mediated vascular diseases.", "section": "DISCUSS", "tags": [{"name": "immune-mediated", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "inflammation,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "For synovial fibroblasts, macrophages, dendritic cells, and ECs, inflammation induced by thrombin, bradykinin, LPS, porphyromonas gingivalis, or advanced glycation end products has been shown to be affected by PLC inhibitors, suggesting that PLC might also be involved in NF-\u03baB activation and proinflammatory cytokine release in inflammatory diseases3334353637.", "section": "DISCUSS", "tags": [{"name": "diseases3334353637.", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "proinflammatory", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "siRNA targeting transcripts for KCNQ5, PLCB1, PLCB4, and PLCL1 (5\u2032\u20133\u2032; siKCNQ5: duplex 1, GGGCAAAUCACAUCAGAUA; duplex 2, CAACACAGGUGCCAAUUAG; duplex 3, GACAUGUUGUGUAGAAUUA; duplex 4, GGGAGGCACUUGGAAAUUA; siPLCB1: duplex 1, GAAGAUAACAGAAGCUAAA; duplex 2, GCAAUUGGCUGCUUUGACA; duplex 3, GAUGAUGACUCAACUAUUG; duplex 4, CAACAGAAAUCGUUUGUGA; siPLCB4: duplex 1, GUAAUUGUCUCGAAAUGAA; duplex 2, GAGAAUAGCUGUGUAUGAU; duplex 3, CAAGAAAGGUAUUGAACUU; duplex 4, CCACUAAUAUCCAUCCAUA; siPLCL1: duplex 1, GCACAGAAGCGCAGUCUUU; duplex 2, GGUAAUGGCUCAACAGAUG; duplex 3, GAAGAAAGUUCGGGAAUAU; duplex 4, GUAGGGAGCUCUCUGAUUU) were purchased from Invitrogen (Carlsbad, CA, USA), as were the non-targeting siRNA scrambled controls (siNC: duplex 1, AUGAACGUGAAUUGCUCAA; duplex 2, UAAGGCUAUGAAGAGAUAC; duplex 3, AUGUAUUGGCCUGUAUUAG; duplex 4, UAGCGACUAAACACAUCAA).", "section": "OTHER", "tags": [{"name": "UAGCGACUAAACACAUCAA).", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "GGGCAAAUCACAUCAGAUA;", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "HUVECs (BCRC Number: H-UV001) were grown in 90% GIBCO medium 199 (Life Technologies) with 25\u2009U/mL heparin (Sigma, St. Louis, MO, USA), 30\u2009\u03bcg/mL endothelial cell growth supplement (Millipore, Billerica, MA, USA) adjusted to contain 1.5\u2009g/L sodium bicarbonate + 10% fetal bovine serum and 100\u2009U/mL penicillin/streptomycin.", "section": "OTHER", "tags": [{"name": "penicillin/streptomycin.", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "Technologies)", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "All patients were diagnosed according to KD criteria5556, including fever lasting 5 days or more and at least 4 of the following symptoms: (1) changes in extremities (e.g., erythema, edema, or desquamation), (2) bilateral conjunctivitis, (3) polymorphous rash, (4) cervical lymphadenopathy, and (5) changes in the lips or oral cavity (e.g. pharyngeal erythema, dry/fissured or swollen lips, or \u201cstrawberry tongue\u201d).", "section": "OTHER", "tags": [{"name": "lymphadenopathy,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "conjunctivitis,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "For cardiomyocytes, PLC beta is the immediate downstream target of G\u03b1q, a heterotrimeric G protein that regulates its activation, and hydrolyzes the plasma membrane phosphatidylinositol 4,5-bisphosphate (PIP2) protein to produce the second messengers inositol 1,4,5-triphosphate (IP3; a regulator of the intracellular calcium response) and diacylglycerol (DAG, an activator of protein kinase C subtypes)50.", "section": "DISCUSS", "tags": [{"name": "phosphatidylinositol", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "1,4,5-triphosphate", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "siRNA targeting transcripts for KCNQ5, PLCB1, PLCB4, and PLCL1 (5\u2032\u20133\u2032; siKCNQ5: duplex 1, GGGCAAAUCACAUCAGAUA; duplex 2, CAACACAGGUGCCAAUUAG; duplex 3, GACAUGUUGUGUAGAAUUA; duplex 4, GGGAGGCACUUGGAAAUUA; siPLCB1: duplex 1, GAAGAUAACAGAAGCUAAA; duplex 2, GCAAUUGGCUGCUUUGACA; duplex 3, GAUGAUGACUCAACUAUUG; duplex 4, CAACAGAAAUCGUUUGUGA; siPLCB4: duplex 1, GUAAUUGUCUCGAAAUGAA; duplex 2, GAGAAUAGCUGUGUAUGAU; duplex 3, CAAGAAAGGUAUUGAACUU; duplex 4, CCACUAAUAUCCAUCCAUA; siPLCL1: duplex 1, GCACAGAAGCGCAGUCUUU; duplex 2, GGUAAUGGCUCAACAGAUG; duplex 3, GAAGAAAGUUCGGGAAUAU; duplex 4, GUAGGGAGCUCUCUGAUUU) were purchased from Invitrogen (Carlsbad, CA, USA), as were the non-targeting siRNA scrambled controls (siNC: duplex 1, AUGAACGUGAAUUGCUCAA; duplex 2, UAAGGCUAUGAAGAGAUAC; duplex 3, AUGUAUUGGCCUGUAUUAG; duplex 4, UAGCGACUAAACACAUCAA).", "section": "OTHER", "tags": [{"name": "UAGCGACUAAACACAUCAA).", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "GGGCAAAUCACAUCAGAUA;", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "HUVECs (BCRC Number: H-UV001) were grown in 90% GIBCO medium 199 (Life Technologies) with 25\u2009U/mL heparin (Sigma, St. Louis, MO, USA), 30\u2009\u03bcg/mL endothelial cell growth supplement (Millipore, Billerica, MA, USA) adjusted to contain 1.5\u2009g/L sodium bicarbonate + 10% fetal bovine serum and 100\u2009U/mL penicillin/streptomycin.", "section": "OTHER", "tags": [{"name": "penicillin/streptomycin.", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "Technologies)", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "For synovial fibroblasts, macrophages, dendritic cells, and ECs, inflammation induced by thrombin, bradykinin, LPS, porphyromonas gingivalis, or advanced glycation end products has been shown to be affected by PLC inhibitors, suggesting that PLC might also be involved in NF-\u03baB activation and proinflammatory cytokine release in inflammatory diseases3334353637.", "section": "DISCUSS", "tags": [{"name": "diseases3334353637.", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "proinflammatory", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "The primers used for quantitative PCR (qPCR) amplification were as follows: KCNQ5, forward: 5\u2032- AGGGGAAGCATCAAGCAGTA -3\u2032 and reverse: 5\u2032- CGCACTCGCTCCTTAAAACT -3\u2032; PLCB1, forward: 5\u2032- GTGGGAGACACGCCAAAG -3\u2032 and reverse: 5\u2032- GGCCCATACACCACTGTGA -3\u2032; PLCB4, forward: 5\u2032- CGGGAAGTCTTCGGTAGAAA -3\u2032 and reverse: 5\u2032- CCCAGCAGTCAAGTTCAACA -3\u2032; PLCL1, forward: 5\u2032- TCACTTGTGATGAAAGACAGCTT -3\u2032 and reverse: 5\u2032- GAGAAACCGGCTCTCTTGAA -3\u2032; IL-1 beta, forward: 5\u2032-TACCTGTCCTGCGTGTTGAA-3\u2032 and reverse: 5\u2032-TCTTTGGGTAATTTTTGGGATCT -3\u2032; IL-6, forward: 5\u2032- CAGGAGCCCAGCTATGAACT -3\u2032 and reverse: 5\u2032- GAAGGCAGCAGGCAACAC -3\u2032; IL-8, forward: 5\u2032- GAGCACTCCATAAGGCACAAA -3\u2032 and reverse: 5\u2032- ATGGTTCCTTCCGGTGGT -3\u2032. Reverse transcription was performed in a 10\u2009\u03bcL reaction mixture consisting of 2\u2009\u03bcL RNA template, 1\u2009\u03bcL RT primer mix, 1\u2009\u03bcL dNTP mix (10\u2009mm each), and 6\u2009\u03bcL RNA/DNAse-free water at 65\u2009\u00b0C for 5\u2009min.", "section": "OTHER", "tags": [{"name": "5\u2032-TACCTGTCCTGCGTGTTGAA-3\u2032", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "5\u2032-TCTTTGGGTAATTTTTGGGATCT", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "siRNA targeting transcripts for KCNQ5, PLCB1, PLCB4, and PLCL1 (5\u2032\u20133\u2032; siKCNQ5: duplex 1, GGGCAAAUCACAUCAGAUA; duplex 2, CAACACAGGUGCCAAUUAG; duplex 3, GACAUGUUGUGUAGAAUUA; duplex 4, GGGAGGCACUUGGAAAUUA; siPLCB1: duplex 1, GAAGAUAACAGAAGCUAAA; duplex 2, GCAAUUGGCUGCUUUGACA; duplex 3, GAUGAUGACUCAACUAUUG; duplex 4, CAACAGAAAUCGUUUGUGA; siPLCB4: duplex 1, GUAAUUGUCUCGAAAUGAA; duplex 2, GAGAAUAGCUGUGUAUGAU; duplex 3, CAAGAAAGGUAUUGAACUU; duplex 4, CCACUAAUAUCCAUCCAUA; siPLCL1: duplex 1, GCACAGAAGCGCAGUCUUU; duplex 2, GGUAAUGGCUCAACAGAUG; duplex 3, GAAGAAAGUUCGGGAAUAU; duplex 4, GUAGGGAGCUCUCUGAUUU) were purchased from Invitrogen (Carlsbad, CA, USA), as were the non-targeting siRNA scrambled controls (siNC: duplex 1, AUGAACGUGAAUUGCUCAA; duplex 2, UAAGGCUAUGAAGAGAUAC; duplex 3, AUGUAUUGGCCUGUAUUAG; duplex 4, UAGCGACUAAACACAUCAA).", "section": "OTHER", "tags": [{"name": "UAGCGACUAAACACAUCAA).", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "GGGCAAAUCACAUCAGAUA;", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "All patients were diagnosed according to KD criteria5556, including fever lasting 5 days or more and at least 4 of the following symptoms: (1) changes in extremities (e.g., erythema, edema, or desquamation), (2) bilateral conjunctivitis, (3) polymorphous rash, (4) cervical lymphadenopathy, and (5) changes in the lips or oral cavity (e.g. pharyngeal erythema, dry/fissured or swollen lips, or \u201cstrawberry tongue\u201d).", "section": "OTHER", "tags": [{"name": "lymphadenopathy,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "conjunctivitis,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "All patients were diagnosed according to KD criteria5556, including fever lasting 5 days or more and at least 4 of the following symptoms: (1) changes in extremities (e.g., erythema, edema, or desquamation), (2) bilateral conjunctivitis, (3) polymorphous rash, (4) cervical lymphadenopathy, and (5) changes in the lips or oral cavity (e.g. pharyngeal erythema, dry/fissured or swollen lips, or \u201cstrawberry tongue\u201d).", "section": "OTHER", "tags": [{"name": "lymphadenopathy,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "conjunctivitis,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "The primers used for quantitative PCR (qPCR) amplification were as follows: KCNQ5, forward: 5\u2032- AGGGGAAGCATCAAGCAGTA -3\u2032 and reverse: 5\u2032- CGCACTCGCTCCTTAAAACT -3\u2032; PLCB1, forward: 5\u2032- GTGGGAGACACGCCAAAG -3\u2032 and reverse: 5\u2032- GGCCCATACACCACTGTGA -3\u2032; PLCB4, forward: 5\u2032- CGGGAAGTCTTCGGTAGAAA -3\u2032 and reverse: 5\u2032- CCCAGCAGTCAAGTTCAACA -3\u2032; PLCL1, forward: 5\u2032- TCACTTGTGATGAAAGACAGCTT -3\u2032 and reverse: 5\u2032- GAGAAACCGGCTCTCTTGAA -3\u2032; IL-1 beta, forward: 5\u2032-TACCTGTCCTGCGTGTTGAA-3\u2032 and reverse: 5\u2032-TCTTTGGGTAATTTTTGGGATCT -3\u2032; IL-6, forward: 5\u2032- CAGGAGCCCAGCTATGAACT -3\u2032 and reverse: 5\u2032- GAAGGCAGCAGGCAACAC -3\u2032; IL-8, forward: 5\u2032- GAGCACTCCATAAGGCACAAA -3\u2032 and reverse: 5\u2032- ATGGTTCCTTCCGGTGGT -3\u2032. Reverse transcription was performed in a 10\u2009\u03bcL reaction mixture consisting of 2\u2009\u03bcL RNA template, 1\u2009\u03bcL RT primer mix, 1\u2009\u03bcL dNTP mix (10\u2009mm each), and 6\u2009\u03bcL RNA/DNAse-free water at 65\u2009\u00b0C for 5\u2009min.", "section": "OTHER", "tags": [{"name": "5\u2032-TACCTGTCCTGCGTGTTGAA-3\u2032", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "5\u2032-TCTTTGGGTAATTTTTGGGATCT", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}]}
{"src": "PMC", "id": "PMC4539664", "provider": "OpenTargets", "anns": [{"type": "Gene Disease Relationship", "exact": "Tyr1183*rs118203998Reid (2007) [2]1--37.0\nHAPS Hunter Area Pathology Service, FCC Familial Cancer Centre, ViP Variants in Practice\naVariant positions are reported in reference to NCBI RefSeq NM_024675.3 (mRNA) and NP_078951.2 (protein)\nbNumber of individuals carrying the variant\ncc.3113G\u2009>\u2009A produces three different PALB2 mRNA sequences: complete deletion of exon 10 (117 bp); use of an alternative splice site within exon 10, and deletion of 31 bp; and an immediate stop at codon 1038 [29]", "section": "RESULTS", "tags": [{"name": "Tyr1183*rs118203998Reid", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "NM_024675.3", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Table 4Synonymous variantsExonNucleotide changea\nProtein changea\ndbSNP IDFirst reported1000 G MAFb\nNHBLI GO ESP MAFc\nExACd\nHAPS cases (n\u2009=\u2009997)e\nFCC-ViP cases (n\u2009=\u2009999)d\nControls (n\u2009=\u20091998)e\nCADD scaledC score1c.12 T\u2009>\u2009Cp.(=)rs145291423-..0.00012-1111.24c.768C\u2009>\u2009Tp.(=)rs45487491..0.00003710.34c.1188C\u2009>\u2009Tp.(=).-..0.00003--17.64c.1194G\u2009>\u2009Ap.(=)rs61755173Rahman (2007) [3]0.00090.001540.001143286.44c.1194G\u2009>\u2009Tp.(=).-...1--6.14c.1242A\u2009>\u2009Cp.(=).-...--17.74c.1431C\u2009>\u2009Tp.(=).Teo (2013)..02--0.04c.1470C\u2009>\u2009Tp.(=)rs45612837Rahman (2007) [3]0.00050.000150.0004051-25.84c.1572A\u2009>\u2009Gp.(=)rs45472400Rahman (2007) [3]0.00320.003390.00411212275.64c.1623G\u2009>\u2009Ap.(=).-..0-124.25c.2067G\u2009>\u2009Ap.(=).Phuah (2013) [38].0.000150.0000181--4.15c.2082A\u2009>\u2009Gp.(=)rs150569240-..0.000055--15.85c.2091C\u2009>\u2009Ap.(=).-..0--14.75c.2244A\u2009>\u2009Gp.(=).-..0.000037--15.65c.2328C\u2009>\u2009Tp.(=)rs45508997-.0.0000801--4.05c.2337A\u2009>\u2009Cp.(=).-...-1-5.25c.2379C\u2009>\u2009Tp.(=).-.0.000080.00011111-0.15c.2478C\u2009>\u2009Tp.(=).-...--14.25c.2484C\u2009>\u2009Tp.(=).-...--16.07c.2742C\u2009>\u2009Tp.(=)rs115759702-0.00180.001460.000032--0.712c.3294G\u2009>\u2009Ap.(=).-...--19.912c.3300 T\u2009>\u2009Gp.(=)rs45516100Rahman (2007) [3]0.01830.028010.027864 (1)68 (4)123 (1)7.913c.3495G\u2009>\u2009Ap.(=)rs45439097Bogdanova (2010).0.001080.0009944798.6\nHAPS Hunter Area Pathology Service, FCC Familial Cancer Centre, ViP Variants in Practice\naVariant positions are reported in reference to NCBI RefSeq NM_024675.3 (mRNA) and NP_078951.2 (protein)\nbMinor allele frequency (MAF) reported in the 1000 Genomes (1000 G) cohort Phase 1\ncMAF reported in the Exome Variant Server, NHLBI GO Exome Sequencing Project (ESP) [46] (data release ESP6500SI-V2)\ndMAF reported in ExAC [45] from non-Finnish Europeans, excluding individuals in the database who were part of The Cancer Genome Atlas and therefore known to have had cancer\neNumber of individuals carrying the variant.", "section": "RESULTS", "tags": [{"name": "Tp.(=)rs115759702-0.00180.001460.000032--0.712c.3294G", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "Gp.(=)rs150569240-..0.000055--15.85c.2091C", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Because early studies focused on screening just for the presumed common pathogenic mutations, in Australia (eviQ Cancer Treatments Online; [11]) it is not recommended to test for PALB2 truncating mutations aside from the recurring c.3113G\u2009>\u2009A variant, however, it is likely that all truncating mutations confer an equivalent loss of gene function and consequent breast cancer risk.", "section": "INTRO", "tags": [{"name": "recommended", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "pathogenic", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Table 4Synonymous variantsExonNucleotide changea\nProtein changea\ndbSNP IDFirst reported1000 G MAFb\nNHBLI GO ESP MAFc\nExACd\nHAPS cases (n\u2009=\u2009997)e\nFCC-ViP cases (n\u2009=\u2009999)d\nControls (n\u2009=\u20091998)e\nCADD scaledC score1c.12 T\u2009>\u2009Cp.(=)rs145291423-..0.00012-1111.24c.768C\u2009>\u2009Tp.(=)rs45487491..0.00003710.34c.1188C\u2009>\u2009Tp.(=).-..0.00003--17.64c.1194G\u2009>\u2009Ap.(=)rs61755173Rahman (2007) [3]0.00090.001540.001143286.44c.1194G\u2009>\u2009Tp.(=).-...1--6.14c.1242A\u2009>\u2009Cp.(=).-...--17.74c.1431C\u2009>\u2009Tp.(=).Teo (2013)..02--0.04c.1470C\u2009>\u2009Tp.(=)rs45612837Rahman (2007) [3]0.00050.000150.0004051-25.84c.1572A\u2009>\u2009Gp.(=)rs45472400Rahman (2007) [3]0.00320.003390.00411212275.64c.1623G\u2009>\u2009Ap.(=).-..0-124.25c.2067G\u2009>\u2009Ap.(=).Phuah (2013) [38].0.000150.0000181--4.15c.2082A\u2009>\u2009Gp.(=)rs150569240-..0.000055--15.85c.2091C\u2009>\u2009Ap.(=).-..0--14.75c.2244A\u2009>\u2009Gp.(=).-..0.000037--15.65c.2328C\u2009>\u2009Tp.(=)rs45508997-.0.0000801--4.05c.2337A\u2009>\u2009Cp.(=).-...-1-5.25c.2379C\u2009>\u2009Tp.(=).-.0.000080.00011111-0.15c.2478C\u2009>\u2009Tp.(=).-...--14.25c.2484C\u2009>\u2009Tp.(=).-...--16.07c.2742C\u2009>\u2009Tp.(=)rs115759702-0.00180.001460.000032--0.712c.3294G\u2009>\u2009Ap.(=).-...--19.912c.3300 T\u2009>\u2009Gp.(=)rs45516100Rahman (2007) [3]0.01830.028010.027864 (1)68 (4)123 (1)7.913c.3495G\u2009>\u2009Ap.(=)rs45439097Bogdanova (2010).0.001080.0009944798.6\nHAPS Hunter Area Pathology Service, FCC Familial Cancer Centre, ViP Variants in Practice\naVariant positions are reported in reference to NCBI RefSeq NM_024675.3 (mRNA) and NP_078951.2 (protein)\nbMinor allele frequency (MAF) reported in the 1000 Genomes (1000 G) cohort Phase 1\ncMAF reported in the Exome Variant Server, NHLBI GO Exome Sequencing Project (ESP) [46] (data release ESP6500SI-V2)\ndMAF reported in ExAC [45] from non-Finnish Europeans, excluding individuals in the database who were part of The Cancer Genome Atlas and therefore known to have had cancer\neNumber of individuals carrying the variant.", "section": "RESULTS", "tags": [{"name": "Tp.(=)rs115759702-0.00180.001460.000032--0.712c.3294G", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "Gp.(=)rs150569240-..0.000055--15.85c.2091C", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Table 4Synonymous variantsExonNucleotide changea\nProtein changea\ndbSNP IDFirst reported1000 G MAFb\nNHBLI GO ESP MAFc\nExACd\nHAPS cases (n\u2009=\u2009997)e\nFCC-ViP cases (n\u2009=\u2009999)d\nControls (n\u2009=\u20091998)e\nCADD scaledC score1c.12 T\u2009>\u2009Cp.(=)rs145291423-..0.00012-1111.24c.768C\u2009>\u2009Tp.(=)rs45487491..0.00003710.34c.1188C\u2009>\u2009Tp.(=).-..0.00003--17.64c.1194G\u2009>\u2009Ap.(=)rs61755173Rahman (2007) [3]0.00090.001540.001143286.44c.1194G\u2009>\u2009Tp.(=).-...1--6.14c.1242A\u2009>\u2009Cp.(=).-...--17.74c.1431C\u2009>\u2009Tp.(=).Teo (2013)..02--0.04c.1470C\u2009>\u2009Tp.(=)rs45612837Rahman (2007) [3]0.00050.000150.0004051-25.84c.1572A\u2009>\u2009Gp.(=)rs45472400Rahman (2007) [3]0.00320.003390.00411212275.64c.1623G\u2009>\u2009Ap.(=).-..0-124.25c.2067G\u2009>\u2009Ap.(=).Phuah (2013) [38].0.000150.0000181--4.15c.2082A\u2009>\u2009Gp.(=)rs150569240-..0.000055--15.85c.2091C\u2009>\u2009Ap.(=).-..0--14.75c.2244A\u2009>\u2009Gp.(=).-..0.000037--15.65c.2328C\u2009>\u2009Tp.(=)rs45508997-.0.0000801--4.05c.2337A\u2009>\u2009Cp.(=).-...-1-5.25c.2379C\u2009>\u2009Tp.(=).-.0.000080.00011111-0.15c.2478C\u2009>\u2009Tp.(=).-...--14.25c.2484C\u2009>\u2009Tp.(=).-...--16.07c.2742C\u2009>\u2009Tp.(=)rs115759702-0.00180.001460.000032--0.712c.3294G\u2009>\u2009Ap.(=).-...--19.912c.3300 T\u2009>\u2009Gp.(=)rs45516100Rahman (2007) [3]0.01830.028010.027864 (1)68 (4)123 (1)7.913c.3495G\u2009>\u2009Ap.(=)rs45439097Bogdanova (2010).0.001080.0009944798.6\nHAPS Hunter Area Pathology Service, FCC Familial Cancer Centre, ViP Variants in Practice\naVariant positions are reported in reference to NCBI RefSeq NM_024675.3 (mRNA) and NP_078951.2 (protein)\nbMinor allele frequency (MAF) reported in the 1000 Genomes (1000 G) cohort Phase 1\ncMAF reported in the Exome Variant Server, NHLBI GO Exome Sequencing Project (ESP) [46] (data release ESP6500SI-V2)\ndMAF reported in ExAC [45] from non-Finnish Europeans, excluding individuals in the database who were part of The Cancer Genome Atlas and therefore known to have had cancer\neNumber of individuals carrying the variant.", "section": "RESULTS", "tags": [{"name": "Tp.(=)rs115759702-0.00180.001460.000032--0.712c.3294G", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "Gp.(=)rs150569240-..0.000055--15.85c.2091C", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Five previously reported variants were detected recurrently (c.196C\u2009>\u2009T (p.Gln66*) and c.758dupT (p.Ser254Illefs*3) each in two cases, c.3113G\u2009>\u2009A (p.Trp1038*) in seven cases and one control, and c.3116delA (p.Asn1039Ilefs*2) and c.3362delG (p.Gly1121Valfs*3) each in one case and one control) with the remaining variants detected in single cases or controls only.", "section": "RESULTS", "tags": [{"name": "(p.Ser254Illefs*3)", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "(p.Asn1039Ilefs*2)", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Because early studies focused on screening just for the presumed common pathogenic mutations, in Australia (eviQ Cancer Treatments Online; [11]) it is not recommended to test for PALB2 truncating mutations aside from the recurring c.3113G\u2009>\u2009A variant, however, it is likely that all truncating mutations confer an equivalent loss of gene function and consequent breast cancer risk.", "section": "INTRO", "tags": [{"name": "recommended", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "pathogenic", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Leu1150Argrs45566737..0.0000368-1-18.2DeleteriousPossibly damagingDeleterious\nHAPS Hunter Area Pathology Service, FCC Familial Cancer Centre, ViP Variants in Practice\naVariant positions are reported in reference to NCBI RefSeq NM_024675.3 (mRNA) and NP_078951.2 (protein)\nbMinor allele frequency (MAF) reported in the 1000 Genomes (1000 G) cohort Phase 1\ncMAF reported in the Exome Variant Server, NHLBI GO Exome Sequencing Project (ESP) [46] (data release ESP6500SI-V2)\ndMAF reported in ExAC [45] from non-Finnish Europeans, excluding individuals in the database who were part of The Cancer Genome Atlas and therefore known to have had cancer\neNumber of individuals carrying the variant.", "section": "RESULTS", "tags": [{"name": "Leu1150Argrs45566737..0.0000368-1-18.2DeleteriousPossibly", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "damagingDeleterious", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Tyr1183*rs118203998Reid (2007) [2]1--37.0\nHAPS Hunter Area Pathology Service, FCC Familial Cancer Centre, ViP Variants in Practice\naVariant positions are reported in reference to NCBI RefSeq NM_024675.3 (mRNA) and NP_078951.2 (protein)\nbNumber of individuals carrying the variant\ncc.3113G\u2009>\u2009A produces three different PALB2 mRNA sequences: complete deletion of exon 10 (117 bp); use of an alternative splice site within exon 10, and deletion of 31 bp; and an immediate stop at codon 1038 [29]", "section": "RESULTS", "tags": [{"name": "Tyr1183*rs118203998Reid", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "NM_024675.3", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Tyr1183*rs118203998Reid (2007) [2]1--37.0\nHAPS Hunter Area Pathology Service, FCC Familial Cancer Centre, ViP Variants in Practice\naVariant positions are reported in reference to NCBI RefSeq NM_024675.3 (mRNA) and NP_078951.2 (protein)\nbNumber of individuals carrying the variant\ncc.3113G\u2009>\u2009A produces three different PALB2 mRNA sequences: complete deletion of exon 10 (117 bp); use of an alternative splice site within exon 10, and deletion of 31 bp; and an immediate stop at codon 1038 [29]", "section": "RESULTS", "tags": [{"name": "Tyr1183*rs118203998Reid", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "NM_024675.3", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Five previously reported variants were detected recurrently (c.196C\u2009>\u2009T (p.Gln66*) and c.758dupT (p.Ser254Illefs*3) each in two cases, c.3113G\u2009>\u2009A (p.Trp1038*) in seven cases and one control, and c.3116delA (p.Asn1039Ilefs*2) and c.3362delG (p.Gly1121Valfs*3) each in one case and one control) with the remaining variants detected in single cases or controls only.", "section": "RESULTS", "tags": [{"name": "(p.Ser254Illefs*3)", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "(p.Asn1039Ilefs*2)", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Nineteen different truncating variants were identified in 30 individuals in this study, 26 of these variants were detected among 1996 breast cancer index cases (1.3 %) and four among 1998 controls (0.2 %), demonstrating a significant enrichment in cases (p\u2009=\u20090.0001, chi-squared test; odds ratio (OR) 6.58, 95 % confidence interval (CI) 2.3\u201318.9) (Table\u00a01).", "section": "RESULTS", "tags": [{"name": "demonstrating", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "individuals", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}]}
{"src": "PMC", "id": "PMC4588721", "provider": "OpenTargets", "anns": [{"type": "Gene Disease Relationship", "exact": "Studies of the MYO15A mutation in humans have usually been performed in the Middle East, where consanguineous families are more common (Bashir et al., 2012; Belguith et al., 2009; Brownstein et al., 2011; Cengiz et al., 2010; Diaz-Horta et al., 2012; Duman et al., 2011; Fattahi et al., 2012; Kalay et al., 2007; Liburd et al., 2001; Nal et al., 2007; Shearer et al., 2009).", "section": "DISCUSS", "tags": [{"name": "consanguineous", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "Brownstein", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Since there is no known 3D structure of motor domain of MYO15A in the Protein Data Bank, the structure for motor domain of MYO15A was built using the homolog modeling method (BLAST, http://blast.ncbi.nlm.nih.gov/Blast.cgi/; HHpred, http://toolkit.tuebingen.mpg.de/hhpred/; PDB, http://pdb.org/pdb/home/home.do/; UNIPROT.", "section": "METHODS", "tags": [{"name": "http://blast.ncbi.nlm.nih.gov/Blast.cgi/;", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "http://toolkit.tuebingen.mpg.de/hhpred/;", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Since there is no known 3D structure of motor domain of MYO15A in the Protein Data Bank, the structure for motor domain of MYO15A was built using the homolog modeling method (BLAST, http://blast.ncbi.nlm.nih.gov/Blast.cgi/; HHpred, http://toolkit.tuebingen.mpg.de/hhpred/; PDB, http://pdb.org/pdb/home/home.do/; UNIPROT.", "section": "METHODS", "tags": [{"name": "http://blast.ncbi.nlm.nih.gov/Blast.cgi/;", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "http://toolkit.tuebingen.mpg.de/hhpred/;", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Based on our findings and analysis of audiologic features of MYO15A mutations, we suggest a hypothetical genotype-phenotype correlation whereby MYO15A mutations that affect domains other than the N-terminal domain, lead to profound SNHL throughout all frequencies, while mutations that affect the N-terminal domain, result in residual hearing at low frequencies, which could make contribution to language development and speech perception.", "section": "DISCUSS", "tags": [{"name": "genotype-phenotype", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "hypothetical", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Alternatively, alterations in the N-terminal extension domain, or even the absence of the class 1 myosin XVA, might be related to functional problems or minor structural defects in the staircase architecture of the hair bundle (Nal et al., 2007), thereby leading to a milder auditory phenotype.", "section": "DISCUSS", "tags": [{"name": "Alternatively,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "architecture", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Conversely, it can be hypothesized that if MYO15A mutations affect a common region shared by both isoforms, other than exon 2, then the phenotype would be profound throughout all frequencies and have no, or minimal, residual hearing to trigger linguistic development, thereby requiring early cochlear implantation for speech development.", "section": "DISCUSS", "tags": [{"name": "hypothesized", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "development,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Therefore our hypothetical genotype-phenotype correlation suggests a customized treatment that preservation of residual hearing during cochlear implantation should be intended for those who carry mutations in the N-terminal domain and that the individuals with mutations elsewhere in MYO15A require early cochlear implantation to timely initiate speech development.", "section": "DISCUSS", "tags": [{"name": "genotype-phenotype", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "hypothetical", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "The possibility of less severe hearing loss associated with mutations residing in the N-terminal extension domain had already been suggested; Belyantseva et al. (2005) transfected a class 2 myosin XVa isoform that had no N-terminal extension, into shaker-2 hair cells, which had abnormally short stereocilia.", "section": "DISCUSS", "tags": [{"name": "stereocilia.", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "possibility", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Based on our findings and analysis of audiologic features of MYO15A mutations, we suggest a hypothetical genotype-phenotype correlation whereby MYO15A mutations that affect domains other than the N-terminal domain, lead to profound SNHL throughout all frequencies, while mutations that affect the N-terminal domain, result in residual hearing at low frequencies, which could make contribution to language development and speech perception.", "section": "DISCUSS", "tags": [{"name": "genotype-phenotype", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "hypothetical", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Therefore our hypothetical genotype-phenotype correlation suggests a customized treatment that preservation of residual hearing during cochlear implantation should be intended for those who carry mutations in the N-terminal domain and that the individuals with mutations elsewhere in MYO15A require early cochlear implantation to timely initiate speech development.", "section": "DISCUSS", "tags": [{"name": "genotype-phenotype", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "hypothetical", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Alternatively, alterations in the N-terminal extension domain, or even the absence of the class 1 myosin XVA, might be related to functional problems or minor structural defects in the staircase architecture of the hair bundle (Nal et al., 2007), thereby leading to a milder auditory phenotype.", "section": "DISCUSS", "tags": [{"name": "Alternatively,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "architecture", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Studies of the MYO15A mutation in humans have usually been performed in the Middle East, where consanguineous families are more common (Bashir et al., 2012; Belguith et al., 2009; Brownstein et al., 2011; Cengiz et al., 2010; Diaz-Horta et al., 2012; Duman et al., 2011; Fattahi et al., 2012; Kalay et al., 2007; Liburd et al., 2001; Nal et al., 2007; Shearer et al., 2009).", "section": "DISCUSS", "tags": [{"name": "consanguineous", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "Brownstein", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "The possibility of less severe hearing loss associated with mutations residing in the N-terminal extension domain had already been suggested; Belyantseva et al. (2005) transfected a class 2 myosin XVa isoform that had no N-terminal extension, into shaker-2 hair cells, which had abnormally short stereocilia.", "section": "DISCUSS", "tags": [{"name": "stereocilia.", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "possibility", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "This feature has been observed in other studies in which mutations in exon 2 (p.E1105*, p.R1113Vfs*12 and p.Y289* homozygote), which encodes the N-terminal extension of MYO15A, resulted in better residual hearing at low frequencies, or even moderate to severe hearing loss compared with mutations in other regions of MYO15A (Cengiz et al., 2010; Nal et al., 2007).", "section": "DISCUSS", "tags": [{"name": "p.R1113Vfs*12", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "homozygote),", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Conversely, it can be hypothesized that if MYO15A mutations affect a common region shared by both isoforms, other than exon 2, then the phenotype would be profound throughout all frequencies and have no, or minimal, residual hearing to trigger linguistic development, thereby requiring early cochlear implantation for speech development.", "section": "DISCUSS", "tags": [{"name": "hypothesized", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "development,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}]}
{"src": "PMC", "id": "PMC4471120", "provider": "OpenTargets", "anns": [{"type": "Gene Disease Relationship", "exact": "In the Atherosclerosis Risk in Communities Study (ARIC), Dallas Heart Study, and the Northern Manhattan Study, non-Hispanic blacks [4, 8] and Hispanics [9] had significantly lower sRAGE levels than whites, and adjustment for multiple confounding variables did not change this racial difference in sRAGE levels [4, 9], leading to a hypothesis that genetic factors may explain at least a proportion of the observed racial difference.", "section": "INTRO", "tags": [{"name": "Atherosclerosis", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "significantly", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "We performed a post-hoc power calculation for blacks and whites separately using the non-centrality-parameter-based method for estimating power in Mendelian randomization studies described by Brion et al, 2013 [23, 24] and estimated power for the analyses of clinical outcomes assuming the following: type I error rate of 0.05; proportion of variance in ln(sRAGE) explained by SNP as reported in this study; event rates observed in this study; odds ratios for ln(sRAGE) and the clinical outcomes estimated using logistic regression in this study (Table B in S1 File).", "section": "METHODS", "tags": [{"name": "non-centrality-parameter-based", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "randomization", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "While some case-control studies have identified associations between AGER SNPs and myocardial infarction and stroke [31] and prevalent coronary heart disease based on angiographic evidence of stenosis >50% [32], two recent meta-analyses including over 25 case-control studies (maximum N for single SNP = 7,111) [29] did not find a consistent association between AGER polymorphisms and coronary heart disease (odds ratios from meta-analyses ranged from 0.97 to 1.16 with P >0.05) [29, 30].", "section": "DISCUSS", "tags": [{"name": "meta-analyses", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "polymorphisms", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "For the analysis of AGER (Gene ID: 177; Entrez Gene) SNPs and clinical outcomes, we were not limited to the ARIC subsample in which sRAGE was available and of the entire cohort of black and white participants with follow-up from visit 1 (1987\u20131989) who consented to non-cardiovascular disease-related research (N = 15,703), we excluded participants without genotyping data (N = 2,778) and those with genotyping samples that did not pass quality control measures (N = 1,037).", "section": "METHODS", "tags": [{"name": "non-cardiovascular", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "disease-related", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "We performed a post-hoc power calculation for blacks and whites separately using the non-centrality-parameter-based method for estimating power in Mendelian randomization studies described by Brion et al, 2013 [23, 24] and estimated power for the analyses of clinical outcomes assuming the following: type I error rate of 0.05; proportion of variance in ln(sRAGE) explained by SNP as reported in this study; event rates observed in this study; odds ratios for ln(sRAGE) and the clinical outcomes estimated using logistic regression in this study (Table B in S1 File).", "section": "METHODS", "tags": [{"name": "non-centrality-parameter-based", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "randomization", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "In our study, BMI and fasting glucose were higher in black vs. white participants; outside of known racial disparities in these factors and their downstream inflammatory diseases (e.g., diabetes and coronary heart disease), proximal environmental factors suggested to underlie the observed increased inflammation among blacks include lower socioeconomic status [39, 41], stress [42] and racial discrimination [43].", "section": "DISCUSS", "tags": [{"name": "discrimination", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "participants;", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "To clarify mixed findings of large associations between sRAGE and outcomes in prior studies and to further understand the black-white difference in sRAGE levels, we used the Atherosclerosis Risk in Communities (ARIC) Study, a multi-ethnic, community-based cohort study to 1) conduct genome-wide association studies (GWAS) of sRAGE levels in whites and blacks separately; 2) evaluate if genetic variation underlies the black-white difference in sRAGE; and 3) conduct a Mendelian randomization study to evaluate the association between genetic determinants of sRAGE and mortality, coronary heart disease, congestive heart failure, diabetes, and chronic kidney disease.", "section": "INTRO", "tags": [{"name": "Atherosclerosis", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "community-based", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "For analyses of the ARIC sub-sample with sRAGE levels (N = 2,318), covariates included self-reported age, sex, race (black or white), and educational level (less than high school, high school or any college, more than four years post-high school); body mass index calculated as measured weight/height2 in kg/m2 [15]; prevalent diabetes mellitus (self-reported diabetes, use of diabetes medications, and/or fasting glucose \u22656.99 mmol/l among those with fasting samples); estimated glomerular filtration rate (eGFR) calculated from measured creatinine [16] and age, sex, and race using the Modification of Diet in Renal Disease Study Group method [17]; and prevalent coronary heart disease by self-report or diagnosis by ARIC procedures described below.", "section": "METHODS", "tags": [{"name": "weight/height2", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "(self-reported", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "For analyses of the ARIC sub-sample with sRAGE levels (N = 2,318), covariates included self-reported age, sex, race (black or white), and educational level (less than high school, high school or any college, more than four years post-high school); body mass index calculated as measured weight/height2 in kg/m2 [15]; prevalent diabetes mellitus (self-reported diabetes, use of diabetes medications, and/or fasting glucose \u22656.99 mmol/l among those with fasting samples); estimated glomerular filtration rate (eGFR) calculated from measured creatinine [16] and age, sex, and race using the Modification of Diet in Renal Disease Study Group method [17]; and prevalent coronary heart disease by self-report or diagnosis by ARIC procedures described below.", "section": "METHODS", "tags": [{"name": "weight/height2", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "(self-reported", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "For the analysis of AGER (Gene ID: 177; Entrez Gene) SNPs and clinical outcomes, we were not limited to the ARIC subsample in which sRAGE was available and of the entire cohort of black and white participants with follow-up from visit 1 (1987\u20131989) who consented to non-cardiovascular disease-related research (N = 15,703), we excluded participants without genotyping data (N = 2,778) and those with genotyping samples that did not pass quality control measures (N = 1,037).", "section": "METHODS", "tags": [{"name": "non-cardiovascular", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "disease-related", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "We performed a post-hoc power calculation for blacks and whites separately using the non-centrality-parameter-based method for estimating power in Mendelian randomization studies described by Brion et al, 2013 [23, 24] and estimated power for the analyses of clinical outcomes assuming the following: type I error rate of 0.05; proportion of variance in ln(sRAGE) explained by SNP as reported in this study; event rates observed in this study; odds ratios for ln(sRAGE) and the clinical outcomes estimated using logistic regression in this study (Table B in S1 File).", "section": "METHODS", "tags": [{"name": "non-centrality-parameter-based", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "randomization", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "While some case-control studies have identified associations between AGER SNPs and myocardial infarction and stroke [31] and prevalent coronary heart disease based on angiographic evidence of stenosis >50% [32], two recent meta-analyses including over 25 case-control studies (maximum N for single SNP = 7,111) [29] did not find a consistent association between AGER polymorphisms and coronary heart disease (odds ratios from meta-analyses ranged from 0.97 to 1.16 with P >0.05) [29, 30].", "section": "DISCUSS", "tags": [{"name": "meta-analyses", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "polymorphisms", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "To clarify mixed findings of large associations between sRAGE and outcomes in prior studies and to further understand the black-white difference in sRAGE levels, we used the Atherosclerosis Risk in Communities (ARIC) Study, a multi-ethnic, community-based cohort study to 1) conduct genome-wide association studies (GWAS) of sRAGE levels in whites and blacks separately; 2) evaluate if genetic variation underlies the black-white difference in sRAGE; and 3) conduct a Mendelian randomization study to evaluate the association between genetic determinants of sRAGE and mortality, coronary heart disease, congestive heart failure, diabetes, and chronic kidney disease.", "section": "INTRO", "tags": [{"name": "Atherosclerosis", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "community-based", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "For the analysis of AGER (Gene ID: 177; Entrez Gene) SNPs and clinical outcomes, we were not limited to the ARIC subsample in which sRAGE was available and of the entire cohort of black and white participants with follow-up from visit 1 (1987\u20131989) who consented to non-cardiovascular disease-related research (N = 15,703), we excluded participants without genotyping data (N = 2,778) and those with genotyping samples that did not pass quality control measures (N = 1,037).", "section": "METHODS", "tags": [{"name": "non-cardiovascular", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "disease-related", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "In the Atherosclerosis Risk in Communities Study (ARIC), Dallas Heart Study, and the Northern Manhattan Study, non-Hispanic blacks [4, 8] and Hispanics [9] had significantly lower sRAGE levels than whites, and adjustment for multiple confounding variables did not change this racial difference in sRAGE levels [4, 9], leading to a hypothesis that genetic factors may explain at least a proportion of the observed racial difference.", "section": "INTRO", "tags": [{"name": "Atherosclerosis", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "significantly", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "In our study, BMI and fasting glucose were higher in black vs. white participants; outside of known racial disparities in these factors and their downstream inflammatory diseases (e.g., diabetes and coronary heart disease), proximal environmental factors suggested to underlie the observed increased inflammation among blacks include lower socioeconomic status [39, 41], stress [42] and racial discrimination [43].", "section": "DISCUSS", "tags": [{"name": "discrimination", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "participants;", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "For the analysis of AGER (Gene ID: 177; Entrez Gene) SNPs and clinical outcomes, we were not limited to the ARIC subsample in which sRAGE was available and of the entire cohort of black and white participants with follow-up from visit 1 (1987\u20131989) who consented to non-cardiovascular disease-related research (N = 15,703), we excluded participants without genotyping data (N = 2,778) and those with genotyping samples that did not pass quality control measures (N = 1,037).", "section": "METHODS", "tags": [{"name": "non-cardiovascular", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "disease-related", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "For analyses of the ARIC sub-sample with sRAGE levels (N = 2,318), covariates included self-reported age, sex, race (black or white), and educational level (less than high school, high school or any college, more than four years post-high school); body mass index calculated as measured weight/height2 in kg/m2 [15]; prevalent diabetes mellitus (self-reported diabetes, use of diabetes medications, and/or fasting glucose \u22656.99 mmol/l among those with fasting samples); estimated glomerular filtration rate (eGFR) calculated from measured creatinine [16] and age, sex, and race using the Modification of Diet in Renal Disease Study Group method [17]; and prevalent coronary heart disease by self-report or diagnosis by ARIC procedures described below.", "section": "METHODS", "tags": [{"name": "weight/height2", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "(self-reported", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "For analyses of the ARIC sub-sample with sRAGE levels (N = 2,318), covariates included self-reported age, sex, race (black or white), and educational level (less than high school, high school or any college, more than four years post-high school); body mass index calculated as measured weight/height2 in kg/m2 [15]; prevalent diabetes mellitus (self-reported diabetes, use of diabetes medications, and/or fasting glucose \u22656.99 mmol/l among those with fasting samples); estimated glomerular filtration rate (eGFR) calculated from measured creatinine [16] and age, sex, and race using the Modification of Diet in Renal Disease Study Group method [17]; and prevalent coronary heart disease by self-report or diagnosis by ARIC procedures described below.", "section": "METHODS", "tags": [{"name": "weight/height2", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "(self-reported", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "We performed a post-hoc power calculation for blacks and whites separately using the non-centrality-parameter-based method for estimating power in Mendelian randomization studies described by Brion et al, 2013 [23, 24] and estimated power for the analyses of clinical outcomes assuming the following: type I error rate of 0.05; proportion of variance in ln(sRAGE) explained by SNP as reported in this study; event rates observed in this study; odds ratios for ln(sRAGE) and the clinical outcomes estimated using logistic regression in this study (Table B in S1 File).", "section": "METHODS", "tags": [{"name": "non-centrality-parameter-based", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "randomization", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "For analyses of the ARIC sub-sample with sRAGE levels (N = 2,318), covariates included self-reported age, sex, race (black or white), and educational level (less than high school, high school or any college, more than four years post-high school); body mass index calculated as measured weight/height2 in kg/m2 [15]; prevalent diabetes mellitus (self-reported diabetes, use of diabetes medications, and/or fasting glucose \u22656.99 mmol/l among those with fasting samples); estimated glomerular filtration rate (eGFR) calculated from measured creatinine [16] and age, sex, and race using the Modification of Diet in Renal Disease Study Group method [17]; and prevalent coronary heart disease by self-report or diagnosis by ARIC procedures described below.", "section": "METHODS", "tags": [{"name": "weight/height2", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "(self-reported", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "For the analysis of AGER (Gene ID: 177; Entrez Gene) SNPs and clinical outcomes, we were not limited to the ARIC subsample in which sRAGE was available and of the entire cohort of black and white participants with follow-up from visit 1 (1987\u20131989) who consented to non-cardiovascular disease-related research (N = 15,703), we excluded participants without genotyping data (N = 2,778) and those with genotyping samples that did not pass quality control measures (N = 1,037).", "section": "METHODS", "tags": [{"name": "non-cardiovascular", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "disease-related", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "While some case-control studies have identified associations between AGER SNPs and myocardial infarction and stroke [31] and prevalent coronary heart disease based on angiographic evidence of stenosis >50% [32], two recent meta-analyses including over 25 case-control studies (maximum N for single SNP = 7,111) [29] did not find a consistent association between AGER polymorphisms and coronary heart disease (odds ratios from meta-analyses ranged from 0.97 to 1.16 with P >0.05) [29, 30].", "section": "DISCUSS", "tags": [{"name": "meta-analyses", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "polymorphisms", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "We performed a post-hoc power calculation for blacks and whites separately using the non-centrality-parameter-based method for estimating power in Mendelian randomization studies described by Brion et al, 2013 [23, 24] and estimated power for the analyses of clinical outcomes assuming the following: type I error rate of 0.05; proportion of variance in ln(sRAGE) explained by SNP as reported in this study; event rates observed in this study; odds ratios for ln(sRAGE) and the clinical outcomes estimated using logistic regression in this study (Table B in S1 File).", "section": "METHODS", "tags": [{"name": "non-centrality-parameter-based", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "randomization", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "To clarify mixed findings of large associations between sRAGE and outcomes in prior studies and to further understand the black-white difference in sRAGE levels, we used the Atherosclerosis Risk in Communities (ARIC) Study, a multi-ethnic, community-based cohort study to 1) conduct genome-wide association studies (GWAS) of sRAGE levels in whites and blacks separately; 2) evaluate if genetic variation underlies the black-white difference in sRAGE; and 3) conduct a Mendelian randomization study to evaluate the association between genetic determinants of sRAGE and mortality, coronary heart disease, congestive heart failure, diabetes, and chronic kidney disease.", "section": "INTRO", "tags": [{"name": "Atherosclerosis", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "community-based", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}]}
{"src": "PMC", "id": "PMC4539360", "provider": "OpenTargets", "anns": [{"type": "Gene Disease Relationship", "exact": "Wasting and weakness of intrinsic hand muscles resulted in split hand deformity (Fig.\u00a01; Table\u00a02).Table\u00a02Genetic and clinical characteristics of patients with AARS-related neuropathy in the UK/Irish cohortFamily/patient/age/sexOriginNucleotide/amino acid changeAge onsetClinical courseFirst signClinical signsMobility/orthoticsNerve conduction studyDistal lower limbDistal upper limbMotor NCV (m/s)Motor/sensoryMotorSensoryDeformityMotorSensoryDeformityF1/PIII.1/50\u00a0years/MUKc.986G>A/p.", "section": "OTHER", "tags": [{"name": "(m/s)Motor/sensoryMotorSensoryDeformityMotorSensoryDeformityF1/PIII.1/50", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "cohortFamily/patient/age/sexOriginNucleotide/amino", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "The relevance of methionyl-tRNA synthetase (MARS, MIM#156560) and histidyl-tRNA synthetase (HARS, MIM#142810) mutations for CMT is supported by strong functional and evolutionary evidence, yet incomplete segregation and absence of additional unrelated cases warrant future studies to substantiate this conclusion [2, 14].", "section": "INTRO", "tags": [{"name": "methionyl-tRNA", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "histidyl-tRNA", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Wasting and weakness of intrinsic hand muscles resulted in split hand deformity (Fig.\u00a01; Table\u00a02).Table\u00a02Genetic and clinical characteristics of patients with AARS-related neuropathy in the UK/Irish cohortFamily/patient/age/sexOriginNucleotide/amino acid changeAge onsetClinical courseFirst signClinical signsMobility/orthoticsNerve conduction studyDistal lower limbDistal upper limbMotor NCV (m/s)Motor/sensoryMotorSensoryDeformityMotorSensoryDeformityF1/PIII.1/50\u00a0years/MUKc.986G>A/p.", "section": "OTHER", "tags": [{"name": "(m/s)Motor/sensoryMotorSensoryDeformityMotorSensoryDeformityF1/PIII.1/50", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "cohortFamily/patient/age/sexOriginNucleotide/amino", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Based on the electrophysiological and pathological characteristics it can be classified further into a demyelinating form (CMT1), where the nerve conduction velocity is reduced due to altered myelination, and to an axonal form (CMT2), where the primary axonal dysfunction leads to reduced amplitudes of evoked muscle action potentials.", "section": "INTRO", "tags": [{"name": "electrophysiological", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "characteristics", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Additionally autosomal recessive loss of function AARS mutations (compound heterozygous p.Lys81Thr and p.Arg751Gly and homozygous p.Arg751Gly) were also described in two unrelated families, causing severe infantile epileptic encephalopathy with a central myelin defect and peripheral neuropathy [12].Table\u00a01Summary of the clinical and electrophysiology findings accompanying the reported different AARS variantsOriginFamily/patient numberNucleotide changeAmino acid changeAge onsetFirst signClinical symptomsNerve conduction studyReferencesLower limbUpper limbSymmetryMotor NCV (m/s)Motor/sensoryTaiwaneseF1/P5c.211A>Tp.", "section": "INTRO", "tags": [{"name": "(m/s)Motor/sensoryTaiwaneseF1/P5c.211A>Tp.", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "variantsOriginFamily/patient", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Glu688Gly<1\u00a0yearsSlow progressSymmetricLL+n/aBilateral tight AchillesBilateral foot drop+n/aMild split handTiptoe walking bilateral AFOsm 29.3MS\nF family, P patient, M male, F female, UL upper limb, LL lower limb, + mild, ++ moderate, +++ severe, AFO ankle foot orthesis, n/a not available, m/s metre per second, m median nerve, p peroneal nerve, u ulnar nerve, intermed. intermediate, MS motor and sensory", "section": "OTHER", "tags": [{"name": "progressSymmetricLL+n/aBilateral", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "AchillesBilateral", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Asn71TyrVaried (11\u201330\u00a0years)LLDistal weakness and wasting, mild sensory lossMild weakness, wasting mild sensory lossSymmetricm 38.1p absentMS[5]F1/P2LLMild weakness and wastingNoneSymmetricFrenchF1/P16c.986G>Ap.Arg329HisVaried (6\u201354\u00a0years)LLBilateral distal weakness, distal sensory lossDistal weakness, distal sensory lossSymmetricm 32.4\u201350MS[4]F1/P1LLSevere distal wasting, sensory lossNoneAsymmetricm 45FrenchF2/P1c.986G>Ap.", "section": "INTRO", "tags": [{"name": "wastingNoneSymmetricFrenchF1/P16c.986G>Ap.Arg329HisVaried", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "32.4\u201350MS[4]F1/P1LLSevere", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Some of these genes have been already associated with axonal dysfunction, such as mitofusin 2 (MFN2) which is responsible for 5\u201310\u00a0% of CMT2 cases, neurofilament light chain (NEFL) in 1\u20135\u00a0% and ganglioside-induced differentiation-associated protein (GDAP1) in less than 1\u00a0% of the cases [1, 3, 4, 11, 13].", "section": "INTRO", "tags": [{"name": "differentiation-associated", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "ganglioside-induced", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Based on the electrophysiological and pathological characteristics it can be classified further into a demyelinating form (CMT1), where the nerve conduction velocity is reduced due to altered myelination, and to an axonal form (CMT2), where the primary axonal dysfunction leads to reduced amplitudes of evoked muscle action potentials.", "section": "INTRO", "tags": [{"name": "electrophysiological", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "characteristics", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Glu688Gly<1\u00a0yearsSlow progressSymmetricLL+n/aBilateral tight AchillesBilateral foot drop+n/aMild split handTiptoe walking bilateral AFOsm 29.3MS\nF family, P patient, M male, F female, UL upper limb, LL lower limb, + mild, ++ moderate, +++ severe, AFO ankle foot orthesis, n/a not available, m/s metre per second, m median nerve, p peroneal nerve, u ulnar nerve, intermed. intermediate, MS motor and sensory", "section": "OTHER", "tags": [{"name": "progressSymmetricLL+n/aBilateral", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "AchillesBilateral", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Wasting and weakness of intrinsic hand muscles resulted in split hand deformity (Fig.\u00a01; Table\u00a02).Table\u00a02Genetic and clinical characteristics of patients with AARS-related neuropathy in the UK/Irish cohortFamily/patient/age/sexOriginNucleotide/amino acid changeAge onsetClinical courseFirst signClinical signsMobility/orthoticsNerve conduction studyDistal lower limbDistal upper limbMotor NCV (m/s)Motor/sensoryMotorSensoryDeformityMotorSensoryDeformityF1/PIII.1/50\u00a0years/MUKc.986G>A/p.", "section": "OTHER", "tags": [{"name": "(m/s)Motor/sensoryMotorSensoryDeformityMotorSensoryDeformityF1/PIII.1/50", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "cohortFamily/patient/age/sexOriginNucleotide/amino", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "The relevance of methionyl-tRNA synthetase (MARS, MIM#156560) and histidyl-tRNA synthetase (HARS, MIM#142810) mutations for CMT is supported by strong functional and evolutionary evidence, yet incomplete segregation and absence of additional unrelated cases warrant future studies to substantiate this conclusion [2, 14].", "section": "INTRO", "tags": [{"name": "methionyl-tRNA", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "histidyl-tRNA", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Glu688Gly<1\u00a0yearsSlow progressSymmetricLL+n/aBilateral tight AchillesBilateral foot drop+n/aMild split handTiptoe walking bilateral AFOsm 29.3MS\nF family, P patient, M male, F female, UL upper limb, LL lower limb, + mild, ++ moderate, +++ severe, AFO ankle foot orthesis, n/a not available, m/s metre per second, m median nerve, p peroneal nerve, u ulnar nerve, intermed. intermediate, MS motor and sensory", "section": "OTHER", "tags": [{"name": "progressSymmetricLL+n/aBilateral", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "AchillesBilateral", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Asn71TyrVaried (11\u201330\u00a0years)LLDistal weakness and wasting, mild sensory lossMild weakness, wasting mild sensory lossSymmetricm 38.1p absentMS[5]F1/P2LLMild weakness and wastingNoneSymmetricFrenchF1/P16c.986G>Ap.Arg329HisVaried (6\u201354\u00a0years)LLBilateral distal weakness, distal sensory lossDistal weakness, distal sensory lossSymmetricm 32.4\u201350MS[4]F1/P1LLSevere distal wasting, sensory lossNoneAsymmetricm 45FrenchF2/P1c.986G>Ap.", "section": "INTRO", "tags": [{"name": "wastingNoneSymmetricFrenchF1/P16c.986G>Ap.Arg329HisVaried", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "32.4\u201350MS[4]F1/P1LLSevere", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Additionally autosomal recessive loss of function AARS mutations (compound heterozygous p.Lys81Thr and p.Arg751Gly and homozygous p.Arg751Gly) were also described in two unrelated families, causing severe infantile epileptic encephalopathy with a central myelin defect and peripheral neuropathy [12].Table\u00a01Summary of the clinical and electrophysiology findings accompanying the reported different AARS variantsOriginFamily/patient numberNucleotide changeAmino acid changeAge onsetFirst signClinical symptomsNerve conduction studyReferencesLower limbUpper limbSymmetryMotor NCV (m/s)Motor/sensoryTaiwaneseF1/P5c.211A>Tp.", "section": "INTRO", "tags": [{"name": "(m/s)Motor/sensoryTaiwaneseF1/P5c.211A>Tp.", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "variantsOriginFamily/patient", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Some of these genes have been already associated with axonal dysfunction, such as mitofusin 2 (MFN2) which is responsible for 5\u201310\u00a0% of CMT2 cases, neurofilament light chain (NEFL) in 1\u20135\u00a0% and ganglioside-induced differentiation-associated protein (GDAP1) in less than 1\u00a0% of the cases [1, 3, 4, 11, 13].", "section": "INTRO", "tags": [{"name": "differentiation-associated", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "ganglioside-induced", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Genetic diagnosis is particularly difficult to achieve in the axonal form (CMT2) which shows genotypic and phenotypic overlap with distal hereditary motor neuropathies (dHMN) or distal spinal muscular atrophy (dSMA), a subgroup of rare inherited motor axonal neuropathies with no significant sensory involvement [9].", "section": "INTRO", "tags": [{"name": "particularly", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "neuropathies", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Based on the electrophysiological and pathological characteristics it can be classified further into a demyelinating form (CMT1), where the nerve conduction velocity is reduced due to altered myelination, and to an axonal form (CMT2), where the primary axonal dysfunction leads to reduced amplitudes of evoked muscle action potentials.", "section": "INTRO", "tags": [{"name": "electrophysiological", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "characteristics", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Wasting and weakness of intrinsic hand muscles resulted in split hand deformity (Fig.\u00a01; Table\u00a02).Table\u00a02Genetic and clinical characteristics of patients with AARS-related neuropathy in the UK/Irish cohortFamily/patient/age/sexOriginNucleotide/amino acid changeAge onsetClinical courseFirst signClinical signsMobility/orthoticsNerve conduction studyDistal lower limbDistal upper limbMotor NCV (m/s)Motor/sensoryMotorSensoryDeformityMotorSensoryDeformityF1/PIII.1/50\u00a0years/MUKc.986G>A/p.", "section": "OTHER", "tags": [{"name": "(m/s)Motor/sensoryMotorSensoryDeformityMotorSensoryDeformityF1/PIII.1/50", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "cohortFamily/patient/age/sexOriginNucleotide/amino", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}]}
{"src": "PMC", "id": "PMC4457031", "provider": "OpenTargets", "anns": [{"type": "Gene Disease Relationship", "exact": "We then searched for potentially pathogenic variants by applying the following filtering criteria: we selected variants that have functional impacts as predicted by Polyphen2 (Adzhubei et al., 2013), are conserved across multiple species, and are absent in the database of The 1000 Genome project (http://www.1000genomes.org/), dbSNP (http://www.ncbi.nlm.nih.gov/SNP/) and The NHLBI Exome Variant Server (http://evs.gs.washington.edu/EVS/).", "section": "RESULTS", "tags": [{"name": "(http://evs.gs.washington.edu/EVS/).", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "(http://www.ncbi.nlm.nih.gov/SNP/)", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "The analysis generated \u2018Acute renal failure panel\u2019 (P=5.86E\u201304, ratio 6/62), \u2018NRF2-mediated oxidative stress response\u2019 (P=6.07E\u201304, ratio 12/234), \u2018Renal necrosis/Cell death\u2019 (P=8.13E\u201304, ratio 18/461), \u2018Oxidative stress\u2019 (P=2.62E\u201303, ratio 5/57) and \u2018Renal safety biomarker panel\u2019 (P=4.01E\u201303, ratio 2/6) as the top five most significant effects (supplementary material Table\u00a0S5).", "section": "RESULTS", "tags": [{"name": "\u2018NRF2-mediated", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "(supplementary", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "We then applied a series of exclusion steps to identify the causative mutation: (1) we removed variants that were heterozygous in the affected animal; (2) we excluded variants that were homozygous in one of the two parents; (3) we rejected variants that were inconsistent with the Mendelian inheritance model; (4) we excluded variants in the non-coding regions.", "section": "RESULTS", "tags": [{"name": "heterozygous", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "inconsistent", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "The analysis generated \u2018Acute renal failure panel\u2019 (P=5.86E\u201304, ratio 6/62), \u2018NRF2-mediated oxidative stress response\u2019 (P=6.07E\u201304, ratio 12/234), \u2018Renal necrosis/Cell death\u2019 (P=8.13E\u201304, ratio 18/461), \u2018Oxidative stress\u2019 (P=2.62E\u201303, ratio 5/57) and \u2018Renal safety biomarker panel\u2019 (P=4.01E\u201303, ratio 2/6) as the top five most significant effects (supplementary material Table\u00a0S5).", "section": "RESULTS", "tags": [{"name": "\u2018NRF2-mediated", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "(supplementary", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "We then searched for potentially pathogenic variants by applying the following filtering criteria: we selected variants that have functional impacts as predicted by Polyphen2 (Adzhubei et al., 2013), are conserved across multiple species, and are absent in the database of The 1000 Genome project (http://www.1000genomes.org/), dbSNP (http://www.ncbi.nlm.nih.gov/SNP/) and The NHLBI Exome Variant Server (http://evs.gs.washington.edu/EVS/).", "section": "RESULTS", "tags": [{"name": "(http://evs.gs.washington.edu/EVS/).", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "(http://www.ncbi.nlm.nih.gov/SNP/)", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "These findings are in agreement with the knowledge that HOXA1 plays a crucial multifaceted role during embryonic patterning and organogenesis, and are also consistent with the fact that the human and mouse HOXA1-related phenotypic presentations often have cardiovascular defects, renal abnormalities, rib deformities and mental retardation (Barrow et al., 2000; Chisaka et al., 1992; Harris et al., 1996; Mastroiacovo et al., 1995; Wang et al., 2001).", "section": "DISCUSS", "tags": [{"name": "organogenesis,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "cardiovascular", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Microtia-affected piglets in our study manifest many symptoms that are present in humans with HOXA1 truncating mutations (Bosley et al., 2008, 2007; Tischfield et al., 2005) or seen in Hoxa1-null mice (Chisaka et al., 1992; Lufkin et al., 1991), including abnormally shaped outer and middle ears, deafness, eyelid defects and, at least in affected humans, hypoventilation, swallowing dysfunction mainly due to cleft palate and mental retardation.", "section": "DISCUSS", "tags": [{"name": "Microtia-affected", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "hypoventilation,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "The analysis generated \u2018Acute renal failure panel\u2019 (P=5.86E\u201304, ratio 6/62), \u2018NRF2-mediated oxidative stress response\u2019 (P=6.07E\u201304, ratio 12/234), \u2018Renal necrosis/Cell death\u2019 (P=8.13E\u201304, ratio 18/461), \u2018Oxidative stress\u2019 (P=2.62E\u201303, ratio 5/57) and \u2018Renal safety biomarker panel\u2019 (P=4.01E\u201303, ratio 2/6) as the top five most significant effects (supplementary material Table\u00a0S5).", "section": "RESULTS", "tags": [{"name": "\u2018NRF2-mediated", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "(supplementary", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "We then searched for potentially pathogenic variants by applying the following filtering criteria: we selected variants that have functional impacts as predicted by Polyphen2 (Adzhubei et al., 2013), are conserved across multiple species, and are absent in the database of The 1000 Genome project (http://www.1000genomes.org/), dbSNP (http://www.ncbi.nlm.nih.gov/SNP/) and The NHLBI Exome Variant Server (http://evs.gs.washington.edu/EVS/).", "section": "RESULTS", "tags": [{"name": "(http://evs.gs.washington.edu/EVS/).", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "(http://www.ncbi.nlm.nih.gov/SNP/)", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "We explored 16,272 qualified SNPs to perform a genome-wide association analysis on the F2 family, after excluding the following single-nucleotide polymorphisms (SNPs): SNPs that had a low call rate (90%) or Hardy\u2013Weinberg equilibrium deviation >10\u22126, were non-informative (minor allele frequencies <0.05), or were not mapped to the reference genome (Sscrofa 10.2).", "section": "RESULTS", "tags": [{"name": "single-nucleotide", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "non-informative", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}]}
{"src": "PMC", "id": "PMC4460277", "provider": "OpenTargets", "anns": [{"type": "Gene Disease Relationship", "exact": "Fig. 4HER2 immunohistochemistry: a strong membranous positivity in 100\u00a0% of the tumor cells of a conventional urothelial bladder cancer, score 3+; b score 3+ in a micropapillary variant; c mosaic pattern, score 3+; d strong positivity in carcinoma in situ, negativity in the adjacent normal urothelium", "section": "OTHER", "tags": [{"name": "immunohistochemistry:", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "micropapillary", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "The primer sequences were as follows: forward primer exon 19, 5\u2032-CCCACGCTCTTCTCACTCAT-3\u2032; reverse primer exon 19; 5\u2032-TCCTTCCTGTCCTCCTAGCA-3\u2032; forward primer exon 20, 5\u2032-TGGTCTCCCATACCCTCTCA-3\u2032; and reverse primer exon 20, 5\u2032-CAAAGAGCCCAGGTGCATA-3\u2032. Sequence analysis was performed using the 3500 genetic analyzer (Applied Biosystems).", "section": "METHODS", "tags": [{"name": "5\u2032-CCCACGCTCTTCTCACTCAT-3\u2032;", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "5\u2032-TCCTTCCTGTCCTCCTAGCA-3\u2032;", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "The primer sequences were as follows: forward primer exon 19, 5\u2032-CCCACGCTCTTCTCACTCAT-3\u2032; reverse primer exon 19; 5\u2032-TCCTTCCTGTCCTCCTAGCA-3\u2032; forward primer exon 20, 5\u2032-TGGTCTCCCATACCCTCTCA-3\u2032; and reverse primer exon 20, 5\u2032-CAAAGAGCCCAGGTGCATA-3\u2032. Sequence analysis was performed using the 3500 genetic analyzer (Applied Biosystems).", "section": "METHODS", "tags": [{"name": "5\u2032-CCCACGCTCTTCTCACTCAT-3\u2032;", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "5\u2032-TCCTTCCTGTCCTCCTAGCA-3\u2032;", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Taken together, these histomorphological features of HER2 amplified UBC\u2014frequent micropapillary architecture, morphological heterogeneity and marked tumor-associated chronic inflammation\u2014allow pathologists to better identify this clinically important, particularly aggressive subset of UBC [12] and herewith to contribute to enhanced survival prediction and preselection for potential anti-HER2 therapies in the future.", "section": "DISCUSS", "tags": [{"name": "histomorphological", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "inflammation\u2014allow", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "HER2 amplified urothelial bladder cancer often presents with marked tumor-associated chronic inflammation (d HE\u2009\u00d7\u200920)\nFig. 2\nHER2 non-amplified urothelial bladder cancers mostly show conventional solid morphology (a HE\u2009\u00d7\u200910); b sarcomatoid variant (HE\u2009\u00d7\u200920)\nFig. 3Comparison of HER2 amplified and non-amplified urothelial bladder cancers (n=13 each) in regard to their morphology (the tumor components are given as percentage in relation to the total tumor mass in each group): micropapillary architecture is a key feature of HER2 amplified urothelial bladder cancer", "section": "OTHER", "tags": [{"name": "tumor-associated", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "micropapillary", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "HER2 amplified urothelial bladder cancer often presents with marked tumor-associated chronic inflammation (d HE\u2009\u00d7\u200920)\nFig. 2\nHER2 non-amplified urothelial bladder cancers mostly show conventional solid morphology (a HE\u2009\u00d7\u200910); b sarcomatoid variant (HE\u2009\u00d7\u200920)\nFig. 3Comparison of HER2 amplified and non-amplified urothelial bladder cancers (n=13 each) in regard to their morphology (the tumor components are given as percentage in relation to the total tumor mass in each group): micropapillary architecture is a key feature of HER2 amplified urothelial bladder cancer", "section": "OTHER", "tags": [{"name": "tumor-associated", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "micropapillary", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Fig. 4HER2 immunohistochemistry: a strong membranous positivity in 100\u00a0% of the tumor cells of a conventional urothelial bladder cancer, score 3+; b score 3+ in a micropapillary variant; c mosaic pattern, score 3+; d strong positivity in carcinoma in situ, negativity in the adjacent normal urothelium", "section": "OTHER", "tags": [{"name": "immunohistochemistry:", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "micropapillary", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Fig. 4HER2 immunohistochemistry: a strong membranous positivity in 100\u00a0% of the tumor cells of a conventional urothelial bladder cancer, score 3+; b score 3+ in a micropapillary variant; c mosaic pattern, score 3+; d strong positivity in carcinoma in situ, negativity in the adjacent normal urothelium", "section": "OTHER", "tags": [{"name": "immunohistochemistry:", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "micropapillary", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "The primer sequences were as follows: forward primer exon 19, 5\u2032-CCCACGCTCTTCTCACTCAT-3\u2032; reverse primer exon 19; 5\u2032-TCCTTCCTGTCCTCCTAGCA-3\u2032; forward primer exon 20, 5\u2032-TGGTCTCCCATACCCTCTCA-3\u2032; and reverse primer exon 20, 5\u2032-CAAAGAGCCCAGGTGCATA-3\u2032. Sequence analysis was performed using the 3500 genetic analyzer (Applied Biosystems).", "section": "METHODS", "tags": [{"name": "5\u2032-CCCACGCTCTTCTCACTCAT-3\u2032;", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "5\u2032-TCCTTCCTGTCCTCCTAGCA-3\u2032;", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Taken together, these histomorphological features of HER2 amplified UBC\u2014frequent micropapillary architecture, morphological heterogeneity and marked tumor-associated chronic inflammation\u2014allow pathologists to better identify this clinically important, particularly aggressive subset of UBC [12] and herewith to contribute to enhanced survival prediction and preselection for potential anti-HER2 therapies in the future.", "section": "DISCUSS", "tags": [{"name": "histomorphological", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "inflammation\u2014allow", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Comparison of HER2 amplified and non-amplified urothelial bladder cancers (n=13 each) in regard to their morphology (the tumor components are given as percentage in relation to the total tumor mass in each group): micropapillary architecture is a key feature of HER2 amplified urothelial bladder cancer", "section": "OTHER", "tags": [{"name": "micropapillary", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "non-amplified", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "The primer sequences were as follows: forward primer exon 19, 5\u2032-CCCACGCTCTTCTCACTCAT-3\u2032; reverse primer exon 19; 5\u2032-TCCTTCCTGTCCTCCTAGCA-3\u2032; forward primer exon 20, 5\u2032-TGGTCTCCCATACCCTCTCA-3\u2032; and reverse primer exon 20, 5\u2032-CAAAGAGCCCAGGTGCATA-3\u2032. Sequence analysis was performed using the 3500 genetic analyzer (Applied Biosystems).", "section": "METHODS", "tags": [{"name": "5\u2032-CCCACGCTCTTCTCACTCAT-3\u2032;", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "5\u2032-TCCTTCCTGTCCTCCTAGCA-3\u2032;", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Comparison of HER2 amplified and non-amplified urothelial bladder cancers (n=13 each) in regard to their morphology (the tumor components are given as percentage in relation to the total tumor mass in each group): micropapillary architecture is a key feature of HER2 amplified urothelial bladder cancer", "section": "OTHER", "tags": [{"name": "micropapillary", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "non-amplified", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "HER2 immunohistochemistry: a strong membranous positivity in 100\u00a0% of the tumor cells of a conventional urothelial bladder cancer, score 3+; b score 3+ in a micropapillary variant; c mosaic pattern, score 3+; d strong positivity in carcinoma in situ, negativity in the adjacent normal urothelium", "section": "OTHER", "tags": [{"name": "immunohistochemistry:", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "micropapillary", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "HER2 amplified urothelial bladder cancer often presents with marked tumor-associated chronic inflammation (d HE\u2009\u00d7\u200920)\nFig. 2\nHER2 non-amplified urothelial bladder cancers mostly show conventional solid morphology (a HE\u2009\u00d7\u200910); b sarcomatoid variant (HE\u2009\u00d7\u200920)\nFig. 3Comparison of HER2 amplified and non-amplified urothelial bladder cancers (n=13 each) in regard to their morphology (the tumor components are given as percentage in relation to the total tumor mass in each group): micropapillary architecture is a key feature of HER2 amplified urothelial bladder cancer", "section": "OTHER", "tags": [{"name": "tumor-associated", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "micropapillary", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Taken together, these histomorphological features of HER2 amplified UBC\u2014frequent micropapillary architecture, morphological heterogeneity and marked tumor-associated chronic inflammation\u2014allow pathologists to better identify this clinically important, particularly aggressive subset of UBC [12] and herewith to contribute to enhanced survival prediction and preselection for potential anti-HER2 therapies in the future.", "section": "DISCUSS", "tags": [{"name": "histomorphological", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "inflammation\u2014allow", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "The primer sequences were as follows: forward primer exon 19, 5\u2032-CCCACGCTCTTCTCACTCAT-3\u2032; reverse primer exon 19; 5\u2032-TCCTTCCTGTCCTCCTAGCA-3\u2032; forward primer exon 20, 5\u2032-TGGTCTCCCATACCCTCTCA-3\u2032; and reverse primer exon 20, 5\u2032-CAAAGAGCCCAGGTGCATA-3\u2032. Sequence analysis was performed using the 3500 genetic analyzer (Applied Biosystems).", "section": "METHODS", "tags": [{"name": "5\u2032-CCCACGCTCTTCTCACTCAT-3\u2032;", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "5\u2032-TCCTTCCTGTCCTCCTAGCA-3\u2032;", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "HER2 amplified urothelial bladder cancer often presents with marked tumor-associated chronic inflammation (d HE\u2009\u00d7\u200920)\nFig. 2\nHER2 non-amplified urothelial bladder cancers mostly show conventional solid morphology (a HE\u2009\u00d7\u200910); b sarcomatoid variant (HE\u2009\u00d7\u200920)\nFig. 3Comparison of HER2 amplified and non-amplified urothelial bladder cancers (n=13 each) in regard to their morphology (the tumor components are given as percentage in relation to the total tumor mass in each group): micropapillary architecture is a key feature of HER2 amplified urothelial bladder cancer", "section": "OTHER", "tags": [{"name": "tumor-associated", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "micropapillary", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Comparison of HER2 amplified and non-amplified urothelial bladder cancers (n=13 each) in regard to their morphology (the tumor components are given as percentage in relation to the total tumor mass in each group): micropapillary architecture is a key feature of HER2 amplified urothelial bladder cancer", "section": "OTHER", "tags": [{"name": "micropapillary", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "non-amplified", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "The primer sequences were as follows: forward primer exon 19, 5\u2032-CCCACGCTCTTCTCACTCAT-3\u2032; reverse primer exon 19; 5\u2032-TCCTTCCTGTCCTCCTAGCA-3\u2032; forward primer exon 20, 5\u2032-TGGTCTCCCATACCCTCTCA-3\u2032; and reverse primer exon 20, 5\u2032-CAAAGAGCCCAGGTGCATA-3\u2032. Sequence analysis was performed using the 3500 genetic analyzer (Applied Biosystems).", "section": "METHODS", "tags": [{"name": "5\u2032-CCCACGCTCTTCTCACTCAT-3\u2032;", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "5\u2032-TCCTTCCTGTCCTCCTAGCA-3\u2032;", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Fig. 4HER2 immunohistochemistry: a strong membranous positivity in 100\u00a0% of the tumor cells of a conventional urothelial bladder cancer, score 3+; b score 3+ in a micropapillary variant; c mosaic pattern, score 3+; d strong positivity in carcinoma in situ, negativity in the adjacent normal urothelium", "section": "OTHER", "tags": [{"name": "immunohistochemistry:", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "micropapillary", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Comparison of HER2 amplified and non-amplified urothelial bladder cancers (n=13 each) in regard to their morphology (the tumor components are given as percentage in relation to the total tumor mass in each group): micropapillary architecture is a key feature of HER2 amplified urothelial bladder cancer", "section": "OTHER", "tags": [{"name": "micropapillary", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "non-amplified", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Fig. 4HER2 immunohistochemistry: a strong membranous positivity in 100\u00a0% of the tumor cells of a conventional urothelial bladder cancer, score 3+; b score 3+ in a micropapillary variant; c mosaic pattern, score 3+; d strong positivity in carcinoma in situ, negativity in the adjacent normal urothelium", "section": "OTHER", "tags": [{"name": "immunohistochemistry:", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "micropapillary", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "HER2 immunohistochemistry: a strong membranous positivity in 100\u00a0% of the tumor cells of a conventional urothelial bladder cancer, score 3+; b score 3+ in a micropapillary variant; c mosaic pattern, score 3+; d strong positivity in carcinoma in situ, negativity in the adjacent normal urothelium", "section": "OTHER", "tags": [{"name": "immunohistochemistry:", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "micropapillary", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "HER2 amplified urothelial bladder cancer often presents with marked tumor-associated chronic inflammation (d HE\u2009\u00d7\u200920)\nFig. 2\nHER2 non-amplified urothelial bladder cancers mostly show conventional solid morphology (a HE\u2009\u00d7\u200910); b sarcomatoid variant (HE\u2009\u00d7\u200920)\nFig. 3Comparison of HER2 amplified and non-amplified urothelial bladder cancers (n=13 each) in regard to their morphology (the tumor components are given as percentage in relation to the total tumor mass in each group): micropapillary architecture is a key feature of HER2 amplified urothelial bladder cancer", "section": "OTHER", "tags": [{"name": "tumor-associated", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "micropapillary", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}]}
{"src": "PMC", "id": "PMC4454778", "provider": "OpenTargets", "anns": [{"type": "Gene Disease Relationship", "exact": "Whole-exome sequencing was carried out in both patients using genomic DNA extracted from peripheral blood lymphocytes, fragmented, and exome enriched by Illumina TruSeq\u2122 62\u2009Mb and sequenced on a HiSeq 2000 with 100\u2009bp paired-end reads.", "section": "METHODS", "tags": [{"name": "lymphocytes,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "Whole-exome", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Whole-exome sequencing was carried out in both patients using genomic DNA extracted from peripheral blood lymphocytes, fragmented, and exome enriched by Illumina TruSeq\u2122 62\u2009Mb and sequenced on a HiSeq 2000 with 100\u2009bp paired-end reads.", "section": "METHODS", "tags": [{"name": "lymphocytes,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "Whole-exome", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Results were further filtered for variants with a minor allele frequency less than 0.01 in several databases: dbSNP135, 1000 genomes (February 2012 data release), the National Heart, Lung and Blood Institute (NHLBI, NIH, Bethesda, MD) Exome Sequencing Project (ESP) 6500 exomes, and 238 unrelated in-house controls, in order to detect rare variants.", "section": "METHODS", "tags": [{"name": "databases:", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "Sequencing", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "We assume that the differences between our patient and the ones reported by Astrea et\u00a0al. [20] and Oates et\u00a0al. [17] are due to the fact that our case is a late onset form of the disease (CMT2C) while the later ones corresponded to congenital forms of SMA.", "section": "DISCUSS", "tags": [{"name": "corresponded", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "differences", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Our finding expands further the clinical variability among TRPV4 mutations and highlight that the presence of skeletal abnormalities in a patient with an axonal neuropathy or neuronopathy should raise the possibility of TRPV4 gene mutations.", "section": "DISCUSS", "tags": [{"name": "abnormalities", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "neuronopathy", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Whole-exome sequencing was carried out in both patients using genomic DNA extracted from peripheral blood lymphocytes, fragmented, and exome enriched by Illumina TruSeq\u2122 62\u2009Mb and sequenced on a HiSeq 2000 with 100\u2009bp paired-end reads.", "section": "METHODS", "tags": [{"name": "lymphocytes,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "Whole-exome", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Among the skeletal dysplasias, TRPV4 mutations have been described in patients with brachyolmia (OMIM 113500), spondylometaphyseal dysplasia Kozlowski type (SMD-K; OMIM 184252), metatropic dysplasia (OMIM 156530), parastremmatic dysplasia (OMIM 168400), and spondyloepimetaphyseal dysplasia Maroteaux type (SEMD-M; OMIM 184095).", "section": "INTRO", "tags": [{"name": "spondyloepimetaphyseal", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "spondylometaphyseal", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "PNSS include hereditary motor and sensory neuropathy type 2C or Charcot\u2013Marie\u2013Tooth disease type 2C (HMSN2C or CMT2C; OMIM 606071), congenital spinal muscular atrophy and arthrogryposis (CSMAA; OMIM 600175) and scapuloperoneal spinal muscular atrophy (SPSMA; OMIM 181405).", "section": "INTRO", "tags": [{"name": "Charcot\u2013Marie\u2013Tooth", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "scapuloperoneal", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Results were further filtered for variants with a minor allele frequency less than 0.01 in several databases: dbSNP135, 1000 genomes (February 2012 data release), the National Heart, Lung and Blood Institute (NHLBI, NIH, Bethesda, MD) Exome Sequencing Project (ESP) 6500 exomes, and 238 unrelated in-house controls, in order to detect rare variants.", "section": "METHODS", "tags": [{"name": "databases:", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "Sequencing", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Results were further filtered for variants with a minor allele frequency less than 0.01 in several databases: dbSNP135, 1000 genomes (February 2012 data release), the National Heart, Lung and Blood Institute (NHLBI, NIH, Bethesda, MD) Exome Sequencing Project (ESP) 6500 exomes, and 238 unrelated in-house controls, in order to detect rare variants.", "section": "METHODS", "tags": [{"name": "databases:", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "Sequencing", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Whole-exome sequencing was carried out in both patients using genomic DNA extracted from peripheral blood lymphocytes, fragmented, and exome enriched by Illumina TruSeq\u2122 62\u2009Mb and sequenced on a HiSeq 2000 with 100\u2009bp paired-end reads.", "section": "METHODS", "tags": [{"name": "lymphocytes,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "Whole-exome", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "PNSS include hereditary motor and sensory neuropathy type 2C or Charcot\u2013Marie\u2013Tooth disease type 2C (HMSN2C or CMT2C; OMIM 606071), congenital spinal muscular atrophy and arthrogryposis (CSMAA; OMIM 600175) and scapuloperoneal spinal muscular atrophy (SPSMA; OMIM 181405).", "section": "INTRO", "tags": [{"name": "Charcot\u2013Marie\u2013Tooth", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "scapuloperoneal", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Whole-exome sequencing was carried out in both patients using genomic DNA extracted from peripheral blood lymphocytes, fragmented, and exome enriched by Illumina TruSeq\u2122 62\u2009Mb and sequenced on a HiSeq 2000 with 100\u2009bp paired-end reads.", "section": "METHODS", "tags": [{"name": "lymphocytes,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "Whole-exome", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Results were further filtered for variants with a minor allele frequency less than 0.01 in several databases: dbSNP135, 1000 genomes (February 2012 data release), the National Heart, Lung and Blood Institute (NHLBI, NIH, Bethesda, MD) Exome Sequencing Project (ESP) 6500 exomes, and 238 unrelated in-house controls, in order to detect rare variants.", "section": "METHODS", "tags": [{"name": "databases:", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "Sequencing", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Our finding expands further the clinical variability among TRPV4 mutations and highlight that the presence of skeletal abnormalities in a patient with an axonal neuropathy or neuronopathy should raise the possibility of TRPV4 gene mutations.", "section": "DISCUSS", "tags": [{"name": "abnormalities", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "neuronopathy", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Whole-exome sequencing was carried out in both patients using genomic DNA extracted from peripheral blood lymphocytes, fragmented, and exome enriched by Illumina TruSeq\u2122 62\u2009Mb and sequenced on a HiSeq 2000 with 100\u2009bp paired-end reads.", "section": "METHODS", "tags": [{"name": "lymphocytes,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "Whole-exome", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Results were further filtered for variants with a minor allele frequency less than 0.01 in several databases: dbSNP135, 1000 genomes (February 2012 data release), the National Heart, Lung and Blood Institute (NHLBI, NIH, Bethesda, MD) Exome Sequencing Project (ESP) 6500 exomes, and 238 unrelated in-house controls, in order to detect rare variants.", "section": "METHODS", "tags": [{"name": "databases:", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "Sequencing", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Among the skeletal dysplasias, TRPV4 mutations have been described in patients with brachyolmia (OMIM 113500), spondylometaphyseal dysplasia Kozlowski type (SMD-K; OMIM 184252), metatropic dysplasia (OMIM 156530), parastremmatic dysplasia (OMIM 168400), and spondyloepimetaphyseal dysplasia Maroteaux type (SEMD-M; OMIM 184095).", "section": "INTRO", "tags": [{"name": "spondyloepimetaphyseal", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "spondylometaphyseal", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "We assume that the differences between our patient and the ones reported by Astrea et\u00a0al. [20] and Oates et\u00a0al. [17] are due to the fact that our case is a late onset form of the disease (CMT2C) while the later ones corresponded to congenital forms of SMA.", "section": "DISCUSS", "tags": [{"name": "corresponded", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "differences", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Results were further filtered for variants with a minor allele frequency less than 0.01 in several databases: dbSNP135, 1000 genomes (February 2012 data release), the National Heart, Lung and Blood Institute (NHLBI, NIH, Bethesda, MD) Exome Sequencing Project (ESP) 6500 exomes, and 238 unrelated in-house controls, in order to detect rare variants.", "section": "METHODS", "tags": [{"name": "databases:", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "Sequencing", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Results were further filtered for variants with a minor allele frequency less than 0.01 in several databases: dbSNP135, 1000 genomes (February 2012 data release), the National Heart, Lung and Blood Institute (NHLBI, NIH, Bethesda, MD) Exome Sequencing Project (ESP) 6500 exomes, and 238 unrelated in-house controls, in order to detect rare variants.", "section": "METHODS", "tags": [{"name": "databases:", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "Sequencing", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}]}
{"src": "PMC", "id": "PMC4363147", "provider": "OpenTargets", "anns": [{"type": "Gene Disease Relationship", "exact": "That is, a further reduction of BDNF due to stress could impact BDNF\u2019s ability to contribute to the survival and functioning of serotoninergic neurons, whereas the less functional serotonin system among S\u2032 carriers has learned to adapt with neurotrophins over time and may be more resistant to stressors.", "section": "DISCUSS", "tags": [{"name": "serotoninergic", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "neurotrophins", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Considering previous studies have indicated that atrophy of the hippocampus [22,33] and reduced hippocampal activity [32] are associated with the Met allele, BDNF Met/Met carriers may be vulnerable to the development of depressive symptoms due to inadequate synaptic formation in the hippocampus, a structure important for mood regulation [26,34,35,65,66].", "section": "DISCUSS", "tags": [{"name": "[26,34,35,65,66].", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "hippocampus,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "As Kendler [79] argues, it is unlikely we will uncover an exclusive genetic pattern revealing a heterogeneous illness such as depression; but it is possible to identify subsets of genetic interactions that delineate particular molecular pathways susceptible under certain genetic and environmental conditions.", "section": "DISCUSS", "tags": [{"name": "heterogeneous", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "environmental", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Participants with hip fracture were excluded if they were unable to provide written informed consent after complete description of the study, were unable to cooperate with the protocol, had a current diagnosis of major depression, had metastatic cancer, were significantly impaired by language, visual or hearing barriers, lived more than one hour away, were taking interferon medications, or had an inoperable fracture.", "section": "OTHER", "tags": [{"name": "significantly", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "Participants", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Depressive symptoms after hip fracture have a pernicious effect on the recovery process: they are associated with higher discharge rates to and increased length of stay in nursing homes [13\u201315], poorer occupational and physical therapy participation, and poorer functional recovery [16,17].", "section": "INTRO", "tags": [{"name": "participation,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "occupational", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "The gene SLC6A4 encodes for the serotonin transporter (5HTT) and this transporter\u2019s efficiency is altered by both a genetic variation of the serotonin transporter gene-linked polymorphic region (5HTTLPR) and a functional A to G single-nucleotide polymorphism (SNP; refSNP: rs25531) [37,38].", "section": "INTRO", "tags": [{"name": "single-nucleotide", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "transporter\u2019s", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "The gene SLC6A4 encodes for the serotonin transporter (5HTT) and this transporter\u2019s efficiency is altered by both a genetic variation of the serotonin transporter gene-linked polymorphic region (5HTTLPR) and a functional A to G single-nucleotide polymorphism (SNP; refSNP: rs25531) [37,38].", "section": "INTRO", "tags": [{"name": "single-nucleotide", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "transporter\u2019s", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Participants with hip fracture were excluded if they were unable to provide written informed consent after complete description of the study, were unable to cooperate with the protocol, had a current diagnosis of major depression, had metastatic cancer, were significantly impaired by language, visual or hearing barriers, lived more than one hour away, were taking interferon medications, or had an inoperable fracture.", "section": "OTHER", "tags": [{"name": "significantly", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "Participants", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Washington University's Human Research Protection Office, Washington University School of Medicine Institutional Review Board, and the review boards at the applicable participating research site (The Christian Hospital Research Committee for Christian Hospital, DePaul Institutional Review Board for DePaul Health Center, Missouri Baptist Medical Center Institutional Review Board for Missouri Baptist Medical Center, Saint Anthony\u2019s Medical Center Institutional Review Board for Saint Anthony's Medical Center, SSM Saint Louis Institutional Review Board for SSM Saint Clare Health Center, Saint Louis University Institutional Review Board for Saint Louis University Medical Center Campus and Saint Mary\u2019s Health Center, and Washington University School of Medicine Institutional Review Board for Barnes-Jewish Hospital) approved this study and approved the informed written consent document that was signed by all participants.", "section": "OTHER", "tags": [{"name": "Institutional", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "participating", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Washington University's Human Research Protection Office, Washington University School of Medicine Institutional Review Board, and the review boards at the applicable participating research site (The Christian Hospital Research Committee for Christian Hospital, DePaul Institutional Review Board for DePaul Health Center, Missouri Baptist Medical Center Institutional Review Board for Missouri Baptist Medical Center, Saint Anthony\u2019s Medical Center Institutional Review Board for Saint Anthony's Medical Center, SSM Saint Louis Institutional Review Board for SSM Saint Clare Health Center, Saint Louis University Institutional Review Board for Saint Louis University Medical Center Campus and Saint Mary\u2019s Health Center, and Washington University School of Medicine Institutional Review Board for Barnes-Jewish Hospital) approved this study and approved the informed written consent document that was signed by all participants.", "section": "OTHER", "tags": [{"name": "Institutional", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "participating", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "That is, a further reduction of BDNF due to stress could impact BDNF\u2019s ability to contribute to the survival and functioning of serotoninergic neurons, whereas the less functional serotonin system among S\u2032 carriers has learned to adapt with neurotrophins over time and may be more resistant to stressors.", "section": "DISCUSS", "tags": [{"name": "serotoninergic", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "neurotrophins", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Participants with hip fracture were excluded if they were unable to provide written informed consent after complete description of the study, were unable to cooperate with the protocol, had a current diagnosis of major depression, had metastatic cancer, were significantly impaired by language, visual or hearing barriers, lived more than one hour away, were taking interferon medications, or had an inoperable fracture.", "section": "OTHER", "tags": [{"name": "significantly", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "Participants", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Depressive symptoms after hip fracture have a pernicious effect on the recovery process: they are associated with higher discharge rates to and increased length of stay in nursing homes [13\u201315], poorer occupational and physical therapy participation, and poorer functional recovery [16,17].", "section": "INTRO", "tags": [{"name": "participation,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "occupational", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "That is, a further reduction of BDNF due to stress could impact BDNF\u2019s ability to contribute to the survival and functioning of serotoninergic neurons, whereas the less functional serotonin system among S\u2032 carriers has learned to adapt with neurotrophins over time and may be more resistant to stressors.", "section": "DISCUSS", "tags": [{"name": "serotoninergic", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "neurotrophins", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Washington University's Human Research Protection Office, Washington University School of Medicine Institutional Review Board, and the review boards at the applicable participating research site (The Christian Hospital Research Committee for Christian Hospital, DePaul Institutional Review Board for DePaul Health Center, Missouri Baptist Medical Center Institutional Review Board for Missouri Baptist Medical Center, Saint Anthony\u2019s Medical Center Institutional Review Board for Saint Anthony's Medical Center, SSM Saint Louis Institutional Review Board for SSM Saint Clare Health Center, Saint Louis University Institutional Review Board for Saint Louis University Medical Center Campus and Saint Mary\u2019s Health Center, and Washington University School of Medicine Institutional Review Board for Barnes-Jewish Hospital) approved this study and approved the informed written consent document that was signed by all participants.", "section": "OTHER", "tags": [{"name": "Institutional", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "participating", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Considering previous studies have indicated that atrophy of the hippocampus [22,33] and reduced hippocampal activity [32] are associated with the Met allele, BDNF Met/Met carriers may be vulnerable to the development of depressive symptoms due to inadequate synaptic formation in the hippocampus, a structure important for mood regulation [26,34,35,65,66].", "section": "DISCUSS", "tags": [{"name": "[26,34,35,65,66].", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "hippocampus,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "The gene SLC6A4 encodes for the serotonin transporter (5HTT) and this transporter\u2019s efficiency is altered by both a genetic variation of the serotonin transporter gene-linked polymorphic region (5HTTLPR) and a functional A to G single-nucleotide polymorphism (SNP; refSNP: rs25531) [37,38].", "section": "INTRO", "tags": [{"name": "single-nucleotide", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "transporter\u2019s", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "As Kendler [79] argues, it is unlikely we will uncover an exclusive genetic pattern revealing a heterogeneous illness such as depression; but it is possible to identify subsets of genetic interactions that delineate particular molecular pathways susceptible under certain genetic and environmental conditions.", "section": "DISCUSS", "tags": [{"name": "heterogeneous", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "environmental", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Washington University's Human Research Protection Office, Washington University School of Medicine Institutional Review Board, and the review boards at the applicable participating research site (The Christian Hospital Research Committee for Christian Hospital, DePaul Institutional Review Board for DePaul Health Center, Missouri Baptist Medical Center Institutional Review Board for Missouri Baptist Medical Center, Saint Anthony\u2019s Medical Center Institutional Review Board for Saint Anthony's Medical Center, SSM Saint Louis Institutional Review Board for SSM Saint Clare Health Center, Saint Louis University Institutional Review Board for Saint Louis University Medical Center Campus and Saint Mary\u2019s Health Center, and Washington University School of Medicine Institutional Review Board for Barnes-Jewish Hospital) approved this study and approved the informed written consent document that was signed by all participants.", "section": "OTHER", "tags": [{"name": "Institutional", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "participating", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Participants with hip fracture were excluded if they were unable to provide written informed consent after complete description of the study, were unable to cooperate with the protocol, had a current diagnosis of major depression, had metastatic cancer, were significantly impaired by language, visual or hearing barriers, lived more than one hour away, were taking interferon medications, or had an inoperable fracture.", "section": "OTHER", "tags": [{"name": "significantly", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "Participants", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}]}
{"src": "PMC", "id": "PMC6680266", "provider": "OpenTargets", "anns": [{"type": "Gene Disease Relationship", "exact": "Each component of the model was: co\u2010dominant model (major allele homozygotes vs. heterozygotes vs. minor allele homozygotes), dominant model (major allele homozygotes vs. heterozygotes + minor allele homozygotes), recessive model (major allele homozygotes vs. minor allele homozygotes), overdominant model (major allele homozygotes + heterozygotes vs. minor allele homozygotes) and log\u2010additive model.", "section": "METHODS", "tags": [{"name": "heterozygotes", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "homozygotes),", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "These genes included TLRs (TLR3, TLR4, TLR5 and TLR9), the TLR adaptin MYD88, the TLR effector molecule IRAK1, receptors for IFNs (IFNGR1, IFNGR2, IL27B and IL12B), ligands for IFN receptors (IFNG and IL15), other genes related to IFNs (IL28A, IL29 and IL6), proteins induced by IFN (MX1, CXCL10), and genes of the NF\u03baB pathway (NFKB1, NFKB2, IL1B, IL2, IL10 and IL12A).", "section": "METHODS", "tags": [{"name": "receptors", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "receptors", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Each component of the model was: co\u2010dominant model (major allele homozygotes vs. heterozygotes vs. minor allele homozygotes), dominant model (major allele homozygotes vs. heterozygotes + minor allele homozygotes), recessive model (major allele homozygotes vs. minor allele homozygotes), overdominant model (major allele homozygotes + heterozygotes vs. minor allele homozygotes) and log\u2010additive model.", "section": "METHODS", "tags": [{"name": "heterozygotes", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "homozygotes),", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "A significant association was seen in several of the TLR\u2013IFN pathway genes, TLR9 rs352140 (OR\u00a0=\u00a00.70, P\u00a0=\u00a00.0088), IL1B rs16944 (OR\u00a0=\u00a00.67, P\u00a0=\u00a00.016), IL12B rs3212227 (OR\u00a0=\u00a01.38, P\u00a0=\u00a00.021), IFNGR1 rs3799488 (OR\u00a0=\u00a01.48, P\u00a0=\u00a00.0048), IFNGR2 rs1059293 (OR\u00a0=\u00a00.27, P\u00a0=\u00a00.011), MX1 rs467960 (OR\u00a0=\u00a00.68, P\u00a0=\u00a00.022), as well as four loci in HLA, rs3077 (OR\u00a0=\u00a00.55, P\u00a0<\u00a00.0001), rs2856718 (OR\u00a0=\u00a00.60, P\u00a0=\u00a04e\u201004), rs9277535 (OR\u00a0=\u00a00.54, P\u00a0<\u00a00.0001) and rs7453920 (OR\u00a0=\u00a00.43, P\u00a0<\u00a00.0001).", "section": "RESULTS", "tags": [{"name": "significant", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "association", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "These were: TLR3 rs3775296, TLR4 rs11536889 and rs1927907, TLR5 rs5744174, TLR9 rs352140, MYD88 rs7744, IRAK1 rs1059702 and rs1059703, IFNG rs2069705, IFNGR1 rs3799488 and rs10457655, IFNGR2 rs1059293 and rs2834211, IL15 rs10519613 and rs10833, IL28B rs12979860 and rs8099917, IL29 rs30461, IL6 rs1800796, IL27B rs4905 and rs6613, IL12B rs3212227, NFKB1 rs4648068, NFKB2 rs7897947, IL1B rs1143623, rs1143627, and rs16944, IL2 rs2069772, IL10 rs1800872 and rs1800896, IL12A rs2243115 and rs568408, CXCL10 rs4256246, rs4508917, and rs8878, MX1 rs1557370, rs2070229, rs467960, and rs469390.", "section": "METHODS", "tags": [{"name": "rs10457655,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "rs3775296,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "These genes included TLRs (TLR3, TLR4, TLR5 and TLR9), the TLR adaptin MYD88, the TLR effector molecule IRAK1, receptors for IFNs (IFNGR1, IFNGR2, IL27B and IL12B), ligands for IFN receptors (IFNG and IL15), other genes related to IFNs (IL28A, IL29 and IL6), proteins induced by IFN (MX1, CXCL10), and genes of the NF\u03baB pathway (NFKB1, NFKB2, IL1B, IL2, IL10 and IL12A).", "section": "METHODS", "tags": [{"name": "receptors", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "receptors", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Exclusion criteria consisted of the following: (a) co\u2010infectionwith HCV, hepatitis D virus or human immunodeficiency virus (HIV); (b) coexisting serious medical or psychiatric illness; (c) organ or bone marrow transplantation; (d) recent treatment with systemic corticosteroids, immunosuppressants or chemotherapeutic agents.", "section": "METHODS", "tags": [{"name": "immunosuppressants", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "co\u2010infectionwith", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Each component of the model was: co\u2010dominant model (major allele homozygotes vs. heterozygotes vs. minor allele homozygotes), dominant model (major allele homozygotes vs. heterozygotes + minor allele homozygotes), recessive model (major allele homozygotes vs. minor allele homozygotes), overdominant model (major allele homozygotes + heterozygotes vs. minor allele homozygotes) and log\u2010additive model.", "section": "METHODS", "tags": [{"name": "heterozygotes", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "homozygotes),", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Susceptibility to chronic infection rather than virus clearance after HBV exposure, presentation of various clinical phenotypes and differing clinical outcomes in chronic HBV infection, as well as differing responses to antivirus treatment demonstrate that the genetic background of the innate immune system is a crucial factor in determining the outcome of HBV infection.", "section": "DISCUSS", "tags": [{"name": "Susceptibility", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "presentation", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "These genes included TLRs (TLR3, TLR4, TLR5 and TLR9), the TLR adaptin MYD88, the TLR effector molecule IRAK1, receptors for IFNs (IFNGR1, IFNGR2, IL27B and IL12B), ligands for IFN receptors (IFNG and IL15), other genes related to IFNs (IL28A, IL29 and IL6), proteins induced by IFN (MX1, CXCL10), and genes of the NF\u03baB pathway (NFKB1, NFKB2, IL1B, IL2, IL10 and IL12A).", "section": "METHODS", "tags": [{"name": "receptors", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "receptors", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Susceptibility to chronic infection rather than virus clearance after HBV exposure, presentation of various clinical phenotypes and differing clinical outcomes in chronic HBV infection, as well as differing responses to antivirus treatment demonstrate that the genetic background of the innate immune system is a crucial factor in determining the outcome of HBV infection.", "section": "DISCUSS", "tags": [{"name": "Susceptibility", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "presentation", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Exclusion criteria consisted of the following: (a) co\u2010infectionwith HCV, hepatitis D virus or human immunodeficiency virus (HIV); (b) coexisting serious medical or psychiatric illness; (c) organ or bone marrow transplantation; (d) recent treatment with systemic corticosteroids, immunosuppressants or chemotherapeutic agents.", "section": "METHODS", "tags": [{"name": "immunosuppressants", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "co\u2010infectionwith", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "These were: TLR3 rs3775296, TLR4 rs11536889 and rs1927907, TLR5 rs5744174, TLR9 rs352140, MYD88 rs7744, IRAK1 rs1059702 and rs1059703, IFNG rs2069705, IFNGR1 rs3799488 and rs10457655, IFNGR2 rs1059293 and rs2834211, IL15 rs10519613 and rs10833, IL28B rs12979860 and rs8099917, IL29 rs30461, IL6 rs1800796, IL27B rs4905 and rs6613, IL12B rs3212227, NFKB1 rs4648068, NFKB2 rs7897947, IL1B rs1143623, rs1143627, and rs16944, IL2 rs2069772, IL10 rs1800872 and rs1800896, IL12A rs2243115 and rs568408, CXCL10 rs4256246, rs4508917, and rs8878, MX1 rs1557370, rs2070229, rs467960, and rs469390.", "section": "METHODS", "tags": [{"name": "rs10457655,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "rs3775296,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}]}
{"src": "PMC", "id": "PMC4583332", "provider": "OpenTargets", "anns": [{"type": "Gene Disease Relationship", "exact": "Given the continuing decline in cost of next generation sequencing reagents, automation of variant calling methods, and potential diagnostic value susceptibility variants such as APOE\u025b4, whole exome approaches should be considered to be a more comprehensive, cost-effective alternative to candidate gene sequencing for the diagnosis of atypical dementias.", "section": "DISCUSS", "tags": [{"name": "susceptibility", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "comprehensive,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Scores of disease processes may ultimately lead to dementia, but there are four major primary disorders with dementia as their main clinical feature: Alzheimer\u2019s disease (AD), frontotemporal lobe degeneration (FTLD), cerebrovascular disease, and dementia with Lewy bodies [1, 2].", "section": "INTRO", "tags": [{"name": "cerebrovascular", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "frontotemporal", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "We believe that the Thr147Ile variant is the primary or sole cause of the disease in our patients for the following reasons: 1) Polyphen-2 analysis indicates the variant is probably damaging; 2) The substitution is located on the helical face of a PS1 transmembrane domain where all deleterious transmembrane variants are known to cluster [25]; 3) The same variant was present in four affected members of three generations of a French family (ALZ047) with early-onset autosomal dominant AD and absent from asymptomatic ALZ047 members \u226560 years of age [19]; 4) The variant was present in four affected members of our family (III-29, IV-1, IV-2, and IV-18); and 5) At least 185 mutations in PSEN1 are known to cause EOAD [12].", "section": "DISCUSS", "tags": [{"name": "transmembrane", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "transmembrane", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Further evidence implicating PKC deficits has emerged from clinical studies that showed with autopsy-confirmation that AD patients have significant abnormalities in PKC isozymes and PKC-elicited phosphorylation of downstream substrates [15, 16, 23, 24].", "section": "OTHER", "tags": [{"name": "autopsy-confirmation", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "phosphorylation", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Further evidence implicating PKC deficits has emerged from clinical studies that showed with autopsy-confirmation that AD patients have significant abnormalities in PKC isozymes and PKC-elicited phosphorylation of downstream substrates [15, 16, 23, 24].", "section": "OTHER", "tags": [{"name": "autopsy-confirmation", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "phosphorylation", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Since variants in known causal loci only explain a fraction of early-onset dementias, we performed whole exome sequencing with discrete filtering on two affected family members in order to identify causal variants and make a more accurate diagnosis.", "section": "INTRO", "tags": [{"name": "early-onset", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "dementias,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "We believe that the Thr147Ile variant is the primary or sole cause of the disease in our patients for the following reasons: 1) Polyphen-2 analysis indicates the variant is probably damaging; 2) The substitution is located on the helical face of a PS1 transmembrane domain where all deleterious transmembrane variants are known to cluster [25]; 3) The same variant was present in four affected members of three generations of a French family (ALZ047) with early-onset autosomal dominant AD and absent from asymptomatic ALZ047 members \u226560 years of age [19]; 4) The variant was present in four affected members of our family (III-29, IV-1, IV-2, and IV-18); and 5) At least 185 mutations in PSEN1 are known to cause EOAD [12].", "section": "DISCUSS", "tags": [{"name": "transmembrane", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "transmembrane", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "The latter pathology frequently leads to speech patterns consistent with the logopenic variant of primary progressive aphasia, with single word retrieval issues and impaired repetition of words or phrases [17], whereas these abnormalities were specifically denied in her history and not seen on earlier neuropsychological testing.", "section": "METHODS", "tags": [{"name": "neuropsychological", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "abnormalities", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Further evidence implicating PKC deficits has emerged from clinical studies that showed with autopsy-confirmation that AD patients have significant abnormalities in PKC isozymes and PKC-elicited phosphorylation of downstream substrates [15, 16, 23, 24].", "section": "OTHER", "tags": [{"name": "autopsy-confirmation", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "phosphorylation", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "The latter pathology frequently leads to speech patterns consistent with the logopenic variant of primary progressive aphasia, with single word retrieval issues and impaired repetition of words or phrases [17], whereas these abnormalities were specifically denied in her history and not seen on earlier neuropsychological testing.", "section": "METHODS", "tags": [{"name": "neuropsychological", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "abnormalities", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Extensive pre-clinical research with AD-transgenic mice [14] and clinical data that included autopsy-confirmed diagnostic specificity of the protein kinase C (PKC) pathway [15, 16] provided a rationale for an FDA approval for a Phase 2a clinical trial with the highly potent PKC activator, bryostatin.", "section": "INTRO", "tags": [{"name": "autopsy-confirmed", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "AD-transgenic", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Given the continuing decline in cost of next generation sequencing reagents, automation of variant calling methods, and potential diagnostic value susceptibility variants such as APOE\u025b4, whole exome approaches should be considered to be a more comprehensive, cost-effective alternative to candidate gene sequencing for the diagnosis of atypical dementias.", "section": "DISCUSS", "tags": [{"name": "susceptibility", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "comprehensive,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Ridge et al. [12] reported a mean age of onset of cognitive symptoms for persons with PSEN1 variants as 45.5 years of age, whereas patient IV-18 was known to have been only 27, and others in the pedigree are either documented or believed to have had symptoms in their late 20\u200as or very early 30\u200as. Patient IV-18 appeared to know what she wanted to say but could not form her words.", "section": "DISCUSS", "tags": [{"name": "documented", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "cognitive", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Scores of disease processes may ultimately lead to dementia, but there are four major primary disorders with dementia as their main clinical feature: Alzheimer\u2019s disease (AD), frontotemporal lobe degeneration (FTLD), cerebrovascular disease, and dementia with Lewy bodies [1, 2].", "section": "INTRO", "tags": [{"name": "cerebrovascular", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "frontotemporal", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Ridge et al. [12] reported a mean age of onset of cognitive symptoms for persons with PSEN1 variants as 45.5 years of age, whereas patient IV-18 was known to have been only 27, and others in the pedigree are either documented or believed to have had symptoms in their late 20\u200as or very early 30\u200as. Patient IV-18 appeared to know what she wanted to say but could not form her words.", "section": "DISCUSS", "tags": [{"name": "documented", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "cognitive", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Since variants in known causal loci only explain a fraction of early-onset dementias, we performed whole exome sequencing with discrete filtering on two affected family members in order to identify causal variants and make a more accurate diagnosis.", "section": "INTRO", "tags": [{"name": "early-onset", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "dementias,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Further evidence implicating PKC deficits has emerged from clinical studies that showed with autopsy-confirmation that AD patients have significant abnormalities in PKC isozymes and PKC-elicited phosphorylation of downstream substrates [15, 16, 23, 24].", "section": "OTHER", "tags": [{"name": "autopsy-confirmation", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "phosphorylation", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "The latter pathology frequently leads to speech patterns consistent with the logopenic variant of primary progressive aphasia, with single word retrieval issues and impaired repetition of words or phrases [17], whereas these abnormalities were specifically denied in her history and not seen on earlier neuropsychological testing.", "section": "METHODS", "tags": [{"name": "neuropsychological", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "abnormalities", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "The latter pathology frequently leads to speech patterns consistent with the logopenic variant of primary progressive aphasia, with single word retrieval issues and impaired repetition of words or phrases [17], whereas these abnormalities were specifically denied in her history and not seen on earlier neuropsychological testing.", "section": "METHODS", "tags": [{"name": "neuropsychological", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "abnormalities", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Extensive pre-clinical research with AD-transgenic mice [14] and clinical data that included autopsy-confirmed diagnostic specificity of the protein kinase C (PKC) pathway [15, 16] provided a rationale for an FDA approval for a Phase 2a clinical trial with the highly potent PKC activator, bryostatin.", "section": "INTRO", "tags": [{"name": "autopsy-confirmed", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "AD-transgenic", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Given the continuing decline in cost of next generation sequencing reagents, automation of variant calling methods, and potential diagnostic value susceptibility variants such as APOE\u025b4, whole exome approaches should be considered to be a more comprehensive, cost-effective alternative to candidate gene sequencing for the diagnosis of atypical dementias.", "section": "DISCUSS", "tags": [{"name": "susceptibility", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "comprehensive,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Scores of disease processes may ultimately lead to dementia, but there are four major primary disorders with dementia as their main clinical feature: Alzheimer\u2019s disease (AD), frontotemporal lobe degeneration (FTLD), cerebrovascular disease, and dementia with Lewy bodies [1, 2].", "section": "INTRO", "tags": [{"name": "cerebrovascular", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "frontotemporal", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}]}
{"src": "PMC", "id": "PMC4151597", "provider": "OpenTargets", "anns": [{"type": "Gene Disease Relationship", "exact": "The meta-analysis assessed association by using 4 different genetic models: (1) dominant genetic model\u2014the comparison groups were the wild-type homozygous genotype versus the variant allele-positive genotypes (AA + Aa versus aa); (2) recessive genetic model\u2014the comparison groups were the variant homozygous genotype versus the rest (AA versus aa + Aa); (3) homozygous genetic model\u2014comparison was between the 2 homozygous genotypes (AA versus aa); and (4) allele contrast genetic model\u2014the comparison was between the heterozygous and the homozygous wild-type genotype groups (Aa versus aa (where \u201ca\u201d is the wild-type allele and \u201cA\u201d is the variant allele)).", "section": "METHODS", "tags": [{"name": "model\u2014comparison", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "allele-positive", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "As shown in Table 3 and Figure 3, there was no association in these four genotypes (A versus G: OR = 0.99, 95% CI = 0.94\u20131.04, P = 0.69; homozygote comparison (AA versus GG): OR = 1.01, 95% CI = 0.88\u20131.15, P = 0.93; heterozygote comparison (AG versus GG): OR = 0.98, 95% CI = 0.92\u20131.05, P = 0.59; recessive model (AA versus GG + AG): OR = 1.01, 95% CI = 0.89\u20131.15, P = 0.85).", "section": "METHODS", "tags": [{"name": "heterozygote", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "association", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "In breast cancer, several studies have suggested that moderate to high COX-2 expression is related to the genesis of mammary tumors and the expression level is associated with the aggressiveness of breast cancer, including large tumor size, positive axillary lymph node metastases, and HER2-positive tumor status [9\u201311].", "section": "INTRO", "tags": [{"name": "aggressiveness", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "HER2-positive", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "The following criteria were used to select studies for further meta-analysis: (1) case-control studies; (2) studies that evaluated the associations between COX-2 polymorphisms and breast cancer risk; (3) studies that contained at least two comparison groups (cancer versus control); (4) studies that included detailed genotyping data.", "section": "METHODS", "tags": [{"name": "meta-analysis:", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "polymorphisms", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "The meta-analysis assessed association by using 4 different genetic models: (1) dominant genetic model\u2014the comparison groups were the wild-type homozygous genotype versus the variant allele-positive genotypes (AA + Aa versus aa); (2) recessive genetic model\u2014the comparison groups were the variant homozygous genotype versus the rest (AA versus aa + Aa); (3) homozygous genetic model\u2014comparison was between the 2 homozygous genotypes (AA versus aa); and (4) allele contrast genetic model\u2014the comparison was between the heterozygous and the homozygous wild-type genotype groups (Aa versus aa (where \u201ca\u201d is the wild-type allele and \u201cA\u201d is the variant allele)).", "section": "METHODS", "tags": [{"name": "model\u2014comparison", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "allele-positive", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "As shown in Table 3 and Figure 4, there was no significant association in rs5275 polymorphism (homozygote comparison: OR = 1.04, 95% CI = 0.96\u20131.12, P = 0.34; heterozygote comparison: OR = 0.99, 95% CI = 0.95\u20131.04, P = 0.81; dominant model: OR = 1.02, 95% CI = 0.98\u20131.07, P = 0.33, and recessive model: OR = 1.04, 95% CI = 0.97\u20131.12, P = 0.27).", "section": "METHODS", "tags": [{"name": "polymorphism", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "heterozygote", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "As shown in Table 3 and Figure 4, there was no significant association in rs5275 polymorphism (homozygote comparison: OR = 1.04, 95% CI = 0.96\u20131.12, P = 0.34; heterozygote comparison: OR = 0.99, 95% CI = 0.95\u20131.04, P = 0.81; dominant model: OR = 1.02, 95% CI = 0.98\u20131.07, P = 0.33, and recessive model: OR = 1.04, 95% CI = 0.97\u20131.12, P = 0.27).", "section": "METHODS", "tags": [{"name": "polymorphism", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "heterozygote", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "The following criteria were used to select studies for further meta-analysis: (1) case-control studies; (2) studies that evaluated the associations between COX-2 polymorphisms and breast cancer risk; (3) studies that contained at least two comparison groups (cancer versus control); (4) studies that included detailed genotyping data.", "section": "METHODS", "tags": [{"name": "meta-analysis:", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "polymorphisms", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "The following criteria were used to select studies for further meta-analysis: (1) case-control studies; (2) studies that evaluated the associations between COX-2 polymorphisms and breast cancer risk; (3) studies that contained at least two comparison groups (cancer versus control); (4) studies that included detailed genotyping data.", "section": "METHODS", "tags": [{"name": "meta-analysis:", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "polymorphisms", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "As shown in Table 3 and Figure 4, there was no significant association in rs5275 polymorphism (homozygote comparison: OR = 1.04, 95% CI = 0.96\u20131.12, P = 0.34; heterozygote comparison: OR = 0.99, 95% CI = 0.95\u20131.04, P = 0.81; dominant model: OR = 1.02, 95% CI = 0.98\u20131.07, P = 0.33, and recessive model: OR = 1.04, 95% CI = 0.97\u20131.12, P = 0.27).", "section": "METHODS", "tags": [{"name": "polymorphism", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "heterozygote", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "We found no significant association of rs5275 polymorphism with breast cancer risk (homozygote comparison: OR = 1.04, 95% CI = 0.96\u20131.12, P = 0.34; heterozygote comparison: OR = 0.99, 95% CI = 0.95\u20131.04, P = 0.81; dominant model: OR = 1.02, 95% CI = 0.98\u20131.07, P = 0.33, and recessive model: OR = 1.04, 95% CI = 0.97\u20131.12, P = 0.27).", "section": "DISCUSS", "tags": [{"name": "polymorphism", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "heterozygote", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "In breast cancer, several studies have suggested that moderate to high COX-2 expression is related to the genesis of mammary tumors and the expression level is associated with the aggressiveness of breast cancer, including large tumor size, positive axillary lymph node metastases, and HER2-positive tumor status [9\u201311].", "section": "INTRO", "tags": [{"name": "aggressiveness", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "HER2-positive", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}]}
{"src": "PMC", "id": "PMC5810984", "provider": "OpenTargets", "anns": [{"type": "Gene Disease Relationship", "exact": "Cardiomyopathy was defined based on characteristic abnormalities on electrocardiogram (ECG) (atrial fibrillation or flutter, atrioventricular blocks, bradycardia <50 beats per minute, bundle branch blocks, junctional rhythms), and/or cardiac insufficiency based on ejection fraction (EF) by echocardiogram (EF<53% for women, <51% for men).", "section": "METHODS", "tags": [{"name": "electrocardiogram", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "atrioventricular", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Confirmed T. cruzi infection was based on having positive results on 2 different commercial assays for anti-T. cruzi IgG antibodies (Wiener Recombinant 3.0 enzyme linked immunosorbent assay, Rosario, Argentina and Chagas Polychaco indirect hemagglutination test kit, Lemos Laboratories, Santiago del Estero, Argentina).", "section": "METHODS", "tags": [{"name": "hemagglutination", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "immunosorbent", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "The Johns Hopkins Bloomberg School of Public Health Institutional Review Board (IRB) approved this study (entitled \u201cPredictors of Cardiomyopathy Progression in a Chagas Disease Cohort in Bolivia\u201d, IRB No: 00005598) on September 30, 2015 in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki.", "section": "METHODS", "tags": [{"name": "Cardiomyopathy", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "Institutional", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "The HapMap populations include: ASW: African ancestry in Southwest USA; CEU: Utah residents with Northern and Western European ancestry from the CEPH collection; CHB: Han Chinese in Beijing, China; CHD: Chinese in Metropolitan Denver, Colorado; GIH: Gujarati Indians in Houston, Texas; JPT: Japanese in Tokyo, Japan; LWK: Luhya in Webuye, Kenya; MEX: Mexican ancestry in Los Angeles, California; MKK: Maasai in Kinyawa, Kenya; TSI: Tuscans in Italy; YRI: Yoruba in Ibadan, Nigeria.", "section": "METHODS", "tags": [{"name": "Metropolitan", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "populations", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "A total of 38 T. cruzi-infected cases (male n = 19, mean/median age: 62/65; female n = 19, mean/median age: 55/58) with a clinical cardiomyopathy diagnosis and 24 asymptomatic T. cruzi-infected controls (male n = 12, mean/median age: 56/56; female n = 12, mean/median age: 53/55) were selected as a stratified sample from the parent study, frequency-matched by age and sex.", "section": "METHODS", "tags": [{"name": "frequency-matched", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "cruzi-infected", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "The Johns Hopkins Bloomberg School of Public Health Institutional Review Board (IRB) approved this study (entitled \u201cPredictors of Cardiomyopathy Progression in a Chagas Disease Cohort in Bolivia\u201d, IRB No: 00005598) on September 30, 2015 in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki.", "section": "METHODS", "tags": [{"name": "Cardiomyopathy", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "Institutional", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "The Johns Hopkins Bloomberg School of Public Health Institutional Review Board (IRB) approved this study (entitled \u201cPredictors of Cardiomyopathy Progression in a Chagas Disease Cohort in Bolivia\u201d, IRB No: 00005598) on September 30, 2015 in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki.", "section": "METHODS", "tags": [{"name": "Cardiomyopathy", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "Institutional", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Cardiomyopathy was defined based on characteristic abnormalities on electrocardiogram (ECG) (atrial fibrillation or flutter, atrioventricular blocks, bradycardia <50 beats per minute, bundle branch blocks, junctional rhythms), and/or cardiac insufficiency based on ejection fraction (EF) by echocardiogram (EF<53% for women, <51% for men).", "section": "METHODS", "tags": [{"name": "electrocardiogram", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "atrioventricular", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "A total of 38 T. cruzi-infected cases (male n = 19, mean/median age: 62/65; female n = 19, mean/median age: 55/58) with a clinical cardiomyopathy diagnosis and 24 asymptomatic T. cruzi-infected controls (male n = 12, mean/median age: 56/56; female n = 12, mean/median age: 53/55) were selected as a stratified sample from the parent study, frequency-matched by age and sex.", "section": "METHODS", "tags": [{"name": "frequency-matched", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "cruzi-infected", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Confirmed T. cruzi infection was based on having positive results on 2 different commercial assays for anti-T. cruzi IgG antibodies (Wiener Recombinant 3.0 enzyme linked immunosorbent assay, Rosario, Argentina and Chagas Polychaco indirect hemagglutination test kit, Lemos Laboratories, Santiago del Estero, Argentina).", "section": "METHODS", "tags": [{"name": "hemagglutination", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "immunosorbent", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "The HapMap populations include: ASW: African ancestry in Southwest USA; CEU: Utah residents with Northern and Western European ancestry from the CEPH collection; CHB: Han Chinese in Beijing, China; CHD: Chinese in Metropolitan Denver, Colorado; GIH: Gujarati Indians in Houston, Texas; JPT: Japanese in Tokyo, Japan; LWK: Luhya in Webuye, Kenya; MEX: Mexican ancestry in Los Angeles, California; MKK: Maasai in Kinyawa, Kenya; TSI: Tuscans in Italy; YRI: Yoruba in Ibadan, Nigeria.", "section": "METHODS", "tags": [{"name": "Metropolitan", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "populations", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "The HapMap populations include: ASW: African ancestry in Southwest USA; CEU: Utah residents with Northern and Western European ancestry from the CEPH collection; CHB: Han Chinese in Beijing, China; CHD: Chinese in Metropolitan Denver, Colorado; GIH: Gujarati Indians in Houston, Texas; JPT: Japanese in Tokyo, Japan; LWK: Luhya in Webuye, Kenya; MEX: Mexican ancestry in Los Angeles, California; MKK: Maasai in Kinyawa, Kenya; TSI: Tuscans in Italy; YRI: Yoruba in Ibadan, Nigeria.", "section": "METHODS", "tags": [{"name": "Metropolitan", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "populations", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Cardiomyopathy was defined based on characteristic abnormalities on electrocardiogram (ECG) (atrial fibrillation or flutter, atrioventricular blocks, bradycardia <50 beats per minute, bundle branch blocks, junctional rhythms), and/or cardiac insufficiency based on ejection fraction (EF) by echocardiogram (EF<53% for women, <51% for men).", "section": "METHODS", "tags": [{"name": "electrocardiogram", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "atrioventricular", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "A total of 38 T. cruzi-infected cases (male n = 19, mean/median age: 62/65; female n = 19, mean/median age: 55/58) with a clinical cardiomyopathy diagnosis and 24 asymptomatic T. cruzi-infected controls (male n = 12, mean/median age: 56/56; female n = 12, mean/median age: 53/55) were selected as a stratified sample from the parent study, frequency-matched by age and sex.", "section": "METHODS", "tags": [{"name": "frequency-matched", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "cruzi-infected", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "A total of 38 T. cruzi-infected cases (male n = 19, mean/median age: 62/65; female n = 19, mean/median age: 55/58) with a clinical cardiomyopathy diagnosis and 24 asymptomatic T. cruzi-infected controls (male n = 12, mean/median age: 56/56; female n = 12, mean/median age: 53/55) were selected as a stratified sample from the parent study, frequency-matched by age and sex.", "section": "METHODS", "tags": [{"name": "frequency-matched", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "cruzi-infected", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "The HapMap populations include: ASW: African ancestry in Southwest USA; CEU: Utah residents with Northern and Western European ancestry from the CEPH collection; CHB: Han Chinese in Beijing, China; CHD: Chinese in Metropolitan Denver, Colorado; GIH: Gujarati Indians in Houston, Texas; JPT: Japanese in Tokyo, Japan; LWK: Luhya in Webuye, Kenya; MEX: Mexican ancestry in Los Angeles, California; MKK: Maasai in Kinyawa, Kenya; TSI: Tuscans in Italy; YRI: Yoruba in Ibadan, Nigeria.", "section": "METHODS", "tags": [{"name": "Metropolitan", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "populations", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Confirmed T. cruzi infection was based on having positive results on 2 different commercial assays for anti-T. cruzi IgG antibodies (Wiener Recombinant 3.0 enzyme linked immunosorbent assay, Rosario, Argentina and Chagas Polychaco indirect hemagglutination test kit, Lemos Laboratories, Santiago del Estero, Argentina).", "section": "METHODS", "tags": [{"name": "hemagglutination", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "immunosorbent", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "A total of 38 T. cruzi-infected cases (male n = 19, mean/median age: 62/65; female n = 19, mean/median age: 55/58) with a clinical cardiomyopathy diagnosis and 24 asymptomatic T. cruzi-infected controls (male n = 12, mean/median age: 56/56; female n = 12, mean/median age: 53/55) were selected as a stratified sample from the parent study, frequency-matched by age and sex.", "section": "METHODS", "tags": [{"name": "frequency-matched", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "cruzi-infected", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Confirmed T. cruzi infection was based on having positive results on 2 different commercial assays for anti-T. cruzi IgG antibodies (Wiener Recombinant 3.0 enzyme linked immunosorbent assay, Rosario, Argentina and Chagas Polychaco indirect hemagglutination test kit, Lemos Laboratories, Santiago del Estero, Argentina).", "section": "METHODS", "tags": [{"name": "hemagglutination", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "immunosorbent", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "The HapMap populations include: ASW: African ancestry in Southwest USA; CEU: Utah residents with Northern and Western European ancestry from the CEPH collection; CHB: Han Chinese in Beijing, China; CHD: Chinese in Metropolitan Denver, Colorado; GIH: Gujarati Indians in Houston, Texas; JPT: Japanese in Tokyo, Japan; LWK: Luhya in Webuye, Kenya; MEX: Mexican ancestry in Los Angeles, California; MKK: Maasai in Kinyawa, Kenya; TSI: Tuscans in Italy; YRI: Yoruba in Ibadan, Nigeria.", "section": "METHODS", "tags": [{"name": "Metropolitan", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "populations", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "The Johns Hopkins Bloomberg School of Public Health Institutional Review Board (IRB) approved this study (entitled \u201cPredictors of Cardiomyopathy Progression in a Chagas Disease Cohort in Bolivia\u201d, IRB No: 00005598) on September 30, 2015 in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki.", "section": "METHODS", "tags": [{"name": "Cardiomyopathy", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "Institutional", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Cardiomyopathy was defined based on characteristic abnormalities on electrocardiogram (ECG) (atrial fibrillation or flutter, atrioventricular blocks, bradycardia <50 beats per minute, bundle branch blocks, junctional rhythms), and/or cardiac insufficiency based on ejection fraction (EF) by echocardiogram (EF<53% for women, <51% for men).", "section": "METHODS", "tags": [{"name": "electrocardiogram", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "atrioventricular", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Cardiomyopathy was defined based on characteristic abnormalities on electrocardiogram (ECG) (atrial fibrillation or flutter, atrioventricular blocks, bradycardia <50 beats per minute, bundle branch blocks, junctional rhythms), and/or cardiac insufficiency based on ejection fraction (EF) by echocardiogram (EF<53% for women, <51% for men).", "section": "METHODS", "tags": [{"name": "electrocardiogram", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "atrioventricular", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}]}
{"src": "PMC", "id": "PMC5671944", "provider": "OpenTargets", "anns": [{"type": "Gene Disease Relationship", "exact": "We demonstrated previously that BIM-induction by FOXO3 triggers a biphasic ROS-accumulation, which critically regulates cell death-induction by FOXO3-activation and/or by addition of DNA-damaging agents in NB.3, 31 The primary ROS-wave is detected after 12\u2009h post FOXO3-activation, the second, much more pronounced ROS-wave reaches a climax between 36 and 48\u2009h after FOXO3-activation in NB15/FOXO3 cells.3 We therefore investigated, whether FOXO3-resistant NB4/FOXO3 and NB8/FOXO3 cells show comparable ROS-accumulation or whether this ROS-burst is absent in the resistant cell lines.", "section": "RESULTS", "tags": [{"name": "ROS-accumulation,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "FOXO3-activation,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "We demonstrated previously that BIM-induction by FOXO3 triggers a biphasic ROS-accumulation, which critically regulates cell death-induction by FOXO3-activation and/or by addition of DNA-damaging agents in NB.3, 31 The primary ROS-wave is detected after 12\u2009h post FOXO3-activation, the second, much more pronounced ROS-wave reaches a climax between 36 and 48\u2009h after FOXO3-activation in NB15/FOXO3 cells.3 We therefore investigated, whether FOXO3-resistant NB4/FOXO3 and NB8/FOXO3 cells show comparable ROS-accumulation or whether this ROS-burst is absent in the resistant cell lines.", "section": "RESULTS", "tags": [{"name": "ROS-accumulation,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "FOXO3-activation,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "The retroviral vectors pLIB-MCS2-iresNeo and pLIB-FOXO3(A3)-ERtm-iresNeo have been described.5 The lentivirus-vector coding for FOXO3-specific shRNA (pLKO-shFOXO3-91617-puro) and SESN3-specific shRNA (pLKO-shSESN3-141228-puro and pLKO-shSESN3-143446-puro) and the control-vector pLKO.1 were described.3 The lentivirus-vectors coding for TP53-specific shRNA pLKO-shTP53-puro, pLKO-shTP53-941-puro and pLKO-shTP53-427-puro were provided by T. Waldmann,52 the pGL3-Bim-promoter was provided by A. Villunger.53 The vector pLIB-EYFP-TP53mut-puro was generated by amplification of mutant-TP53 from NB15 cDNA (p53-fwd: 5\u2032-GAATTCATGGATGATTTGATGC-3\u2032 p53-rev: 5\u2032-GGATCCTCAGTCTGAGTCAG)-3\u2032 and inserted into the EcoR1- and BamH1-site of pLIB-EYFP-Mcl1JAM-iresPuro54 replacing MCL1JAM by the TP53-mutant and generating pLIB-EYFP-p53m-iresPuro.", "section": "OTHER", "tags": [{"name": "5\u2032-GAATTCATGGATGATTTGATGC-3\u2032", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "pLIB-EYFP-Mcl1JAM-iresPuro54", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Hyper-activation of the phosphatidylinositol3-kinase/PKB signaling pathway frequently observed in NB is associated with FOXO3-inactivation and its re-localization into the cytoplasm.4, 5, 11, 12, 13 However, in high-stage-derived NB cell lines FOXO3 partly localizes to the nucleus despite high PKB-activity and regulates the response to hypoxia within these cells (Figure 1).14 Activation by etoposide-treatment further increases the amount of nuclear FOXO3 (Figure 1c) suggesting that shuttling and oxidative stress response regulation of FOXO3 is still intact within these cells.", "section": "DISCUSS", "tags": [{"name": "phosphatidylinositol3-kinase/PKB", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "etoposide-treatment", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "The retroviral vectors pLIB-MCS2-iresNeo and pLIB-FOXO3(A3)-ERtm-iresNeo have been described.5 The lentivirus-vector coding for FOXO3-specific shRNA (pLKO-shFOXO3-91617-puro) and SESN3-specific shRNA (pLKO-shSESN3-141228-puro and pLKO-shSESN3-143446-puro) and the control-vector pLKO.1 were described.3 The lentivirus-vectors coding for TP53-specific shRNA pLKO-shTP53-puro, pLKO-shTP53-941-puro and pLKO-shTP53-427-puro were provided by T. Waldmann,52 the pGL3-Bim-promoter was provided by A. Villunger.53 The vector pLIB-EYFP-TP53mut-puro was generated by amplification of mutant-TP53 from NB15 cDNA (p53-fwd: 5\u2032-GAATTCATGGATGATTTGATGC-3\u2032 p53-rev: 5\u2032-GGATCCTCAGTCTGAGTCAG)-3\u2032 and inserted into the EcoR1- and BamH1-site of pLIB-EYFP-Mcl1JAM-iresPuro54 replacing MCL1JAM by the TP53-mutant and generating pLIB-EYFP-p53m-iresPuro.", "section": "OTHER", "tags": [{"name": "5\u2032-GAATTCATGGATGATTTGATGC-3\u2032", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "pLIB-EYFP-Mcl1JAM-iresPuro54", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "The retroviral vectors pLIB-MCS2-iresNeo and pLIB-FOXO3(A3)-ERtm-iresNeo have been described.5 The lentivirus-vector coding for FOXO3-specific shRNA (pLKO-shFOXO3-91617-puro) and SESN3-specific shRNA (pLKO-shSESN3-141228-puro and pLKO-shSESN3-143446-puro) and the control-vector pLKO.1 were described.3 The lentivirus-vectors coding for TP53-specific shRNA pLKO-shTP53-puro, pLKO-shTP53-941-puro and pLKO-shTP53-427-puro were provided by T. Waldmann,52 the pGL3-Bim-promoter was provided by A. Villunger.53 The vector pLIB-EYFP-TP53mut-puro was generated by amplification of mutant-TP53 from NB15 cDNA (p53-fwd: 5\u2032-GAATTCATGGATGATTTGATGC-3\u2032 p53-rev: 5\u2032-GGATCCTCAGTCTGAGTCAG)-3\u2032 and inserted into the EcoR1- and BamH1-site of pLIB-EYFP-Mcl1JAM-iresPuro54 replacing MCL1JAM by the TP53-mutant and generating pLIB-EYFP-p53m-iresPuro.", "section": "OTHER", "tags": [{"name": "5\u2032-GAATTCATGGATGATTTGATGC-3\u2032", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "pLIB-EYFP-Mcl1JAM-iresPuro54", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "The mammalian forkhead box O (FOXO) transcription factor family consists of four members, FOXO1/FKHR, FOXO3/FKHRL1, FOXO4/AFX and FOXO6, which are involved in multiple cellular processes ranging from apoptosis induction to longevity.1 FOXO3-mediated cell death in neuroblastoma (NB), an aggressive childhood tumor that develops form precursor cells of the neural crest during embryogenesis,2 has been associated with induction of the pro-apoptotic BH3-only proteins B-cell-lymphoma-gene-2-like-11 (BCL2L11/BIM), phorbol-12-myristate-13-acetate-induced-protein-1 (PMAIP1/NOXA) and repression of pro-survival BCL2-like-1 (BCL2L1/BCLXL) and the baculoviral-inhibitor-of-apoptosis-repeat-containing-5 (BIRC5/survivin) and is modulated by the ROS-regulating chromosome-10-open-reading-frame-10-protein (C10ORF10/DEPP).3, 4, 5, 6, 7 FOXO3-activity is mainly regulated by post-translational modifications (reviewed in Ausserlechner et al.8 and Hagenbuchner and Ausserlechner9), resulting in changes of its cellular localization or affecting its binding to DNA or proteins.", "section": "INTRO", "tags": [{"name": "baculoviral-inhibitor-of-apoptosis-repeat-containing-5", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "phorbol-12-myristate-13-acetate-induced-protein-1", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Hyper-activation of the phosphatidylinositol3-kinase/PKB signaling pathway frequently observed in NB is associated with FOXO3-inactivation and its re-localization into the cytoplasm.4, 5, 11, 12, 13 However, in high-stage-derived NB cell lines FOXO3 partly localizes to the nucleus despite high PKB-activity and regulates the response to hypoxia within these cells (Figure 1).14 Activation by etoposide-treatment further increases the amount of nuclear FOXO3 (Figure 1c) suggesting that shuttling and oxidative stress response regulation of FOXO3 is still intact within these cells.", "section": "DISCUSS", "tags": [{"name": "phosphatidylinositol3-kinase/PKB", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "etoposide-treatment", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "In NB, FOXO3-induced cell death depends on the induction of the pro-apoptotic BH3-only proteins BIM and NOXA, the repression of the pro-survival BCL2-protein BCLXL and the inhibitor-of-apoptosis-protein survivin.3, 4, 5 Expression analysis of these proteins in FOXO3-resistant NB4/FOXO3 and NB8/FOXO3 and FOXO3-sensitive NB15/FOXO3 cells as well as in their corresponding controls revealed that in NB15/FOXO3 cells BIM and NOXA strongly increased5 on protein- and mRNA-level, and BCLXL and survivin were repressed (Figures 2a and b and Supplementary Figure S3).", "section": "RESULTS", "tags": [{"name": "inhibitor-of-apoptosis-protein", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "FOXO3-resistant", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}]}
{"src": "PMC", "id": "PMC4902368", "provider": "OpenTargets", "anns": [{"type": "Gene Disease Relationship", "exact": "The rs7421861 CT genotype was significantly associated with the risk of colorectal cancer compared to the wild-type TT genotype.41 However, rs7421861 was found to have no association with gastric cardia adenocarcinoma.35 In the present study, there was also no significant association between the rs7421861 polymorphism and breast cancer risk in any of the genetic models.", "section": "DISCUSS", "tags": [{"name": "adenocarcinoma.35", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "significantly", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "In a subgroup of thymic T-lymphocytes, PD-1 is produced in a way of constitutively expression, with up-regulated expression found in activated T-cells, B-cells, and myeloid cells.9,10 Through interactions between PD-1 and its ligands PD-L1 (B7-H1; CD274) or PD-L2 (B7-DC; CD273), PD-1 strongly inhibits the proliferation of CD4 and CD8 T lymphocytes and their cytokine production.11\u201313 Previous studies have emphasized the significant role of PD-1 in human disease.", "section": "INTRO", "tags": [{"name": "production.11\u201313", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "T-lymphocytes,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "The genetic variation in rs2227982 may result in an amino acid substitution from alanine to valine, which could lead to a different structure and different function for PD-1 and further influence the progression of different diseases.39,40 Therefore, whether this amino acid change alters the protein structure or affects its function needs to be further studied.", "section": "DISCUSS", "tags": [{"name": "diseases.39,40", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "substitution", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Data outlining the clinicopathological characteristics of the patients, including tumor size, clinical stages, lymph node involvement, menopausal status, procreative times, estrogenic receptor (ER) status, progesterone receptor (PR) status, and human epidermal growth factor receptor type 2 (Her-2) status, were obtained from the patients\u2019 medical records (Table 1).", "section": "METHODS", "tags": [{"name": "clinicopathological", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "characteristics", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Previous studies have shown that blocking the PD-1/PD-L1 pathway can result in an efficient antitumor T-cell response and better control of tumor growth.24 Immunotherapy clinical trials using antibody-mediated PD-1 blockade as a strategy are in progress in patients with various cancers.25,26 Patients suffering from melanoma, renal cell carcinoma, or nonsmall cell lung cancer, showed objective responses (responses rates, 6\u201328%), with intravenous injection of these antibodies.", "section": "INTRO", "tags": [{"name": "antibody-mediated", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "Immunotherapy", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "The rs7421861 CT genotype was significantly associated with the risk of colorectal cancer compared to the wild-type TT genotype.41 However, rs7421861 was found to have no association with gastric cardia adenocarcinoma.35 In the present study, there was also no significant association between the rs7421861 polymorphism and breast cancer risk in any of the genetic models.", "section": "DISCUSS", "tags": [{"name": "adenocarcinoma.35", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "significantly", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "The genetic variation in rs2227982 may result in an amino acid substitution from alanine to valine, which could lead to a different structure and different function for PD-1 and further influence the progression of different diseases.39,40 Therefore, whether this amino acid change alters the protein structure or affects its function needs to be further studied.", "section": "DISCUSS", "tags": [{"name": "diseases.39,40", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "substitution", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Data outlining the clinicopathological characteristics of the patients, including tumor size, clinical stages, lymph node involvement, menopausal status, procreative times, estrogenic receptor (ER) status, progesterone receptor (PR) status, and human epidermal growth factor receptor type 2 (Her-2) status, were obtained from the patients\u2019 medical records (Table 1).", "section": "METHODS", "tags": [{"name": "clinicopathological", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "characteristics", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "These results conflict with studies in hepatocellular carcinoma29 and esophageal cancer.30 These studies also found that the G allele of this SNP was likely to be associated with the decreased risk of hepatocellular carcinoma and esophageal squamous cell carcinoma, suggesting that the PD-1 rs10204525 G allele may be related to the increase in T-cell activity.", "section": "DISCUSS", "tags": [{"name": "hepatocellular", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "hepatocellular", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Data outlining the clinicopathological characteristics of the patients, including tumor size, clinical stages, lymph node involvement, menopausal status, procreative times, estrogenic receptor (ER) status, progesterone receptor (PR) status, and human epidermal growth factor receptor type 2 (Her-2) status, were obtained from the patients\u2019 medical records (Table 1).", "section": "METHODS", "tags": [{"name": "clinicopathological", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "characteristics", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Previous studies have shown that blocking the PD-1/PD-L1 pathway can result in an efficient antitumor T-cell response and better control of tumor growth.24 Immunotherapy clinical trials using antibody-mediated PD-1 blockade as a strategy are in progress in patients with various cancers.25,26 Patients suffering from melanoma, renal cell carcinoma, or nonsmall cell lung cancer, showed objective responses (responses rates, 6\u201328%), with intravenous injection of these antibodies.", "section": "INTRO", "tags": [{"name": "antibody-mediated", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "Immunotherapy", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "The Sequenom MassARRAY Assay Design 3.0 software was used to design the Multiplexed SNP MassEXTEND assay.33 Single nucleotide polymorphism (SNP) genotyping was performed by using the Sequenom MassARRAY RS1000 according to the standard protocol recommended by the manufacturer.34 The corresponding primers used for each SNP in the present study are listed in Table 2.", "section": "METHODS", "tags": [{"name": "manufacturer.34", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "corresponding", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Genetic mutations and environmental factors play an important role in the development and progression of breast cancer.3 The APE1 656 T>G polymorphism is reported to have a protective effect against breast cancer.4 In Caucasians, the CC homozygote of rs1800872 polymorphism in IL-10 gene has a 25% decreased risk of breast cancer compared to patients with the AA and AC genotypes.5 An increasing number of studies have shown that the immune system plays an important role in resisting and eliminating cancer cells, and can influence the occurrence of breast cancer.6,7 T cells have been shown to play the major role in the antitumor immune response.8", "section": "INTRO", "tags": [{"name": "environmental", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "polymorphism", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "The Sequenom MassARRAY Assay Design 3.0 software was used to design the Multiplexed SNP MassEXTEND assay.33 Single nucleotide polymorphism (SNP) genotyping was performed by using the Sequenom MassARRAY RS1000 according to the standard protocol recommended by the manufacturer.34 The corresponding primers used for each SNP in the present study are listed in Table 2.", "section": "METHODS", "tags": [{"name": "manufacturer.34", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "corresponding", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "In a subgroup of thymic T-lymphocytes, PD-1 is produced in a way of constitutively expression, with up-regulated expression found in activated T-cells, B-cells, and myeloid cells.9,10 Through interactions between PD-1 and its ligands PD-L1 (B7-H1; CD274) or PD-L2 (B7-DC; CD273), PD-1 strongly inhibits the proliferation of CD4 and CD8 T lymphocytes and their cytokine production.11\u201313 Previous studies have emphasized the significant role of PD-1 in human disease.", "section": "INTRO", "tags": [{"name": "production.11\u201313", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "T-lymphocytes,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Data outlining the clinicopathological characteristics of the patients, including tumor size, clinical stages, lymph node involvement, menopausal status, procreative times, estrogenic receptor (ER) status, progesterone receptor (PR) status, and human epidermal growth factor receptor type 2 (Her-2) status, were obtained from the patients\u2019 medical records (Table 1).", "section": "METHODS", "tags": [{"name": "clinicopathological", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "characteristics", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Previous studies have shown that blocking the PD-1/PD-L1 pathway can result in an efficient antitumor T-cell response and better control of tumor growth.24 Immunotherapy clinical trials using antibody-mediated PD-1 blockade as a strategy are in progress in patients with various cancers.25,26 Patients suffering from melanoma, renal cell carcinoma, or nonsmall cell lung cancer, showed objective responses (responses rates, 6\u201328%), with intravenous injection of these antibodies.", "section": "INTRO", "tags": [{"name": "antibody-mediated", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "Immunotherapy", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "These results conflict with studies in hepatocellular carcinoma29 and esophageal cancer.30 These studies also found that the G allele of this SNP was likely to be associated with the decreased risk of hepatocellular carcinoma and esophageal squamous cell carcinoma, suggesting that the PD-1 rs10204525 G allele may be related to the increase in T-cell activity.", "section": "DISCUSS", "tags": [{"name": "hepatocellular", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "hepatocellular", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "The rs7421861 CT genotype was significantly associated with the risk of colorectal cancer compared to the wild-type TT genotype.41 However, rs7421861 was found to have no association with gastric cardia adenocarcinoma.35 In the present study, there was also no significant association between the rs7421861 polymorphism and breast cancer risk in any of the genetic models.", "section": "DISCUSS", "tags": [{"name": "adenocarcinoma.35", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "significantly", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Genetic mutations and environmental factors play an important role in the development and progression of breast cancer.3 The APE1 656 T>G polymorphism is reported to have a protective effect against breast cancer.4 In Caucasians, the CC homozygote of rs1800872 polymorphism in IL-10 gene has a 25% decreased risk of breast cancer compared to patients with the AA and AC genotypes.5 An increasing number of studies have shown that the immune system plays an important role in resisting and eliminating cancer cells, and can influence the occurrence of breast cancer.6,7 T cells have been shown to play the major role in the antitumor immune response.8", "section": "INTRO", "tags": [{"name": "environmental", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "polymorphism", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "In a subgroup of thymic T-lymphocytes, PD-1 is produced in a way of constitutively expression, with up-regulated expression found in activated T-cells, B-cells, and myeloid cells.9,10 Through interactions between PD-1 and its ligands PD-L1 (B7-H1; CD274) or PD-L2 (B7-DC; CD273), PD-1 strongly inhibits the proliferation of CD4 and CD8 T lymphocytes and their cytokine production.11\u201313 Previous studies have emphasized the significant role of PD-1 in human disease.", "section": "INTRO", "tags": [{"name": "production.11\u201313", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "T-lymphocytes,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}]}
{"src": "PMC", "id": "PMC4766352", "provider": "OpenTargets", "anns": [{"type": "Gene Disease Relationship", "exact": "After washing, membranes were reblocked and incubated for 2\u2009h at room temperature in the presence of horseradish peroxidase-linked donkey anti-rabbit IgG antibody (1\u2009:\u200910,000; GE Healthcare, Little Chalfont, UK) and developed using the SuperSignal West Dura Extended Duration Substrate (Thermo Scientific, Waltham, MA, USA).", "section": "METHODS", "tags": [{"name": "peroxidase-linked", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "temperature", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Forty-eight hours after transfection, HeLa cells in the 6-well plates were washed twice with phosphate-buffered saline (PBS) and scraped into 200\u2009\u03bcL/well of lysis buffer [150\u2009mM NaCl, 50\u2009mM Tris-HCl (pH 7.5), 1% NP40, 0.25% sodium deoxycholate, and 1\u2009mM EDTA with one tablet of protease inhibitor cocktail tablet (Complete Mini, Roche) per 10\u2009mL], sonicated for 2-3\u2009s, and then centrifuged.", "section": "METHODS", "tags": [{"name": "phosphate-buffered", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "transfection,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "PCR products were purified on spin columns (Watson Biotechnologies Inc., Shanghai, China) and directly sequenced by the PCR or sequencing primers described above using the BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems) performed on a 3730 DNA analyzer according to the manufacturer's manual.", "section": "METHODS", "tags": [{"name": "Biotechnologies", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "manufacturer's", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "PCR products were purified on spin columns (Watson Biotechnologies Inc., Shanghai, China) and directly sequenced by the PCR or sequencing primers described above using the BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems) performed on a 3730 DNA analyzer according to the manufacturer's manual.", "section": "METHODS", "tags": [{"name": "Biotechnologies", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "manufacturer's", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Although p.I27L and p.S487N have been identified as polymorphisms that might not be associated with DM by some researchers [36], our evolutionary conservation analysis and protein tertiary structure predictions indicate that these two missense mutations, especially p.I27L, still might play role in the development of DM in the family examined in our study.", "section": "DISCUSS", "tags": [{"name": "polymorphisms", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "evolutionary", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "After washing, membranes were reblocked and incubated for 2\u2009h at room temperature in the presence of horseradish peroxidase-linked donkey anti-rabbit IgG antibody (1\u2009:\u200910,000; GE Healthcare, Little Chalfont, UK) and developed using the SuperSignal West Dura Extended Duration Substrate (Thermo Scientific, Waltham, MA, USA).", "section": "METHODS", "tags": [{"name": "peroxidase-linked", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "temperature", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Forty-eight hours after transfection, HeLa cells in the 6-well plates were washed twice with phosphate-buffered saline (PBS) and scraped into 200\u2009\u03bcL/well of lysis buffer [150\u2009mM NaCl, 50\u2009mM Tris-HCl (pH 7.5), 1% NP40, 0.25% sodium deoxycholate, and 1\u2009mM EDTA with one tablet of protease inhibitor cocktail tablet (Complete Mini, Roche) per 10\u2009mL], sonicated for 2-3\u2009s, and then centrifuged.", "section": "METHODS", "tags": [{"name": "phosphate-buffered", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "transfection,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Interestingly, threonine (T130) residue is located within two putative protein kinase C phosphorylation sites (PKC phosphorylation sites, 129\u2013131: STR and 130\u2013132: TRR), while the isoleucine (I130) mutation would only allow one of these PKC phosphorylation sites (129\u2013131: SIR) to be retained.", "section": "DISCUSS", "tags": [{"name": "phosphorylation", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "phosphorylation", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "An evolutionary conservation analysis revealed that mutations p.T130I in HNF4A and p.S487N in HNF1A occur at highly conserved positions in the protein sequences and do not involve similar amino acids, while mutation p.I27L in HNF1A is a conservative change at a relatively conserved isoleucine (Figure 4).", "section": "OTHER", "tags": [{"name": "evolutionary", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "conservation", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Although p.I27L and p.S487N have been identified as polymorphisms that might not be associated with DM by some researchers [36], our evolutionary conservation analysis and protein tertiary structure predictions indicate that these two missense mutations, especially p.I27L, still might play role in the development of DM in the family examined in our study.", "section": "DISCUSS", "tags": [{"name": "polymorphisms", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "evolutionary", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Interestingly, threonine (T130) residue is located within two putative protein kinase C phosphorylation sites (PKC phosphorylation sites, 129\u2013131: STR and 130\u2013132: TRR), while the isoleucine (I130) mutation would only allow one of these PKC phosphorylation sites (129\u2013131: SIR) to be retained.", "section": "DISCUSS", "tags": [{"name": "phosphorylation", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "phosphorylation", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Forty-eight hours after transfection, HeLa cells in the 6-well plates were washed twice with phosphate-buffered saline (PBS) and scraped into 200\u2009\u03bcL/well of lysis buffer [150\u2009mM NaCl, 50\u2009mM Tris-HCl (pH 7.5), 1% NP40, 0.25% sodium deoxycholate, and 1\u2009mM EDTA with one tablet of protease inhibitor cocktail tablet (Complete Mini, Roche) per 10\u2009mL], sonicated for 2-3\u2009s, and then centrifuged.", "section": "METHODS", "tags": [{"name": "phosphate-buffered", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "transfection,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "After washing, membranes were reblocked and incubated for 2\u2009h at room temperature in the presence of horseradish peroxidase-linked donkey anti-rabbit IgG antibody (1\u2009:\u200910,000; GE Healthcare, Little Chalfont, UK) and developed using the SuperSignal West Dura Extended Duration Substrate (Thermo Scientific, Waltham, MA, USA).", "section": "METHODS", "tags": [{"name": "peroxidase-linked", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "temperature", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Forty-eight hours after transfection, HeLa cells in the 6-well plates were washed twice with phosphate-buffered saline (PBS) and scraped into 200\u2009\u03bcL/well of lysis buffer [150\u2009mM NaCl, 50\u2009mM Tris-HCl (pH 7.5), 1% NP40, 0.25% sodium deoxycholate, and 1\u2009mM EDTA with one tablet of protease inhibitor cocktail tablet (Complete Mini, Roche) per 10\u2009mL], sonicated for 2-3\u2009s, and then centrifuged.", "section": "METHODS", "tags": [{"name": "phosphate-buffered", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "transfection,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "After washing, membranes were reblocked and incubated for 2\u2009h at room temperature in the presence of horseradish peroxidase-linked donkey anti-rabbit IgG antibody (1\u2009:\u200910,000; GE Healthcare, Little Chalfont, UK) and developed using the SuperSignal West Dura Extended Duration Substrate (Thermo Scientific, Waltham, MA, USA).", "section": "METHODS", "tags": [{"name": "peroxidase-linked", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "temperature", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}]}
{"src": "PMC", "id": "PMC4735314", "provider": "OpenTargets", "anns": [{"type": "Gene Disease Relationship", "exact": "Recent observations have suggested that improvement of diet by whole grain supplement may induce concurrent intestinal microbiota changes, decreased IL-6 levels and associate with changes indicating improvement of metabolic function.42 These results suggest a role for IL-6 in systemic responses caused by dietary changes and their associated changes in the commensal mucosal flora.", "section": "DISCUSS", "tags": [{"name": "observations", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "improvement", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "H. pylori infection and peptic ulcers have been associated with increased IL-6 expression18\n36 and high IL-6 serum levels have been associated with low HDL serum levels.37 IL-6 has been documented to reduce the activity of lipoprotein lipase38 and decreased lipoprotein lipase activity has been associated with a decrease in HDL,39 which offers a possible mechanism for the interaction between IL-6 and HDL.", "section": "DISCUSS", "tags": [{"name": "expression18", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "lipoprotein", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "We also did not have data on the use of statin medication, but statin use was not common in Finland during the study period.35 Since there are no clear reasons, why the use of statins would be enriched in H. pylori negative patients, who had higher HDL levels, it is unlikely that the use of statin medication confounds our results.", "section": "DISCUSS", "tags": [{"name": "medication,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "medication", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "On the basis of the sample size and the specified significance and power levels, we conclude that the association of H. pylori infection on the HDL serum level is notable in the IL-6 -174 CC genotype patients, but in the other genotypes, especially in the GG genotype, the association is smaller and possibly clinically insignificant.", "section": "DISCUSS", "tags": [{"name": "insignificant.", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "significance", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "The cut-off point of <1.00\u2005mmol/L for low HDL was chosen because it is a common cut-off point in Finnish guidelines.32 The patients\u2019 DNA was extracted from blood leucocytes as previously described.29 The restriction fragment length polymorphism method with an NlaIII restriction enzyme using previously published primers20 was used to detect the IL-6 -174 gene polymorphisms from the DNA samples.", "section": "METHODS", "tags": [{"name": "guidelines.32", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "polymorphisms", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "On the basis of our current findings, which indicate that the IL-6 -174 polymorphism modifies systemic effects induced by changes in the composition of gastric bacteria, we suggest that IL-6 polymorphisms should be investigated as a possible mechanism explaining associations between intestinal microbiome and the cardiovascular disease risk factors.", "section": "DISCUSS", "tags": [{"name": "cardiovascular", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "polymorphisms", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Previous studies have shown that exercise lowers IL-6 serum levels only in IL-6 -174 C allele carriers.23 Similarly, exercise and lifestyle interventions have been documented to increase HDL levels significantly more in the IL-6 -174 C allele carriers than in the G allele carriers.25\n26 In line with these studies, our results suggest that the HDL levels are more prone to decrease by H. pylori infection in the IL-6 -174 C carriers than in the other genotypes.", "section": "DISCUSS", "tags": [{"name": "interventions", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "significantly", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "H. pylori infection causes a varied cytokine response including the release of interleukin 6.18 High IL-6 serum levels have been connected to changes in lipid metabolism and to coronary heart disease.19 A polymorphic allele, guanine/cytosine (G/C), at the IL-6 gene promoter at location -174 in the 5\u2019 flanking region (rs1800795) has been previously associated with higher IL-6 serum levels20 and the effect has also been documented in Finnish populations.21 The relationship between IL-6 -174 polymorphisms and IL-6 serum levels seems to vary in different participant groups22 and to be modified by external factors such as exercise.23 The IL-6 -174 polymorphism has also been associated with lipid abnormalities24 and serum lipid changes during lifestyle interventions.25\n26 IL-6 -174 has also been associated with the risk of coronary heart disease, but this association seems to vary between different participant groups.27\n28", "section": "INTRO", "tags": [{"name": "guanine/cytosine", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "interventions.25", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "The IL-6 -174 genotype frequencies did not associate with the Sydney system-based variables of histopathological findings.30 The HDL serum levels showed strong negative correlations with the antrum mononuclear cell score (r=\u22120.579), antrum neutrophil score (r=\u22120.636), antrum H. pylori score (r=\u22120.525), body mononuclear cell score (r=\u22120.685), body neutrophil score (r=\u22120.494) and body H. pylori score (r=\u22120.585; all p values<0.001) in the IL-6 -174 CC genotype patients but not in the GG or GC patients.", "section": "RESULTS", "tags": [{"name": "histopathological", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "values<0.001)", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Recent observations have suggested that improvement of diet by whole grain supplement may induce concurrent intestinal microbiota changes, decreased IL-6 levels and associate with changes indicating improvement of metabolic function.42 These results suggest a role for IL-6 in systemic responses caused by dietary changes and their associated changes in the commensal mucosal flora.", "section": "DISCUSS", "tags": [{"name": "observations", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "improvement", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "H. pylori infection causes a varied cytokine response including the release of interleukin 6.18 High IL-6 serum levels have been connected to changes in lipid metabolism and to coronary heart disease.19 A polymorphic allele, guanine/cytosine (G/C), at the IL-6 gene promoter at location -174 in the 5\u2019 flanking region (rs1800795) has been previously associated with higher IL-6 serum levels20 and the effect has also been documented in Finnish populations.21 The relationship between IL-6 -174 polymorphisms and IL-6 serum levels seems to vary in different participant groups22 and to be modified by external factors such as exercise.23 The IL-6 -174 polymorphism has also been associated with lipid abnormalities24 and serum lipid changes during lifestyle interventions.25\n26 IL-6 -174 has also been associated with the risk of coronary heart disease, but this association seems to vary between different participant groups.27\n28", "section": "INTRO", "tags": [{"name": "guanine/cytosine", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "interventions.25", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "On the basis of the sample size and the specified significance and power levels, we conclude that the association of H. pylori infection on the HDL serum level is notable in the IL-6 -174 CC genotype patients, but in the other genotypes, especially in the GG genotype, the association is smaller and possibly clinically insignificant.", "section": "DISCUSS", "tags": [{"name": "insignificant.", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "significance", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "We also did not have data on the use of statin medication, but statin use was not common in Finland during the study period.35 Since there are no clear reasons, why the use of statins would be enriched in H. pylori negative patients, who had higher HDL levels, it is unlikely that the use of statin medication confounds our results.", "section": "DISCUSS", "tags": [{"name": "medication,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "medication", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "The cut-off point of <1.00\u2005mmol/L for low HDL was chosen because it is a common cut-off point in Finnish guidelines.32 The patients\u2019 DNA was extracted from blood leucocytes as previously described.29 The restriction fragment length polymorphism method with an NlaIII restriction enzyme using previously published primers20 was used to detect the IL-6 -174 gene polymorphisms from the DNA samples.", "section": "METHODS", "tags": [{"name": "guidelines.32", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "polymorphisms", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "On the basis of our current findings, which indicate that the IL-6 -174 polymorphism modifies systemic effects induced by changes in the composition of gastric bacteria, we suggest that IL-6 polymorphisms should be investigated as a possible mechanism explaining associations between intestinal microbiome and the cardiovascular disease risk factors.", "section": "DISCUSS", "tags": [{"name": "cardiovascular", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "polymorphisms", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "H. pylori infection and peptic ulcers have been associated with increased IL-6 expression18\n36 and high IL-6 serum levels have been associated with low HDL serum levels.37 IL-6 has been documented to reduce the activity of lipoprotein lipase38 and decreased lipoprotein lipase activity has been associated with a decrease in HDL,39 which offers a possible mechanism for the interaction between IL-6 and HDL.", "section": "DISCUSS", "tags": [{"name": "expression18", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "lipoprotein", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "The IL-6 -174 genotype frequencies did not associate with the Sydney system-based variables of histopathological findings.30 The HDL serum levels showed strong negative correlations with the antrum mononuclear cell score (r=\u22120.579), antrum neutrophil score (r=\u22120.636), antrum H. pylori score (r=\u22120.525), body mononuclear cell score (r=\u22120.685), body neutrophil score (r=\u22120.494) and body H. pylori score (r=\u22120.585; all p values<0.001) in the IL-6 -174 CC genotype patients but not in the GG or GC patients.", "section": "RESULTS", "tags": [{"name": "histopathological", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "values<0.001)", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Previous studies have shown that exercise lowers IL-6 serum levels only in IL-6 -174 C allele carriers.23 Similarly, exercise and lifestyle interventions have been documented to increase HDL levels significantly more in the IL-6 -174 C allele carriers than in the G allele carriers.25\n26 In line with these studies, our results suggest that the HDL levels are more prone to decrease by H. pylori infection in the IL-6 -174 C carriers than in the other genotypes.", "section": "DISCUSS", "tags": [{"name": "interventions", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "significantly", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "The IL-6 -174 genotype frequencies did not associate with the Sydney system-based variables of histopathological findings.30 The HDL serum levels showed strong negative correlations with the antrum mononuclear cell score (r=\u22120.579), antrum neutrophil score (r=\u22120.636), antrum H. pylori score (r=\u22120.525), body mononuclear cell score (r=\u22120.685), body neutrophil score (r=\u22120.494) and body H. pylori score (r=\u22120.585; all p values<0.001) in the IL-6 -174 CC genotype patients but not in the GG or GC patients.", "section": "RESULTS", "tags": [{"name": "histopathological", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "values<0.001)", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "On the basis of our current findings, which indicate that the IL-6 -174 polymorphism modifies systemic effects induced by changes in the composition of gastric bacteria, we suggest that IL-6 polymorphisms should be investigated as a possible mechanism explaining associations between intestinal microbiome and the cardiovascular disease risk factors.", "section": "DISCUSS", "tags": [{"name": "cardiovascular", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "polymorphisms", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "The cut-off point of <1.00\u2005mmol/L for low HDL was chosen because it is a common cut-off point in Finnish guidelines.32 The patients\u2019 DNA was extracted from blood leucocytes as previously described.29 The restriction fragment length polymorphism method with an NlaIII restriction enzyme using previously published primers20 was used to detect the IL-6 -174 gene polymorphisms from the DNA samples.", "section": "METHODS", "tags": [{"name": "guidelines.32", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "polymorphisms", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "We also did not have data on the use of statin medication, but statin use was not common in Finland during the study period.35 Since there are no clear reasons, why the use of statins would be enriched in H. pylori negative patients, who had higher HDL levels, it is unlikely that the use of statin medication confounds our results.", "section": "DISCUSS", "tags": [{"name": "medication,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "medication", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Recent observations have suggested that improvement of diet by whole grain supplement may induce concurrent intestinal microbiota changes, decreased IL-6 levels and associate with changes indicating improvement of metabolic function.42 These results suggest a role for IL-6 in systemic responses caused by dietary changes and their associated changes in the commensal mucosal flora.", "section": "DISCUSS", "tags": [{"name": "observations", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "improvement", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "The association between H. pylori infection and low HDL has been demonstrated previously in several studies.1\n3\n5\n6\n9\u201315\nH. pylori eradication has also been documented to increase serum HDL levels.7\n8\n13\n40\n41 On the basis of our results, we hypothesise that the benefits of eradication, especially considering HDL levels, could be more prominent in the IL-6 -174 CC genotype patients than in the patients of other IL-6 -174 genotypes.", "section": "DISCUSS", "tags": [{"name": "demonstrated", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "eradication,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "H. pylori infection causes a varied cytokine response including the release of interleukin 6.18 High IL-6 serum levels have been connected to changes in lipid metabolism and to coronary heart disease.19 A polymorphic allele, guanine/cytosine (G/C), at the IL-6 gene promoter at location -174 in the 5\u2019 flanking region (rs1800795) has been previously associated with higher IL-6 serum levels20 and the effect has also been documented in Finnish populations.21 The relationship between IL-6 -174 polymorphisms and IL-6 serum levels seems to vary in different participant groups22 and to be modified by external factors such as exercise.23 The IL-6 -174 polymorphism has also been associated with lipid abnormalities24 and serum lipid changes during lifestyle interventions.25\n26 IL-6 -174 has also been associated with the risk of coronary heart disease, but this association seems to vary between different participant groups.27\n28", "section": "INTRO", "tags": [{"name": "guanine/cytosine", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "interventions.25", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "On the basis of the sample size and the specified significance and power levels, we conclude that the association of H. pylori infection on the HDL serum level is notable in the IL-6 -174 CC genotype patients, but in the other genotypes, especially in the GG genotype, the association is smaller and possibly clinically insignificant.", "section": "DISCUSS", "tags": [{"name": "insignificant.", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "significance", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "H. pylori infection and peptic ulcers have been associated with increased IL-6 expression18\n36 and high IL-6 serum levels have been associated with low HDL serum levels.37 IL-6 has been documented to reduce the activity of lipoprotein lipase38 and decreased lipoprotein lipase activity has been associated with a decrease in HDL,39 which offers a possible mechanism for the interaction between IL-6 and HDL.", "section": "DISCUSS", "tags": [{"name": "expression18", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "lipoprotein", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}]}
{"src": "PMC", "id": "PMC4713070", "provider": "OpenTargets", "anns": [{"type": "Gene Disease Relationship", "exact": "Third, the multiplex SNaPshot sequencing reactions were carried out in a final volume of 7 \u03bcl containing 2 \u03bcl of purified multiple PCR products, 1 \u03bcl SNaPshot Multiplex Mix, 1 \u03bcl 5\u00d7Sequencing buffer (Applied Biosystems) and 3 \u03bcl SNaPshot sequencing primers (the final concentrations are listed in Table 2).", "section": "METHODS", "tags": [{"name": "concentrations", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "5\u00d7Sequencing", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Immunohistochemical staining of Lewis a indicated increased expression in the cryptic epithelium of inflammatory lesions in UC patients than the normal mucosa of patients with benign colonic polyps (P = 0.028), although there was no difference of Lewis a expression in surface epithelium between the two groups.", "section": "RESULTS", "tags": [{"name": "Immunohistochemical", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "inflammatory", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Immunohistochemical staining of Lewis a indicated increased expression in the cryptic epithelium of inflammatory lesions in UC patients than the normal mucosa of patients with benign colonic polyps (P = 0.028), although there was no difference of Lewis a expression in surface epithelium between the two groups.", "section": "RESULTS", "tags": [{"name": "Immunohistochemical", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "inflammatory", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Immunohistochemical staining of Lewis a indicated increased expression in the cryptic epithelium of inflammatory lesions in UC patients than the normal mucosa of patients with benign colonic polyps (P = 0.028), although there was no difference of Lewis a expression in surface epithelium between the two groups.", "section": "RESULTS", "tags": [{"name": "Immunohistochemical", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "inflammatory", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Immunohistochemical staining of Lewis a indicated increased expression in the cryptic epithelium of inflammatory lesions in UC patients than the normal mucosa of patients with benign colonic polyps (P = 0.028), although there was no difference of Lewis a expression in surface epithelium between the two groups.", "section": "RESULTS", "tags": [{"name": "Immunohistochemical", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "inflammatory", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Two LD blocks were presented as follows: block rs281377-rs1047781 in FUT2 (D' = 0.96, r2 = 0.11) and block rs3894326-rs3745635-rs28362459 in FUT3 [rs3894326/rs3745635 (D' = 1, r2 = 0.01), rs3894326/rs28362459 (D' = 0.86, r2 = 0.23), rs3745635/rs28362459 (D' = 0.92, r2 = 0.47)] (Fig 1).", "section": "METHODS", "tags": [{"name": "rs3894326-rs3745635-rs28362459", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "[rs3894326/rs3745635", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "In recent years, several studies have linked several nucleotide polymorphisms in FUT2 to intestinal microbiota composition [21] and predisposition to CD [22, 23], celiac disease [24], type 1 diabetes [25] and primary sclerosing cholangitis [26], highlighting the essential role of host gene-microbiota interaction in autoimmune diseases.", "section": "INTRO", "tags": [{"name": "gene-microbiota", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "predisposition", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "First, 10 ng of genomic DNA was added to a 10 \u03bcl PCR mixture containing 20 \u03bcmol dNTPs (Promega, Wisconsin, USA), 0.5 U FastStart Taq DNA polymerase (Roche, Basel, Switzerland), 1\u03bcl 10\u00d7PCR buffer with MgCl2 (15 mmol/L) (Roche, Basel, Switzerland) and amplification primers with a specific final concentration (Table 2).", "section": "METHODS", "tags": [{"name": "Switzerland),", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "amplification", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "However, in a Finnish population the wild GG genotype of FUT2 (rs601338) was associated with enhanced risk of UC [24]. And in a Chinese Han population mutations in FUT2 (rs281377 and rs601338) predisposed patients to UC, while FUT2 (rs1047781 and rs601338) polymorphisms were associated with UC in Uyghur population from northwest China [37].", "section": "DISCUSS", "tags": [{"name": "polymorphisms", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "predisposed", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Two LD blocks were presented as follows: block rs281377-rs1047781 in FUT2 (D' = 0.96, r2 = 0.11) and block rs3894326-rs3745635-rs28362459 in FUT3 [rs3894326/rs3745635 (D' = 1, r2 = 0.01), rs3894326/rs28362459 (D' = 0.86, r2 = 0.23), rs3745635/rs28362459 (D' = 0.92, r2 = 0.47)] (Fig 1).", "section": "METHODS", "tags": [{"name": "rs3894326-rs3745635-rs28362459", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "[rs3894326/rs3745635", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "First, 10 ng of genomic DNA was added to a 10 \u03bcl PCR mixture containing 20 \u03bcmol dNTPs (Promega, Wisconsin, USA), 0.5 U FastStart Taq DNA polymerase (Roche, Basel, Switzerland), 1\u03bcl 10\u00d7PCR buffer with MgCl2 (15 mmol/L) (Roche, Basel, Switzerland) and amplification primers with a specific final concentration (Table 2).", "section": "METHODS", "tags": [{"name": "Switzerland),", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "amplification", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "However, in a Finnish population the wild GG genotype of FUT2 (rs601338) was associated with enhanced risk of UC [24]. And in a Chinese Han population mutations in FUT2 (rs281377 and rs601338) predisposed patients to UC, while FUT2 (rs1047781 and rs601338) polymorphisms were associated with UC in Uyghur population from northwest China [37].", "section": "DISCUSS", "tags": [{"name": "polymorphisms", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "predisposed", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "In recent years, several studies have linked several nucleotide polymorphisms in FUT2 to intestinal microbiota composition [21] and predisposition to CD [22, 23], celiac disease [24], type 1 diabetes [25] and primary sclerosing cholangitis [26], highlighting the essential role of host gene-microbiota interaction in autoimmune diseases.", "section": "INTRO", "tags": [{"name": "gene-microbiota", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "predisposition", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}]}
{"src": "PMC", "id": "PMC4682834", "provider": "OpenTargets", "anns": [{"type": "Gene Disease Relationship", "exact": "In a 2013 study by Chiaretti et al., influenza A (H1N1) virus infection was shown to induce the early and significant up-regulation of IL-1\u03b2 and IL-6 in plasma, suggesting that these cytokines are responsible for different molecular reactions that lead to inflammation of the airway and increased disease severity [32].", "section": "DISCUSS", "tags": [{"name": "up-regulation", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "inflammation", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "One major limitation of this study was that samples were only collected in the central region of the country where mortality was higher; therefore, we believe that expanding the sampling area to other geographical regions would enable us to clearly identify areas with greater \"genetic vulnerability\" to be able to overcome future challenges of potentially lethal subtypes of influenza.", "section": "DISCUSS", "tags": [{"name": "vulnerability\"", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "geographical", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "This study was reviewed and approved by both the Bioethics Committee and Science Committee in Research, with protocol number B05-10 at INER (National Institute of Respiratory Diseases Ismael Cosio Villegas) and Institutional Review Board No. 13CI 09015 213 at IMSS (Mexican Institute of Social Security) authorized by COFEPRIS/SSA.", "section": "METHODS", "tags": [{"name": "Institutional", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "COFEPRIS/SSA.", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "When the pA/H1N1 group was compared with the AHC group, we observed that the LTA rs909253 TC heterozygous genotype showed a risk association with disease susceptibility (p = 0.003; OR = 1.9, 95% CI: 1.25\u20132.87); a similar association occurred with the IL1B rs3136558 CC genotype (p = 0.041; OR = 1.89, 95% CI: 1.02\u20133.51).", "section": "RESULTS", "tags": [{"name": "susceptibility", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "heterozygous", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Concerning age at presentation, our results indicate that many patients who are not in the age groups at greatest risk of death or who have no comorbidities associated with an increased risk of death from influenza may have genetic characteristics that make them more susceptible to developing influenza and presenting with greater disease severity.", "section": "DISCUSS", "tags": [{"name": "characteristics", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "presentation,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "This study was reviewed and approved by both the Bioethics Committee and Science Committee in Research, with protocol number B05-10 at INER (National Institute of Respiratory Diseases Ismael Cosio Villegas) and Institutional Review Board No. 13CI 09015 213 at IMSS (Mexican Institute of Social Security) authorized by COFEPRIS/SSA.", "section": "METHODS", "tags": [{"name": "Institutional", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "COFEPRIS/SSA.", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "When the pA/H1N1 group was compared with the AHC group, we observed that the LTA rs909253 TC heterozygous genotype showed a risk association with disease susceptibility (p = 0.003; OR = 1.9, 95% CI: 1.25\u20132.87); a similar association occurred with the IL1B rs3136558 CC genotype (p = 0.041; OR = 1.89, 95% CI: 1.02\u20133.51).", "section": "RESULTS", "tags": [{"name": "susceptibility", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "heterozygous", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "In a 2013 study by Chiaretti et al., influenza A (H1N1) virus infection was shown to induce the early and significant up-regulation of IL-1\u03b2 and IL-6 in plasma, suggesting that these cytokines are responsible for different molecular reactions that lead to inflammation of the airway and increased disease severity [32].", "section": "DISCUSS", "tags": [{"name": "up-regulation", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "inflammation", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}]}
{"src": "PMC", "id": "PMC4690073", "provider": "OpenTargets", "anns": [{"type": "Gene Disease Relationship", "exact": "Based on the questionnaires and sensitization tests at 13 years of age, the subjects were divided into three diagnostic groups: (1) atopic eczema with no other allergic manifestations, in all, 79 adolescents out of the 788 fulfilled these criteria; (2) respiratory allergy with no other allergic manifestations, all of whom were also sensitized to airborne allergens, in all, 130 adolescents in the cohort fulfilled these criteria and (3) no allergy and no sensitization at any of the follow-ups (1, 4, 7 and 13 years of age), in all, 331 adolescents in the cohort fulfilled these criteria.", "section": "METHODS", "tags": [{"name": "manifestations,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "manifestations,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "The power of this study may be limited by the relative small population size, however, the prospective birth cohort design allowed us to select very clear cases with only one allergic manifestations as well as non-allergic controls that had not been sensitized nor had any allergic symptoms in any of the follow-ups at 1, 4, 7, or 13 years of age.", "section": "DISCUSS", "tags": [{"name": "manifestations", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "non-allergic", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Respiratory allergy was defined as a positive skin prick test to an inhalant allergen, in combination with two or more of the following criteria: wheeze in the past year, doctor\u2019s diagnosed asthma, asthma inhalation treatment, or a positive answer to the question: \u201cHave you had any signs of pollen allergy or allergy to furry pets during the last 12 months?\u201d.", "section": "METHODS", "tags": [{"name": "Respiratory", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "combination", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "1 All subjects that were invited to take part in the follow up at 13 years of age; 2 Subjects that were selected for blood sampling at 13 years of age and approved participation in genetic analyses; 3 No allergy and no sensitization at any of the follow-ups (1, 4, 7, and 13 years of age); 4 Atopic eczema was defined as a pruritic, chronic, or chronically relapsing non-infectious dermatitis with typical features and distribution, fulfilling three of the main criteria suggested by Hanifin and Rajka 6; 5 Respiratory allergy was defined as a positive skin prick test to an inhalant allergen, in combination with two or more of the following criteria: wheeze in the past year, doctor\u2019s diagnosed asthma, asthma inhalation treatment, or a positive answer to the question: \u201cHave you had any signs of pollen allergy or allergy to furry pets during the last 12 months?\u201d; 6 Data obtained from the Swedish Medical Birth Register kept by The Swedish National Board of Health and Welfare (Stockholm, Sweden).", "section": "METHODS", "tags": [{"name": "non-infectious", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "participation", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "For each gene separately and for three separate outcome groups\u201415 phospholipid variables in cord serum and in adolescent serum and also for the two diagnosis atopic eczema and respiratory allergy\u2014100 000 permutations were carried out to get an empirical null distribution of the minP (minimum p-value) statistic from which the corrected p-values could be estimated Two-tailed p \u2264 0.05 was considered significant [41].", "section": "METHODS", "tags": [{"name": "phospholipid", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "permutations", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Respiratory allergy was defined as a positive skin prick test to an inhalant allergen, in combination with two or more of the following criteria: wheeze in the past year, doctor\u2019s diagnosed asthma, asthma inhalation treatment, or a positive answer to the question: \u201cHave you had any signs of pollen allergy or allergy to furry pets during the last 12 months?\u201d.", "section": "METHODS", "tags": [{"name": "Respiratory", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "combination", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Based on the questionnaires and sensitization tests at 13 years of age, the subjects were divided into three diagnostic groups: (1) atopic eczema with no other allergic manifestations, in all, 79 adolescents out of the 788 fulfilled these criteria; (2) respiratory allergy with no other allergic manifestations, all of whom were also sensitized to airborne allergens, in all, 130 adolescents in the cohort fulfilled these criteria and (3) no allergy and no sensitization at any of the follow-ups (1, 4, 7 and 13 years of age), in all, 331 adolescents in the cohort fulfilled these criteria.", "section": "METHODS", "tags": [{"name": "manifestations,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "manifestations,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "1 All subjects that were invited to take part in the follow up at 13 years of age; 2 Subjects that were selected for blood sampling at 13 years of age and approved participation in genetic analyses; 3 No allergy and no sensitization at any of the follow-ups (1, 4, 7, and 13 years of age); 4 Atopic eczema was defined as a pruritic, chronic, or chronically relapsing non-infectious dermatitis with typical features and distribution, fulfilling three of the main criteria suggested by Hanifin and Rajka 6; 5 Respiratory allergy was defined as a positive skin prick test to an inhalant allergen, in combination with two or more of the following criteria: wheeze in the past year, doctor\u2019s diagnosed asthma, asthma inhalation treatment, or a positive answer to the question: \u201cHave you had any signs of pollen allergy or allergy to furry pets during the last 12 months?\u201d; 6 Data obtained from the Swedish Medical Birth Register kept by The Swedish National Board of Health and Welfare (Stockholm, Sweden).", "section": "METHODS", "tags": [{"name": "non-infectious", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "participation", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "1 All subjects that were invited to take part in the follow up at 13 years of age; 2 Subjects that were selected for blood sampling at 13 years of age and approved participation in genetic analyses; 3 No allergy and no sensitization at any of the follow-ups (1, 4, 7, and 13 years of age); 4 Atopic eczema was defined as a pruritic, chronic, or chronically relapsing non-infectious dermatitis with typical features and distribution, fulfilling three of the main criteria suggested by Hanifin and Rajka 6; 5 Respiratory allergy was defined as a positive skin prick test to an inhalant allergen, in combination with two or more of the following criteria: wheeze in the past year, doctor\u2019s diagnosed asthma, asthma inhalation treatment, or a positive answer to the question: \u201cHave you had any signs of pollen allergy or allergy to furry pets during the last 12 months?\u201d; 6 Data obtained from the Swedish Medical Birth Register kept by The Swedish National Board of Health and Welfare (Stockholm, Sweden).", "section": "METHODS", "tags": [{"name": "non-infectious", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "participation", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Respiratory allergy was defined as a positive skin prick test to an inhalant allergen, in combination with two or more of the following criteria: wheeze in the past year, doctor\u2019s diagnosed asthma, asthma inhalation treatment, or a positive answer to the question: \u201cHave you had any signs of pollen allergy or allergy to furry pets during the last 12 months?\u201d.", "section": "METHODS", "tags": [{"name": "Respiratory", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "combination", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}]}
{"src": "PMC", "id": "PMC4593004", "provider": "OpenTargets", "anns": [{"type": "Gene Disease Relationship", "exact": "siRNA targeting transcripts for KCNQ5, PLCB1, PLCB4, and PLCL1 (5\u2032\u20133\u2032; siKCNQ5: duplex 1, GGGCAAAUCACAUCAGAUA; duplex 2, CAACACAGGUGCCAAUUAG; duplex 3, GACAUGUUGUGUAGAAUUA; duplex 4, GGGAGGCACUUGGAAAUUA; siPLCB1: duplex 1, GAAGAUAACAGAAGCUAAA; duplex 2, GCAAUUGGCUGCUUUGACA; duplex 3, GAUGAUGACUCAACUAUUG; duplex 4, CAACAGAAAUCGUUUGUGA; siPLCB4: duplex 1, GUAAUUGUCUCGAAAUGAA; duplex 2, GAGAAUAGCUGUGUAUGAU; duplex 3, CAAGAAAGGUAUUGAACUU; duplex 4, CCACUAAUAUCCAUCCAUA; siPLCL1: duplex 1, GCACAGAAGCGCAGUCUUU; duplex 2, GGUAAUGGCUCAACAGAUG; duplex 3, GAAGAAAGUUCGGGAAUAU; duplex 4, GUAGGGAGCUCUCUGAUUU) were purchased from Invitrogen (Carlsbad, CA, USA), as were the non-targeting siRNA scrambled controls (siNC: duplex 1, AUGAACGUGAAUUGCUCAA; duplex 2, UAAGGCUAUGAAGAGAUAC; duplex 3, AUGUAUUGGCCUGUAUUAG; duplex 4, UAGCGACUAAACACAUCAA).", "section": "OTHER", "tags": [{"name": "UAGCGACUAAACACAUCAA).", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "GGGCAAAUCACAUCAGAUA;", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "The primers used for quantitative PCR (qPCR) amplification were as follows: KCNQ5, forward: 5\u2032- AGGGGAAGCATCAAGCAGTA -3\u2032 and reverse: 5\u2032- CGCACTCGCTCCTTAAAACT -3\u2032; PLCB1, forward: 5\u2032- GTGGGAGACACGCCAAAG -3\u2032 and reverse: 5\u2032- GGCCCATACACCACTGTGA -3\u2032; PLCB4, forward: 5\u2032- CGGGAAGTCTTCGGTAGAAA -3\u2032 and reverse: 5\u2032- CCCAGCAGTCAAGTTCAACA -3\u2032; PLCL1, forward: 5\u2032- TCACTTGTGATGAAAGACAGCTT -3\u2032 and reverse: 5\u2032- GAGAAACCGGCTCTCTTGAA -3\u2032; IL-1 beta, forward: 5\u2032-TACCTGTCCTGCGTGTTGAA-3\u2032 and reverse: 5\u2032-TCTTTGGGTAATTTTTGGGATCT -3\u2032; IL-6, forward: 5\u2032- CAGGAGCCCAGCTATGAACT -3\u2032 and reverse: 5\u2032- GAAGGCAGCAGGCAACAC -3\u2032; IL-8, forward: 5\u2032- GAGCACTCCATAAGGCACAAA -3\u2032 and reverse: 5\u2032- ATGGTTCCTTCCGGTGGT -3\u2032. Reverse transcription was performed in a 10\u2009\u03bcL reaction mixture consisting of 2\u2009\u03bcL RNA template, 1\u2009\u03bcL RT primer mix, 1\u2009\u03bcL dNTP mix (10\u2009mm each), and 6\u2009\u03bcL RNA/DNAse-free water at 65\u2009\u00b0C for 5\u2009min.", "section": "OTHER", "tags": [{"name": "5\u2032-TACCTGTCCTGCGTGTTGAA-3\u2032", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "5\u2032-TCTTTGGGTAATTTTTGGGATCT", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "For synovial fibroblasts, macrophages, dendritic cells, and ECs, inflammation induced by thrombin, bradykinin, LPS, porphyromonas gingivalis, or advanced glycation end products has been shown to be affected by PLC inhibitors, suggesting that PLC might also be involved in NF-\u03baB activation and proinflammatory cytokine release in inflammatory diseases3334353637.", "section": "DISCUSS", "tags": [{"name": "diseases3334353637.", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "proinflammatory", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "All patients were diagnosed according to KD criteria5556, including fever lasting 5 days or more and at least 4 of the following symptoms: (1) changes in extremities (e.g., erythema, edema, or desquamation), (2) bilateral conjunctivitis, (3) polymorphous rash, (4) cervical lymphadenopathy, and (5) changes in the lips or oral cavity (e.g. pharyngeal erythema, dry/fissured or swollen lips, or \u201cstrawberry tongue\u201d).", "section": "OTHER", "tags": [{"name": "lymphadenopathy,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "conjunctivitis,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Our results demonstrated that the effect of LPS-induced EC inflammation was inhibited with the most significant inhibition by using siPLCB1 or a PLC inhibitor, suggesting that PLCB1 might be involved in EC inflammation, a possibility that has important implications for understanding the pathogenesis of immune-mediated vascular diseases.", "section": "DISCUSS", "tags": [{"name": "immune-mediated", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "inflammation,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "For cardiomyocytes, PLC beta is the immediate downstream target of G\u03b1q, a heterotrimeric G protein that regulates its activation, and hydrolyzes the plasma membrane phosphatidylinositol 4,5-bisphosphate (PIP2) protein to produce the second messengers inositol 1,4,5-triphosphate (IP3; a regulator of the intracellular calcium response) and diacylglycerol (DAG, an activator of protein kinase C subtypes)50.", "section": "DISCUSS", "tags": [{"name": "phosphatidylinositol", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "1,4,5-triphosphate", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "All patients were diagnosed according to KD criteria5556, including fever lasting 5 days or more and at least 4 of the following symptoms: (1) changes in extremities (e.g., erythema, edema, or desquamation), (2) bilateral conjunctivitis, (3) polymorphous rash, (4) cervical lymphadenopathy, and (5) changes in the lips or oral cavity (e.g. pharyngeal erythema, dry/fissured or swollen lips, or \u201cstrawberry tongue\u201d).", "section": "OTHER", "tags": [{"name": "lymphadenopathy,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "conjunctivitis,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "HUVECs (BCRC Number: H-UV001) were grown in 90% GIBCO medium 199 (Life Technologies) with 25\u2009U/mL heparin (Sigma, St. Louis, MO, USA), 30\u2009\u03bcg/mL endothelial cell growth supplement (Millipore, Billerica, MA, USA) adjusted to contain 1.5\u2009g/L sodium bicarbonate + 10% fetal bovine serum and 100\u2009U/mL penicillin/streptomycin.", "section": "OTHER", "tags": [{"name": "penicillin/streptomycin.", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "Technologies)", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "The primers used for quantitative PCR (qPCR) amplification were as follows: KCNQ5, forward: 5\u2032- AGGGGAAGCATCAAGCAGTA -3\u2032 and reverse: 5\u2032- CGCACTCGCTCCTTAAAACT -3\u2032; PLCB1, forward: 5\u2032- GTGGGAGACACGCCAAAG -3\u2032 and reverse: 5\u2032- GGCCCATACACCACTGTGA -3\u2032; PLCB4, forward: 5\u2032- CGGGAAGTCTTCGGTAGAAA -3\u2032 and reverse: 5\u2032- CCCAGCAGTCAAGTTCAACA -3\u2032; PLCL1, forward: 5\u2032- TCACTTGTGATGAAAGACAGCTT -3\u2032 and reverse: 5\u2032- GAGAAACCGGCTCTCTTGAA -3\u2032; IL-1 beta, forward: 5\u2032-TACCTGTCCTGCGTGTTGAA-3\u2032 and reverse: 5\u2032-TCTTTGGGTAATTTTTGGGATCT -3\u2032; IL-6, forward: 5\u2032- CAGGAGCCCAGCTATGAACT -3\u2032 and reverse: 5\u2032- GAAGGCAGCAGGCAACAC -3\u2032; IL-8, forward: 5\u2032- GAGCACTCCATAAGGCACAAA -3\u2032 and reverse: 5\u2032- ATGGTTCCTTCCGGTGGT -3\u2032. Reverse transcription was performed in a 10\u2009\u03bcL reaction mixture consisting of 2\u2009\u03bcL RNA template, 1\u2009\u03bcL RT primer mix, 1\u2009\u03bcL dNTP mix (10\u2009mm each), and 6\u2009\u03bcL RNA/DNAse-free water at 65\u2009\u00b0C for 5\u2009min.", "section": "OTHER", "tags": [{"name": "5\u2032-TACCTGTCCTGCGTGTTGAA-3\u2032", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "5\u2032-TCTTTGGGTAATTTTTGGGATCT", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "The primers used for quantitative PCR (qPCR) amplification were as follows: KCNQ5, forward: 5\u2032- AGGGGAAGCATCAAGCAGTA -3\u2032 and reverse: 5\u2032- CGCACTCGCTCCTTAAAACT -3\u2032; PLCB1, forward: 5\u2032- GTGGGAGACACGCCAAAG -3\u2032 and reverse: 5\u2032- GGCCCATACACCACTGTGA -3\u2032; PLCB4, forward: 5\u2032- CGGGAAGTCTTCGGTAGAAA -3\u2032 and reverse: 5\u2032- CCCAGCAGTCAAGTTCAACA -3\u2032; PLCL1, forward: 5\u2032- TCACTTGTGATGAAAGACAGCTT -3\u2032 and reverse: 5\u2032- GAGAAACCGGCTCTCTTGAA -3\u2032; IL-1 beta, forward: 5\u2032-TACCTGTCCTGCGTGTTGAA-3\u2032 and reverse: 5\u2032-TCTTTGGGTAATTTTTGGGATCT -3\u2032; IL-6, forward: 5\u2032- CAGGAGCCCAGCTATGAACT -3\u2032 and reverse: 5\u2032- GAAGGCAGCAGGCAACAC -3\u2032; IL-8, forward: 5\u2032- GAGCACTCCATAAGGCACAAA -3\u2032 and reverse: 5\u2032- ATGGTTCCTTCCGGTGGT -3\u2032. Reverse transcription was performed in a 10\u2009\u03bcL reaction mixture consisting of 2\u2009\u03bcL RNA template, 1\u2009\u03bcL RT primer mix, 1\u2009\u03bcL dNTP mix (10\u2009mm each), and 6\u2009\u03bcL RNA/DNAse-free water at 65\u2009\u00b0C for 5\u2009min.", "section": "OTHER", "tags": [{"name": "5\u2032-TACCTGTCCTGCGTGTTGAA-3\u2032", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "5\u2032-TCTTTGGGTAATTTTTGGGATCT", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Our results demonstrated that the effect of LPS-induced EC inflammation was inhibited with the most significant inhibition by using siPLCB1 or a PLC inhibitor, suggesting that PLCB1 might be involved in EC inflammation, a possibility that has important implications for understanding the pathogenesis of immune-mediated vascular diseases.", "section": "DISCUSS", "tags": [{"name": "immune-mediated", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "inflammation,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "All patients were diagnosed according to KD criteria5556, including fever lasting 5 days or more and at least 4 of the following symptoms: (1) changes in extremities (e.g., erythema, edema, or desquamation), (2) bilateral conjunctivitis, (3) polymorphous rash, (4) cervical lymphadenopathy, and (5) changes in the lips or oral cavity (e.g. pharyngeal erythema, dry/fissured or swollen lips, or \u201cstrawberry tongue\u201d).", "section": "OTHER", "tags": [{"name": "lymphadenopathy,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "conjunctivitis,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "siRNA targeting transcripts for KCNQ5, PLCB1, PLCB4, and PLCL1 (5\u2032\u20133\u2032; siKCNQ5: duplex 1, GGGCAAAUCACAUCAGAUA; duplex 2, CAACACAGGUGCCAAUUAG; duplex 3, GACAUGUUGUGUAGAAUUA; duplex 4, GGGAGGCACUUGGAAAUUA; siPLCB1: duplex 1, GAAGAUAACAGAAGCUAAA; duplex 2, GCAAUUGGCUGCUUUGACA; duplex 3, GAUGAUGACUCAACUAUUG; duplex 4, CAACAGAAAUCGUUUGUGA; siPLCB4: duplex 1, GUAAUUGUCUCGAAAUGAA; duplex 2, GAGAAUAGCUGUGUAUGAU; duplex 3, CAAGAAAGGUAUUGAACUU; duplex 4, CCACUAAUAUCCAUCCAUA; siPLCL1: duplex 1, GCACAGAAGCGCAGUCUUU; duplex 2, GGUAAUGGCUCAACAGAUG; duplex 3, GAAGAAAGUUCGGGAAUAU; duplex 4, GUAGGGAGCUCUCUGAUUU) were purchased from Invitrogen (Carlsbad, CA, USA), as were the non-targeting siRNA scrambled controls (siNC: duplex 1, AUGAACGUGAAUUGCUCAA; duplex 2, UAAGGCUAUGAAGAGAUAC; duplex 3, AUGUAUUGGCCUGUAUUAG; duplex 4, UAGCGACUAAACACAUCAA).", "section": "OTHER", "tags": [{"name": "UAGCGACUAAACACAUCAA).", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "GGGCAAAUCACAUCAGAUA;", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "For cardiomyocytes, PLC beta is the immediate downstream target of G\u03b1q, a heterotrimeric G protein that regulates its activation, and hydrolyzes the plasma membrane phosphatidylinositol 4,5-bisphosphate (PIP2) protein to produce the second messengers inositol 1,4,5-triphosphate (IP3; a regulator of the intracellular calcium response) and diacylglycerol (DAG, an activator of protein kinase C subtypes)50.", "section": "DISCUSS", "tags": [{"name": "phosphatidylinositol", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "1,4,5-triphosphate", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "For synovial fibroblasts, macrophages, dendritic cells, and ECs, inflammation induced by thrombin, bradykinin, LPS, porphyromonas gingivalis, or advanced glycation end products has been shown to be affected by PLC inhibitors, suggesting that PLC might also be involved in NF-\u03baB activation and proinflammatory cytokine release in inflammatory diseases3334353637.", "section": "DISCUSS", "tags": [{"name": "diseases3334353637.", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "proinflammatory", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "siRNA targeting transcripts for KCNQ5, PLCB1, PLCB4, and PLCL1 (5\u2032\u20133\u2032; siKCNQ5: duplex 1, GGGCAAAUCACAUCAGAUA; duplex 2, CAACACAGGUGCCAAUUAG; duplex 3, GACAUGUUGUGUAGAAUUA; duplex 4, GGGAGGCACUUGGAAAUUA; siPLCB1: duplex 1, GAAGAUAACAGAAGCUAAA; duplex 2, GCAAUUGGCUGCUUUGACA; duplex 3, GAUGAUGACUCAACUAUUG; duplex 4, CAACAGAAAUCGUUUGUGA; siPLCB4: duplex 1, GUAAUUGUCUCGAAAUGAA; duplex 2, GAGAAUAGCUGUGUAUGAU; duplex 3, CAAGAAAGGUAUUGAACUU; duplex 4, CCACUAAUAUCCAUCCAUA; siPLCL1: duplex 1, GCACAGAAGCGCAGUCUUU; duplex 2, GGUAAUGGCUCAACAGAUG; duplex 3, GAAGAAAGUUCGGGAAUAU; duplex 4, GUAGGGAGCUCUCUGAUUU) were purchased from Invitrogen (Carlsbad, CA, USA), as were the non-targeting siRNA scrambled controls (siNC: duplex 1, AUGAACGUGAAUUGCUCAA; duplex 2, UAAGGCUAUGAAGAGAUAC; duplex 3, AUGUAUUGGCCUGUAUUAG; duplex 4, UAGCGACUAAACACAUCAA).", "section": "OTHER", "tags": [{"name": "UAGCGACUAAACACAUCAA).", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "GGGCAAAUCACAUCAGAUA;", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "All patients were diagnosed according to KD criteria5556, including fever lasting 5 days or more and at least 4 of the following symptoms: (1) changes in extremities (e.g., erythema, edema, or desquamation), (2) bilateral conjunctivitis, (3) polymorphous rash, (4) cervical lymphadenopathy, and (5) changes in the lips or oral cavity (e.g. pharyngeal erythema, dry/fissured or swollen lips, or \u201cstrawberry tongue\u201d).", "section": "OTHER", "tags": [{"name": "lymphadenopathy,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "conjunctivitis,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "For synovial fibroblasts, macrophages, dendritic cells, and ECs, inflammation induced by thrombin, bradykinin, LPS, porphyromonas gingivalis, or advanced glycation end products has been shown to be affected by PLC inhibitors, suggesting that PLC might also be involved in NF-\u03baB activation and proinflammatory cytokine release in inflammatory diseases3334353637.", "section": "DISCUSS", "tags": [{"name": "diseases3334353637.", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "proinflammatory", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "All patients were diagnosed according to KD criteria5556, including fever lasting 5 days or more and at least 4 of the following symptoms: (1) changes in extremities (e.g., erythema, edema, or desquamation), (2) bilateral conjunctivitis, (3) polymorphous rash, (4) cervical lymphadenopathy, and (5) changes in the lips or oral cavity (e.g. pharyngeal erythema, dry/fissured or swollen lips, or \u201cstrawberry tongue\u201d).", "section": "OTHER", "tags": [{"name": "lymphadenopathy,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "conjunctivitis,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "The primers used for quantitative PCR (qPCR) amplification were as follows: KCNQ5, forward: 5\u2032- AGGGGAAGCATCAAGCAGTA -3\u2032 and reverse: 5\u2032- CGCACTCGCTCCTTAAAACT -3\u2032; PLCB1, forward: 5\u2032- GTGGGAGACACGCCAAAG -3\u2032 and reverse: 5\u2032- GGCCCATACACCACTGTGA -3\u2032; PLCB4, forward: 5\u2032- CGGGAAGTCTTCGGTAGAAA -3\u2032 and reverse: 5\u2032- CCCAGCAGTCAAGTTCAACA -3\u2032; PLCL1, forward: 5\u2032- TCACTTGTGATGAAAGACAGCTT -3\u2032 and reverse: 5\u2032- GAGAAACCGGCTCTCTTGAA -3\u2032; IL-1 beta, forward: 5\u2032-TACCTGTCCTGCGTGTTGAA-3\u2032 and reverse: 5\u2032-TCTTTGGGTAATTTTTGGGATCT -3\u2032; IL-6, forward: 5\u2032- CAGGAGCCCAGCTATGAACT -3\u2032 and reverse: 5\u2032- GAAGGCAGCAGGCAACAC -3\u2032; IL-8, forward: 5\u2032- GAGCACTCCATAAGGCACAAA -3\u2032 and reverse: 5\u2032- ATGGTTCCTTCCGGTGGT -3\u2032. Reverse transcription was performed in a 10\u2009\u03bcL reaction mixture consisting of 2\u2009\u03bcL RNA template, 1\u2009\u03bcL RT primer mix, 1\u2009\u03bcL dNTP mix (10\u2009mm each), and 6\u2009\u03bcL RNA/DNAse-free water at 65\u2009\u00b0C for 5\u2009min.", "section": "OTHER", "tags": [{"name": "5\u2032-TACCTGTCCTGCGTGTTGAA-3\u2032", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "5\u2032-TCTTTGGGTAATTTTTGGGATCT", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}]}
{"src": "PMC", "id": "PMC4539664", "provider": "OpenTargets", "anns": [{"type": "Gene Disease Relationship", "exact": "Table 4Synonymous variantsExonNucleotide changea\nProtein changea\ndbSNP IDFirst reported1000 G MAFb\nNHBLI GO ESP MAFc\nExACd\nHAPS cases (n\u2009=\u2009997)e\nFCC-ViP cases (n\u2009=\u2009999)d\nControls (n\u2009=\u20091998)e\nCADD scaledC score1c.12 T\u2009>\u2009Cp.(=)rs145291423-..0.00012-1111.24c.768C\u2009>\u2009Tp.(=)rs45487491..0.00003710.34c.1188C\u2009>\u2009Tp.(=).-..0.00003--17.64c.1194G\u2009>\u2009Ap.(=)rs61755173Rahman (2007) [3]0.00090.001540.001143286.44c.1194G\u2009>\u2009Tp.(=).-...1--6.14c.1242A\u2009>\u2009Cp.(=).-...--17.74c.1431C\u2009>\u2009Tp.(=).Teo (2013)..02--0.04c.1470C\u2009>\u2009Tp.(=)rs45612837Rahman (2007) [3]0.00050.000150.0004051-25.84c.1572A\u2009>\u2009Gp.(=)rs45472400Rahman (2007) [3]0.00320.003390.00411212275.64c.1623G\u2009>\u2009Ap.(=).-..0-124.25c.2067G\u2009>\u2009Ap.(=).Phuah (2013) [38].0.000150.0000181--4.15c.2082A\u2009>\u2009Gp.(=)rs150569240-..0.000055--15.85c.2091C\u2009>\u2009Ap.(=).-..0--14.75c.2244A\u2009>\u2009Gp.(=).-..0.000037--15.65c.2328C\u2009>\u2009Tp.(=)rs45508997-.0.0000801--4.05c.2337A\u2009>\u2009Cp.(=).-...-1-5.25c.2379C\u2009>\u2009Tp.(=).-.0.000080.00011111-0.15c.2478C\u2009>\u2009Tp.(=).-...--14.25c.2484C\u2009>\u2009Tp.(=).-...--16.07c.2742C\u2009>\u2009Tp.(=)rs115759702-0.00180.001460.000032--0.712c.3294G\u2009>\u2009Ap.(=).-...--19.912c.3300 T\u2009>\u2009Gp.(=)rs45516100Rahman (2007) [3]0.01830.028010.027864 (1)68 (4)123 (1)7.913c.3495G\u2009>\u2009Ap.(=)rs45439097Bogdanova (2010).0.001080.0009944798.6\nHAPS Hunter Area Pathology Service, FCC Familial Cancer Centre, ViP Variants in Practice\naVariant positions are reported in reference to NCBI RefSeq NM_024675.3 (mRNA) and NP_078951.2 (protein)\nbMinor allele frequency (MAF) reported in the 1000 Genomes (1000 G) cohort Phase 1\ncMAF reported in the Exome Variant Server, NHLBI GO Exome Sequencing Project (ESP) [46] (data release ESP6500SI-V2)\ndMAF reported in ExAC [45] from non-Finnish Europeans, excluding individuals in the database who were part of The Cancer Genome Atlas and therefore known to have had cancer\neNumber of individuals carrying the variant.", "section": "RESULTS", "tags": [{"name": "Tp.(=)rs115759702-0.00180.001460.000032--0.712c.3294G", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "Gp.(=)rs150569240-..0.000055--15.85c.2091C", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Leu1150Argrs45566737..0.0000368-1-18.2DeleteriousPossibly damagingDeleterious\nHAPS Hunter Area Pathology Service, FCC Familial Cancer Centre, ViP Variants in Practice\naVariant positions are reported in reference to NCBI RefSeq NM_024675.3 (mRNA) and NP_078951.2 (protein)\nbMinor allele frequency (MAF) reported in the 1000 Genomes (1000 G) cohort Phase 1\ncMAF reported in the Exome Variant Server, NHLBI GO Exome Sequencing Project (ESP) [46] (data release ESP6500SI-V2)\ndMAF reported in ExAC [45] from non-Finnish Europeans, excluding individuals in the database who were part of The Cancer Genome Atlas and therefore known to have had cancer\neNumber of individuals carrying the variant.", "section": "RESULTS", "tags": [{"name": "Leu1150Argrs45566737..0.0000368-1-18.2DeleteriousPossibly", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "damagingDeleterious", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Five previously reported variants were detected recurrently (c.196C\u2009>\u2009T (p.Gln66*) and c.758dupT (p.Ser254Illefs*3) each in two cases, c.3113G\u2009>\u2009A (p.Trp1038*) in seven cases and one control, and c.3116delA (p.Asn1039Ilefs*2) and c.3362delG (p.Gly1121Valfs*3) each in one case and one control) with the remaining variants detected in single cases or controls only.", "section": "RESULTS", "tags": [{"name": "(p.Ser254Illefs*3)", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "(p.Asn1039Ilefs*2)", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Tyr1183*rs118203998Reid (2007) [2]1--37.0\nHAPS Hunter Area Pathology Service, FCC Familial Cancer Centre, ViP Variants in Practice\naVariant positions are reported in reference to NCBI RefSeq NM_024675.3 (mRNA) and NP_078951.2 (protein)\nbNumber of individuals carrying the variant\ncc.3113G\u2009>\u2009A produces three different PALB2 mRNA sequences: complete deletion of exon 10 (117 bp); use of an alternative splice site within exon 10, and deletion of 31 bp; and an immediate stop at codon 1038 [29]", "section": "RESULTS", "tags": [{"name": "Tyr1183*rs118203998Reid", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "NM_024675.3", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Because early studies focused on screening just for the presumed common pathogenic mutations, in Australia (eviQ Cancer Treatments Online; [11]) it is not recommended to test for PALB2 truncating mutations aside from the recurring c.3113G\u2009>\u2009A variant, however, it is likely that all truncating mutations confer an equivalent loss of gene function and consequent breast cancer risk.", "section": "INTRO", "tags": [{"name": "recommended", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "pathogenic", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Five previously reported variants were detected recurrently (c.196C\u2009>\u2009T (p.Gln66*) and c.758dupT (p.Ser254Illefs*3) each in two cases, c.3113G\u2009>\u2009A (p.Trp1038*) in seven cases and one control, and c.3116delA (p.Asn1039Ilefs*2) and c.3362delG (p.Gly1121Valfs*3) each in one case and one control) with the remaining variants detected in single cases or controls only.", "section": "RESULTS", "tags": [{"name": "(p.Ser254Illefs*3)", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "(p.Asn1039Ilefs*2)", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Nineteen different truncating variants were identified in 30 individuals in this study, 26 of these variants were detected among 1996 breast cancer index cases (1.3 %) and four among 1998 controls (0.2 %), demonstrating a significant enrichment in cases (p\u2009=\u20090.0001, chi-squared test; odds ratio (OR) 6.58, 95 % confidence interval (CI) 2.3\u201318.9) (Table\u00a01).", "section": "RESULTS", "tags": [{"name": "demonstrating", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "individuals", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Nineteen different truncating variants were identified in 30 individuals in this study, 26 of these variants were detected among 1996 breast cancer index cases (1.3 %) and four among 1998 controls (0.2 %), demonstrating a significant enrichment in cases (p\u2009=\u20090.0001, chi-squared test; odds ratio (OR) 6.58, 95 % confidence interval (CI) 2.3\u201318.9) (Table\u00a01).", "section": "RESULTS", "tags": [{"name": "demonstrating", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "individuals", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Because early studies focused on screening just for the presumed common pathogenic mutations, in Australia (eviQ Cancer Treatments Online; [11]) it is not recommended to test for PALB2 truncating mutations aside from the recurring c.3113G\u2009>\u2009A variant, however, it is likely that all truncating mutations confer an equivalent loss of gene function and consequent breast cancer risk.", "section": "INTRO", "tags": [{"name": "recommended", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "pathogenic", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Five previously reported variants were detected recurrently (c.196C\u2009>\u2009T (p.Gln66*) and c.758dupT (p.Ser254Illefs*3) each in two cases, c.3113G\u2009>\u2009A (p.Trp1038*) in seven cases and one control, and c.3116delA (p.Asn1039Ilefs*2) and c.3362delG (p.Gly1121Valfs*3) each in one case and one control) with the remaining variants detected in single cases or controls only.", "section": "RESULTS", "tags": [{"name": "(p.Ser254Illefs*3)", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "(p.Asn1039Ilefs*2)", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Table 4Synonymous variantsExonNucleotide changea\nProtein changea\ndbSNP IDFirst reported1000 G MAFb\nNHBLI GO ESP MAFc\nExACd\nHAPS cases (n\u2009=\u2009997)e\nFCC-ViP cases (n\u2009=\u2009999)d\nControls (n\u2009=\u20091998)e\nCADD scaledC score1c.12 T\u2009>\u2009Cp.(=)rs145291423-..0.00012-1111.24c.768C\u2009>\u2009Tp.(=)rs45487491..0.00003710.34c.1188C\u2009>\u2009Tp.(=).-..0.00003--17.64c.1194G\u2009>\u2009Ap.(=)rs61755173Rahman (2007) [3]0.00090.001540.001143286.44c.1194G\u2009>\u2009Tp.(=).-...1--6.14c.1242A\u2009>\u2009Cp.(=).-...--17.74c.1431C\u2009>\u2009Tp.(=).Teo (2013)..02--0.04c.1470C\u2009>\u2009Tp.(=)rs45612837Rahman (2007) [3]0.00050.000150.0004051-25.84c.1572A\u2009>\u2009Gp.(=)rs45472400Rahman (2007) [3]0.00320.003390.00411212275.64c.1623G\u2009>\u2009Ap.(=).-..0-124.25c.2067G\u2009>\u2009Ap.(=).Phuah (2013) [38].0.000150.0000181--4.15c.2082A\u2009>\u2009Gp.(=)rs150569240-..0.000055--15.85c.2091C\u2009>\u2009Ap.(=).-..0--14.75c.2244A\u2009>\u2009Gp.(=).-..0.000037--15.65c.2328C\u2009>\u2009Tp.(=)rs45508997-.0.0000801--4.05c.2337A\u2009>\u2009Cp.(=).-...-1-5.25c.2379C\u2009>\u2009Tp.(=).-.0.000080.00011111-0.15c.2478C\u2009>\u2009Tp.(=).-...--14.25c.2484C\u2009>\u2009Tp.(=).-...--16.07c.2742C\u2009>\u2009Tp.(=)rs115759702-0.00180.001460.000032--0.712c.3294G\u2009>\u2009Ap.(=).-...--19.912c.3300 T\u2009>\u2009Gp.(=)rs45516100Rahman (2007) [3]0.01830.028010.027864 (1)68 (4)123 (1)7.913c.3495G\u2009>\u2009Ap.(=)rs45439097Bogdanova (2010).0.001080.0009944798.6\nHAPS Hunter Area Pathology Service, FCC Familial Cancer Centre, ViP Variants in Practice\naVariant positions are reported in reference to NCBI RefSeq NM_024675.3 (mRNA) and NP_078951.2 (protein)\nbMinor allele frequency (MAF) reported in the 1000 Genomes (1000 G) cohort Phase 1\ncMAF reported in the Exome Variant Server, NHLBI GO Exome Sequencing Project (ESP) [46] (data release ESP6500SI-V2)\ndMAF reported in ExAC [45] from non-Finnish Europeans, excluding individuals in the database who were part of The Cancer Genome Atlas and therefore known to have had cancer\neNumber of individuals carrying the variant.", "section": "RESULTS", "tags": [{"name": "Tp.(=)rs115759702-0.00180.001460.000032--0.712c.3294G", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "Gp.(=)rs150569240-..0.000055--15.85c.2091C", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Leu1150Argrs45566737..0.0000368-1-18.2DeleteriousPossibly damagingDeleterious\nHAPS Hunter Area Pathology Service, FCC Familial Cancer Centre, ViP Variants in Practice\naVariant positions are reported in reference to NCBI RefSeq NM_024675.3 (mRNA) and NP_078951.2 (protein)\nbMinor allele frequency (MAF) reported in the 1000 Genomes (1000 G) cohort Phase 1\ncMAF reported in the Exome Variant Server, NHLBI GO Exome Sequencing Project (ESP) [46] (data release ESP6500SI-V2)\ndMAF reported in ExAC [45] from non-Finnish Europeans, excluding individuals in the database who were part of The Cancer Genome Atlas and therefore known to have had cancer\neNumber of individuals carrying the variant.", "section": "RESULTS", "tags": [{"name": "Leu1150Argrs45566737..0.0000368-1-18.2DeleteriousPossibly", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "damagingDeleterious", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Table 4Synonymous variantsExonNucleotide changea\nProtein changea\ndbSNP IDFirst reported1000 G MAFb\nNHBLI GO ESP MAFc\nExACd\nHAPS cases (n\u2009=\u2009997)e\nFCC-ViP cases (n\u2009=\u2009999)d\nControls (n\u2009=\u20091998)e\nCADD scaledC score1c.12 T\u2009>\u2009Cp.(=)rs145291423-..0.00012-1111.24c.768C\u2009>\u2009Tp.(=)rs45487491..0.00003710.34c.1188C\u2009>\u2009Tp.(=).-..0.00003--17.64c.1194G\u2009>\u2009Ap.(=)rs61755173Rahman (2007) [3]0.00090.001540.001143286.44c.1194G\u2009>\u2009Tp.(=).-...1--6.14c.1242A\u2009>\u2009Cp.(=).-...--17.74c.1431C\u2009>\u2009Tp.(=).Teo (2013)..02--0.04c.1470C\u2009>\u2009Tp.(=)rs45612837Rahman (2007) [3]0.00050.000150.0004051-25.84c.1572A\u2009>\u2009Gp.(=)rs45472400Rahman (2007) [3]0.00320.003390.00411212275.64c.1623G\u2009>\u2009Ap.(=).-..0-124.25c.2067G\u2009>\u2009Ap.(=).Phuah (2013) [38].0.000150.0000181--4.15c.2082A\u2009>\u2009Gp.(=)rs150569240-..0.000055--15.85c.2091C\u2009>\u2009Ap.(=).-..0--14.75c.2244A\u2009>\u2009Gp.(=).-..0.000037--15.65c.2328C\u2009>\u2009Tp.(=)rs45508997-.0.0000801--4.05c.2337A\u2009>\u2009Cp.(=).-...-1-5.25c.2379C\u2009>\u2009Tp.(=).-.0.000080.00011111-0.15c.2478C\u2009>\u2009Tp.(=).-...--14.25c.2484C\u2009>\u2009Tp.(=).-...--16.07c.2742C\u2009>\u2009Tp.(=)rs115759702-0.00180.001460.000032--0.712c.3294G\u2009>\u2009Ap.(=).-...--19.912c.3300 T\u2009>\u2009Gp.(=)rs45516100Rahman (2007) [3]0.01830.028010.027864 (1)68 (4)123 (1)7.913c.3495G\u2009>\u2009Ap.(=)rs45439097Bogdanova (2010).0.001080.0009944798.6\nHAPS Hunter Area Pathology Service, FCC Familial Cancer Centre, ViP Variants in Practice\naVariant positions are reported in reference to NCBI RefSeq NM_024675.3 (mRNA) and NP_078951.2 (protein)\nbMinor allele frequency (MAF) reported in the 1000 Genomes (1000 G) cohort Phase 1\ncMAF reported in the Exome Variant Server, NHLBI GO Exome Sequencing Project (ESP) [46] (data release ESP6500SI-V2)\ndMAF reported in ExAC [45] from non-Finnish Europeans, excluding individuals in the database who were part of The Cancer Genome Atlas and therefore known to have had cancer\neNumber of individuals carrying the variant.", "section": "RESULTS", "tags": [{"name": "Tp.(=)rs115759702-0.00180.001460.000032--0.712c.3294G", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "Gp.(=)rs150569240-..0.000055--15.85c.2091C", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Tyr1183*rs118203998Reid (2007) [2]1--37.0\nHAPS Hunter Area Pathology Service, FCC Familial Cancer Centre, ViP Variants in Practice\naVariant positions are reported in reference to NCBI RefSeq NM_024675.3 (mRNA) and NP_078951.2 (protein)\nbNumber of individuals carrying the variant\ncc.3113G\u2009>\u2009A produces three different PALB2 mRNA sequences: complete deletion of exon 10 (117 bp); use of an alternative splice site within exon 10, and deletion of 31 bp; and an immediate stop at codon 1038 [29]", "section": "RESULTS", "tags": [{"name": "Tyr1183*rs118203998Reid", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "NM_024675.3", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Leu1150Argrs45566737..0.0000368-1-18.2DeleteriousPossibly damagingDeleterious\nHAPS Hunter Area Pathology Service, FCC Familial Cancer Centre, ViP Variants in Practice\naVariant positions are reported in reference to NCBI RefSeq NM_024675.3 (mRNA) and NP_078951.2 (protein)\nbMinor allele frequency (MAF) reported in the 1000 Genomes (1000 G) cohort Phase 1\ncMAF reported in the Exome Variant Server, NHLBI GO Exome Sequencing Project (ESP) [46] (data release ESP6500SI-V2)\ndMAF reported in ExAC [45] from non-Finnish Europeans, excluding individuals in the database who were part of The Cancer Genome Atlas and therefore known to have had cancer\neNumber of individuals carrying the variant.", "section": "RESULTS", "tags": [{"name": "Leu1150Argrs45566737..0.0000368-1-18.2DeleteriousPossibly", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "damagingDeleterious", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Tyr1183*rs118203998Reid (2007) [2]1--37.0\nHAPS Hunter Area Pathology Service, FCC Familial Cancer Centre, ViP Variants in Practice\naVariant positions are reported in reference to NCBI RefSeq NM_024675.3 (mRNA) and NP_078951.2 (protein)\nbNumber of individuals carrying the variant\ncc.3113G\u2009>\u2009A produces three different PALB2 mRNA sequences: complete deletion of exon 10 (117 bp); use of an alternative splice site within exon 10, and deletion of 31 bp; and an immediate stop at codon 1038 [29]", "section": "RESULTS", "tags": [{"name": "Tyr1183*rs118203998Reid", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "NM_024675.3", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Leu1150Argrs45566737..0.0000368-1-18.2DeleteriousPossibly damagingDeleterious\nHAPS Hunter Area Pathology Service, FCC Familial Cancer Centre, ViP Variants in Practice\naVariant positions are reported in reference to NCBI RefSeq NM_024675.3 (mRNA) and NP_078951.2 (protein)\nbMinor allele frequency (MAF) reported in the 1000 Genomes (1000 G) cohort Phase 1\ncMAF reported in the Exome Variant Server, NHLBI GO Exome Sequencing Project (ESP) [46] (data release ESP6500SI-V2)\ndMAF reported in ExAC [45] from non-Finnish Europeans, excluding individuals in the database who were part of The Cancer Genome Atlas and therefore known to have had cancer\neNumber of individuals carrying the variant.", "section": "RESULTS", "tags": [{"name": "Leu1150Argrs45566737..0.0000368-1-18.2DeleteriousPossibly", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "damagingDeleterious", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}]}
{"src": "PMC", "id": "PMC4588721", "provider": "OpenTargets", "anns": [{"type": "Gene Disease Relationship", "exact": "Since there is no known 3D structure of motor domain of MYO15A in the Protein Data Bank, the structure for motor domain of MYO15A was built using the homolog modeling method (BLAST, http://blast.ncbi.nlm.nih.gov/Blast.cgi/; HHpred, http://toolkit.tuebingen.mpg.de/hhpred/; PDB, http://pdb.org/pdb/home/home.do/; UNIPROT.", "section": "METHODS", "tags": [{"name": "http://blast.ncbi.nlm.nih.gov/Blast.cgi/;", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "http://toolkit.tuebingen.mpg.de/hhpred/;", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "The possibility of less severe hearing loss associated with mutations residing in the N-terminal extension domain had already been suggested; Belyantseva et al. (2005) transfected a class 2 myosin XVa isoform that had no N-terminal extension, into shaker-2 hair cells, which had abnormally short stereocilia.", "section": "DISCUSS", "tags": [{"name": "stereocilia.", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "possibility", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Since there is no known 3D structure of motor domain of MYO15A in the Protein Data Bank, the structure for motor domain of MYO15A was built using the homolog modeling method (BLAST, http://blast.ncbi.nlm.nih.gov/Blast.cgi/; HHpred, http://toolkit.tuebingen.mpg.de/hhpred/; PDB, http://pdb.org/pdb/home/home.do/; UNIPROT.", "section": "METHODS", "tags": [{"name": "http://blast.ncbi.nlm.nih.gov/Blast.cgi/;", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "http://toolkit.tuebingen.mpg.de/hhpred/;", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Based on our findings and analysis of audiologic features of MYO15A mutations, we suggest a hypothetical genotype-phenotype correlation whereby MYO15A mutations that affect domains other than the N-terminal domain, lead to profound SNHL throughout all frequencies, while mutations that affect the N-terminal domain, result in residual hearing at low frequencies, which could make contribution to language development and speech perception.", "section": "DISCUSS", "tags": [{"name": "genotype-phenotype", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "hypothetical", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Therefore our hypothetical genotype-phenotype correlation suggests a customized treatment that preservation of residual hearing during cochlear implantation should be intended for those who carry mutations in the N-terminal domain and that the individuals with mutations elsewhere in MYO15A require early cochlear implantation to timely initiate speech development.", "section": "DISCUSS", "tags": [{"name": "genotype-phenotype", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "hypothetical", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Studies of the MYO15A mutation in humans have usually been performed in the Middle East, where consanguineous families are more common (Bashir et al., 2012; Belguith et al., 2009; Brownstein et al., 2011; Cengiz et al., 2010; Diaz-Horta et al., 2012; Duman et al., 2011; Fattahi et al., 2012; Kalay et al., 2007; Liburd et al., 2001; Nal et al., 2007; Shearer et al., 2009).", "section": "DISCUSS", "tags": [{"name": "consanguineous", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "Brownstein", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Conversely, it can be hypothesized that if MYO15A mutations affect a common region shared by both isoforms, other than exon 2, then the phenotype would be profound throughout all frequencies and have no, or minimal, residual hearing to trigger linguistic development, thereby requiring early cochlear implantation for speech development.", "section": "DISCUSS", "tags": [{"name": "hypothesized", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "development,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "This feature has been observed in other studies in which mutations in exon 2 (p.E1105*, p.R1113Vfs*12 and p.Y289* homozygote), which encodes the N-terminal extension of MYO15A, resulted in better residual hearing at low frequencies, or even moderate to severe hearing loss compared with mutations in other regions of MYO15A (Cengiz et al., 2010; Nal et al., 2007).", "section": "DISCUSS", "tags": [{"name": "p.R1113Vfs*12", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "homozygote),", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Based on our findings and analysis of audiologic features of MYO15A mutations, we suggest a hypothetical genotype-phenotype correlation whereby MYO15A mutations that affect domains other than the N-terminal domain, lead to profound SNHL throughout all frequencies, while mutations that affect the N-terminal domain, result in residual hearing at low frequencies, which could make contribution to language development and speech perception.", "section": "DISCUSS", "tags": [{"name": "genotype-phenotype", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "hypothetical", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Recently, conflicting descriptions of auditory phenotypes of the MYO15A mutation have been reported; Fattahi et al. (2012) reported seven mutations throughout the N-terminal extension, motor domain, IQ domain and FERM domain of MYO15A and suggested that a down-sloping audioprofile was the defining audiologic feature of MYO15A-associated deafness.", "section": "DISCUSS", "tags": [{"name": "MYO15A-associated", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "descriptions", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Therefore our hypothetical genotype-phenotype correlation suggests a customized treatment that preservation of residual hearing during cochlear implantation should be intended for those who carry mutations in the N-terminal domain and that the individuals with mutations elsewhere in MYO15A require early cochlear implantation to timely initiate speech development.", "section": "DISCUSS", "tags": [{"name": "genotype-phenotype", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "hypothetical", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Alternatively, alterations in the N-terminal extension domain, or even the absence of the class 1 myosin XVA, might be related to functional problems or minor structural defects in the staircase architecture of the hair bundle (Nal et al., 2007), thereby leading to a milder auditory phenotype.", "section": "DISCUSS", "tags": [{"name": "Alternatively,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "architecture", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "The possibility of less severe hearing loss associated with mutations residing in the N-terminal extension domain had already been suggested; Belyantseva et al. (2005) transfected a class 2 myosin XVa isoform that had no N-terminal extension, into shaker-2 hair cells, which had abnormally short stereocilia.", "section": "DISCUSS", "tags": [{"name": "stereocilia.", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "possibility", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Since there is no known 3D structure of motor domain of MYO15A in the Protein Data Bank, the structure for motor domain of MYO15A was built using the homolog modeling method (BLAST, http://blast.ncbi.nlm.nih.gov/Blast.cgi/; HHpred, http://toolkit.tuebingen.mpg.de/hhpred/; PDB, http://pdb.org/pdb/home/home.do/; UNIPROT.", "section": "METHODS", "tags": [{"name": "http://blast.ncbi.nlm.nih.gov/Blast.cgi/;", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "http://toolkit.tuebingen.mpg.de/hhpred/;", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Since there is no known 3D structure of motor domain of MYO15A in the Protein Data Bank, the structure for motor domain of MYO15A was built using the homolog modeling method (BLAST, http://blast.ncbi.nlm.nih.gov/Blast.cgi/; HHpred, http://toolkit.tuebingen.mpg.de/hhpred/; PDB, http://pdb.org/pdb/home/home.do/; UNIPROT.", "section": "METHODS", "tags": [{"name": "http://blast.ncbi.nlm.nih.gov/Blast.cgi/;", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "http://toolkit.tuebingen.mpg.de/hhpred/;", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Studies of the MYO15A mutation in humans have usually been performed in the Middle East, where consanguineous families are more common (Bashir et al., 2012; Belguith et al., 2009; Brownstein et al., 2011; Cengiz et al., 2010; Diaz-Horta et al., 2012; Duman et al., 2011; Fattahi et al., 2012; Kalay et al., 2007; Liburd et al., 2001; Nal et al., 2007; Shearer et al., 2009).", "section": "DISCUSS", "tags": [{"name": "consanguineous", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "Brownstein", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Recently, conflicting descriptions of auditory phenotypes of the MYO15A mutation have been reported; Fattahi et al. (2012) reported seven mutations throughout the N-terminal extension, motor domain, IQ domain and FERM domain of MYO15A and suggested that a down-sloping audioprofile was the defining audiologic feature of MYO15A-associated deafness.", "section": "DISCUSS", "tags": [{"name": "MYO15A-associated", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "descriptions", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "This feature has been observed in other studies in which mutations in exon 2 (p.E1105*, p.R1113Vfs*12 and p.Y289* homozygote), which encodes the N-terminal extension of MYO15A, resulted in better residual hearing at low frequencies, or even moderate to severe hearing loss compared with mutations in other regions of MYO15A (Cengiz et al., 2010; Nal et al., 2007).", "section": "DISCUSS", "tags": [{"name": "p.R1113Vfs*12", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "homozygote),", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Conversely, it can be hypothesized that if MYO15A mutations affect a common region shared by both isoforms, other than exon 2, then the phenotype would be profound throughout all frequencies and have no, or minimal, residual hearing to trigger linguistic development, thereby requiring early cochlear implantation for speech development.", "section": "DISCUSS", "tags": [{"name": "hypothesized", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "development,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Since there is no known 3D structure of motor domain of MYO15A in the Protein Data Bank, the structure for motor domain of MYO15A was built using the homolog modeling method (BLAST, http://blast.ncbi.nlm.nih.gov/Blast.cgi/; HHpred, http://toolkit.tuebingen.mpg.de/hhpred/; PDB, http://pdb.org/pdb/home/home.do/; UNIPROT.", "section": "METHODS", "tags": [{"name": "http://blast.ncbi.nlm.nih.gov/Blast.cgi/;", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "http://toolkit.tuebingen.mpg.de/hhpred/;", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Alternatively, alterations in the N-terminal extension domain, or even the absence of the class 1 myosin XVA, might be related to functional problems or minor structural defects in the staircase architecture of the hair bundle (Nal et al., 2007), thereby leading to a milder auditory phenotype.", "section": "DISCUSS", "tags": [{"name": "Alternatively,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "architecture", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Therefore our hypothetical genotype-phenotype correlation suggests a customized treatment that preservation of residual hearing during cochlear implantation should be intended for those who carry mutations in the N-terminal domain and that the individuals with mutations elsewhere in MYO15A require early cochlear implantation to timely initiate speech development.", "section": "DISCUSS", "tags": [{"name": "genotype-phenotype", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "hypothetical", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Since there is no known 3D structure of motor domain of MYO15A in the Protein Data Bank, the structure for motor domain of MYO15A was built using the homolog modeling method (BLAST, http://blast.ncbi.nlm.nih.gov/Blast.cgi/; HHpred, http://toolkit.tuebingen.mpg.de/hhpred/; PDB, http://pdb.org/pdb/home/home.do/; UNIPROT.", "section": "METHODS", "tags": [{"name": "http://blast.ncbi.nlm.nih.gov/Blast.cgi/;", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "http://toolkit.tuebingen.mpg.de/hhpred/;", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Based on our findings and analysis of audiologic features of MYO15A mutations, we suggest a hypothetical genotype-phenotype correlation whereby MYO15A mutations that affect domains other than the N-terminal domain, lead to profound SNHL throughout all frequencies, while mutations that affect the N-terminal domain, result in residual hearing at low frequencies, which could make contribution to language development and speech perception.", "section": "DISCUSS", "tags": [{"name": "genotype-phenotype", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "hypothetical", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}]}
{"src": "PMC", "id": "PMC4471120", "provider": "OpenTargets", "anns": [{"type": "Gene Disease Relationship", "exact": "To clarify mixed findings of large associations between sRAGE and outcomes in prior studies and to further understand the black-white difference in sRAGE levels, we used the Atherosclerosis Risk in Communities (ARIC) Study, a multi-ethnic, community-based cohort study to 1) conduct genome-wide association studies (GWAS) of sRAGE levels in whites and blacks separately; 2) evaluate if genetic variation underlies the black-white difference in sRAGE; and 3) conduct a Mendelian randomization study to evaluate the association between genetic determinants of sRAGE and mortality, coronary heart disease, congestive heart failure, diabetes, and chronic kidney disease.", "section": "INTRO", "tags": [{"name": "Atherosclerosis", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "community-based", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "In our study, BMI and fasting glucose were higher in black vs. white participants; outside of known racial disparities in these factors and their downstream inflammatory diseases (e.g., diabetes and coronary heart disease), proximal environmental factors suggested to underlie the observed increased inflammation among blacks include lower socioeconomic status [39, 41], stress [42] and racial discrimination [43].", "section": "DISCUSS", "tags": [{"name": "discrimination", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "participants;", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "We performed a post-hoc power calculation for blacks and whites separately using the non-centrality-parameter-based method for estimating power in Mendelian randomization studies described by Brion et al, 2013 [23, 24] and estimated power for the analyses of clinical outcomes assuming the following: type I error rate of 0.05; proportion of variance in ln(sRAGE) explained by SNP as reported in this study; event rates observed in this study; odds ratios for ln(sRAGE) and the clinical outcomes estimated using logistic regression in this study (Table B in S1 File).", "section": "METHODS", "tags": [{"name": "non-centrality-parameter-based", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "randomization", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "For analyses of the ARIC sub-sample with sRAGE levels (N = 2,318), covariates included self-reported age, sex, race (black or white), and educational level (less than high school, high school or any college, more than four years post-high school); body mass index calculated as measured weight/height2 in kg/m2 [15]; prevalent diabetes mellitus (self-reported diabetes, use of diabetes medications, and/or fasting glucose \u22656.99 mmol/l among those with fasting samples); estimated glomerular filtration rate (eGFR) calculated from measured creatinine [16] and age, sex, and race using the Modification of Diet in Renal Disease Study Group method [17]; and prevalent coronary heart disease by self-report or diagnosis by ARIC procedures described below.", "section": "METHODS", "tags": [{"name": "weight/height2", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "(self-reported", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "While some case-control studies have identified associations between AGER SNPs and myocardial infarction and stroke [31] and prevalent coronary heart disease based on angiographic evidence of stenosis >50% [32], two recent meta-analyses including over 25 case-control studies (maximum N for single SNP = 7,111) [29] did not find a consistent association between AGER polymorphisms and coronary heart disease (odds ratios from meta-analyses ranged from 0.97 to 1.16 with P >0.05) [29, 30].", "section": "DISCUSS", "tags": [{"name": "meta-analyses", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "polymorphisms", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "To clarify mixed findings of large associations between sRAGE and outcomes in prior studies and to further understand the black-white difference in sRAGE levels, we used the Atherosclerosis Risk in Communities (ARIC) Study, a multi-ethnic, community-based cohort study to 1) conduct genome-wide association studies (GWAS) of sRAGE levels in whites and blacks separately; 2) evaluate if genetic variation underlies the black-white difference in sRAGE; and 3) conduct a Mendelian randomization study to evaluate the association between genetic determinants of sRAGE and mortality, coronary heart disease, congestive heart failure, diabetes, and chronic kidney disease.", "section": "INTRO", "tags": [{"name": "Atherosclerosis", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "community-based", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "For the analysis of AGER (Gene ID: 177; Entrez Gene) SNPs and clinical outcomes, we were not limited to the ARIC subsample in which sRAGE was available and of the entire cohort of black and white participants with follow-up from visit 1 (1987\u20131989) who consented to non-cardiovascular disease-related research (N = 15,703), we excluded participants without genotyping data (N = 2,778) and those with genotyping samples that did not pass quality control measures (N = 1,037).", "section": "METHODS", "tags": [{"name": "non-cardiovascular", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "disease-related", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "In our study, BMI and fasting glucose were higher in black vs. white participants; outside of known racial disparities in these factors and their downstream inflammatory diseases (e.g., diabetes and coronary heart disease), proximal environmental factors suggested to underlie the observed increased inflammation among blacks include lower socioeconomic status [39, 41], stress [42] and racial discrimination [43].", "section": "DISCUSS", "tags": [{"name": "discrimination", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "participants;", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "For analyses of the ARIC sub-sample with sRAGE levels (N = 2,318), covariates included self-reported age, sex, race (black or white), and educational level (less than high school, high school or any college, more than four years post-high school); body mass index calculated as measured weight/height2 in kg/m2 [15]; prevalent diabetes mellitus (self-reported diabetes, use of diabetes medications, and/or fasting glucose \u22656.99 mmol/l among those with fasting samples); estimated glomerular filtration rate (eGFR) calculated from measured creatinine [16] and age, sex, and race using the Modification of Diet in Renal Disease Study Group method [17]; and prevalent coronary heart disease by self-report or diagnosis by ARIC procedures described below.", "section": "METHODS", "tags": [{"name": "weight/height2", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "(self-reported", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "To clarify mixed findings of large associations between sRAGE and outcomes in prior studies and to further understand the black-white difference in sRAGE levels, we used the Atherosclerosis Risk in Communities (ARIC) Study, a multi-ethnic, community-based cohort study to 1) conduct genome-wide association studies (GWAS) of sRAGE levels in whites and blacks separately; 2) evaluate if genetic variation underlies the black-white difference in sRAGE; and 3) conduct a Mendelian randomization study to evaluate the association between genetic determinants of sRAGE and mortality, coronary heart disease, congestive heart failure, diabetes, and chronic kidney disease.", "section": "INTRO", "tags": [{"name": "Atherosclerosis", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "community-based", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}]}
{"src": "PMC", "id": "PMC4539360", "provider": "OpenTargets", "anns": [{"type": "Gene Disease Relationship", "exact": "Glu688Gly<1\u00a0yearsSlow progressSymmetricLL+n/aBilateral tight AchillesBilateral foot drop+n/aMild split handTiptoe walking bilateral AFOsm 29.3MS\nF family, P patient, M male, F female, UL upper limb, LL lower limb, + mild, ++ moderate, +++ severe, AFO ankle foot orthesis, n/a not available, m/s metre per second, m median nerve, p peroneal nerve, u ulnar nerve, intermed. intermediate, MS motor and sensory", "section": "OTHER", "tags": [{"name": "progressSymmetricLL+n/aBilateral", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "AchillesBilateral", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Based on the electrophysiological and pathological characteristics it can be classified further into a demyelinating form (CMT1), where the nerve conduction velocity is reduced due to altered myelination, and to an axonal form (CMT2), where the primary axonal dysfunction leads to reduced amplitudes of evoked muscle action potentials.", "section": "INTRO", "tags": [{"name": "electrophysiological", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "characteristics", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Wasting and weakness of intrinsic hand muscles resulted in split hand deformity (Fig.\u00a01; Table\u00a02).Table\u00a02Genetic and clinical characteristics of patients with AARS-related neuropathy in the UK/Irish cohortFamily/patient/age/sexOriginNucleotide/amino acid changeAge onsetClinical courseFirst signClinical signsMobility/orthoticsNerve conduction studyDistal lower limbDistal upper limbMotor NCV (m/s)Motor/sensoryMotorSensoryDeformityMotorSensoryDeformityF1/PIII.1/50\u00a0years/MUKc.986G>A/p.", "section": "OTHER", "tags": [{"name": "(m/s)Motor/sensoryMotorSensoryDeformityMotorSensoryDeformityF1/PIII.1/50", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "cohortFamily/patient/age/sexOriginNucleotide/amino", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Wasting and weakness of intrinsic hand muscles resulted in split hand deformity (Fig.\u00a01; Table\u00a02).Table\u00a02Genetic and clinical characteristics of patients with AARS-related neuropathy in the UK/Irish cohortFamily/patient/age/sexOriginNucleotide/amino acid changeAge onsetClinical courseFirst signClinical signsMobility/orthoticsNerve conduction studyDistal lower limbDistal upper limbMotor NCV (m/s)Motor/sensoryMotorSensoryDeformityMotorSensoryDeformityF1/PIII.1/50\u00a0years/MUKc.986G>A/p.", "section": "OTHER", "tags": [{"name": "(m/s)Motor/sensoryMotorSensoryDeformityMotorSensoryDeformityF1/PIII.1/50", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "cohortFamily/patient/age/sexOriginNucleotide/amino", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Asn71TyrVaried (11\u201330\u00a0years)LLDistal weakness and wasting, mild sensory lossMild weakness, wasting mild sensory lossSymmetricm 38.1p absentMS[5]F1/P2LLMild weakness and wastingNoneSymmetricFrenchF1/P16c.986G>Ap.Arg329HisVaried (6\u201354\u00a0years)LLBilateral distal weakness, distal sensory lossDistal weakness, distal sensory lossSymmetricm 32.4\u201350MS[4]F1/P1LLSevere distal wasting, sensory lossNoneAsymmetricm 45FrenchF2/P1c.986G>Ap.", "section": "INTRO", "tags": [{"name": "wastingNoneSymmetricFrenchF1/P16c.986G>Ap.Arg329HisVaried", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "32.4\u201350MS[4]F1/P1LLSevere", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Additionally autosomal recessive loss of function AARS mutations (compound heterozygous p.Lys81Thr and p.Arg751Gly and homozygous p.Arg751Gly) were also described in two unrelated families, causing severe infantile epileptic encephalopathy with a central myelin defect and peripheral neuropathy [12].Table\u00a01Summary of the clinical and electrophysiology findings accompanying the reported different AARS variantsOriginFamily/patient numberNucleotide changeAmino acid changeAge onsetFirst signClinical symptomsNerve conduction studyReferencesLower limbUpper limbSymmetryMotor NCV (m/s)Motor/sensoryTaiwaneseF1/P5c.211A>Tp.", "section": "INTRO", "tags": [{"name": "(m/s)Motor/sensoryTaiwaneseF1/P5c.211A>Tp.", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "variantsOriginFamily/patient", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Some of these genes have been already associated with axonal dysfunction, such as mitofusin 2 (MFN2) which is responsible for 5\u201310\u00a0% of CMT2 cases, neurofilament light chain (NEFL) in 1\u20135\u00a0% and ganglioside-induced differentiation-associated protein (GDAP1) in less than 1\u00a0% of the cases [1, 3, 4, 11, 13].", "section": "INTRO", "tags": [{"name": "differentiation-associated", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "ganglioside-induced", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Genetic diagnosis is particularly difficult to achieve in the axonal form (CMT2) which shows genotypic and phenotypic overlap with distal hereditary motor neuropathies (dHMN) or distal spinal muscular atrophy (dSMA), a subgroup of rare inherited motor axonal neuropathies with no significant sensory involvement [9].", "section": "INTRO", "tags": [{"name": "particularly", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "neuropathies", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Glu688Gly<1\u00a0yearsSlow progressSymmetricLL+n/aBilateral tight AchillesBilateral foot drop+n/aMild split handTiptoe walking bilateral AFOsm 29.3MS\nF family, P patient, M male, F female, UL upper limb, LL lower limb, + mild, ++ moderate, +++ severe, AFO ankle foot orthesis, n/a not available, m/s metre per second, m median nerve, p peroneal nerve, u ulnar nerve, intermed. intermediate, MS motor and sensory", "section": "OTHER", "tags": [{"name": "progressSymmetricLL+n/aBilateral", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "AchillesBilateral", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Some of these genes have been already associated with axonal dysfunction, such as mitofusin 2 (MFN2) which is responsible for 5\u201310\u00a0% of CMT2 cases, neurofilament light chain (NEFL) in 1\u20135\u00a0% and ganglioside-induced differentiation-associated protein (GDAP1) in less than 1\u00a0% of the cases [1, 3, 4, 11, 13].", "section": "INTRO", "tags": [{"name": "differentiation-associated", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "ganglioside-induced", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Glu688Gly<1\u00a0yearsSlow progressSymmetricLL+n/aBilateral tight AchillesBilateral foot drop+n/aMild split handTiptoe walking bilateral AFOsm 29.3MS\nF family, P patient, M male, F female, UL upper limb, LL lower limb, + mild, ++ moderate, +++ severe, AFO ankle foot orthesis, n/a not available, m/s metre per second, m median nerve, p peroneal nerve, u ulnar nerve, intermed. intermediate, MS motor and sensory", "section": "OTHER", "tags": [{"name": "progressSymmetricLL+n/aBilateral", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "AchillesBilateral", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Genetic diagnosis is particularly difficult to achieve in the axonal form (CMT2) which shows genotypic and phenotypic overlap with distal hereditary motor neuropathies (dHMN) or distal spinal muscular atrophy (dSMA), a subgroup of rare inherited motor axonal neuropathies with no significant sensory involvement [9].", "section": "INTRO", "tags": [{"name": "particularly", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "neuropathies", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Asn71TyrVaried (11\u201330\u00a0years)LLDistal weakness and wasting, mild sensory lossMild weakness, wasting mild sensory lossSymmetricm 38.1p absentMS[5]F1/P2LLMild weakness and wastingNoneSymmetricFrenchF1/P16c.986G>Ap.Arg329HisVaried (6\u201354\u00a0years)LLBilateral distal weakness, distal sensory lossDistal weakness, distal sensory lossSymmetricm 32.4\u201350MS[4]F1/P1LLSevere distal wasting, sensory lossNoneAsymmetricm 45FrenchF2/P1c.986G>Ap.", "section": "INTRO", "tags": [{"name": "wastingNoneSymmetricFrenchF1/P16c.986G>Ap.Arg329HisVaried", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "32.4\u201350MS[4]F1/P1LLSevere", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Wasting and weakness of intrinsic hand muscles resulted in split hand deformity (Fig.\u00a01; Table\u00a02).Table\u00a02Genetic and clinical characteristics of patients with AARS-related neuropathy in the UK/Irish cohortFamily/patient/age/sexOriginNucleotide/amino acid changeAge onsetClinical courseFirst signClinical signsMobility/orthoticsNerve conduction studyDistal lower limbDistal upper limbMotor NCV (m/s)Motor/sensoryMotorSensoryDeformityMotorSensoryDeformityF1/PIII.1/50\u00a0years/MUKc.986G>A/p.", "section": "OTHER", "tags": [{"name": "(m/s)Motor/sensoryMotorSensoryDeformityMotorSensoryDeformityF1/PIII.1/50", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "cohortFamily/patient/age/sexOriginNucleotide/amino", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Wasting and weakness of intrinsic hand muscles resulted in split hand deformity (Fig.\u00a01; Table\u00a02).Table\u00a02Genetic and clinical characteristics of patients with AARS-related neuropathy in the UK/Irish cohortFamily/patient/age/sexOriginNucleotide/amino acid changeAge onsetClinical courseFirst signClinical signsMobility/orthoticsNerve conduction studyDistal lower limbDistal upper limbMotor NCV (m/s)Motor/sensoryMotorSensoryDeformityMotorSensoryDeformityF1/PIII.1/50\u00a0years/MUKc.986G>A/p.", "section": "OTHER", "tags": [{"name": "(m/s)Motor/sensoryMotorSensoryDeformityMotorSensoryDeformityF1/PIII.1/50", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "cohortFamily/patient/age/sexOriginNucleotide/amino", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Glu688Gly<1\u00a0yearsSlow progressSymmetricLL+n/aBilateral tight AchillesBilateral foot drop+n/aMild split handTiptoe walking bilateral AFOsm 29.3MS\nF family, P patient, M male, F female, UL upper limb, LL lower limb, + mild, ++ moderate, +++ severe, AFO ankle foot orthesis, n/a not available, m/s metre per second, m median nerve, p peroneal nerve, u ulnar nerve, intermed. intermediate, MS motor and sensory", "section": "OTHER", "tags": [{"name": "progressSymmetricLL+n/aBilateral", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "AchillesBilateral", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Additionally autosomal recessive loss of function AARS mutations (compound heterozygous p.Lys81Thr and p.Arg751Gly and homozygous p.Arg751Gly) were also described in two unrelated families, causing severe infantile epileptic encephalopathy with a central myelin defect and peripheral neuropathy [12].Table\u00a01Summary of the clinical and electrophysiology findings accompanying the reported different AARS variantsOriginFamily/patient numberNucleotide changeAmino acid changeAge onsetFirst signClinical symptomsNerve conduction studyReferencesLower limbUpper limbSymmetryMotor NCV (m/s)Motor/sensoryTaiwaneseF1/P5c.211A>Tp.", "section": "INTRO", "tags": [{"name": "(m/s)Motor/sensoryTaiwaneseF1/P5c.211A>Tp.", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "variantsOriginFamily/patient", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}]}
{"src": "PMC", "id": "PMC4457031", "provider": "OpenTargets", "anns": [{"type": "Gene Disease Relationship", "exact": "The analysis generated \u2018Acute renal failure panel\u2019 (P=5.86E\u201304, ratio 6/62), \u2018NRF2-mediated oxidative stress response\u2019 (P=6.07E\u201304, ratio 12/234), \u2018Renal necrosis/Cell death\u2019 (P=8.13E\u201304, ratio 18/461), \u2018Oxidative stress\u2019 (P=2.62E\u201303, ratio 5/57) and \u2018Renal safety biomarker panel\u2019 (P=4.01E\u201303, ratio 2/6) as the top five most significant effects (supplementary material Table\u00a0S5).", "section": "RESULTS", "tags": [{"name": "\u2018NRF2-mediated", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "(supplementary", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "We then applied a series of exclusion steps to identify the causative mutation: (1) we removed variants that were heterozygous in the affected animal; (2) we excluded variants that were homozygous in one of the two parents; (3) we rejected variants that were inconsistent with the Mendelian inheritance model; (4) we excluded variants in the non-coding regions.", "section": "RESULTS", "tags": [{"name": "heterozygous", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "inconsistent", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "We explored 16,272 qualified SNPs to perform a genome-wide association analysis on the F2 family, after excluding the following single-nucleotide polymorphisms (SNPs): SNPs that had a low call rate (90%) or Hardy\u2013Weinberg equilibrium deviation >10\u22126, were non-informative (minor allele frequencies <0.05), or were not mapped to the reference genome (Sscrofa 10.2).", "section": "RESULTS", "tags": [{"name": "single-nucleotide", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "non-informative", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "These findings are in agreement with the knowledge that HOXA1 plays a crucial multifaceted role during embryonic patterning and organogenesis, and are also consistent with the fact that the human and mouse HOXA1-related phenotypic presentations often have cardiovascular defects, renal abnormalities, rib deformities and mental retardation (Barrow et al., 2000; Chisaka et al., 1992; Harris et al., 1996; Mastroiacovo et al., 1995; Wang et al., 2001).", "section": "DISCUSS", "tags": [{"name": "organogenesis,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "cardiovascular", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "The analysis generated \u2018Acute renal failure panel\u2019 (P=5.86E\u201304, ratio 6/62), \u2018NRF2-mediated oxidative stress response\u2019 (P=6.07E\u201304, ratio 12/234), \u2018Renal necrosis/Cell death\u2019 (P=8.13E\u201304, ratio 18/461), \u2018Oxidative stress\u2019 (P=2.62E\u201303, ratio 5/57) and \u2018Renal safety biomarker panel\u2019 (P=4.01E\u201303, ratio 2/6) as the top five most significant effects (supplementary material Table\u00a0S5).", "section": "RESULTS", "tags": [{"name": "\u2018NRF2-mediated", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "(supplementary", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Mutations in this gene cause Ellis van Creveld syndrome and Weyers acrofacial dysostosis, clinically characterized by polydactyly, short ribs and limbs, growth retardation, congenital heart disease and ectodermal dysplasia (Baujat and Le Merrer, 2007; D'Asdia et al., 2013; Shen et al., 2011; Ye et al., 2006), which are phenotypes commonly associated with microtia.", "section": "DISCUSS", "tags": [{"name": "characterized", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "polydactyly,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "We then applied a series of exclusion steps to identify the causative mutation: (1) we removed variants that were heterozygous in the affected animal; (2) we excluded variants that were homozygous in one of the two parents; (3) we rejected variants that were inconsistent with the Mendelian inheritance model; (4) we excluded variants in the non-coding regions.", "section": "RESULTS", "tags": [{"name": "heterozygous", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "inconsistent", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "We explored 16,272 qualified SNPs to perform a genome-wide association analysis on the F2 family, after excluding the following single-nucleotide polymorphisms (SNPs): SNPs that had a low call rate (90%) or Hardy\u2013Weinberg equilibrium deviation >10\u22126, were non-informative (minor allele frequencies <0.05), or were not mapped to the reference genome (Sscrofa 10.2).", "section": "RESULTS", "tags": [{"name": "single-nucleotide", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "non-informative", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Mutations in this gene cause Ellis van Creveld syndrome and Weyers acrofacial dysostosis, clinically characterized by polydactyly, short ribs and limbs, growth retardation, congenital heart disease and ectodermal dysplasia (Baujat and Le Merrer, 2007; D'Asdia et al., 2013; Shen et al., 2011; Ye et al., 2006), which are phenotypes commonly associated with microtia.", "section": "DISCUSS", "tags": [{"name": "characterized", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "polydactyly,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "The analysis generated \u2018Acute renal failure panel\u2019 (P=5.86E\u201304, ratio 6/62), \u2018NRF2-mediated oxidative stress response\u2019 (P=6.07E\u201304, ratio 12/234), \u2018Renal necrosis/Cell death\u2019 (P=8.13E\u201304, ratio 18/461), \u2018Oxidative stress\u2019 (P=2.62E\u201303, ratio 5/57) and \u2018Renal safety biomarker panel\u2019 (P=4.01E\u201303, ratio 2/6) as the top five most significant effects (supplementary material Table\u00a0S5).", "section": "RESULTS", "tags": [{"name": "\u2018NRF2-mediated", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "(supplementary", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "We explored 16,272 qualified SNPs to perform a genome-wide association analysis on the F2 family, after excluding the following single-nucleotide polymorphisms (SNPs): SNPs that had a low call rate (90%) or Hardy\u2013Weinberg equilibrium deviation >10\u22126, were non-informative (minor allele frequencies <0.05), or were not mapped to the reference genome (Sscrofa 10.2).", "section": "RESULTS", "tags": [{"name": "single-nucleotide", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "non-informative", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}]}
{"src": "PMC", "id": "PMC4460277", "provider": "OpenTargets", "anns": [{"type": "Gene Disease Relationship", "exact": "Fig. 4HER2 immunohistochemistry: a strong membranous positivity in 100\u00a0% of the tumor cells of a conventional urothelial bladder cancer, score 3+; b score 3+ in a micropapillary variant; c mosaic pattern, score 3+; d strong positivity in carcinoma in situ, negativity in the adjacent normal urothelium", "section": "OTHER", "tags": [{"name": "immunohistochemistry:", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "micropapillary", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "The primer sequences were as follows: forward primer exon 19, 5\u2032-CCCACGCTCTTCTCACTCAT-3\u2032; reverse primer exon 19; 5\u2032-TCCTTCCTGTCCTCCTAGCA-3\u2032; forward primer exon 20, 5\u2032-TGGTCTCCCATACCCTCTCA-3\u2032; and reverse primer exon 20, 5\u2032-CAAAGAGCCCAGGTGCATA-3\u2032. Sequence analysis was performed using the 3500 genetic analyzer (Applied Biosystems).", "section": "METHODS", "tags": [{"name": "5\u2032-CCCACGCTCTTCTCACTCAT-3\u2032;", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "5\u2032-TCCTTCCTGTCCTCCTAGCA-3\u2032;", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "HER2 amplified urothelial bladder cancer often presents with marked tumor-associated chronic inflammation (d HE\u2009\u00d7\u200920)\nFig. 2\nHER2 non-amplified urothelial bladder cancers mostly show conventional solid morphology (a HE\u2009\u00d7\u200910); b sarcomatoid variant (HE\u2009\u00d7\u200920)\nFig. 3Comparison of HER2 amplified and non-amplified urothelial bladder cancers (n=13 each) in regard to their morphology (the tumor components are given as percentage in relation to the total tumor mass in each group): micropapillary architecture is a key feature of HER2 amplified urothelial bladder cancer", "section": "OTHER", "tags": [{"name": "tumor-associated", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "micropapillary", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Comparison of HER2 amplified and non-amplified urothelial bladder cancers (n=13 each) in regard to their morphology (the tumor components are given as percentage in relation to the total tumor mass in each group): micropapillary architecture is a key feature of HER2 amplified urothelial bladder cancer", "section": "OTHER", "tags": [{"name": "micropapillary", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "non-amplified", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "The primer sequences were as follows: forward primer exon 19, 5\u2032-CCCACGCTCTTCTCACTCAT-3\u2032; reverse primer exon 19; 5\u2032-TCCTTCCTGTCCTCCTAGCA-3\u2032; forward primer exon 20, 5\u2032-TGGTCTCCCATACCCTCTCA-3\u2032; and reverse primer exon 20, 5\u2032-CAAAGAGCCCAGGTGCATA-3\u2032. Sequence analysis was performed using the 3500 genetic analyzer (Applied Biosystems).", "section": "METHODS", "tags": [{"name": "5\u2032-CCCACGCTCTTCTCACTCAT-3\u2032;", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "5\u2032-TCCTTCCTGTCCTCCTAGCA-3\u2032;", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Comparison of HER2 amplified and non-amplified urothelial bladder cancers (n=13 each) in regard to their morphology (the tumor components are given as percentage in relation to the total tumor mass in each group): micropapillary architecture is a key feature of HER2 amplified urothelial bladder cancer", "section": "OTHER", "tags": [{"name": "micropapillary", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "non-amplified", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Taken together, these histomorphological features of HER2 amplified UBC\u2014frequent micropapillary architecture, morphological heterogeneity and marked tumor-associated chronic inflammation\u2014allow pathologists to better identify this clinically important, particularly aggressive subset of UBC [12] and herewith to contribute to enhanced survival prediction and preselection for potential anti-HER2 therapies in the future.", "section": "DISCUSS", "tags": [{"name": "histomorphological", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "inflammation\u2014allow", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Fig. 4HER2 immunohistochemistry: a strong membranous positivity in 100\u00a0% of the tumor cells of a conventional urothelial bladder cancer, score 3+; b score 3+ in a micropapillary variant; c mosaic pattern, score 3+; d strong positivity in carcinoma in situ, negativity in the adjacent normal urothelium", "section": "OTHER", "tags": [{"name": "immunohistochemistry:", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "micropapillary", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "HER2 amplified urothelial bladder cancer often presents with marked tumor-associated chronic inflammation (d HE\u2009\u00d7\u200920)\nFig. 2\nHER2 non-amplified urothelial bladder cancers mostly show conventional solid morphology (a HE\u2009\u00d7\u200910); b sarcomatoid variant (HE\u2009\u00d7\u200920)\nFig. 3Comparison of HER2 amplified and non-amplified urothelial bladder cancers (n=13 each) in regard to their morphology (the tumor components are given as percentage in relation to the total tumor mass in each group): micropapillary architecture is a key feature of HER2 amplified urothelial bladder cancer", "section": "OTHER", "tags": [{"name": "tumor-associated", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "micropapillary", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "HER2 amplified urothelial bladder cancer often presents with marked tumor-associated chronic inflammation (d HE\u2009\u00d7\u200920)\nFig. 2\nHER2 non-amplified urothelial bladder cancers mostly show conventional solid morphology (a HE\u2009\u00d7\u200910); b sarcomatoid variant (HE\u2009\u00d7\u200920)\nFig. 3Comparison of HER2 amplified and non-amplified urothelial bladder cancers (n=13 each) in regard to their morphology (the tumor components are given as percentage in relation to the total tumor mass in each group): micropapillary architecture is a key feature of HER2 amplified urothelial bladder cancer", "section": "OTHER", "tags": [{"name": "tumor-associated", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "micropapillary", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "The primer sequences were as follows: forward primer exon 19, 5\u2032-CCCACGCTCTTCTCACTCAT-3\u2032; reverse primer exon 19; 5\u2032-TCCTTCCTGTCCTCCTAGCA-3\u2032; forward primer exon 20, 5\u2032-TGGTCTCCCATACCCTCTCA-3\u2032; and reverse primer exon 20, 5\u2032-CAAAGAGCCCAGGTGCATA-3\u2032. Sequence analysis was performed using the 3500 genetic analyzer (Applied Biosystems).", "section": "METHODS", "tags": [{"name": "5\u2032-CCCACGCTCTTCTCACTCAT-3\u2032;", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "5\u2032-TCCTTCCTGTCCTCCTAGCA-3\u2032;", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Comparison of HER2 amplified and non-amplified urothelial bladder cancers (n=13 each) in regard to their morphology (the tumor components are given as percentage in relation to the total tumor mass in each group): micropapillary architecture is a key feature of HER2 amplified urothelial bladder cancer", "section": "OTHER", "tags": [{"name": "micropapillary", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "non-amplified", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Comparison of HER2 amplified and non-amplified urothelial bladder cancers (n=13 each) in regard to their morphology (the tumor components are given as percentage in relation to the total tumor mass in each group): micropapillary architecture is a key feature of HER2 amplified urothelial bladder cancer", "section": "OTHER", "tags": [{"name": "micropapillary", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "non-amplified", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Fig. 4HER2 immunohistochemistry: a strong membranous positivity in 100\u00a0% of the tumor cells of a conventional urothelial bladder cancer, score 3+; b score 3+ in a micropapillary variant; c mosaic pattern, score 3+; d strong positivity in carcinoma in situ, negativity in the adjacent normal urothelium", "section": "OTHER", "tags": [{"name": "immunohistochemistry:", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "micropapillary", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "HER2 immunohistochemistry: a strong membranous positivity in 100\u00a0% of the tumor cells of a conventional urothelial bladder cancer, score 3+; b score 3+ in a micropapillary variant; c mosaic pattern, score 3+; d strong positivity in carcinoma in situ, negativity in the adjacent normal urothelium", "section": "OTHER", "tags": [{"name": "immunohistochemistry:", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "micropapillary", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}]}
{"src": "PMC", "id": "PMC4454778", "provider": "OpenTargets", "anns": [{"type": "Gene Disease Relationship", "exact": "Results were further filtered for variants with a minor allele frequency less than 0.01 in several databases: dbSNP135, 1000 genomes (February 2012 data release), the National Heart, Lung and Blood Institute (NHLBI, NIH, Bethesda, MD) Exome Sequencing Project (ESP) 6500 exomes, and 238 unrelated in-house controls, in order to detect rare variants.", "section": "METHODS", "tags": [{"name": "databases:", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "Sequencing", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Results were further filtered for variants with a minor allele frequency less than 0.01 in several databases: dbSNP135, 1000 genomes (February 2012 data release), the National Heart, Lung and Blood Institute (NHLBI, NIH, Bethesda, MD) Exome Sequencing Project (ESP) 6500 exomes, and 238 unrelated in-house controls, in order to detect rare variants.", "section": "METHODS", "tags": [{"name": "databases:", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "Sequencing", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "PNSS include hereditary motor and sensory neuropathy type 2C or Charcot\u2013Marie\u2013Tooth disease type 2C (HMSN2C or CMT2C; OMIM 606071), congenital spinal muscular atrophy and arthrogryposis (CSMAA; OMIM 600175) and scapuloperoneal spinal muscular atrophy (SPSMA; OMIM 181405).", "section": "INTRO", "tags": [{"name": "Charcot\u2013Marie\u2013Tooth", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "scapuloperoneal", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Results were further filtered for variants with a minor allele frequency less than 0.01 in several databases: dbSNP135, 1000 genomes (February 2012 data release), the National Heart, Lung and Blood Institute (NHLBI, NIH, Bethesda, MD) Exome Sequencing Project (ESP) 6500 exomes, and 238 unrelated in-house controls, in order to detect rare variants.", "section": "METHODS", "tags": [{"name": "databases:", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "Sequencing", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Whole-exome sequencing was carried out in both patients using genomic DNA extracted from peripheral blood lymphocytes, fragmented, and exome enriched by Illumina TruSeq\u2122 62\u2009Mb and sequenced on a HiSeq 2000 with 100\u2009bp paired-end reads.", "section": "METHODS", "tags": [{"name": "lymphocytes,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "Whole-exome", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "We assume that the differences between our patient and the ones reported by Astrea et\u00a0al. [20] and Oates et\u00a0al. [17] are due to the fact that our case is a late onset form of the disease (CMT2C) while the later ones corresponded to congenital forms of SMA.", "section": "DISCUSS", "tags": [{"name": "corresponded", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "differences", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Results were further filtered for variants with a minor allele frequency less than 0.01 in several databases: dbSNP135, 1000 genomes (February 2012 data release), the National Heart, Lung and Blood Institute (NHLBI, NIH, Bethesda, MD) Exome Sequencing Project (ESP) 6500 exomes, and 238 unrelated in-house controls, in order to detect rare variants.", "section": "METHODS", "tags": [{"name": "databases:", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "Sequencing", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Whole-exome sequencing was carried out in both patients using genomic DNA extracted from peripheral blood lymphocytes, fragmented, and exome enriched by Illumina TruSeq\u2122 62\u2009Mb and sequenced on a HiSeq 2000 with 100\u2009bp paired-end reads.", "section": "METHODS", "tags": [{"name": "lymphocytes,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "Whole-exome", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Results were further filtered for variants with a minor allele frequency less than 0.01 in several databases: dbSNP135, 1000 genomes (February 2012 data release), the National Heart, Lung and Blood Institute (NHLBI, NIH, Bethesda, MD) Exome Sequencing Project (ESP) 6500 exomes, and 238 unrelated in-house controls, in order to detect rare variants.", "section": "METHODS", "tags": [{"name": "databases:", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "Sequencing", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Whole-exome sequencing was carried out in both patients using genomic DNA extracted from peripheral blood lymphocytes, fragmented, and exome enriched by Illumina TruSeq\u2122 62\u2009Mb and sequenced on a HiSeq 2000 with 100\u2009bp paired-end reads.", "section": "METHODS", "tags": [{"name": "lymphocytes,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "Whole-exome", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Whole-exome sequencing was carried out in both patients using genomic DNA extracted from peripheral blood lymphocytes, fragmented, and exome enriched by Illumina TruSeq\u2122 62\u2009Mb and sequenced on a HiSeq 2000 with 100\u2009bp paired-end reads.", "section": "METHODS", "tags": [{"name": "lymphocytes,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "Whole-exome", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Our finding expands further the clinical variability among TRPV4 mutations and highlight that the presence of skeletal abnormalities in a patient with an axonal neuropathy or neuronopathy should raise the possibility of TRPV4 gene mutations.", "section": "DISCUSS", "tags": [{"name": "abnormalities", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "neuronopathy", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}]}
{"src": "PMC", "id": "PMC4363147", "provider": "OpenTargets", "anns": [{"type": "Gene Disease Relationship", "exact": "As Kendler [79] argues, it is unlikely we will uncover an exclusive genetic pattern revealing a heterogeneous illness such as depression; but it is possible to identify subsets of genetic interactions that delineate particular molecular pathways susceptible under certain genetic and environmental conditions.", "section": "DISCUSS", "tags": [{"name": "heterogeneous", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "environmental", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Washington University's Human Research Protection Office, Washington University School of Medicine Institutional Review Board, and the review boards at the applicable participating research site (The Christian Hospital Research Committee for Christian Hospital, DePaul Institutional Review Board for DePaul Health Center, Missouri Baptist Medical Center Institutional Review Board for Missouri Baptist Medical Center, Saint Anthony\u2019s Medical Center Institutional Review Board for Saint Anthony's Medical Center, SSM Saint Louis Institutional Review Board for SSM Saint Clare Health Center, Saint Louis University Institutional Review Board for Saint Louis University Medical Center Campus and Saint Mary\u2019s Health Center, and Washington University School of Medicine Institutional Review Board for Barnes-Jewish Hospital) approved this study and approved the informed written consent document that was signed by all participants.", "section": "OTHER", "tags": [{"name": "Institutional", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "participating", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Washington University's Human Research Protection Office, Washington University School of Medicine Institutional Review Board, and the review boards at the applicable participating research site (The Christian Hospital Research Committee for Christian Hospital, DePaul Institutional Review Board for DePaul Health Center, Missouri Baptist Medical Center Institutional Review Board for Missouri Baptist Medical Center, Saint Anthony\u2019s Medical Center Institutional Review Board for Saint Anthony's Medical Center, SSM Saint Louis Institutional Review Board for SSM Saint Clare Health Center, Saint Louis University Institutional Review Board for Saint Louis University Medical Center Campus and Saint Mary\u2019s Health Center, and Washington University School of Medicine Institutional Review Board for Barnes-Jewish Hospital) approved this study and approved the informed written consent document that was signed by all participants.", "section": "OTHER", "tags": [{"name": "Institutional", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "participating", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Considering previous studies have indicated that atrophy of the hippocampus [22,33] and reduced hippocampal activity [32] are associated with the Met allele, BDNF Met/Met carriers may be vulnerable to the development of depressive symptoms due to inadequate synaptic formation in the hippocampus, a structure important for mood regulation [26,34,35,65,66].", "section": "DISCUSS", "tags": [{"name": "[26,34,35,65,66].", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "hippocampus,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Participants with hip fracture were excluded if they were unable to provide written informed consent after complete description of the study, were unable to cooperate with the protocol, had a current diagnosis of major depression, had metastatic cancer, were significantly impaired by language, visual or hearing barriers, lived more than one hour away, were taking interferon medications, or had an inoperable fracture.", "section": "OTHER", "tags": [{"name": "significantly", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "Participants", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "The gene SLC6A4 encodes for the serotonin transporter (5HTT) and this transporter\u2019s efficiency is altered by both a genetic variation of the serotonin transporter gene-linked polymorphic region (5HTTLPR) and a functional A to G single-nucleotide polymorphism (SNP; refSNP: rs25531) [37,38].", "section": "INTRO", "tags": [{"name": "single-nucleotide", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "transporter\u2019s", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "That is, a further reduction of BDNF due to stress could impact BDNF\u2019s ability to contribute to the survival and functioning of serotoninergic neurons, whereas the less functional serotonin system among S\u2032 carriers has learned to adapt with neurotrophins over time and may be more resistant to stressors.", "section": "DISCUSS", "tags": [{"name": "serotoninergic", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "neurotrophins", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Considering previous studies have indicated that atrophy of the hippocampus [22,33] and reduced hippocampal activity [32] are associated with the Met allele, BDNF Met/Met carriers may be vulnerable to the development of depressive symptoms due to inadequate synaptic formation in the hippocampus, a structure important for mood regulation [26,34,35,65,66].", "section": "DISCUSS", "tags": [{"name": "[26,34,35,65,66].", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "hippocampus,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Participants with hip fracture were excluded if they were unable to provide written informed consent after complete description of the study, were unable to cooperate with the protocol, had a current diagnosis of major depression, had metastatic cancer, were significantly impaired by language, visual or hearing barriers, lived more than one hour away, were taking interferon medications, or had an inoperable fracture.", "section": "OTHER", "tags": [{"name": "significantly", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "Participants", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Washington University's Human Research Protection Office, Washington University School of Medicine Institutional Review Board, and the review boards at the applicable participating research site (The Christian Hospital Research Committee for Christian Hospital, DePaul Institutional Review Board for DePaul Health Center, Missouri Baptist Medical Center Institutional Review Board for Missouri Baptist Medical Center, Saint Anthony\u2019s Medical Center Institutional Review Board for Saint Anthony's Medical Center, SSM Saint Louis Institutional Review Board for SSM Saint Clare Health Center, Saint Louis University Institutional Review Board for Saint Louis University Medical Center Campus and Saint Mary\u2019s Health Center, and Washington University School of Medicine Institutional Review Board for Barnes-Jewish Hospital) approved this study and approved the informed written consent document that was signed by all participants.", "section": "OTHER", "tags": [{"name": "Institutional", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "participating", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "The gene SLC6A4 encodes for the serotonin transporter (5HTT) and this transporter\u2019s efficiency is altered by both a genetic variation of the serotonin transporter gene-linked polymorphic region (5HTTLPR) and a functional A to G single-nucleotide polymorphism (SNP; refSNP: rs25531) [37,38].", "section": "INTRO", "tags": [{"name": "single-nucleotide", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "transporter\u2019s", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "That is, a further reduction of BDNF due to stress could impact BDNF\u2019s ability to contribute to the survival and functioning of serotoninergic neurons, whereas the less functional serotonin system among S\u2032 carriers has learned to adapt with neurotrophins over time and may be more resistant to stressors.", "section": "DISCUSS", "tags": [{"name": "serotoninergic", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "neurotrophins", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "The gene SLC6A4 encodes for the serotonin transporter (5HTT) and this transporter\u2019s efficiency is altered by both a genetic variation of the serotonin transporter gene-linked polymorphic region (5HTTLPR) and a functional A to G single-nucleotide polymorphism (SNP; refSNP: rs25531) [37,38].", "section": "INTRO", "tags": [{"name": "single-nucleotide", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "transporter\u2019s", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Depressive symptoms after hip fracture have a pernicious effect on the recovery process: they are associated with higher discharge rates to and increased length of stay in nursing homes [13\u201315], poorer occupational and physical therapy participation, and poorer functional recovery [16,17].", "section": "INTRO", "tags": [{"name": "participation,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "occupational", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Washington University's Human Research Protection Office, Washington University School of Medicine Institutional Review Board, and the review boards at the applicable participating research site (The Christian Hospital Research Committee for Christian Hospital, DePaul Institutional Review Board for DePaul Health Center, Missouri Baptist Medical Center Institutional Review Board for Missouri Baptist Medical Center, Saint Anthony\u2019s Medical Center Institutional Review Board for Saint Anthony's Medical Center, SSM Saint Louis Institutional Review Board for SSM Saint Clare Health Center, Saint Louis University Institutional Review Board for Saint Louis University Medical Center Campus and Saint Mary\u2019s Health Center, and Washington University School of Medicine Institutional Review Board for Barnes-Jewish Hospital) approved this study and approved the informed written consent document that was signed by all participants.", "section": "OTHER", "tags": [{"name": "Institutional", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "participating", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "As Kendler [79] argues, it is unlikely we will uncover an exclusive genetic pattern revealing a heterogeneous illness such as depression; but it is possible to identify subsets of genetic interactions that delineate particular molecular pathways susceptible under certain genetic and environmental conditions.", "section": "DISCUSS", "tags": [{"name": "heterogeneous", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "environmental", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Participants with hip fracture were excluded if they were unable to provide written informed consent after complete description of the study, were unable to cooperate with the protocol, had a current diagnosis of major depression, had metastatic cancer, were significantly impaired by language, visual or hearing barriers, lived more than one hour away, were taking interferon medications, or had an inoperable fracture.", "section": "OTHER", "tags": [{"name": "significantly", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "Participants", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}]}
{"src": "PMC", "id": "PMC6680266", "provider": "OpenTargets", "anns": [{"type": "Gene Disease Relationship", "exact": "A significant association was seen in several of the TLR\u2013IFN pathway genes, TLR9 rs352140 (OR\u00a0=\u00a00.70, P\u00a0=\u00a00.0088), IL1B rs16944 (OR\u00a0=\u00a00.67, P\u00a0=\u00a00.016), IL12B rs3212227 (OR\u00a0=\u00a01.38, P\u00a0=\u00a00.021), IFNGR1 rs3799488 (OR\u00a0=\u00a01.48, P\u00a0=\u00a00.0048), IFNGR2 rs1059293 (OR\u00a0=\u00a00.27, P\u00a0=\u00a00.011), MX1 rs467960 (OR\u00a0=\u00a00.68, P\u00a0=\u00a00.022), as well as four loci in HLA, rs3077 (OR\u00a0=\u00a00.55, P\u00a0<\u00a00.0001), rs2856718 (OR\u00a0=\u00a00.60, P\u00a0=\u00a04e\u201004), rs9277535 (OR\u00a0=\u00a00.54, P\u00a0<\u00a00.0001) and rs7453920 (OR\u00a0=\u00a00.43, P\u00a0<\u00a00.0001).", "section": "RESULTS", "tags": [{"name": "significant", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "association", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Exclusion criteria consisted of the following: (a) co\u2010infectionwith HCV, hepatitis D virus or human immunodeficiency virus (HIV); (b) coexisting serious medical or psychiatric illness; (c) organ or bone marrow transplantation; (d) recent treatment with systemic corticosteroids, immunosuppressants or chemotherapeutic agents.", "section": "METHODS", "tags": [{"name": "immunosuppressants", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "co\u2010infectionwith", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Each component of the model was: co\u2010dominant model (major allele homozygotes vs. heterozygotes vs. minor allele homozygotes), dominant model (major allele homozygotes vs. heterozygotes + minor allele homozygotes), recessive model (major allele homozygotes vs. minor allele homozygotes), overdominant model (major allele homozygotes + heterozygotes vs. minor allele homozygotes) and log\u2010additive model.", "section": "METHODS", "tags": [{"name": "heterozygotes", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "homozygotes),", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "These genes included TLRs (TLR3, TLR4, TLR5 and TLR9), the TLR adaptin MYD88, the TLR effector molecule IRAK1, receptors for IFNs (IFNGR1, IFNGR2, IL27B and IL12B), ligands for IFN receptors (IFNG and IL15), other genes related to IFNs (IL28A, IL29 and IL6), proteins induced by IFN (MX1, CXCL10), and genes of the NF\u03baB pathway (NFKB1, NFKB2, IL1B, IL2, IL10 and IL12A).", "section": "METHODS", "tags": [{"name": "receptors", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "receptors", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "These genes included TLRs (TLR3, TLR4, TLR5 and TLR9), the TLR adaptin MYD88, the TLR effector molecule IRAK1, receptors for IFNs (IFNGR1, IFNGR2, IL27B and IL12B), ligands for IFN receptors (IFNG and IL15), other genes related to IFNs (IL28A, IL29 and IL6), proteins induced by IFN (MX1, CXCL10), and genes of the NF\u03baB pathway (NFKB1, NFKB2, IL1B, IL2, IL10 and IL12A).", "section": "METHODS", "tags": [{"name": "receptors", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "receptors", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "These were: TLR3 rs3775296, TLR4 rs11536889 and rs1927907, TLR5 rs5744174, TLR9 rs352140, MYD88 rs7744, IRAK1 rs1059702 and rs1059703, IFNG rs2069705, IFNGR1 rs3799488 and rs10457655, IFNGR2 rs1059293 and rs2834211, IL15 rs10519613 and rs10833, IL28B rs12979860 and rs8099917, IL29 rs30461, IL6 rs1800796, IL27B rs4905 and rs6613, IL12B rs3212227, NFKB1 rs4648068, NFKB2 rs7897947, IL1B rs1143623, rs1143627, and rs16944, IL2 rs2069772, IL10 rs1800872 and rs1800896, IL12A rs2243115 and rs568408, CXCL10 rs4256246, rs4508917, and rs8878, MX1 rs1557370, rs2070229, rs467960, and rs469390.", "section": "METHODS", "tags": [{"name": "rs10457655,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "rs3775296,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Each component of the model was: co\u2010dominant model (major allele homozygotes vs. heterozygotes vs. minor allele homozygotes), dominant model (major allele homozygotes vs. heterozygotes + minor allele homozygotes), recessive model (major allele homozygotes vs. minor allele homozygotes), overdominant model (major allele homozygotes + heterozygotes vs. minor allele homozygotes) and log\u2010additive model.", "section": "METHODS", "tags": [{"name": "heterozygotes", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "homozygotes),", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}]}
{"src": "PMC", "id": "PMC4583332", "provider": "OpenTargets", "anns": [{"type": "Gene Disease Relationship", "exact": "Given the continuing decline in cost of next generation sequencing reagents, automation of variant calling methods, and potential diagnostic value susceptibility variants such as APOE\u025b4, whole exome approaches should be considered to be a more comprehensive, cost-effective alternative to candidate gene sequencing for the diagnosis of atypical dementias.", "section": "DISCUSS", "tags": [{"name": "susceptibility", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "comprehensive,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Extensive pre-clinical research with AD-transgenic mice [14] and clinical data that included autopsy-confirmed diagnostic specificity of the protein kinase C (PKC) pathway [15, 16] provided a rationale for an FDA approval for a Phase 2a clinical trial with the highly potent PKC activator, bryostatin.", "section": "INTRO", "tags": [{"name": "autopsy-confirmed", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "AD-transgenic", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Since variants in known causal loci only explain a fraction of early-onset dementias, we performed whole exome sequencing with discrete filtering on two affected family members in order to identify causal variants and make a more accurate diagnosis.", "section": "INTRO", "tags": [{"name": "early-onset", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "dementias,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "The latter pathology frequently leads to speech patterns consistent with the logopenic variant of primary progressive aphasia, with single word retrieval issues and impaired repetition of words or phrases [17], whereas these abnormalities were specifically denied in her history and not seen on earlier neuropsychological testing.", "section": "METHODS", "tags": [{"name": "neuropsychological", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "abnormalities", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Further evidence implicating PKC deficits has emerged from clinical studies that showed with autopsy-confirmation that AD patients have significant abnormalities in PKC isozymes and PKC-elicited phosphorylation of downstream substrates [15, 16, 23, 24].", "section": "OTHER", "tags": [{"name": "autopsy-confirmation", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "phosphorylation", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "Scores of disease processes may ultimately lead to dementia, but there are four major primary disorders with dementia as their main clinical feature: Alzheimer\u2019s disease (AD), frontotemporal lobe degeneration (FTLD), cerebrovascular disease, and dementia with Lewy bodies [1, 2].", "section": "INTRO", "tags": [{"name": "cerebrovascular", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "frontotemporal", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "The latter pathology frequently leads to speech patterns consistent with the logopenic variant of primary progressive aphasia, with single word retrieval issues and impaired repetition of words or phrases [17], whereas these abnormalities were specifically denied in her history and not seen on earlier neuropsychological testing.", "section": "METHODS", "tags": [{"name": "neuropsychological", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "abnormalities", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "We believe that the Thr147Ile variant is the primary or sole cause of the disease in our patients for the following reasons: 1) Polyphen-2 analysis indicates the variant is probably damaging; 2) The substitution is located on the helical face of a PS1 transmembrane domain where all deleterious transmembrane variants are known to cluster [25]; 3) The same variant was present in four affected members of three generations of a French family (ALZ047) with early-onset autosomal dominant AD and absent from asymptomatic ALZ047 members \u226560 years of age [19]; 4) The variant was present in four affected members of our family (III-29, IV-1, IV-2, and IV-18); and 5) At least 185 mutations in PSEN1 are known to cause EOAD [12].", "section": "DISCUSS", "tags": [{"name": "transmembrane", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "transmembrane", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Extensive pre-clinical research with AD-transgenic mice [14] and clinical data that included autopsy-confirmed diagnostic specificity of the protein kinase C (PKC) pathway [15, 16] provided a rationale for an FDA approval for a Phase 2a clinical trial with the highly potent PKC activator, bryostatin.", "section": "INTRO", "tags": [{"name": "autopsy-confirmed", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "AD-transgenic", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "We believe that the Thr147Ile variant is the primary or sole cause of the disease in our patients for the following reasons: 1) Polyphen-2 analysis indicates the variant is probably damaging; 2) The substitution is located on the helical face of a PS1 transmembrane domain where all deleterious transmembrane variants are known to cluster [25]; 3) The same variant was present in four affected members of three generations of a French family (ALZ047) with early-onset autosomal dominant AD and absent from asymptomatic ALZ047 members \u226560 years of age [19]; 4) The variant was present in four affected members of our family (III-29, IV-1, IV-2, and IV-18); and 5) At least 185 mutations in PSEN1 are known to cause EOAD [12].", "section": "DISCUSS", "tags": [{"name": "transmembrane", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "transmembrane", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Scores of disease processes may ultimately lead to dementia, but there are four major primary disorders with dementia as their main clinical feature: Alzheimer\u2019s disease (AD), frontotemporal lobe degeneration (FTLD), cerebrovascular disease, and dementia with Lewy bodies [1, 2].", "section": "INTRO", "tags": [{"name": "cerebrovascular", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "frontotemporal", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Since variants in known causal loci only explain a fraction of early-onset dementias, we performed whole exome sequencing with discrete filtering on two affected family members in order to identify causal variants and make a more accurate diagnosis.", "section": "INTRO", "tags": [{"name": "early-onset", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "dementias,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Further evidence implicating PKC deficits has emerged from clinical studies that showed with autopsy-confirmation that AD patients have significant abnormalities in PKC isozymes and PKC-elicited phosphorylation of downstream substrates [15, 16, 23, 24].", "section": "OTHER", "tags": [{"name": "autopsy-confirmation", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "phosphorylation", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "The latter pathology frequently leads to speech patterns consistent with the logopenic variant of primary progressive aphasia, with single word retrieval issues and impaired repetition of words or phrases [17], whereas these abnormalities were specifically denied in her history and not seen on earlier neuropsychological testing.", "section": "METHODS", "tags": [{"name": "neuropsychological", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "abnormalities", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Given the continuing decline in cost of next generation sequencing reagents, automation of variant calling methods, and potential diagnostic value susceptibility variants such as APOE\u025b4, whole exome approaches should be considered to be a more comprehensive, cost-effective alternative to candidate gene sequencing for the diagnosis of atypical dementias.", "section": "DISCUSS", "tags": [{"name": "susceptibility", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "comprehensive,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "The latter pathology frequently leads to speech patterns consistent with the logopenic variant of primary progressive aphasia, with single word retrieval issues and impaired repetition of words or phrases [17], whereas these abnormalities were specifically denied in her history and not seen on earlier neuropsychological testing.", "section": "METHODS", "tags": [{"name": "neuropsychological", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "abnormalities", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "Ridge et al. [12] reported a mean age of onset of cognitive symptoms for persons with PSEN1 variants as 45.5 years of age, whereas patient IV-18 was known to have been only 27, and others in the pedigree are either documented or believed to have had symptoms in their late 20\u200as or very early 30\u200as. Patient IV-18 appeared to know what she wanted to say but could not form her words.", "section": "DISCUSS", "tags": [{"name": "documented", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "cognitive", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Given the continuing decline in cost of next generation sequencing reagents, automation of variant calling methods, and potential diagnostic value susceptibility variants such as APOE\u025b4, whole exome approaches should be considered to be a more comprehensive, cost-effective alternative to candidate gene sequencing for the diagnosis of atypical dementias.", "section": "DISCUSS", "tags": [{"name": "susceptibility", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "comprehensive,", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Extensive pre-clinical research with AD-transgenic mice [14] and clinical data that included autopsy-confirmed diagnostic specificity of the protein kinase C (PKC) pathway [15, 16] provided a rationale for an FDA approval for a Phase 2a clinical trial with the highly potent PKC activator, bryostatin.", "section": "INTRO", "tags": [{"name": "autopsy-confirmed", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "AD-transgenic", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "Ridge et al. [12] reported a mean age of onset of cognitive symptoms for persons with PSEN1 variants as 45.5 years of age, whereas patient IV-18 was known to have been only 27, and others in the pedigree are either documented or believed to have had symptoms in their late 20\u200as or very early 30\u200as. Patient IV-18 appeared to know what she wanted to say but could not form her words.", "section": "DISCUSS", "tags": [{"name": "documented", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "cognitive", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}]}
{"src": "PMC", "id": "PMC4151597", "provider": "OpenTargets", "anns": [{"type": "Gene Disease Relationship", "exact": "As shown in Table 3 and Figure 4, there was no significant association in rs5275 polymorphism (homozygote comparison: OR = 1.04, 95% CI = 0.96\u20131.12, P = 0.34; heterozygote comparison: OR = 0.99, 95% CI = 0.95\u20131.04, P = 0.81; dominant model: OR = 1.02, 95% CI = 0.98\u20131.07, P = 0.33, and recessive model: OR = 1.04, 95% CI = 0.97\u20131.12, P = 0.27).", "section": "METHODS", "tags": [{"name": "polymorphism", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "heterozygote", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Disease Relationship", "exact": "As shown in Table 3 and Figure 3, there was no association in these four genotypes (A versus G: OR = 0.99, 95% CI = 0.94\u20131.04, P = 0.69; homozygote comparison (AA versus GG): OR = 1.01, 95% CI = 0.88\u20131.15, P = 0.93; heterozygote comparison (AG versus GG): OR = 0.98, 95% CI = 0.92\u20131.05, P = 0.59; recessive model (AA versus GG + AG): OR = 1.01, 95% CI = 0.89\u20131.15, P = 0.85).", "section": "METHODS", "tags": [{"name": "heterozygote", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "association", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Gene Drug Relationship", "exact": "We found no significant association of rs5275 polymorphism with breast cancer risk (homozygote comparison: OR = 1.04, 95% CI = 0.96\u20131.12, P = 0.34; heterozygote comparison: OR = 0.99, 95% CI = 0.95\u20131.04, P = 0.81; dominant model: OR = 1.02, 95% CI = 0.98\u20131.07, P = 0.33, and recessive model: OR = 1.04, 95% CI = 0.97\u20131.12, P = 0.27).", "section": "DISCUSS", "tags": [{"name": "polymorphism", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "heterozygote", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "The following criteria were used to select studies for further meta-analysis: (1) case-control studies; (2) studies that evaluated the associations between COX-2 polymorphisms and breast cancer risk; (3) studies that contained at least two comparison groups (cancer versus control); (4) studies that included detailed genotyping data.", "section": "METHODS", "tags": [{"name": "meta-analysis:", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "polymorphisms", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "The following criteria were used to select studies for further meta-analysis: (1) case-control studies; (2) studies that evaluated the associations between COX-2 polymorphisms and breast cancer risk; (3) studies that contained at least two comparison groups (cancer versus control); (4) studies that included detailed genotyping data.", "section": "METHODS", "tags": [{"name": "meta-analysis:", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "polymorphisms", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "The meta-analysis assessed association by using 4 different genetic models: (1) dominant genetic model\u2014the comparison groups were the wild-type homozygous genotype versus the variant allele-positive genotypes (AA + Aa versus aa); (2) recessive genetic model\u2014the comparison groups were the variant homozygous genotype versus the rest (AA versus aa + Aa); (3) homozygous genetic model\u2014comparison was between the 2 homozygous genotypes (AA versus aa); and (4) allele contrast genetic model\u2014the comparison was between the heterozygous and the homozygous wild-type genotype groups (Aa versus aa (where \u201ca\u201d is the wild-type allele and \u201cA\u201d is the variant allele)).", "section": "METHODS", "tags": [{"name": "model\u2014comparison", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "allele-positive", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "As shown in Table 3 and Figure 4, there was no significant association in rs5275 polymorphism (homozygote comparison: OR = 1.04, 95% CI = 0.96\u20131.12, P = 0.34; heterozygote comparison: OR = 0.99, 95% CI = 0.95\u20131.04, P = 0.81; dominant model: OR = 1.02, 95% CI = 0.98\u20131.07, P = 0.33, and recessive model: OR = 1.04, 95% CI = 0.97\u20131.12, P = 0.27).", "section": "METHODS", "tags": [{"name": "polymorphism", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "heterozygote", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "As shown in Table 3 and Figure 4, there was no significant association in rs5275 polymorphism (homozygote comparison: OR = 1.04, 95% CI = 0.96\u20131.12, P = 0.34; heterozygote comparison: OR = 0.99, 95% CI = 0.95\u20131.04, P = 0.81; dominant model: OR = 1.02, 95% CI = 0.98\u20131.07, P = 0.33, and recessive model: OR = 1.04, 95% CI = 0.97\u20131.12, P = 0.27).", "section": "METHODS", "tags": [{"name": "polymorphism", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "heterozygote", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}, {"type": "Disease Drug Relationship", "exact": "As shown in Table 3 and Figure 3, there was no association in these four genotypes (A versus G: OR = 0.99, 95% CI = 0.94\u20131.04, P = 0.69; homozygote comparison (AA versus GG): OR = 1.01, 95% CI = 0.88\u20131.15, P = 0.93; heterozygote comparison (AG versus GG): OR = 0.98, 95% CI = 0.92\u20131.05, P = 0.59; recessive model (AA versus GG + AG): OR = 1.01, 95% CI = 0.89\u20131.15, P = 0.85).", "section": "METHODS", "tags": [{"name": "heterozygote", "uri": "http://purl.uniprot.org/uniprot/Q13228"}, {"name": "association", "uri": "http://purl.uniprot.org/uniprot/Q13228"}]}]}
